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ABSTRACT 
 
Lung cancer outcomes in the UK show significant variation which are not entirely explained 
by case mix. Differences in access to lung cancer services contribute. However, the specific 
factors that underlie the relationship between service organisation and disease outcomes are 
not known.  
The systematic review highlights that co-ordinated access to specialist care is likely to be an 
important determinant of patient outcomes. In addition, a bundle of service factors, rather than 
an individual factor is a more robust proxy for hospital infrastructure quality. This hypothesis 
is explored through the creation of a novel organisational score. When adjusted for patient 
factors a higher score is associated with higher curative intent treatment rates, increased 
likelihood of patients receiving treatment within 62 days and improved one-year survival.  
To achieve these improved outcomes national variation in the provision of services and 
workforce as well as gaps in the optimal care of stage III patients in England need to be 
addressed. As well as aligning units with national commissioning guidance, qualitative work 
into decision making suggests that clinician preconceptions and nihilistic attitudes also 
require consideration.  
This work shows that inequity in access to essential services exists in the UK and this has a 
direct impact on patients. 
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SDM Shared Decision Making 
SEER Surveillance Epidemiology and End Results programme 
SES Socio-economic status 
TBNA Trans-Bronchial Needle Aspiration (ultrasound guided) 
TS Thoracic Surgeon 
VAT Video Assisted Thoracoscopy 
WTE Whole time equivalent  
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CHAPTER 1 INTRODUCTION 
1.1 Epidemiology of lung cancer 
 
Lung cancer is the most common cancer worldwide with 1.8 million new cases diagnosed in 
2012. (1) The number of worldwide lung cancer deaths is projected to increase from 1.6 
million in 2012 to 3 million in 2035. (2) In England, lung cancer accounts for approximately 
28, 000 deaths per year. (3) As such it is the most common cause of cancer death in England 
and worldwide. Yet, current survival rates for lung cancer are the second lowest out of twenty 
common cancers in the UK.
 
 Figures from the most recent National Lung Cancer Audit report 
a one-year survival of 37% which has not shown much improvement over the last forty years. 
(4)  
Currently, slightly more men are diagnosed with lung cancer than women. (3) In 2016, 47% 
of cases were female and 53% male. (4) In males the incidence rate has decreased from the 
early 1990’s. However, in females, the rate has increased by an average of ~ 33% in those 
over 50 years old. (3) This corresponds to the pattern of smoking in the UK and a subsequent 
increase in lung cancer death is projected for women over the next twenty years. (2) Figure 
1.1 demonstrates age standardised rates of lung cancer for males and females over time.  
2 
 
Figure 1.1 European age standardised incidence rates in the UK, 1993-2015 (taken from 
Cancer Research UK, 2013) (3) 
 
 
The median age of presentation is 73 years old with approximately two thirds of individuals 
being diagnosed over the age of 70. (4) The majority of patients in the UK are white males 
with an age standardised rate of 62 per 100,000 compared to 40 per 100,000 for black males 
and 30 per 100,000 for Asian males. (5) However, the accuracy of this data is questionable 
given that approximately one third of ethnicity data is missing from national datasets.  
Studies have shown that lung cancer is directly correlated with socio-economic status. (6) In 
the UK, people in the most deprived quintile are twice as likely to develop lung cancer as 
those in the most affluent. (3) It is estimated that there would be 11,700 fewer lung cancer 
cases each year in England in 2006-2010 if all people experienced the same incidence rates as 
the least deprived. (3) This difference is thought to be because of increased rates of smoking 
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in deprived areas, nature of employment (manual versus professional), educational attainment 
and access to health services.  
1.2 Aetiology of lung cancer 
 
Tobacco smoking is attributable to 85% of lung cancer cases. (7) Approximately 19% of 
adults in the UK currently smoke which equates to an estimated 9.4 million UK adult 
smokers. (3) This is likely to be an underestimate of the true number as data is self-reported. 
(3) A systematic review investigating the concordance between self-reported smoking status 
and that determined through objectives measures (such as Continine in biological fluids) 
found a difference in rates between 1%-47%. (8) 
The mechanism by which tobacco smoke leads to genetic mutation is a complex multistep 
process. (7) However, only 10-20% of smokers develop cancer, suggesting genetic 
determinants of susceptibility. (7) The carcinogenic process is driven by the accumulation of 
genetic and epigenetic alterations that result in the dysregulation of key oncogenes, tumour 
suppressor genes and DNA repair genes. (9) Changes of cytochrome P450 1A1 gene and 
GSTM1 homozygous deletion are amongst some of the many polymorphisms associated with 
increased lung cancer risk. (7)  
Genetic abnormalities associated with lung cancer occur in the context of altered signalling 
pathways. (10) Oncogenes drive stimulatory signalling pathways leading to cell proliferation 
and prevention of apoptosis. (10) Mutated oncogenic proteins have abnormal functions and 
‘oncogene addiction’ occurs when tumour cells are dependent on these abnormal oncogene 
functions for their sustained proliferation and survival. (10) These pathways include those 
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involving epidermal growth factor receptor (EGFR), anaplastic lymphoma fusion proteins and 
thyroid transcription factor 1. (7) The key mechanisms in the EGFR pathway are illustrated in 
figure 1.2. The components of such pathways are becoming increasingly important with 
regards to targeted therapy which will be discussed in section 1.6.4. 
Figure 1.2 Epidermal growth factor receptor pathway (modified from Brambilla et al. 
Pathogenesis of lung cancer signalling pathways: a roadmap for therapies. Eur Respir J. 
2009;33:1485-97) (7) 
Ligands such as epidermal growth factor (EGF) bind to the domain (TK) leading to activation and receptor 
transphosphorylation. This creates docking sites for the adaptor proteins, Grb2 and Sos, which recruit Ras and 
phosphatidylinositol 3-kinase (PI3K), leading to the formation of two major signal pathway branches- 
Ras/mitogen-activated kinase-like protein (MAPK) and PI3K/Akt. This results in proliferation, evasion of 
apoptosis and angiogenesis.  
 
The probability of incurring these genetic alterations and hence an individuals’ risk of 
malignancy is dependent on genetic heterogeneity as well as epigenetic variability, including 
DNA methylation, histone modifications and non-coding RNA expression. (9) 
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Approximately 7000 people, in the UK, develop lung cancer unrelated to smoking each year. 
(11) Other important risk factors include genetic factors, occupational agents and 
environmental factors such as Environmental Tobacco Smoke (ETS) or second-hand smoke. 
(3)  
1.2.1 Environmental Factors 
 
It is estimated that 15% of lung cancers are linked to ETS in non-smokers. (12) One meta-
analysis showed lung cancer risk in never smokers is as high as 31% greater in those exposed 
to ETS at home or work compared to those not exposed. (13) Other environmental agents that 
have been linked to lung cancer include ionising radiation, radon and X ray radiation. (3) 
 In terms of cases linked to occupational exposure it is thought that this equates to 
approximately 21% of men and 4-5% of women in the UK. (3) These include exposure to 
asbestos, silica, diesel engine exhaust and substances from metal and pesticide production. 
The most commonly linked occupational exposure to lung cancer is asbestos accounting for 6-
8% of lung cancer deaths. (14)  
1.2.2 Genetic factors 
 
25% of lung cancer cases worldwide are not attributable to smoking. (7) Studies have shown 
that the risk is 82% higher in people whose sibling has had lung cancer and 25-37% higher for 
a parent. (15) This association was shown to be independent of smoking. (15) The cause has 
not been conclusively identified. (7) However, a susceptibility at the genetic locus at 6q23-25 
has been reported and differences in the mutation patterns in key genes (such as TP53, KRAS 
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and EGFR) between smokers and never smokers has been found. (7,16) Further research is 
required to fully understand aetiological mechanisms in what is increasingly being considered 
a distinct disease from the more common tobacco related forms of lung cancer. (7) 
1.3 Histology and staging of lung cancer 
 
Lung cancer is classified into non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC). NSCLC is the most common subtype and accounted for 88.5% of cases in 2016. (4) 
NSCLC has two major subtypes: squamous cell carcinoma and adenocarcinoma. Examples of 
the histological appearance of the major types are shown in Figure 1.3. 
 
Figure 1.3 Histological appearance of the major lung cancer subtypes 
 
 
Obtaining a histological confirmation of the lung cancer is vital to treatment planning.  Latest 
data from the NLCA demonstrate that 21% of patients in the UK with early stage lung cancer 
that are considered fit did not receive a pathological diagnosis. Across  individual 
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organisations (excluding tertiary trusts) the results, adjusted for casemix, varied from 44% to 
0%. (17)   
The extent of a person’s lung cancer is another important determinant of treatment planning 
and prognosis. The stage classification provides a system for categorising the anatomic extent 
of the cancer. The International Association for the Study of Lung Cancer group (IASLC) 
published the eighth edition of the TNM staging system in January 2017, and a summary of 
the staging criteria are shown in Table 1.1. (18) In 2016, over half of newly diagnosed 
patients presented with Stage IV disease. (4)  
Table 1.1 The 8th TNM Staging System  
Stage Description 
Tx Tumour in sputum/bronchial washings but not visible on imaging or 
bronchoscopy 
T0 No evidence of tumour 
Tis Carcinoma in situ 
T1 ≤ 3cm surrounded by lung/visceral pleura, not involving main bronchus 
T1a(mi) Minimally invasive carcinoma 
T1a ≤1cm 
T1b >1 to ≤2cm 
T1c >2 to ≤3cm 
T2 >3 to ≤5cm or involvement of main bronchus without carina, regardless of 
distance to carina or invasion of visceral pleura or atelectasis or post 
obstructive pneumonitis extending to hilum 
T2a >3 to ≤4cm 
T2b >4 to ≤5cm 
T3 >5 to ≤7cm in greatest dimension or tumour of any size that involves the chest 
wall, pericardium, phrenic nerve or satellite nodules in the same lobe.  
T4 >7cm in greatest dimension or any tumour with invasion of mediastinum, 
diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, 
oesophagus, spine or separate tumour in different lobe of ipsilateral lung 
N1 Ipsilateral peri-bronchial and/or hilar nodes and intrapulmonary nodes.  
N2 Ipsilateral mediastinal and/or subcarinal nodes 
N3 Contralateral mediastinal or hilar; ipsilateral/contra-
lateral/scalene/supraclavicular 
M1 Distant metastasis 
M1a Tumour in contralateral lung or pleural/pericardial nodule/malignant effusion 
M1b Single extra-thoracic metastasis, including non-regional lymph node 
M1c Multiple extra-thoracic metastases in one or more organs.  
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1.4 Clinical presentation 
 
The commonest referring symptoms of patients with lung cancer are breathlessness (55%), 
cough (41%), haemoptysis (22%), chest/shoulder pain (39%) and weight loss (47%). (19) The 
symptoms are nonspecific therefore the most sensitive method to identify lung cancer cases is 
an assessment of combinations of symptoms and baseline risk factors.  
It is notable that approximately 35% of patients that are diagnosed with lung cancer present as 
an emergency. (20) This is one of the highest emergency presentation rates in the UK out of 
all cancers. (20) These patients tend to be older and have a more advanced stage of disease. 
(21) Hence there is a direct correlation with a lower one-year survival of about 13% in this 
subgroup of patients. (21) Lung cancer is curable if found at an earlier stage hence there has 
been a focus on prevention and ways to detect lung cancer earlier which will be discussed in 
the following section.  
1.4.1 Prevention and early detection initiatives 
 
In terms of prevention, the single most important measure that has been shown to have the 
greatest impact on lung cancer incidence is reducing smoking prevalence. This is highlighted 
by the government in the White Paper, “Smoking Kills” in 1999. (22) It recommended 
implementation of an advertising ban on tobacco and the creation of NHS smoking cessation 
services. The format of these services includes regular meetings with a trained advisor that 
uses withdrawal orientated behavioural therapy as well as smoking cessation medications 
such as Nicotine Replacement Therapy (NRT), Bupropion or Varenicline. These NHS stop 
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smoking services have been shown to be effective in supporting smokers motivated to quit in 
the short and longer term. (23) The UK is the only country in the world to have a cessation 
service, free at the point of access. Despite the effectiveness of the service and direct proven 
public health benefits, local funding has been decreasing since 2016.  
Achieving an earlier diagnosis through public health campaigns was a key aim of the 
government in the “Improving Outcomes: A strategy for cancer” document published in 2011. 
(24) The “Be Clear on Cancer” programme for lung cancer was delivered in 2011. (25) It 
consisted of national and regional media advertising campaigns and events. The evaluation of 
the campaign revealed an estimated 700 additional lung cancers were diagnosed compared to 
the same period the previous year. (25) The success of such campaigns to reduce variation in 
lung cancer outcomes is clear. However, continued investment on awareness raising 
initiatives is required to sustain this change.  
Another method of improving early diagnosis and outcomes for patients is through the 
adoption of a national screening programme. Results from the US National Lung Screening 
Trial (NLST) led to the implementation of a national low dose CT screening programme in 
USA and Canada in 2013. Pilot programmes of low dose CT lung cancer screening have been 
running in the UK but a national screening programme as not been implemented The ongoing 
NELSON (Nederlands Leuvens Longkander Screenings Onderzoek) Dutch-Belgian 
Randomised Lung Cancer Screening Trial results add weight to the mounting evidence in 
favour of low dose CT screening for individuals at high risk of developing lung cancer in 
Europe. This randomised controlled trial reports that at year ten, the lung cancer mortality rate 
ratio in the screened arm versus the unscreened group was 0.74 (26% reduction, p=0.0003) 
for men and 0.61 (39% reduction, p=0.0054) for women. (26) In addition, pilot studies such 
as the Lung Screen Uptake Trial (LSUT) and the Manchester Health Check Pilot have 
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explored how a screening programme could be implemented in the UK. (27,28) Currently, 
The UK National Screening Committee (UKNSC) does not recommend lung cancer screening 
due to concerns about the benefits and cost effectiveness of such a programme. (29) 
Information about gaps in the lung cancer service infrastructure will be essential in 
establishing whether screening has the potential to be successfully implemented in the UK.   
1.5 Investigations and Diagnostic Procedures 
 
The diagnosis and assessment of a patient with suspected lung cancer is complex. The optimal 
pathway to achieving this is described by the NICE guidelines (“The diagnosis and treatment 
of lung cancer”) and the “National Optimal Lung Cancer Pathway” document produced by the 
NHS England Lung Clinical Expert Group in 2017. There are two main aims of this pathway. 
Firstly, to obtain maximal diagnostic and staging information with least risk to the patient and 
secondly, to assess the patient’s fitness to formulate an appropriate management plan.  Figure 
1.4 is a flowchart of the basic clinical pathway. 
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Figure 1.4 The lung cancer clinical pathway 
 
 
 
Patients are initially seen by a member of the lung cancer team where a history and physical 
examination is performed. This will include an assessment of the individuals’ fitness 
according to their performance status. The Eastern Co-operative Oncology Group (ECOG) 
performance status is assessment of a patients’ fitness and summarised in Table 1.2. (30) This 
grading is used to inform the choice of subsequent investigations in a multidisciplinary team 
(MDT) meeting. Figure 1.5 shows the stage distribution of cases in England according to 
performance status. The commonly used investigation modalities used to achieve the pathway 
aims are summarised in Tables 1.3-1.5. 
 
Prevention and early detection 
Presentation, initial investigations and referral 
Diagnosis, staging and treatment planning 
Treatment 
Care after initial treatment and recovery 
Managing recurrent, residual or metastatic disease 
End of life care 
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Table 1.2 The Eastern Co-operative Oncology Group (ECOG) performance status 
Score Description 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature e.g. light housework, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. 
Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled. Cannot carry out self-care. Totally confined to bed or chair 
5 Dead 
 
Figure 1.5 Performance status (PS) distribution of patients diagnosed with lung cancer 
in England/Wales in 2016 (4) 
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Table 1.3 Investigations used for staging 
Procedure Description Benefits/Advantages Risks/Disadvantages 
CT scan A scan that uses x-
rays to create 
detailed images of 
the body 
Quick and accurate 
 
Radiation exposure 
Harm to unborn babies if 
pregnant 
Reactions to contrast material 
PET- CT 
scan 
An imaging 
technique that uses 
radioactive tracers 
to measure cell 
metabolism.  
Gives unique information 
on function and structure 
of the disease 
Can detect early disease 
Scans the whole-body 
allowing identification of 
potentially affected 
regional lymph nodes and 
distant sites.  
Radiation exposure 
Allergic reaction to 
radioactive material 
Other factors can affect 
interpretation of the result  
Time consuming and 
expensive 
Not all units have on site 
access 
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Table 1.4: Investigations used for gaining a histological diagnosis 
Procedure Description Benefits/Advantages Significant risks/Disadvantages 
Bronchoscopy Using an endoscopy to visualise the 
airways and take biopsies 
Can be done under local anaesthetic (LA) 
Day case 
Bleeding 
Infection 
Pneumothorax 
Irritation of airways or vocal cords 
Complications associated with the sedation 
Endobronchial 
ultrasound 
(EBUS) 
Using a bronchoscope and 
ultrasound to visualise and sample 
the airway wall and surrounding 
structures (e.g. lymph nodes).  
Can diagnose and stage lung cancer at the 
same time.  
Can be done under LA as a day case 
As above  
Transthoracic 
needle biopsy 
A biopsy is obtained by inserting a 
needle under direct image guidance 
(Ultrasound/CT) under LA 
Day case 
Quick 
Dependent on site of biopsy. If lung: 
Pneumothorax, internal bleeding and air 
embolism 
Pleural 
aspiration 
Removal of pleural fluid for 
investigation. 
Simple procedure that can be performed in 
clinic/by the bedside 
Sensitivity: 60% in malignancy (31) 
Bleeding 
Infection 
Organ puncture 
Thoracoscopy A camera is inserted to visualise 
the pleural cavity. This can be done 
under local (LAT) or general 
anaesthetic (VAT). 
LAT: Direct of visualisation of pleura.  
Sensitivity 92.6% for malignancy. (32)  
Diagnostic and therapeutic benefits 
Empyema 
Haemorrhage 
Port tumour growth 
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VAT: as above with the benefits of being 
able to biopsy the mass directly, 
investigate for invasion and perform a 
surgical procedure to manage the cancer.  
Bronchopleural fistula 
Postoperative pneumothorax/pneumonia 
Risk of anaesthetic (VAT)/sedation (LAT) 
Mediastinoscopy A camera is inserted via the neck to 
examine and take biopsies from the 
mediastinum.  
Allows accurate staging of the 
mediastinum with the ability to remove 
whole lymph nodes 
Bleeding 
Infection 
Pneumothorax 
Organ perforation 
Temporary or permanent paralysis of the 
laryngeal nerve.  
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Table 1.5 Investigations used for assessment of fitness 
Procedure Description 
Spirometry A physiological test to determine how well the 
lungs are functioning 
Cardiopulmonary exercise testing 
(CPET) 
A test to determine how well the heart and lungs 
perform under exercise 
ECHO An ultrasound scan that examines the structure and 
function of the heart and surrounding vessels.  
Shuttle walk test Examines an individuals’ functional capacity by 
assessing how far and fast they can walk.  
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1.6 Management 
 
Lung cancer treatment is determined by stage, cell type, fitness and patient preference. The 
main modalities are surgery, radiotherapy, chemotherapy, immunotherapy and supportive 
care.  The MDT considers the most appropriate choice of treatments that can be offered which 
fulfils the aims of improving quality of life and survival.  
1.6.1 Surgery 
 
Surgical resection offers patients the best chance of cure for patients with NSCLC and early 
stage SCLC. Survival after surgery is estimated as high as 98% at 30 days. (3) In the latest 
NLCA audit, 17% of non-small cell lung cancer patients received surgical treatment. (4) 
The suitability of surgical management of a patients’ cancer is dependent on the likelihood of 
complete removal of the cancer as well as the patients’ fitness. The types of surgery that can 
be performed include a wedge resection, lobectomy, pneumonectomy or sleeve resection; 
these are illustrated diagrammatically in Figure 1.6. If lymph nodes are affected, then a more 
extensive procedure is required. The use of minimally invasive techniques such as video 
assisted thorascopic surgery (VATS) have meant that patients that may have previously been 
unsuitable for open surgery can benefit from a surgical approach. This technique uses 
videoscopic guidance through a 4-8cm incision site and two port incisions without the use of 
rib spreading. (33) Meta-analyses examining outcomes for VATS compared with an open 
thoracotomy approach demonstrate reduced overall systemic recurrence rate, reduced 
perioperative complication rates and an improved five-year survival rate with VATS. (34,35)  
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Figure 1.6 Surgical procedures performed for lung cancer 
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1.6.2 Radiotherapy 
 
Radiotherapy has an established role in the treatment of lung cancer. It can be given with 
curative intent in early inoperable and locally advanced NSCLC as well as in the adjuvant 
treatment of limited SCLC. In addition, it is used in the palliation of all types of lung cancer. 
(36) 
Radiotherapy delivered by Stereotactic Ablative Body Radiotherapy (SABR) is now 
established as the standard of care for patients with inoperable peripheral early stage NSCLC. 
This technique delivers higher doses of radiation compared to conventional radiotherapy 
avoiding surrounding healthy tissue facilitated by 3-dimensional computed tomography 
(3DCT). Beams from different angles are shaped precisely to target the tumour. (36) The 
precision of this technique coupled with the use of patient immobilisation to minimise 
movement during delivery leads to minimal treatment related toxicities. The use of SABR for 
operable patients is controversial. (37) A pooled analysis of two randomised controlled trials 
of operable patients with early stage NSCLC showed that the three-year survival was higher 
with SABR by 16% compared to surgery (p=0.037). (38) In addition, a propensity score 
matched analysis found decreased rates of severe toxicity with SABR compared to a 
lobectomy performed by VATS for early stage NSCLC. (39) However, a recent meta-analysis 
(n=13,598) showed SABR was associated with a lower three year overall survival (p=0.001) 
and an increased hazard ratio for all-cause mortality (p<0.001). (40) Consequently, poorly 
examined factors such as quality of life and patient experience are relevant for patients to 
make informed treatment decisions. 
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In patients with early stage NSCLC where SABR is contraindicated, conventional 
fractionated radical radiotherapy can be offered as 55 Gray (Gy) in 20 fractions over four 
weeks or 60-66 Gy in 30-33 fractions over 6-6 ½ weeks. (41) 
Radiotherapy delivered in locally advanced NSCLC (stage III) is also a challenging area of 
management. At one end of the spectrum of this diverse stage are surgical patients identified 
with pathologically confirmed N2 disease (spread to the ipsilateral mediastinum) where the 
recently updated National Institute of Clinical Excellence (NICE) lung cancer guidance 
(March 2019) recommends tri-modality therapy with surgery, chemotherapy and 
radiotherapy. (41) Whereas at the other end are patients presenting with bulky mediastinal 
nodal disease where concurrent chemoradiotherapy is advised with the addition of the 
immunotherapy agent Durvalumab as recommended by the new NICE technology appraisal. 
(42) 
The role of thoracic adjuvant radiation and prophylactic cranial irradiation in the curative 
management of limited stage SCLC is well established. (43) Two meta-analyses have 
demonstrated that combining chemotherapy with thoracic radiotherapy significantly decreases 
local relapse and improves overall survival in patients with limited SCLC. (44,45) In addition, 
several studies show that the delivery of concurrent therapy compared to sequential treatment 
leads to better disease control. (46,47) However, the optimum dose and timing of such 
treatments and the use of thoracic radiation therapy in extensive disease is subject to ongoing 
research.  
Approximately 45% of patients who achieve a complete response to initial treatment for 
SCLC with chemoradiotherapy will present with central nervous system (CNS) metastases as 
the only site of recurrence at two years. (48) It is estimated that the delivery of prophylactic 
21 
 
radiotherapy to the CNS has reduced the incidence of brain metastases by 52-54% with a 
survival improvement of 16-18% in patients with a good performance status who have 
achieved a complete response to initial treatment. (49,50) However, the optimal dose of each 
fraction is still unknown.   
When curative intent treatment is inappropriate, radiotherapy delivered at palliative doses is 
shown to effectively manage symptoms. (36) One study reported an improvement in 
performance status in 73% of patients with the median duration of palliation from 28%-57% 
of patient survival. (51) Additionally, Langendijk et al show improvement in the following 
symptoms: haemoptysis (79%), pain and cough (50%) dyspnoea (40%), fatigue (22%) and 
anorexia in 11%. (52) 
The clinical benefits of radiation treatment must be carefully balanced against potential 
toxicities to surrounding healthy tissue which has been reported to occur in up to 37% of 
irradiated patients. (53) The risk has been shown to be related to performance status, 
underlying lung function, lung volume being exposed, radiotherapy dose and the addition of 
chemotherapy. (53) The advent of new technologies in treatment planning and delivery, such 
as Intensity Modulated Radiotherapy (IMRT) mean that optimal doses of radiation can be 
delivered with minimal toxicity. (54) However, further knowledge is required on optimal 
patient selection to further improve patient outcomes through the application of such 
innovations.  
1.6.3 Systemic therapies 
 
The cornerstone of treatment for SCLC is platinum-based combination chemotherapy. This is 
optimally delivered concurrently with radiotherapy in curative intent treatment for limited 
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stage disease (as described in section 1.6.2) and with palliative intent in extensive disease. In 
the latter a regimen of Cisplatin or Carboplatin plus Etoposide for up to six cycles followed 
by active surveillance has been shown to achieve responses of up to 75% with an acceptable 
toxicity profile. (55)  
In NSCLC, chemotherapy is beneficial for palliation in stage III-IV disease or part of curative 
intent multi-modality treatment in locally advanced disease. In the palliative setting, the goal 
of treatment is to improve survival and reduce disease related adverse events.  
Up until recently the only option for patients with advanced lung cancer was chemotherapy. 
Over recent years the use of medicines targeted at genetic mutations (epidermal growth factor 
receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS proto oncogene 1 (ROS-1)) in 
a patients’ cancer has become a key part of the future for patients with lung cancer, 
particularly as these newer treatments are better tolerated by patients than standard 
chemotherapy.   The first genetically targeted treatment for NSCLC was gefitinib, an oral 
treatment targeting the EGFR signally pathway depicted in Figure 1.2. Abnormal activation of 
this pathway through genetic mutations of the receptor leads to prevention of apoptosis, 
uncontrolled proliferation and metastasis of tumour cells. (56) EGFR tyrosine kinase 
inhibitors function on the principle that EGFR’s possess an intracellular tyrosine kinase 
domain with an ATP-binding cleft. (56) If this cleft can be blocked chemically, the receptor 
efficacy is decreased – hence reducing the oncogenic processes it facilitates. (56) Oncogenic 
driver mutations account for approximately one quarter of lung adenocarcinoma cases and are 
targetable with approved drugs. (57) Clinical trials have demonstrated improved progression 
free survival with targeted therapy compared to chemotherapy. (58–60) 
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The newest class of systemic treatments are immune checkpoint inhibitors (pembrolizumab, 
nivolumab and atezolizumab). These act on the programmed death ligand 1 or 2 (PD-L1 and 
PD-L2) and programmed death 1 (PD-1) receptor pathway. PDL-1 proteins supress the 
immune system by binding to PDL-1 receptors on cytotoxic T cells. Some cancer cells 
express PD-L1/2. Inhibitors prevent protection of cancer cells from the immune system and 
allow cancer cells to be identified and undergo cytotoxic T cell mediated death. The 
KEYNOTE-010 trial demonstrated that pembrolizumab significantly improved overall 
survival compared to standard chemotherapy in people with previously treated NSCLC who 
had >1% expression of PD-L1 tumour cells. (61)  Similar findings have been seen with 
Nicolumab as well. (62) In addition, significant improvements in overall survival have been 
demonstrated with patients with >50% expression of PD-L1 and no driver mutations 
compared to being treated with chemotherapy. (63) 
 The updated NICE guidelines present the large number of currently approved systemic 
therapy options for people with Stage IIIB-IV NSCLC summarised in Table 1.6. (41) 
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Table 1.6 NICE recommended first line Systemic anti-cancer management options for 
people with Non-Small Cell Lung Cancer (NSCLC) (41)  
Treatment 
Agent 
Key trial/s Comparator Results 
Non-squamous/NSCLC (non-otherwise specified) 
EGFR-TK positive 
Afatinib LUX lung 3/LUX lung 6 
(64) 
Platinum doublet 
chemotherapy 
Increased overall 
survival, p=0.00015 
(LUX Lung 3); 
p=0.023 (LUX Lung 6) 
Erlotinib EURTAC(65)/OPTIMAL 
(66) 
Platinum doublet 
chemotherapy 
Improved PFS p<0.001 
(EURTAC); p<0.0001 
(OPTIMAL) 
Gefitinib IPASS (67) Platinum doublet 
chemotherapy 
Improved ORR 
(p=0.004) 
ALK positive 
Ceritinib ASCEND-4 (68) Platinum doublet 
chemotherapy 
Improved survival, 
p<0.0001 
Alectinib ALEX (69) Crizotinib Improved survival and 
disease-free 
progression, p<0.001 
Crizotinib PROFILE 101 (70)  Platinum doublet 
chemotherapy 
Improved survival and 
PFS, p<0.001 
ROS-1 positive 
Crizotinib PROFILE 1001 (71) Single arm study ORR: 70% (95% CI 
56-82%); Median PFS: 
19.3 months (95% CI 
14.8-NR) 
No gene mutation or fusion protein 
PD-L1 <50% 
Pembrolizumab 
and platinum 
doublet 
chemotherapy 
KEYNOTE-189(72) Platinum doublet 
chemotherapy and 
placebo 
Improved survival, 
p<0.008 
Platinum doublet 
chemotherapy 
(48,73–75) Supportive 
care/Single agent 
Improved one-year 
survival, p<0.001; 
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chemotherapy/non 
platinum based 
treatment 
Reduction in overall 
mortality/improved 
PFS 
Improved response rate 
and overall 
prolongation of 
survival   
PD-L1>50% 
Pembrolizumab 
and platinum 
doublet 
chemotherapy 
KEYNOTE-189(72) Platinum doublet 
chemotherapy and 
placebo 
Improved survival, 
p<0.008 
Pembrolizumab KEYNOTE-024(73) Platinum doublet 
chemotherapy 
Improved survival, 
p<0.05 
Advanced Squamous cell carcinoma 
PD-L1<50% 
Platinum doublet 
chemotherapy 
Several Single agent 
chemotherapy/non 
platinum based 
treatment 
Improved survival, 
p<0.05 
PD-L1>50% 
Pembrolizumab KEYNOTE-024(73) Platinum doublet 
chemotherapy 
Improved survival, 
p<0.05 
ORR: Odd rate ratio; PFS: Progression free survival; NR: Not reported 
Innovations in this area are occurring at an impressive rate for patients with metastatic 
NSCLC as well as those with earlier stage disease and in combination with other therapies. 
Durvalumab, a monoclonal antibody directed against PD-L1, significantly improves 
progression free survival in addition to chemoradiotherapy in stage III NSCLC. (76) Clinical 
trials are ongoing investigating such novel therapies as monotherapies and in combination 
with other treatments in diverse stages of the disease and are likely to offer further treatment 
options for patients in the future. 
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1.6.5 Supportive care 
 
Adequate control of symptoms to improve quality of life is crucial for patients with lung 
cancer, particularly as over half of patients present with an advanced stage (stage IV). (4) In 
addition to the palliative radiotherapy treatments described above, other treatments are 
available to control specific symptoms. These include endobronchial tumour treatment for 
airway obstruction (brachytherapy, electrocautery, laser ablation, cryotherapy, stent insertion 
and photodynamic therapy), pleural procedures for fluid drainage via tube insertion or 
placement of an indwelling catheter, and supportive care with specialist palliative care input.  
Temel et al demonstrated the importance of specialist palliative care support in lung cancer 
care by examining the effect of early specialist palliative care support compared with standard 
care in ambulatory patients with metastatic NSCLC referred to the medical oncology 
outpatient department.(77) They showed a significant difference in median survival in the 
specialist care support group compared with standard care (11.6 months vs 8.9 months). 
These patients also had a better quality of life scare and fewer depressive symptoms and were 
less likely to require aggressive end of life care support.  
1.7 The organisation of lung cancer services in the UK 
 
Lung cancer services in the NHS are commissioned locally by clinical commissioning groups 
(CCG’s), with specialist services (chemotherapy, radiotherapy and thoracic surgery) being 
commissioned directly by NHS England.  
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The Cancer Taskforce recommended the formation of cancer alliances with the aim of 
offering flexibility to best serve local communities. Each alliance has an Expert Advisory 
Group (EAG) covering lung cancer that is made up of clinicians across the network who 
specialise in thoracic oncology. (11)  
The aim of a local commissioning structure is to allow providers to implement cancer services 
based on their knowledge of the local situation. However, it also has the potential to increase 
variation in access to services. The implementation of several national standards aims to 
standardise care. These include the Care Quality Commission (CQC) care standards, cancer 
surveillance quality indicators as well as speciality specific guidelines such as Royal College 
of Pathologists guidelines. In addition, lung cancer services are required to adhere to NICE 
guidelines target of a definitive diagnosis by 28 days and 62 days from referral to first 
treatment.  
The above standards aim to reduce variation in care across the country. However, each case 
presents in a unique manner and management should be considered on an individual basis. To 
ensure that appropriate care is considered in all patients the NHS cancer plan in England and 
the Cameron report in Wales recommend cancer multidisciplinary team (MDT) meetings to 
discuss all lung cancer cases. (11) There are 156 MDTs in England and Wales.  
1.7.1 Understanding variation in lung cancer care 
 
Survival rates for lung cancer in the UK consistently lag behind other benchmarked countries. 
A European cancer registry based study (EUROCARE project) reported a five year survival 
of 9.72% in the UK and Ireland compared to 13.4% in central Europe for adults diagnosed 
between 2000 and 2002. (78) More recently, a study comparing lung cancer survival in six 
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developed countries between 2004 and 2007 found the age standardised one-year survival 
from NSCLC ranged from 30% in the UK to 46% in Sweden. Additionally, England fared 
worse than other countries in this study even after stratifying for stage as seen in Figure 1.7.
 
These results are a cause for concern and it is estimated that at least 1300 lives could be saved 
per year if survival rates were as good as the best in Europe. (79)  
 
Figure 1.7 Age standardised one-year net survival from NSCLC by stage at diagnosis 
(80) 
 
Some of the international variation seen in the aforementioned study may be due to 
differences in the collection and presentation of data. For example, ten of the countries 
involved in the EUROCARE project only used regional registries which do not represent the 
whole of the population. In addition., some national cancer registries (such as the 
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Scandinavian registries) do capture the whole population but do not include death certificate 
information. However, the consistency of international comparisons suggest that there are 
other contributory factors. (81) Firstly, national audit data from England and Wales show that 
over two thirds of patients present at an advanced stage. (82) Studies investigating reasons for 
this sugest that there is a delay in patients seeking attention from their GP from the onset of 
their symptoms. Additionally from the point of referral, delays in pathway speed in secondary 
care have been related to poor outcomes. (83) 
Secondly, understanding the characteristics of the population, such as the co-morbidities and 
performance status, is crucial in survival comparisons as they are key determinants of 
treatment choice and outcomes. However, even after accounting for case mix, there is still 
significant variation in outcomes. For example, the latest national lung cancer audit report 
showed that one year survival varies across various organisations from 27% to 49% after 
accounting for case mjx. (17) This suggests that differences in management of patients may 
contribute to such variation. This is demonstrated by the audit finding that in 2017, the 
curative intent treatment rate for patients with early stage NSCLC and a good performance 
status varied across organisations in England from 50% to 100%. (84)      
Finally, it has additionally been hypothesised that the organisation of lung cancer services 
impacts UK survival rates. (85) Preliminary analysis of the NLCA organisational audit found 
that patients seen in trusts in England with the following onsite facilities were more likely to 
have surgery after accounting for case mix: PET scan (OR 1.2, 95% CI 1.01-1.41), 
stereotactic radiotherapy (OR 1.55, 95% CI 1.26-1.92) or video assisted thoracoscopy (VAT) 
lobectomy (OR 1.28, 95% CI 1.06-1.56).   
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1.7.2 Initiatives to improve provision of lung cancer services 
In response to the need to improve national lung cancer outcomes, several initiatives have 
been established.  
The National Optimal Pathway is designed to improve local lung cancer organisation of    
services with the aim of achieving a faster pathway and better patient outcomes. (86) It 
provides clear guidance for commissioners such as the adoption of the following key features:  
i.) CXR to CT and clinic in less than 24 hours  
ii.) Rapid turnaround times for testing and reporting  
iii.) Daily respiratory clinic opportunities and  
iv.) Direct to biopsy option.  
A document that provides commissioning advice accompanies this pathway. This document 
recommends a list of resource metrics that can be used to benchmark a service. The 
widespread implementation of this pathway along with the commissioning guidelines is 
awaited. However, there is evidence that faster pathways influence patient outcome but robust 
evidence to underpin the recommendations in the commissioning guidance is lacking. (11,87–
89)  
1.7.3 Using population-based data to improve patient outcomes 
 
Local and national initiatives that change the organisation of lung cancer care have the 
potential to improve patient outcomes. However, good quality national data are required to 
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accurately assess the impact such programmes have on lung cancer outcomes.  The analysis of 
this data is vital in informing service development.  
In the UK, data collection is carried out by The National Cancer Registration and Analysis 
Service (part of PHE) and the National Lung Cancer Audit group (part of the Royal College 
of Physicians (RCP)).  
The National Lung Cancer Audit (NLCA) was developed in response to the finding in the late 
1990’s that outcomes for lung cancer patient in the UK lag behind those in other westernised 
countries and varied considerably between organisations. The NLCA attempts to address this 
performance gap by: i) the establishment of challenging standards for lung cancer 
management and ii) the collection of detailed data on lung cancer management and 
assessment of individual lung cancer units against these standards.  The audit began collecting 
national data in 2005 and it is the largest, most detailed lung cancer dataset in the world. The 
dataset has been shown to be unbiased and representative of lung cancer patients in England. 
(90) It currently forms part of the National Clinical Audit and Patient Outcomes Programme 
(NCAPOP) commissioned by the Healthcare Quality Improvement Partnership (HQIP). The 
data has been used to underpin National Institute for Health and Care Excellence (NICE) 
guidelines and guide national service improvement projects. Locally, it drives quality 
improvement programmes and opens discussions with health managers/commissioners. 
1.8 Conclusion 
For the last ten years, lung cancer is the biggest cause of cancer death in the UK. Despite, 
advances in diagnostics and therapeutic modalities survival, there has not been much 
improvement in the last fourty years and consistently lags behind other countries. (91) In 
addition. audit data shows significant national variation in survival outcomes which can not 
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be fully explained by patient level features such as age and performance status. Understanding 
the role of organisational and resource factors in determining lung cancer outcomes is key to 
understanding this variation and how improvements can be achieved. However, there is little 
data that examines the organisation of lung cancer services in the UK and robustly links this 
with patient outcomes; a knowledge gap that requires urgent attention.   
 
National publications have set out key priorities for commissioning patient centred services 
for people with lung cancer in the UK. This study aims to provide robust evidence to underpin 
future recommendations for a safe and effective lung cancer service. Commissioning services 
that are evidenced to achieve the best outcomes would result in a significant improvement in 
survival for people with lung cancer in the UK.  
1.9 Aims of thesis 
 
The overarching goal of this project is to identify the primary independent factors linking lung 
cancer management to outcomes. Defining these factors both locally and nationally will be 
critical in guiding policy and recommendations about the minimum resources required for a 
hospital to deliver a safe and effective lung cancer service. A chapter outline is described 
below 
 
1.9.1 Aim 1: Determine the optimum structure for cancer services in England 
Chapter 2: The impact of organisation of care on patient outcomes in lung cancer: A 
systematic review. 
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The objective of the first chapter is to report the current published evidence linking lung 
cancer service delivery interventions and patient outcomes by standard systematic review 
methodology. The aim is to identify the effectiveness and challenges of such interventions 
and generate a set of factors to benchmark services.  
 
1.9.2 Aim 2: Establish national variation of lung cancer services and explore the 
impact of specialist service delivery on lung cancer outcomes.  
Chapter 3: The second National Lung Cancer Organisational Audit: results and impact of 
organisation and specialist service delivery on lung cancer outcomes. 
This chapter describes the results of the second NLCA organisational audit performed in 2016 
and links the results with patient related data. This was done using the NLCA and associated 
datasets. There are three main objectives of the chapter. Firstly, to describe the national 
provision of diagnostic and treatment modalities. Secondly, to ascertain an accurate picture of 
speciality staffing provision in lung cancer units in England/Wales. Thirdly to identify 
primary independent factors linking lung cancer management to patient outcomes. The 
objectives were in part determined by the results from the systematic review. 
 
1.9.3 Aim 3: Investigate the uptake of treatment regimens and the corresponding 
survival outcomes for patients with Stage III NSCLC in England and examine 
the impact of hospital infrastructure on patient outcomes in this stage.  
Chapter 4: Management of Stage III NSCLC in England  
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In this chapter, treatment patterns and outcomes for stage III NSCLC patients in England are 
presented and are benchmarked against results from international population-based studies. 
The management of this diverse stage is complex and controversial reflected in international 
variability in treatment patterns and outcomes. (92) Therefore this stage was chosen to fill the 
knowledge gap between clinical trial data and clinical practice in the UK.  
1.9.4 Aim 4: Critically examine the process of local decision making with a 
focus on the MDT meeting in one hospital trust. 
Chapter 5: Decision making in lung cancer: A local qualitative study 
The variability of care across the country, even in areas where the classical evidence base is 
relatively clear, suggests that organisational factors not typically measured or reported in 
population-based studies might be impacting on choices made by MDT’s. The objective of 
the final results chapter is to describe these factors. This study investigates organisational and 
patient factors that influence decision making in lung cancer using qualitative methodology. 
The objective of this analysis is to provide multi-disciplinary recommendations to optimise 
the efficiency and effectiveness of a local lung cancer service organisation.  
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CHAPTER 2 THE IMPACT OF 
ORGANISATION OF CARE ON PATIENT 
OUTCOMES IN LUNG CANCER: A 
SYSTEMATIC REVIEW 
2.1 Introduction 
 
It is likely that the way health systems are organised contribute to patient outcomes; an aspect 
of healthcare that has been poorly investigated. (85) The following section discusses the 
importance of health systems research, gaps in the existing research and challenges to 
conducting such research.  
2.1.1 The importance of health systems research in lung cancer 
 
A working paper published by the World Health Organisation in 2012 recognised that health 
systems research is essential for achieving better worldwide health status. (93) The report 
estimates that two thirds of child mortality and three quarters of maternal mortality could 
potentially be eliminated if research on the effective implementation of existing interventions 
was completed. (93) 
Several initiatives in the UK, have been established to improve the delivery of lung cancer 
services, such as the “Independent Cancer Taskforce” and the lung cancer commissioning 
guidance. (11,94) Yet, little is known about how these strategies impact patients. The 
identification of best practice models that have been evidenced to improve outcomes for 
patients is vital for the patient, provider and health system.  
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For the patient, the identification of key organisational determinants of healthcare has the 
potential to reduce unwarranted national variation in care and consequently improve survival 
rates, symptom control and patient experience. For health care providers, awareness of models 
that have been shown to benefit patients is essential in ensuring the hospital infrastructure is 
sufficiently resourced. Not only does timely care confer benefit to the patient but also 
financial savings mean there are benefits to the health system as well 
2.1.2 Gaps in the existing lung cancer literature 
 
A European taskforce report investigating the quality of management in lung cancer care 
concluded that there is little research activity involving quality improvement in lung cancer. 
(95) They report that lives could be saved if models of healthcare evidenced to improve 
patient outcomes are applied to health systems. (95) However, robust information collating 
this information is sparse and reviews that have been published have generally examined only 
a single process of the lung cancer pathway such as timeliness of care or multidisciplinary 
aspects of lung cancer management. (96,97) Lung cancer patients require a co-ordinated and 
connected approach for optimal care, therefore a co-ordinated approach to research is also 
needed. A robust systematic synthesis of lung cancer health service delivery interventions is 
crucial in achieving this.  
In 2007, the Australian government published a review of models of best practice approaches 
to lung cancer care to inform future quality improvement activities. (98) They found the 
following important aspects of service delivery 1.) Involvement of an MDT 2.) Involvement 
of a specialist medical practitioner in diagnosis and treatment 3.) Care co-ordination including 
the role of nurse navigators/care co-ordinators 4.) Early integration of palliative care 5.) 
Consideration of supportive and quality of life needs and finally 6.) The involvement of 
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primary/community-based care. (98) Though this review provides a useful summary of the 
literature, the majority of the included studies examined data from nearly thirty years ago and 
several important changes to the practice of lung cancer care have since occurred. This 
includes the widespread use of PET scanning for staging, improvements in EBUS techniques, 
and novel therapeutic options e.g. immunotherapy and SABR.  
The previously mentioned European taskforce report also conducted a narrative literature 
search in lung cancer care performance. (95) Similar to the Australian study, they reported 
benefits to lung cancer patients with multidisciplinary team care, fast track clinics and lung 
cancer centres. (95) However, both reviews have two main limitations. Firstly, and 
importantly the impact on patient outcomes is lacking. Several interventions were described 
but not all associations with patient outcomes were reported. Secondly, systematic 
methodology was not applied. The Australian report limited their search to one database and 
neither conducted formal quality assessments. The incorporation of these techniques would 
enhance knowledge of the subject through increased article capture and precise evaluation of 
the methodological quality of the included articles.  
2.1.3 Challenges of conducting systematic reviews in health care service 
delivery 
 
The majority of published systematic reviews focus on estimating the effectiveness of 
therapeutic interventions, assessing the accuracy of diagnostic tests or quantifying 
epidemiological relationships. (99) Despite increasing interest in reviews concerning the 
organisation of healthcare, they are not as commonplace. Moreover, there is little guidance 
detailing optimal methodology. (99)  
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Challenges in conducting health system reviews contribute to this disparity. According to the 
Cooper model of research synthesis there are three stages of evidence synthesis: problem 
formulation, data collection and analysis with interpretation. (100) Table 2.1 summarises the 
challenges associated with each of these stages.   
Table 2.1 Challenges with conducting health system systematic reviews 
Systematic review stage Issues 
Research question 
formulation and inclusion 
criteria 
- Difficulty in clarifying the boundaries and 
characteristics of the study subject due to the complex 
and changing nature of health systems.  
Data collection - Lack of expertise and guidance 
- Relevant health system articles are poorly indexed by 
MESH terms 
- Time consuming: several searches are required to be 
performed and assimilation of background subject 
knowledge is required to ensure a comprehensive 
search strategy is performed. 
- Definitions of key concepts differ between articles 
Data synthesis and 
interpretation 
- Heterogeneity: studies tend to be heterogenous in 
study design, reported outcomes and quality.  
- Lack of standards in reporting and evaluating such 
studies 
- Dependent on context limiting generalisability and 
applicability.  
 
To address these challenges, a scoping review of the impact of service delivery on patient 
outcomes was performed with the aim of providing a more robust search strategy for the main 
review.  
2.1.4 Rationale of scoping review 
The primary aim of the scoping review is to uncover areas for improvement in the main 
review process. The five main reasons for this are summarised in Table 2.2. 
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Table 2.2 Rationale of scoping review 
Rationale Description Example Reference 
Theme 
identification 
The principles of health service 
design are likely to be 
generalisable. Therefore, 
highlighting themes in the general 
medical literature clarifies the 
final research question.  
Stroke medicine implemented a “door to needle time” for the timely 
administration of thrombolytic therapy, which led to a decrease in 
mortality and morbidity Subsequently, infectious diseases 
recommended a “door to needle time” of one hour for antibiotic 
administration in severe sepsis, which has also decreased patient 
mortality  
(101–103) 
The exploration 
of data bases 
Exploration of databases and 
thesauri optimises the search 
strategy 
Adequate understanding of terms that deliver relevant articles has 
been shown to improve the final search strategy.  
(103) 
Investigate 
established 
theoretical 
frameworks 
Uncovering established models on 
the subject aids search strategy 
development 
A review on “The Effect of Health Care Working Conditions on 
Patient Safety” adapted two identified models found in a scoping 
review describing the major characteristics of work environments to 
enhance capture in the main review. 
(104) 
Highlight 
heterogeneity in 
the research 
question 
Examination of study types and 
outcomes likely to result from the 
search demonstrates heterogeneity 
with the research question. 
This has been shown to aid quality assessment and inclusion criteria 
selection.  
(103) 
Facilitate 
discussion with 
the research 
team 
Expertise can be gained from the 
scoping review in formulating a 
robust methodology. 
Input from multiple specialist sources in a scoping review has shown 
to increase article capture.  
(103) 
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To fulfil the described benefits of a scoping review, the remit of the scoping review is broad. 
This will enable a process of scoping, piloting and refinement that has been previously used 
successfully. (103) The following section describes the methodology and results of the 
scoping review. This is followed by a discussion of how the results apply to the main review.  
 
2.1.5 A scoping systematic review on the impact of hospital resources and 
organisation of care on patient outcome 
 
2.1.5.1 Methods  
 
Standard systematic review methodology aimed at minimising bias was used, with reference 
to the Cochrane Handbook for Systematic Reviews of Interventions to identify articles 
reporting organisation of care interventions associated with patient outcomes. (105) 
 
2.1.5.1.1 Search Strategy 
 
The following databases were searched: MEDLINE (via Ovoid), Cochrane Library (Wiley) 
CENTRAL and PubMed. No language or date restrictions were applied. The full search 
strategy is shown in the appendix (A1). Additional studies were identified by review of 
reference lists of relevant publications and contact with field experts.  
 
2.1.5.1.2 Study selection criteria 
 
The selection criteria are summarised in Figure 2.1. 
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Figure 2.1 PICO chart detailing inclusion criteria for scoping review 
 
 
 
 
 
 
 
 
 
 
Articles were searched irrespective of clinical condition, patient population or specific 
outcomes to include a wide base of articles. Interventions conducted either exclusively in an 
outpatient, inpatient or across settings were included. Also included were other reviews where 
only a part of the review evaluated an intervention of interest. Studies where education was 
the main intervention or could not be separated were excluded. Titles and abstracts of studies 
were retrieved and screened independently by two reviewers (J.A and A.B) to identify studies 
potentially meeting the inclusion criteria. The full text was retrieved and assessed similarly 
(J.A and A.B), with any disagreement resolved by discussion. Additionally, the researchers 
met regularly to discuss specific articles. Figure 2.2 summarises the article selection process.  
 
Population 
Intervention 
Comparison 
Outcome 
Adults (≥18 years old) 
A component of healthcare delivery or organisation of care 
Provision of resources 
 
Usual care or comparatory stated in the results  
 
Any patient related outcome including (but not restricted to): 
mortality, length of stay, readmission rate, patient experience and 
disease outcomes 
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Figure 2.2 PRISMA flow diagram for scoping review 
 
 
2.1.5.1.3 Data extraction and assessment of bias 
 
The primary reviewer (J.A) used a standardised form to extract data including assessment of 
study quality, quality of evidence synthesis, study setting/population, details of the 
intervention, study methodology and outcomes. A second reviewer (A.B) checked and 
validated the extracted information.  
The evidence synthesis included a wide range of study designs, including systematic reviews 
and primary studies. Therefore, a single bias tool was not appropriate. The ROBIS tool was 
used for systematic reviews and the modified ROBINS I tool for other study designs. 
(106,107) These tools are discussed in greater detail in section 2.2.5.1.  
2.1.5.2 Results 
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Table 2.3 shows the characteristics of the 294 included studies. A summary of the study 
outcomes is shown in Table 2.4. Due to heterogeneity of studies in terms of subject area and 
outcomes, the data was suitable for narrative synthesis only. The following themes were 
identified: staff workload, specialist care, co-ordination of care, use of technology, home 
care/day case procedures and clinical pathways/record keeping. 
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Table 2.3a Table of characteristics of included observational studies in the scoping review 
Author 
Date 
Population Inclusion 
Criteria 
Participants Intervention Outcomes 
Price 
2003 (108) 
Units within the UK 
admitting medical cases. 
40 consecutive patients 
admitted with acute COPD 
cases. 
N= 7529 
7986 episodes of care from 
234 units.  
Demographics: not 
published.  
Organisational score 
Staffing levels 
Inpatient death within 90 days of admission: 
statistically significantly lower with increased 
medical staffing at all levels  
Length of stay: significantly decreased with 
greater number of respiratory consultants, 
EDS and local guidance on follow-up.  
Readmission within 90 days: nil significant 
Organisational score not significantly 
associated with any outcome.  
 
Ozdemir  
2015 (109) 
Patients in UK admitted 
with a ruptured AAA (ICD 
codes I713&I718) 
between 1/04/05-31/03/10 
identified by the HES data 
warehouse.  
N=9877 
From 153 trusts 
Mean Age (yrs.): 78 
Sex (male) n (%): 7310 (74) 
 
 
Staffing, physical hospital 
structure, use of radiology, 
teaching status of trust, 
weekend admission and 
critical care bed 
90-day mortality: significantly greater 
(multivariate analysis) with lower: consultant 
staffing, fluoroscopy use and nursing staffing. 
Greater if hospital had teaching status.  
Non-corrective treatment: significantly greater 
(multivariate analysis) with lower consultant 
staffing, & nursing staffing; hospital status 
and weekend admission.  
Roberts 
2003 (108) 
All acute hospitals in 
England and Wales 
N= 1274 
From 30 hospitals 
Hospital type, staffing, 
speciality of staff, 
Death within 90 days: Significantly greater 
for less medical staff availability; decreased 
proportion of physician estimated proportion 
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Cases of acute COPD 
(physician made 
diagnosis) admitted to 
hospital identified 
prospectively over 8 
weeks. 
Mean age: (yrs): 72.1 
Sex (male), n (%): 716 (56) 
Mean FEV1, n, (% 
predicted): 405 (41%) 
availability of NIV. of patients cared for by respiratory specialists; 
non-availability of NIV.  
  
Jarman 1999 
(110) 
All NHS hospitals in 
England.  
Patient discharged with a 
primary diagnosis that is 
one of the diagnoses 
accounting for 80% of 
inpatient deaths. In 1991-
1992 & 1994-1995.  
183 trusts with 7.7 million 
admissions.  
Demographics not included.  
Discharge, hospital and 
community independent 
variables. Relevant variables 
include medical and nursing 
staffing levels, bed 
availability, teaching status, 
provision of specialist units.   
Hospital standardised mortality ratios: 
Statistically significantly associated with 
lower number of doctors per 100 hospital 
beds, lower number of GP’s per 100,000 
population, increased reported number of 
grade A nurses.  
Hannan 
1989 (111) 
Patients discharged in 
1986 from an acute care 
facility in New York State 
following a surgical 
procedure.  
N=48139 
No demographic published.  
Hospital volume, physician 
volume.  
In hospital mortality: Five procedures have a 
significant relationship: total 
cholecystectomies, coronary artery bypass 
surgeries, resection of abdominal aortic 
aneurysms, partial gastrectomies and 
colectomies.  
Sequeiros 
2010 (112) 
(Conference 
abstract only) 
All patients with a 
pulmonary exacerbation of 
CF referred to the CF 
MDT at a single UK 
hospital site.  
N=58 
Reported demographics: No 
differences in age, gender or 
baseline spirometry. 
Baseline BMI significantly 
higher in the new home 
service.  
Hospital care vs home care 
with intensive treatment by 
MDT vs standard home 
care.  
FEV1 and BMI improved significantly in 
hospital/standard home care group. 
Time to next pulmonary exacerbation similar 
in all groups.  
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Table 2.3b Table of characteristics of included systematic reviews in the scoping review 
Author 
Date 
Study Inclusion Criteria Participants Intervention Outcomes 
Aubin 2012 
(113) 
RCT, CCT, Controlled before 
and after studies.  
>50% of participants in the 
study were adults with cancer.  
51 studies 
29 RCT’s and 2 CCT 
N= 28-1388 
 
An intervention designed to 
improve the continuity of 
care for cancer patients. E.g. 
case management, shared 
care and interdisciplinary 
team models.   
Physical/functional/psychological health, 
satisfaction and global quality of life:  no 
significant difference in median effect sizes 
between patients assigned to the intervention vs 
usual care.  
Ellis 2017 
(114) 
Randomised controlled trials.  
65 years old or older who are 
admitted to hospital for acute 
care or inpatient rehabilitation 
with medical, psychological, 
functional or social problems.  
29 RCT’s 
N=13,766 
Comprehensive geriatric 
assessment on wards or by 
mobile teams which 
included: tailoring plans to 
individual, MDT meetings, 
providing clinical leadership, 
involving patients and carers 
in goal setting.  
Living at home at 3-12 months: RR 1.06 (95% 
CI: 1.01-1.10; n=6799) 
Mortality at 3-12 months: RR 1.11 (95% CI: 
0.93-1.07; n=10023) 
Admission to a nursing home at 3-12 months: 
RR 0.80 (95% CI: 0.72-0.89; n=6285) 
Dependence: 0.97 (95% CI: 0.89-1.04; n=6551) 
 
McGaughey 
2007 (115) 
All patients who deteriorated 
on general adult wards in 
hospital 
2 cluster RCTs The implementation of 
outreach using an EWS in an 
acute hospital setting to 
identify deteriorating patients 
versus a general ward-based 
care approach with no EWS 
and outreach.  
Composite outcome (Incidence of unexpected 
cardiac arrest, death and unplanned ICU 
admissions): adjusted OR=0.98 (95% CI: 0.83-
1.16, p=0.640) 
Mortality: Priestly study: OR= 0.52 (95% CI: 
0.32-0.85 ); MERIT study: OR= 1.18 versus 
1.06 per 100 admission, adjusted p=0.752)  
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Flodgren 
2015 (116) 
Randomised controlled trials.  
Patients receiving interactive 
telemedicine from a HCP 
versus usual care.  
93 RCTs Telemedicine used in direct 
patients care. Including face 
to face/telephone 
consultations.  
All-cause mortality at median of 6 months 
follow-up: RR (95% CI): 0.89 (0.76-1.03); 
n=5239. 
Admission to hospital at median follow-up 8 
months: RR: 0.36-1.60; n=4529 
Disease specific quality of life: Median 
difference -4.39 (-7.94 to -0.83), p=0.02 at 
median 3 months. N=482. 
 
Gillaizeau 
2013 (117) 
RCTs, non RCT’s, controlled 
before and after studies, 
interrupted time series 
analyses.  
Health care professionals with 
responsibility for patient care 
42 studies 
40 RCTs and 2 non 
RCT’s 
Computerised advice on drug 
dosage versus routine care.  
Proportion of people with drug plasma 
concentrations in the therapeutic range after 2 
days: pooled RR 4.44 (95% CI: 1.94-10.13) for 
aminoglycoside antibiotics.  
Time for studies physiological parameter 
maintained in target range. SMD ((5% CI) for 
INR (Warfarin): +0.19 (0.06-0.33) and glucose 
(Insulin):  +1.27 (0.56-1.98) 
Time to achieve therapeutic control for oral 
anticoagulants: SMD (95% CI): -0.56 (-1.07 to 
-0.04)  
Proportion of people with toxic drug levels: 
VTE for oral anticoagulants: Rate ratio (95% 
CI): 0.68 (0.49-0.94)/Bleeding events 0.81 
(0.60-1.08). Nephrotoxicity in aminoglycoside 
antibiotics: RR (95% CI): 0.67 (0.42-1.06) and 
CMV infection with anti-rejection drugs: 0.90 
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(0.58-1.40) 
Mortality or clinical adverse event for Insulin, 
anaesthetic agents, anti-rejection drugs and 
antidepressants: no difference 
Length of stay:  SMD (95% CI): -0.15 (-0.33-
0.02) 
Rotter 2010 
(118) 
RCTs, CCT, controlled before 
and after studies and 
Interrupted time series.  
Hospitalised patients (inpatient 
and outpatient settings) with 
conditions managed on a 
clinical pathway (CPW), 
irrespective of diagnosis.    
27 studies 
19+ RCTs; 4 CBA; 2 
CCT, 2 ITS.  
N=11,398 
Clinical pathways versus 
usual care including clinical 
pathways used as part of a 
multi-faceted intervention.  
In hospital complications: OR (95% CI): 0.58 
(0.36-0.94) 
LOS: 11 out of 15 studies showed significant 
reduction in LOS. (Data could not be pooled 
due to heterogeneity).  
In patient mortality: OR (95% CI): 0.84 (0.61-
1.11) 
Hospital readmission: OR (95% CI): 0.60 (0.32-
1.13) 
Urquhart 
2009 (119) 
RCTS, Controlled before and 
after studies, ITS 
Patients receiving care 
recorded or planned using 
nursing record systems.   
9 trials 
8 x RCTs, 1 
controlled before and 
after study.  
N=1846 
Nursing record system in 
hospital, community or 
primary care setting.  
Client held records vs patient held (3x studies): 
no significant difference in all clinical outcomes 
Paper records vs a different structure (2x 
studies): Pain management study: improvement 
in pain scores using flow sheet (p<0.01); 
Integrated record study: higher accuracy of 
planned LOS when using planning forms 
(p=0.02).  
Manual nursing care planning with 
computerised nursing care planning: (1x study): 
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No significant difference in clinical outcomes 
 
Lawrence 
2015 (120) 
Randomised Controlled Trials 
People with age related 
cataracts.  
2 x RCTs 
 
Cataract extraction and IOL 
implantation done as day 
cases compared to inpatient 
cases.  
Best corrected visual acuity 6/18 or better in 
operated eye four months postoperatively: 
Mean change: 4.1, p=0.74.  
Post-operative complications. Castells study: 
(Intra-ocular pressure >30 mmHg): RR (95% 
CI): 3.33 (1.21-9.16). Galins study: none 
Quality of Life: Mean change of VF14 scores 
(25.2 in day case vs 23.5 for inpatient, p=0.30).  
Stroke Unit 
Trialists 
2013 (121) 
Randomised controlled trials 
People admitted to hospital 
who had suffered a stroke 
(excluding subarachnoid 
haemorrhage and subdural 
haematoma).  
28 RCT’s 
N=5855 
Organised inpatient (stroke 
units) care providing multi-
disciplinary staffing 
delivering a complex 
package of care to stroke 
patients in hospital compared 
to an alternative service.   
Mortality: OR (95% CI): 0.81 (0.69-0.94), 
p=0.005.  
Death of institutionalised care: OR (95% CI): 
0.78 (0.68-0.89), p=0.0003.  
Death or dependency: OR (95% CI): 0.79 
(0.68-0.90) 
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Table 2.4 Summary table of outcomes of included studies in the scoping review 
 +: positive association reported; NA: No association found; NR: Not reported 
 
  
  ASSOCIATION  
THEME Disease Area Survival Treatment 
rates 
Patient 
reported 
outcomes 
Reduced 
healthcare 
utilisation 
INCREASED 
STAFF/BED 
COPD + + NR + 
 All hospital 
admissions 
+ NR NR NR 
 AAA + NR NR NR 
 Lung Cancer NR + + NR 
SPECIALIST 
CARE 
Surgical 
procedures 
+ NR NR NR 
 Stroke units + NR + + 
 Lung Cancer + + + + 
CO-
ORDINATION 
OF CARE 
Cancer  NR NR NA NA 
 Acute care NA NR NR NA 
 Elderly care NA NR NA + 
 Lung Cancer NA + + NR 
CLINICAL 
PATHWAYS 
All hospital 
patients 
NA NR + + 
RECORD 
KEEPING 
All patients in 
hospital, 
primary care 
or community 
NA NA + + 
USE OF 
TECHNOLOGY 
Heart failure NA NR + NR 
 Diabetes NR + NR NR 
 Lung Cancer NR + NR NR 
HOME CARE Cataract 
surgery 
NR NA NA NA 
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2.1.5.2.1 Staff workload 
 
Four studies investigated the relationship between staff workload (staff/bed) and patient 
outcome. (122)(108)(110)(109) Two (where one was a pilot for the other) used retrospective 
audit data in patients with chronic pulmonary obstructive disease (COPD), (122)(108) and 
two used  national datasets. (110)(109) All demonstrated a significant relationship between 
hospital staffing workload and mortality.  
In COPD the authors also demonstrated that the percentage of patients staying in hospital over 
seven days decreased with greater number of respiratory consultants (>2: OR 0.67, 95% CI: 
0.60-0.98 compared to <1.6); presence of an early discharge scheme (OR 0.69, 95% CI 0.60-
0.81) and local guidelines for follow-up of COPD (OR 0.84, 95% CI 0.72-0.98).(108) Similar 
findings were not reproduced with general medical staff at senior or junior level suggesting 
that it is not only staffing numbers that is important, but also their speciality.  
A large study of national datasets reviewing 7.7 million hospital admissions in England over 
four years, (110) incorporated numerous independent variables in a weighted linear regression 
analysis to predict hospital standardised mortality ratios. They found a key predictor of 
mortality was the ratio of hospital doctors to beds (regression co-efficient: -0.47; 95% CI: -
0.64 to -0.30; p <0.001).  
Ozdemir et al reviewed mortality rates in 9877 patients admitted with a ruptured abdominal 
aortic aneurysm (AAA) over a five-year period from 153 trusts, categorising  into high, 
expected and low mortality trusts. (109) Low mortality trusts had a significantly greater mean 
number of staff per bed (doctors: 0.922 versus 0.513, p<0.001; consultants: 0.316 versus 
0.168, p<0.001; nurses: 2.341 versus 1.770, p<0.001) compared to high mortality trusts.  
52 
 
2.1.5.2.2 Specialist care 
 
Two studies explored the impact of specialist care. (111,123) Hannan et al investigated the 
hypothesis that hospitals and doctors that have a high degree of specialisation, as determined 
by case volume for a specific procedure, are associated with better outcomes. (111) The 
authors studied the number of times five specified surgical procedures were performed by the 
same surgeon in any hospital in one year (n= 48,139 patients). They found that higher 
physician volume was significantly associated with lower inpatient mortality rates for the 
following procedures: coronary artery bypass, aneurysm resections, partial gastrectomies and 
colectomies.  
The existence of specialised units has also been shown to improve care in stroke as 
demonstrated by a Cochrane review comparing inpatient stroke unit care with an alternative 
service. (123) The review reported a significant reduction in several outcomes: death 
(unadjusted OR 0.76, 95% CI 0.66-0.88, p=0.0001); death/institutional care (unadjusted OR 
0.76, 95% CI 0.67-0.86), p=0.0001) and death/dependency (unadjusted OR 0.80, 95% CI 
0.67-0.97), P=0.00001).  
2.1.5.2.3 Co-ordination of care 
 
Three Cochrane  reviews (46 included studies) were identified investigating how the co-
ordination of care affects outcomes for patients. (113–115) Respectively, they examined care 
across a cancer pathway, in an acute setting and chronic condition (frailty).  
Two interventions were not beneficial, (113,115) although disparities in study designs, 
settings and outcomes limit the confidence in this conclusion. One review (n=51 studies) 
investigated how interventions designed to improve the continuity of care for cancer patients 
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(including case management, shared care and interdisciplinary team models) impacted patient 
health (physical/functional health and quality of life). (113) No significant difference was 
reported in the median effect sizes for the patient health outcomes between the interventions 
versus usual care group.   
The other review (n=2 studies) that reported no conclusive improvement in outcome, 
evaluated the implementation of an outreach team using a ‘Early warning system’ (EWS) in 
an acute hospital setting on hospital mortality, unanticipated ICU admissions, ICU admission, 
length of stay and adverse events in patients on general hospital wards. (115)  
The third review (29 RCTs, n=13766 patients) assessed how introducing specialist co-
ordinated care known as ‘Comprehensive Geriatric Assessment’ (CGA) impacted on patient 
outcomes (mortality, likelihood of living at home and dependence). (114)  CGA includes a 
ward/mobile team that tailors treatment plans to the individual and MDT meetings. They 
found that CGA increases the likelihood patients will be living at home at 3 and 12 months 
(RR 1.06, 95% CI: 1.01-1.1.0, 6799 participants). However, there was no significant 
difference in mortality.  
2.5.5.2.4 Clinical Pathways and Record Keeping 
 
A Cochrane review (27 studies) evaluating the impact of clinical pathways found a decrease 
in hospital complications (pooled OR 0.58 (95% CI 0.36-0.94)) compared to usual care but no 
difference in patient mortality or hospital readmission. (124) Eleven out of 15 studies that 
looked at length of stay as an outcome, reported a significant reduction. Urquhart et al 
investigated the effects of nursing record systems on patient outcomes. (119) Four (n=491) 
out of 5 (n=795) studies that examined patient related outcomes found no significant 
difference, however there were some reports of improved patient satisfaction.  
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2.5.5.2.5 Use of Technology 
 
Two Cochrane reviews evaluated the use of technology to improve patient outcomes. 
(116,117) Flodgren et al investigated the impact of patients receiving care from a health care 
professional via telemedicine. Meta-analysis was possible in the studies involving heart 
failure patients (n=16, 5239 patients) and diabetic patients (n=16, 2768 patients). For heart 
failure patients, there was no significant difference in all-cause mortality but some evidence 
of improved quality of life (n=482; MD -4.39, 95% CI -7.94 to -0.83, p<0.02) for those 
allocated to telemedicine compared to usual care at a median of three months follow-up. In 
the studies involving diabetic patients, there was better diabetic control in the telemedicine 
group defined by a lower glycated haemoglobin level at a median of nine months (MD -0.31, 
95% CI -0.37 to -0.24; p<0.00001).  
The other review investigated the use of a computer programme to generate advice on drug 
dosage on drug or disease specific outcomes. (117) A variety of drugs were evaluated with 
some evidence for increased therapeutic availability of certain drugs. For example, there was 
increased time that a patients’ INR/glucose was in the desired range (SMD +0.19, 95% CI 
0.06 to 0.33 for INR; +1.27, 95% CI 0.56 to 1.98 for glucose).  
2.5.5.2.6 Home care and day case procedures 
 
Lawrence et al (2 studies) showed no impact of day care versus inpatient surgery for age 
related cataract on visual acuity, risk of post-operative complications and quality of life. (120)  
Home treatment was not shown to be beneficial in a single site case control study that looked 
at the outcome of patients with cystic fibrosis treated for a pulmonary exacerbation in a home 
setting (with or without intensive MDT input) or in hospital. (112) The hospital group 
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demonstrated significant improvements in FEV1 and body mass index (BMI) measures than 
the home group with MDT input.  
2.5.5.2.7 Risk of Bias 
 
The risk of bias across all the included observational studies was high and is summarised in 
Table 2.5a. Details of attrition and reporting bias were unclear mainly due to poor reporting. 
Table 2.5b summarises the risk of bias for the systematic reviews. Overall, all the studies had 
a low risk of bias having followed Cochrane methodology.  
Table 2.5 Assessment of risk of bias tables in included studies in the scoping review 
Table 2.5a Assessment of risk of bias in included cross sectional observational studies  
Study Confou
nding 
Selection 
Bias 
Misclassifi
cation 
Bias 
Performance 
Bias 
Attrition 
Bias 
Detec
tion 
Bias 
Repo
rting 
Bias 
Ozdemir 
2015 
Moderat
e 
Moderate High High Moderate High  Uncle
ar 
Price 
2006 
High High High High Unclear High Uncle
ar 
Roberts 
2003 
High High high High Unclear High High 
Jarman 
1999 
High High high High High High High 
Hannan 
1989 
Unclear High High High Unclear High Uncle
ar 
Sequerio
s 2010 
Unclear High High Unclear Unclear High High 
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Table 2.5b Assessment of risk of bias in included systematic reviews 
Study Study 
Eligibility 
criteria 
Identification 
and Selection 
of studies 
Data 
collection 
and study 
appraisal 
Synthesis 
and findings 
Risk of 
bias 
Aubin 2012 Low Low Low Low Low 
Ellis 2017 Low Low Low Low Low 
McGaughey 
2007 
Low Low Low Low Low 
Flodgren 
2015 
Low Low Low Low Low 
Gillizeau 
2013 
Low Low Low Low Low 
Rotter 2010 Low Low Low Low Low 
Urquhart  Low Low Low Low Low 
Lawrence 
2015 
Low Low Low Low Low 
Stroke Unit 
Trialists 2013 
Low Low Low Low Low 
 
2.1.5.3 Discussion 
 
To my knowledge this is the first systematic scoping review of the delivery of healthcare 
across a broad range of settings. The literature highlighted the following themes: staff 
workload, specialist care, co-ordination of care, use of technology, home care/day case 
procedures and clinical pathways/record keeping. The most robust literature implies that 
specialist staffing and co-ordination of care may be important determinates of patient 
outcomes.  
The primary aim of the scoping review was to uncover areas for improvement in the main 
review process. The following three lessons are highlighted.  
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2.1.5.3.1 Data collection was an iterative process 
 
Several searches and changes to searches with the involvement of experts in literature 
searching were required. The thesauri of various databases were studied to identify 
appropriate subject terms likely to identify relevant articles. Small changes in wording of 
terms raised vastly differing search outputs. The WHO paper on issues related to health 
systems research illustrate this in a search for the term “health systems research”. (93) 192 
citations are revealed in MEDLINE, of which approximately half are based in Canada. 
However, the term “health services research” appears 37,894 times, of which half of the 
corresponding authors are in the United States or UK. (93) Similarly, the search of the term 
“Delivery of Health Care” in MEDLINE discovered 82,524 results. Whereas searching 
“Organisation of Health Care” showed 78 results.  
Two further techniques were required to ensure a comprehensive search strategy: free text 
searching and snowballing. The initial search results were scanned by the team for relevance. 
On further discussion, relevant articles not captured were highlighted. Therefore, the key 
words from these articles were examined and incorporated as free text into the search strategy. 
In addition, the references of papers were scanned for further sources.  
2.1.5.3.2 The search refined the inclusion/exclusion criteria 
 
A total of 765377 studies were found using an initial search strategy but after several 
modifications to the strategy the number of studies was reduced to a manageable number. The 
majority of articles were excluded due to inappropriate intervention or outcomes. This process 
clarified the boundaries required for the main review. For example, many studies examined 
the impact of adherence to treatment guidelines on patient outcomes. Discussion amongst the 
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research team concluded that this revealed little about optimal models of service delivery 
given that such guidelines are well established and accepted as ‘gold standard’ care. 
Additionally, several epidemiological studies used data from the early 1990’s. The 
management of lung cancer has changed considerably since this time and its findings are 
likely to be irrelevant to modern practice. Consequently, a date restriction from 1
st
 January 
2000 onwards was applied. Lastly, publications from a variety of countries resulted from the 
search. A key purpose of the main review is to apply the findings to the delivery of lung 
cancer services in the UK. Therefore, the results were restricted to countries where the 
management of lung cancer is comparable to the UK such as Australia, Canada, United States 
and Western Europe.  
2.1.5.3.3 The scoping review demonstrated heterogeneity in study intervention, results and 
design.  
 
Firstly, the importance of a clear definition of the intervention was highlighted by the 
included Cochrane review examining the impact of a comprehensive geriatric assessment 
(CGA) in older adults admitted to hospital. (114) The authors report variation in the 
interpretation of the definition of CGA. One trial defined CGA as a specialist medical and 
mental health unit. Whereas, in another study CGA was described as an elderly care physician 
reviewing cases at the point of discharge. This limited interpretation of results.  
Therefore, a model of the intervention for the main review was formulated by the research 
team to guide the search strategy and clarify the inclusion criteria. After a search of the 
literature for an established framework, an adaptation of the model of care described by the 
previously mentioned Australian publication was developed. (98) The final definition of a 
lung cancer service delivery model was: “A multifaceted concept which defines the way lung 
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cancer care is delivered including the roles, structure for the delivery of health services and 
co-ordination of care”.    
Secondly, the boundaries of included interventions were explored. For example, an important 
component of health systems research is cost effectiveness. However, due to resource 
limitations this was considered to be out of the remit of this review. Similarly, to increase 
applicability to a hospital setting and limit the variability in studied interventions, 
interventions that occurred before the point of referral were not included (for example 
screening trials and community lung cancer awareness programmes).  
Heterogeneity in results highlights that a structured approach to analysis is required to enable 
meaningful interpretation of the data. Established methods of evidence synthesis centre on 
synthesising randomised controlled trials. However, the majority of data collected in the 
scoping review was observational in nature in keeping with most health systems research. 
(125) Qualitative and quantitative data were included in the results, therefore an approach to 
joint synthesis that considers differing interventions is required. A summary of the main 
methods of joint synthesis are considered in Table 2.6. 
Table 2.6 Summary of approaches to joint synthesis of qualitative and quantitative 
evidence (125) 
Method Description Strengths Limitations 
Narrative 
summary 
Narrative description with 
commentary and interpretation 
Good for large 
evidence base with 
diverse evidence types 
Allows flexibility 
Dependent on 
reviewer judgement 
No published standard  
Thematic 
analysis 
Identification of major recurrent 
themes: a summary of findings 
under thematic headings 
Flexible approach 
Good for diverse 
evidence type 
 
Mainly descriptive 
based on the themes 
and may overlook 
contradictions between 
themes 
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Content 
analysis 
Evidence from each study coded 
under thematic headings and 
occurrences of each theme 
counted and tabulated 
Incorporated diverse 
evidence types 
May overlook the 
context of the data 
Over-emphasis on 
frequency 
 
The included studies could easily be categorised by subject therefore, a thematic analysis was 
conducted. This allowed identification of themes likely to also be important in the main 
review and incorporated as terms into the search strategy. However, it is recognised that 
despite several search iterations and expert input, the number of resulting number of articles is 
unlikely to represent a comprehensive review of the literature with several relevant articles in 
a specific disease area not being captured. That being said, the conclusions are in keeping 
with previous similar reviews, adding validity to the results. (126) 
Finally, heterogeneity in study design meant a single risk of bias tool was not appropriate. 
Several tools were evaluated as part of the scoping review and will be discussed in section 
2.2.5.1. The ROBIN I tool was found to be the most appropriate for the included primary 
studies. The assessment process of the studies in the scoping review led to the development of 
a modified ROBIS I tool. Specific judgement criteria were also created aimed at improving 
transparency and reducing judgement variability between reviewers. The modified tool and 
judgement criteria are shown in the appendix (A2). 
 
2.1.5.4 Conclusions 
 
A broad review of the medical literature highlights key organisational factors that impact on 
patient outcomes. Application of these themes and lessons learnt from the conduct of the 
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scoping review is likely to improve the quality and capture of the main review which will now 
follow  
2.1.6 The impact of organisation of care on lung cancer patient outcomes: A 
systematic review 
 
2.1.6.1 Aims and Objectives 
 
The aim of this review is to explore the association between lung cancer service delivery 
interventions with patient outcome in order to identify the effectiveness, benefits and 
challenges of such interventions. This is to provide evidence about best practice approaches 
for commissioners and health policy makers. The specific objectives are: 
1.) What initiatives/models have been established which aim to improve the delivery 
of care for patients (in the UK and other comparable countries) referred for the 
investigation of symptoms of lung cancer?  
2.) What are the characteristics of lung cancer service delivery interventions that have 
improved patient outcomes? 
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2.2 Methods 
 
Standard systematic review methodology was used with reference to the Cochrane Handbook 
for Systematic Reviews of Interventions. (105)  
 
2.2.1 Criteria for considering studies for this review 
 
The selection criteria are summarised in Figure 2.3.  
Figure 2.3 PICO chart detailing inclusion criteria for the systematic review  
 
2.2.1.1 Types of studies 
 
This review considered randomised controlled trials, all types of observational studies (that 
included over one participant), systematic reviews (where at least one database was searched) 
and qualitative studies. Narrative reviews, commentaries, non-human/laboratory studies and 
Population 
Intervention 
Comparison 
Outcome 
Adults (≥18 years old) referred for the investigation of lung cancer 
in the UK or comparable countries 
An initiative or characteristic of lung cancer service delivery aimed 
to improve the delivery of care for patients with lung cancer 
Usual care or comparatory stated in the results  
 
Patient level outcome 
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single case reports were not considered.  Conference abstracts or reviews were only included 
if a full report was found. Studies published in the English language were considered.  
2.2.1.2 Types of participants 
 
Studies were included if the participants were over the age of 18 and referred for the 
investigation of lung cancer.  
2.2.1.3 Types of Interventions 
 
Any type of intervention that aimed at investigating a specific aspect or structural 
characteristic of the delivery of care for lung cancer after the point of referral to a specialist 
for management or diagnosis was considered. This included studies that studied a specified 
intervention as well as studies that described the impact of different existing organisation of 
care models on patient outcomes.  
A definition of a model of lung cancer service delivery was developed from the scoping 
review as defined in section 2.1.5.3.3  
Key elements of service-based interventions were informed by the scoping review and 
provide guidance to the types of interventions included. This encompassed (but were not 
restricted to): the care delivery process, case management, staffing profile, communication 
structures, MDT working, interdisciplinary care, care co-ordination, proximity to care and 
timeliness of care.  
For relevance, studies were considered if the intervention was conducted in the UK or 
comparable countries including New Zealand, Australia, Canada, USA or western Europe.  
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A key aim was to collate evidence on how service interventions directly impact patients. 
Results from the scoping review highlighted boundaries which are listed below. Studies 
where the focus (or could not be separated) from the following were excluded.  
1.) Education aimed to alter patient/staff behaviour  
2.) Informing clinical practice guidelines or treatment regimens 
3.) Assessing the uptake or impact of existing guidelines 
4.) Continuing professional education 
The comparator group could be usual care, or another intervention in equivalent settings.   
2.2.1.4 Outcomes 
 
The following outcomes were identified as important in the scoping review: survival, patient 
experience, timeliness of care and treatment rates. Therefore, these patient related outcomes 
were the primary focus of the review. Studies investigating cost effectiveness were out of the 
scope of the review.  
2.2.2 Search methods for identification of studies 
 
The following databases were searched for articles: MEDLINE (via Ovoid), EMBASE 
(Wiley) CENTRAL, Cochrane Library (Wiley) CENTRAL and PubMed. A full search 
strategy is included in the appendix (A3). Electronic reference databases were searched using 
a combination of Medical Subject Health (MeSH) terms, free text and key words. Articles 
were included if published between 1 January 2000 - November 2018, in English and 
available in full text.  
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Hand searching, citation checking and snowballing search strategies were also used. 
Extensive searches of national and international websites, review of reference lists of relevant 
publications and contact with field expert were conducted.  
2.2.3 Study selection 
 
Titles and abstracts of studies were retrieved using the search strategy and screened 
independently by four review authors (J.A, A.T, SK and C.G) to identify studies that meet the 
inclusion criteria outlined in Figure 2.4. The full text of potentially eligible studies was 
retrieved and assessed for eligibility by two reviewers Disagreement regarding study inclusion 
was resolved by discussion between the research team.  
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Figure 2.4 PRISMA flow diagram for the systematic review  
 
2.2.4 Data extraction  
 
The primary reviewer (J.A) used a standardised form developed from the results of the 
scoping review to extract data from the primary studies. Extracted information included 
assessment of study quality, setting and population. In addition, details of the intervention, 
study methodology and outcomes were documented. Three reviewers (A.T, CG, A.B) 
checked and validated the extracted information. Any discrepancies identified were resolved 
through discussion.  
2.2.5 Assessment of Risk of bias 
2.2.5.1 Selection of risk of bias tools 
 
A wide range of study designs were included as found in the scoping review. Pubmed and 
Google Scholar were used to search for relevant tools. The ROBIN-I tool was used in the 
Records identified 
through database search, 
(n=3,087) 
Records screened by title 
and abstract,  
(n=3,101)) 
Full text articles assessed 
for eligibility 
(n=172) 
Included studies=85 
Additional records 
through reference 
searching (n=14)) Records excluded  
(n=3,028) 
Full text articles excluded  
(n=87) 
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scoping review to assess applicability for non-randomised studies and the Cochrane Risk of 
Bias tool was used to assess randomised controlled trials.  
The majority of studies assessing the impact of the organisation of care are non-randomised 
studies based on real world evidence. (107) This is for three reasons. Firstly, service delivery 
interventions are complex and consist of several components that can be applied and assessed 
in several ways. Secondly, interventions need to be in place over a long period of time during 
which the usual management of the studied condition is carried out, before an accurate 
assessment can be made. Finally, linked databases and electronic health records represent 
large population cohorts in the investigation of organisational interventions.  Therefore, a 
randomised design, in this context, may not be feasible or reflect clinical practice. Moreover, 
it may be unethical, expensive and time consuming.  
An evaluation of the risk of bias in non-randomised studies needs to acknowledge inherent 
flaws with this design and can adequately deal with confounding in different contexts, 
populations, comparators and follow-up times. The ROBINS-I tool is the most comprehensive 
tool for non-randomised studies evaluating the effects of healthcare interventions. (107) Other 
tools (such as the Newcastle-Ottawa tool/SIGN tool/Downs Black tool) that have been 
designed for observational studies, focus on the methodological quality (such as the accuracy 
of the results or applicability) of the study rather than the internal validity. (107,127) These 
tools are often used to assign an overall score to the study. This can be misleading in 
observational studies, because a critical weakness in a certain type of bias can be left 
unidentified through reporting of a composite score. Therefore, more recently published tools 
advocate a structured approach to the assessment of risk of bias where each type of bias is 
considered independently. The ROBINS-I tool is the only tool that uses this approach in non-
randomised studies. Additionally, it specifically addresses the risk of bias occurring when 
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there is no control for factors that may affect the outcome other than the intervention. 
Therefore, the ROBINS- I tool was chosen to assess the observational studies included in the 
scoping review and subsequently modified to meet the needs of this review.  
The Cochrane Risk of Bias tool was chosen for included randomised controlled trials for two 
reasons. (105) Firstly, this tool has been used successfully in the literature examining 
healthcare interventions in RCT’s because it allows judgements to be used as to whether a 
confounding factor is likely to have affected the results. In this review a variety of 
interventions are considered. Therefore, flexibility to apply consideration to how a risk of bias 
domain applied to that outcome is important. Secondly, guidance is available from the 
Cochrane Effective Practice and Organisation of Care Group on how to use this tool and make 
judgements consistently.  
2.2.5.2 Risk of bias assessment 
 
The above tools were applied to all included studies by the primary reviewer (J.A). This was 
independently assessed by four second reviewers (A.T, C.G, SK and A.B) with any 
discrepancies resolved through discussion.
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2.3 Results 
 
A total of 3,087 references were identified from searching the electronic databases.  After an 
initial screen by title/abstract and removal of duplicates, 158 studies met the inclusion criteria. 
Full text copies of 157 studies (full text was not able to be obtained for one study) as well as 
14 studies identified through reference searching were reviewed. 87 studies were excluded at 
this stage because the selection criteria were not met. This was mainly because the 
intervention or population was inappropriate. Therefore, a total of 84 articles were included in 
the final analysis.  
2.3.1 Study Design 
 
Figure 2.5 graphically demonstrates the distribution of studies by study design. All but 4 
(95%) studies were observational with over half (54%) being cohort design.  
Figure 2.5 Number of studies by study design 
 
70 
 
2.3.2 Geographical distribution 
 
The geographical distribution of the included studies is shown in Figure 2.6. Approximately 
half (49%) of the studies are from the USA. The second most frequent country (21%) is the 
UK.  
Figure 2.6 Number of studies by country 
 
2.3.3 Study time frames 
 
The majority of studies were retrospective in nature using data ranging from 1985 to 2017. 
Approximately one third of studies (34%) included data from the nineties. The management 
of lung cancer in the UK has changed since this era and this should be taken into account 
when interpreting the results.  
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2.3.4 Results by study theme 
 
The literature describes a range of interventions employed to improve access and delivery of 
care to patients referred for the investigation of a diagnosis of lung cancer. Two major themes 
were identified: Specialist care and the co-ordination of care. The subthemes associated with 
each theme are detailed in Table 2.7. The following section reports the results of each theme.
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 Table 2.7 Components of study themes 
THEME/SUBTHEME Number of 
studies 
Number of 
patients 
Intervention Comparator 
SPECIALIST CARE  
Hospital volume 23 954,709 High volume hospitals Low volume hospitals 
Surgeon procedure volume 3 58,387 High volume surgeons Low volume surgeons 
Surgeon speciality 4 119,495 Thoracic surgeons General/cardiac surgeons 
Hospital teaching status 4 84,340 Teaching hospital Non-teaching hospitals 
Specialist centre 10 607,215 Specialist centre Non-specialist centre 
Site of care 8 99,651 Low travel burden High travel burden 
Specialist staff 6 192,336 Seen by specialist staff Not seen by specialist staff 
Staff workload 3 109,711 Low staff workload High staff workload 
CO-ORDINATION OF CARE  
MDT meetings 9 >19,232 Discussed at an MDT 
meeting 
Not discussed at an MDT 
meeting 
MDT clinic 4 >1345 Managed in an MDT clinic Not managed in an MDT 
clinic 
Rapid diagnostic programme 
(RDP) 
7 779 Managed on an RDP Not managed in an RDP 
Care Co-ordination programme 
(CCP) 
7 >11269 Managed on a CCP Not managed on a CCP 
OTHERS 
Patient led care 2 3125 Patient led care Usual care 
Nurse led follow-up 1 203 Nurse led follow-up Usual care 
Technology based interventions 3 566 Use of technology Usual care/different 
technology 
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2.3.4.1 The impact of specialist care 
 
The impact of specialist care was the focus of 61 studies in total. These studies were 
categorised into eight subthemes: The impact of 1.) Annual hospital volume 2.) Annual 
surgeon procedure volume 3.) Surgeon speciality 4.) Hospital teaching status 5.) Specialist 
centres 6.) Site of care 7.) Specialist staff and 8.) Staff workload. Each subtheme will be 
discussed in turn with results presented in table format.  
2.3.4.1.1 Hospital volume – outcome relationship 
 
23 studies (n= 954,709 patients) examined the hypothesis that hospitals that have a high 
degree of specialisation determined by case volume are associated with better patient 
outcomes. 21 studies investigate the hospital volume-outcome relationship after lung cancer 
resection reporting differing survival outcomes. (128–147) Table 2.8 summarises the 
outcomes for these studies of which 15 (65%) were conducted in USA.  
All studies were observational in nature with only one study based on clinical data. (132) The 
remaining were based on administrative data. The number of patients and hospitals varied 
widely. In all studies the results were adjusted for case mix, but the variables used differed. 
Similarly, there was variability in cut off values describing hospital volume categories. Cut 
off values tended to be based on splitting volume into equal groups and further rationale was 
unclear in the papers. 
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Table 2.8 Outcomes for studies investigating the hospital volume-outcome relationship in patients undergoing surgical resection for lung 
cancer  
Author/country Data source Data 
year 
No 
patients 
No 
hospitals 
Volume 
categories 
(cases/year) 
Outcome 
High volume Centre (HVC) compared to low volume centre 
(LVC) 
Bach et al 
USA (128) 
SEER database 
(only >65 years) 
1985-
1996 
2116 76 1-8;9-14;15-
19;20-66;67-100 
30-day mortality: 3% vs 6% 
5-year mortality: 56% vs 67% 
Adjusted 30-day mortality OR: 0.48, p<0.001 
Adjusted HR for overall survival: 0.77, p=0.003 (LVC reference) 
Birkmeyer et al 
USA (140) 
Medicare and NIS 
database 
1994-
1999 
85,973 2753 Unclear 30-day mortality: 4.2% vs 6.4% 
Adjusted operative mortality OR for lobectomy: 0.70 (95% CI 0.60-
0.81) (LVC reference) 
Adjusted operative mortality OR for pneumonectomy: 0.62 (95% CI 
0.50-0.77) * 
Cheung et al 
USA (141) 
Florida Administrative 
Database 
1998-
2002 
13,469 13469 Unclear 30-day mortality: 1.6% vs 2.7%, p<0.001 
90-day mortality: 4% vs 7.5%, p<0.001 
5-year mortality: 59.3% vs 63.5%, p=0.002 
Adjusted HR: 0.93 (95% CI 0.879-0.992), p=0.027 (LVC reference) 
Hannan et al 
USA (142) 
New York State 
administrative database 
1994-
1997 
32,000 178 Unclear Absolute difference in mortality: 1.7% 
Observed mortality rate: 1.86% vs 3.05% 
Risk adjusted inpatient mortality in LVC 1.65% higher than in HVC 
(p=0.006) 
Luchtenborg et 
al 
UK (148)  
Hospital Discharge 
Data and National 
Cancer Data 
2004-
2008 
134,293 83 <70; 70-99;100-
129;130-149; 
≥150 
Overall mortality HR: 0.78 (95% CI 0.67-0.90), p<0.01 (LVC 
reference) 
30-day mortality: 0.58 (95% CI 0.38-0.89), p=0.07 
1-year mortality 0.80 (95% CI 0.67-0.95), p=0.01 
>1-year mortality 0.84 (95%CI 0.71-0.99), p=0.10 
Stukenborg et al 
USA (143) 
California State 
Hospital Discharge 
data 
1996-
1999 
14,456 330 Unclear In hospital mortality OR: 0.76 (95% CI 0.64-0.90), (LVC reference) 
No significant association if volume expressed as a continuous 
variable 
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Lieberman-
Cribbin et al 
USA (144) 
New York State 
administrative database 
1997-
2011 
28,471 NR <=7.75;7.76-
16.59;16.60-
39.59;>39.59 
Mean patient risk estimate for mortality: (+/-SD): 0.027 (+/- 0.028) 
vs 0.035 (+/- 0.034) 
  
Moller et al 
UK (139) 
Hospital discharge data 
and national cancer 
registration data 
2006-
2010 
15,738 
(NSCLC)  
152 
(primary 
care 
trusts) 
1-75;77-
112;114-
155;156-
186;189-287 
30-day mortality: 0.5% vs 1.0%, p=0.01 
90-day mortality: 2.2% vs 3.1%, p=0.02 
 
Tchouta et al 
USA (146) 
Administrative 
database (HCUP/NIS) 
(Robotic VAT 
lobectomy) 
2008-
2013 
8,253 NR 1-3;4-6;7-
14;>=15 
 
Adjusted OR for mortality: 0.134, p<0.001, (LVC reference) 
 
David et al 
USA (138) 
California Cancer 
Registry 
2004-
2011 
7587 
(Stage I 
NSCLC) 
>50 <20;20-50;>50 
 
Adjusted overall HR for survival (HVC reference): 1.777 (95% CI 
1.474-2.141) 
Better cancer specific survival for HVC (log rank test, p<0.0001) 
Park et al 
USA (149) 
HCUP/NIS 
(VATS procedures) 
2008 6,292 
 
NR <20;>20 
 
No significant difference in in hospital mortality 
 
Urbach et al 
Canada (147) 
National database for 
Ontario 
1994-
1999 
5156 54 (Average) 
18.2;45;86;129.4 
No significant difference in risk of death or adjusted relative risk of 
death 
Pezzi et al 
USA (130) 
National Cancer 
Database 
2007-
2011 
124,418 1233 <=32;33-85;86-
130;>=131 
 
30-day mortality: 1.7% vs 3.7%, p<0.05 
90-day conditional mortality: 2.2% vs 2.9%, p<0.05 
Adjusted OR for 30-day mortality: 2.1 (95% CI 1.7-2.6), reference 
HVC 
Adjusted OR for 90-day mortality: 1.3 (95% CI 1.2-1.5), reference 
HVC 
Finlayson et al 
USA (131) 
NIS 1995-
1997 
21,890 674 (Average) 
<19;19-27;>37 
 Adjusted OR for inpatient mortality for lobectomy: no significant 
difference 
Adjusted OR for inpatient mortality for pneumonectomy: no 
significant difference 
Freixinet et al 
Spain (132) 
Multicentre 
prospective data 
1993-
1997 
2994 19 1-43;44-54;>=55 No significant difference in overall adjusted 30 day or 5-year 
mortality  
Simunovic et al 
Canada (133) 
Ontario Cancer 
Registry 
1990-
2000 
2698 67 <=32;33-85;86-
130;>=131 
 
Inpatient operative death: 5.8% vs 2.4% 
In hospital adjusted operative mortality OR: No significant 
difference 
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Long term patient survival HR for LVC (reference HVC): 1.3 (95% 
CI 1.1-1.6), p<0.01 
Sioris et al 
Finland (134) 
National cancer 
registries 
1998-
2002 
4878 26 0-4;5-10;11-
20;>20 
Adjusted OR for inpatient mortality: no significant difference 
Adjusted OR for cancer survival for HVC: 0.8 95% CI (0.7-0.9), 
p=0.01 (reference LVC) 
Adjusted OR for overall survival for HVC: 0.8 (95% CI 0.8-0.9), 
p=0.01(reference LVC) 
Hollenbeck et al 
USA (135) 
HCUP-NIS 1993-
2003 
90,088 NR Unclear Operative mortality: 2.7% vs 4.9%  
Adjusted operative mortality OR: 1.4 (95% CI 1.2-1.7), p<0.05 
Li et al 
Netherlands 
(136) 
Amsterdam Cancer 
Registry 
1998-
2003 
1591 20 <40;40-59>=60 5-year mortality HVC vs LVC: 50% vs 53% 
HR for mortality for HVC: 1.18 95% CI (0.88-1.60) 
Birkmeyer et al 
USA (129) 
SEER, Medicare/NIS 1992-
2002 
4325 407 <9;9-17;18-
27;28-46;>46 
 
5-year survival HVC vs LVC: 37.5% vs 43.5% 
Adjusted HR for death for HVC: 0.83 (95% CI 0.78-0.89) reference 
LVC 
Adjusted HR for death for those surviving the perioperative period 
for HVC: 0.83 (95% CI 0.77-0.90), reference LVC 
Bilimoria et al 
USA (137) 
NCDB 1994-
1999 
40,754 1528 <21;>83 60-day mortality HVC vs LVC: 5.5% vs 6.4%, p<0.05 
5-year overall survival HVC vs LVC: 36%, 32.7%, p<0.05 
5-year conditional survival HVC vs LVC: 38.1% vs 35%, p<0.05 
Adjusted perioperative HR for death for LVC: 1.31 (95% CI 1.14-
1.51), p<0.0001 (reference HVC) 
Adjusted 5-year HR for death for LVC: 1.09 (95% CI 1.04-1.14), 
p<0.0001 (reference HVC) 
Adjusted conditional 5-year HR for death for LVC: 1.06 (1.01-
1.12), p=0.018 (reference HVC) 
SEER=Surveillance Epidemiology and Ends Results Cancer Registries; NIS: National Inpatient Sample Database; HCUP: Healthcare cost and utilisation 
project; NSCLC: Non-small cell lung cancer; VATS: Video assisted thoracoscopic surgery; OR: Odd ratio; HR: Hazard ratio; * Statistically significant result 
favouring HVC 
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Twelve studies conclude that patients in hospitals with higher procedure volumes have 
significantly lower mortality. (128–130,134,137–142,146,148) These studies estimate a 
decrease in 30-day mortality rates of between 0.5%-3% between the highest and lowest 
volume centres.  
Bach et al used Surveillance Epidemiology, and End Results (SEER) Program data linked to 
Medicare hospitalisations and the Nationwide Inpatient Sample data and examined 2118 
patients over the age of 65 with NSCLC from 1985-1996. (128) The authors divided volume 
into five groups and used survival models to examine the association between hospital 
volume and survival. They found a 30-day mortality of 3% vs 6% favouring high volume 
centres (HVC). This paper was the first to report longer term survival with improved 5-year 
mortality of 56% in high volume centres (HVC) compared to 67% in low volume centres 
(LVC).  
The following year (2002) Birkmeyer et al and Hannan et al published findings on the 
volume-outcome relationship. (140,142) Birkmeyer used Medicare claims and National 
Inpatient Sample (NIS) data to examine 8 different major cancer resections from 1994 to 1999 
including 75,563 patients undergoing lobectomy of the lung and 10,410 pneumonectomies.  
They divided volume into quintiles and found that the odds of death in those undergoing a 
lobectomy at a high volume hospital were 30% less likely (OR: 0.70, 95% CI: 0.60-0.81) as 
an inpatient compared to those being operated on in a low volume centre when adjusted for 
age >75 years, female sex, black race, non-elective admission and Charlson co-morbidity 
score of ≥3 and 38% less likely for pneumonectomy (OR: 0.62 (95% CI 0.50-0.77)). In 2007 
the authors published a further paper using the same data bases and found that HVC had 
better 5 year survival (adjusted HR for mortality for HVC: 0.83 (95% CI: 0.78-0.89).(129) 
For the subgroup of patients surviving the perioperative period, HVC’s remained significantly 
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associated with better survival (adjusted HR for mortality for HVC: 0.83 (95% CI 0.77-0.90)). 
Bilmoria et al replicated these findings in 2008 (adjusted conditional 5-year HR for LVC: 
1.06 (95% CI 1.01-1.12), p=0.018). (137) It is notable that the longer-term survival outcomes 
reported by Birkmeyer and Bilmoria are modest in comparison to the perioperative outcomes.  
Cheung et al added further long term outcome data to the literature with their findings 
examining 13,469 patients undergoing lung resection in the state of Florida using an 
administrative database. (141) A decrease in 30-day mortality of 1.1% for high volume 
centres was reported and this effect was sustained at 90 days (mortality rate for HVC (1
st
 
tertile) vs LVC (3
rd
 tertile): 7.5% vs 4%, p<0.001) and 5 years (63.5% vs 59.3%, p=0.002).  
More recent publications (2013 onwards) quote modest reductions in 30- and 90-day 
mortality rates compared to the earlier studies. (130,139) UK based study by Moller et al 
quote a 30-day mortality rate decrease of 0.5% and 90 day of 0.9%. (139)   
Several of the studies present findings as adjusted odd ratios of early post-operative death. 
(128,130,131,140,143,146) Quoted figures vary from 0.13 by Tchouta et al to 0.70 by 
Birkmeyer et al favouring HVC’s. (140,146) However, comparison of odds ratios in studies 
that have different methods of categorising hospital volume should be undertaken with 
caution. In addition, it should be noted that Tchouta et al investigated 8,253 patients 
undergoing robotic video assisted thoracoscopic (VAT) operations rather than all resections 
for lung cancer. (146) 
Stukenborg et al demonstrates the issue of arbitrarily defined hospital volume categories in 
their examination of 40,460 lung resections performed at 436 hospitals in 2007 using NIS 
data and three different methods. (143) They found a statistically significant relationship for 
hospital volume when they were categorised into quintiles (In hospital mortality OR: 0.76 
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(95% CI 0.64-0.90), LVC as reference), but this did not hold true when expressed as a 
continuous variable or expressed using restricted cubic spline regression. The authors 
concluded firstly, that hospital lung cancer volume is likely not to be associated with 
mortality; secondly, that the most important predictors of mortality are patient characteristics 
such as age and co-morbidities and the contribution of hospital volume to the association is 
relatively small and finally, that the magnitude of the impact of hospital volume is dependent 
on how volume is defined and entered into the logistic regression model. Their comparison of 
three techniques advocates the analysis of hospital volume as a nonlinear function using 
restricted cubic spline regression.  
Seven studies did not find that high volume hospitals were associated with better outcomes. 
(131–133,136,143,147,149) Finalyson et al compared inpatient mortality for eight cancer 
resections including pulmonary lobectomy and pneumonectomy. They found a significant 
reduction in the unadjusted mortality risk for lobectomy in HVC of 1.2% compared to LVC 
(categorised as tertiles) but not for pneumonectomy. This association did not remain 
statistically significant after risk adjustment. The authors highlight that their results are based 
on patient level information from the NIS database only where long-term outcomes are not 
reported. This is also noted to be the case for two further studies that did not demonstrate a 
significant association. (135,149) 
Two studies reporting non-significant results did report long term outcomes. (132,136) 
Firstly, Freixinet and colleagues report 30 day and 5-year mortality in a Spanish multicentre 
prospective study of 2994 cases. They found no difference in adjusted overall operative 
mortality between the hospital volume tertiles at either time point. (132) Secondly, similar 
results were published by Li et al for 5 year mortality rates ((50% (HVC) vs 53% (LVC)) and 
hazard ratio for mortality for HVC (1.18, 95% CI: 0.88-1.60).(136) This study was unique on 
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two accounts. Firstly, it was the only study that did not categorise volume by number of 
operations but by the number of newly diagnosed NSCLC cases at each centre. Secondly, the 
authors investigate the impact of hospital volume on receipt of treatment, finding that the 
odds of receiving a surgical resection at an HVC were increased by 58% compared to those at 
a LVC (adjusted OR: 1.58 (95% CI: 1.07-2.35), p<0.05).  
One study found surgery in HVC did not have a significant influence on the odds of inpatient 
operative death for lung cancer resections but the risk of long term death was increased for 
LVC (HR 1.3 (95% CI 1.1-1.6), p<0.01). (133) However, statistical significance was not 
maintained when the analyses were restricted to patients where pathology data was available. 
Paradoxical results were reported by a Finnish study using national registries from 1998-2002 
categorising volume into quartiles. (134) Sioris et al found that very low volume hospitals (0-
4 operations per year) had better cancer specific and overall survival compared to high 
volume hospitals (adjusted odds ratio for HVC for:- cancer survival 0.8 95% CI:0.7-
0.9),p=0.01; overall survival 0.8 (95% CI 0.8-0.9),p=0.01) but there was no significant 
difference in adjusted analyses for inpatient mortality. The authors state that many resections 
in this very low volume category occurred in private hospitals suggesting that other factors 
are likely to influence the relationship. Finland has a health system that is publicly funded 
with a small private sector similar to the UK.  
Six studies examine outcomes other than mortality including complication rate, readmission 
risk and length of stay. (128,135,139,144,146,149) These outcomes are summarised in Table 
2.9. Bach et al reports lower complications rates at HVC compared to LVC which supports 
their hypothesis that the postoperative course at LVC is more complex. (128) This hypothesis 
is given further weight by a lower readmission risk at 30 and 90 days reported by Moller et al 
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(30-day readmission risk 19% vs 22%, p for trend=0.08;90 day readmission risk 44% vs 
47%,p<0.0001) and shorter length of stay (9.35 days compared to 9.82 days at LVC) by 
Tchouta et al (adjusted OR for length of stay: 0.2 (SE: 0.05), p<0.001) and Park et al (shorter 
length of stay in HVC by 0.9 days ((+/- 0.4), p=0.001) at HVC compared to LVC. 
(139,146,149) However, two studies found no significant difference for complication rate 
(144,146) and one study for length of stay between the two groups. (135) 
Two studies investigated the hospital volume- outcome relationship amongst a non-surgical 
population. (150,151) Goyal et al conducted a retrospective study of 338, 445 stage IV 
NSCLC patients diagnosed between 2004-2014 using the US National Cancer Database. 
(150) The authors categorised hospital volume into quartiles based on the total number of 
patients with stage IV NSCLC treated at an institution. They found an unadjusted survival of 
6 months in the quartile 1 (LVC) compared to 8 in quartile 4 (HVC), p<0.001. In an adjusted 
analysis, patients treated at lower volume facilities had a significantly higher risk of death 
(HR for LVC: 1.1 (95% CI 1.10-1.12), reference HVC). The paper concludes that there may 
be a small advantage to being treated at an HVC for patients with Stage IV NSCLC. 
The second study is a UK based study primarily investigating LCNS working practices. The 
authors presented results on the association between annual service volume and receipt of 
cancer specific treatment (surgery, chemotherapy and radiotherapy). (151) They found that 
compared to caseloads of <175 new lung cancer patients seen per year that volumes of 175-
264 or ≥265 patients/year was not significantly associated with improved receipt of treatment. 
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Table 2.9 Table of studies examining the relationship between hospital volume-
healthcare utilisation for lung cancer resections 
Study Healthcare utilisation outcome 
Bach et al (128) Complication rate for HVC vs LVC: 20% vs 44%, p<0.05 
Liebermann-
Cribbin et al (144) 
Risk estimate for the highest volume quartile vs lowest volume quartile 
(SD): 
- For complications: 0.247 (0.082) vs 0.241 (0.084) 
- For long length of stay: 0.454 (0.151) vs 0.506 (0.139) 
Moller et al (139) For HVC compared to LVC: 
- 30-day readmission risk: 19% vs 22%, p for trend=0.08 (HVC 
compared to LVC) 
- 90-day readmission risk 44% vs 47%, p<0.0001 
- Average length of stay: 9.35 days vs 9.82 days. Linear 
regression of log transformed difference for length of stay: 0.3 
days, p (gradient)=0.004 
Tchouta et al (146) Adjusted OR for length of stay: 0.2 (SE: 0.05), p<0.001 
No significant difference for complication rate 
Park et al (149) Multivariate analysis, shorter LOS by 0.9 days (+/-0.4), p=0.001 for 
HVC 
Hollenbeck et al 
(135) 
Long length of stay for HVC vs LVC: 7.8% vs 13.7% 
Adjusted OR for long length of stay: 1.3 (1.0-1.6) 
HVC: High volume centre; LVC: Low volume centre; SD: Standard deviation 
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2.3.4.1.2 Impact of Surgeon procedure volume 
 
Studies investigating the hospital volume relationship propose that the outcome of a 
procedure for lung cancer is likely to depend on how well that operation is performed which 
in turn is determined by the experience of the operating surgeon. (129,132)  
Three studies (n=58,387 patients) were identified investigating the impact of surgeon 
procedure volume for patients undergoing lung cancer resections with mixed results presented 
in Table 2.10. (140,142,152) 
The most recent study by Smith et al uses the SEER registry linked to Medicare to examine 
2295 patients with Stage I NSCLC over the age of 65 undergoing a VATS procedure for lung 
cancer. (152) Although the authors do not report the cut-off points to define their surgeon 
volume tertiles, they conclude that patients undergoing VATS by high volume surgeons 
(HVS) experience improved overall and lung cancer specific survival when adjusted for 
patient and surgical confounders. (Overall adjusted mortality for HVS (reference LVS): HR 
0.70 (95% 0.58-0.84); Lung cancer specific adjusted mortality for HVS (reference LVS): HR 
0.71 (95% CI 0.53-0.95)). In addition, they found that patients operated on by HVS had 
decreased odds of ICU admission (adjusted OR: 0.68 (95% CI 0.53-0.87)) or having a 
complication (adjusted OR 0.84 (95% CI 0.73-0.97) compared to low volume surgical groups 
(LVS). However, after adjustment for patient and surgical characteristics having a specific 
complication (including extrapulmonary, cardiovascular, thromboembolic, respiratory), 
receiving a transfusion or being admitted within 30 days was not significantly associated with 
surgeon volume.  
In contrast Birmeyer et al and Hannan et al do not find that surgeon volume on its own is a 
significant predictor of mortality. (140,142) Hannan et al found that the adjusted mortality of 
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patients in the LVS group was 1.12% higher than in the HVS group but this did not reach 
statistical significance (p=0.08). (142) However, the correlation between hospital volume and 
surgeon volume is high (r=0.76, p0.0001). Birkmeyer additionally demonstrated a statistically 
insignificant association between surgeon volume and mortality with an adjusted odds for 
postoperative death for LVS of 1.24 (95% CI 1.08-1.44; reference HVS). (140) However, 
they go further to demonstrate that much of the observed association is contributed by 
hospital volume. When the OR is adjusted for hospital volume, significance is attenuated 
(adjusted OR of operative death for LVS: 1.16 (95% CI 0.99-1.36); reference HVC). They 
estimate that approximately one third of the effect of the association of surgical volume with 
mortality is attributable to hospital volume 
.
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Table 2.10 Studies examining the impact of surgeon procedure volume in lung cancer resection patients 
Study Data 
source 
Data 
year 
Number 
of 
patients 
Number 
of 
surgeons 
Volume 
categories* 
Outcome 
High volume surgeons (HVS) compared to low volume surgeons 
(LVS) Low  High 
Hannan et 
al 
USA (142) 
Admin 1994-
1997 
6954 373 1-22 >131 Inpatient mortality rate for HVS vs LVS: 1.80% vs 2.56% 
Relative risk adjusted inpatient mortality rate (reference HVS): 1.12 
(p=0.08) 
Birkmeyer 
et al 
USA (140) 
Admin 1998-
1999 
24092 4178 <7 >17 Adjusted OR of operative death with LVS: 1.24 (95% CI 1.08-1.44), 
reference HVS 
Adjusted OR of operative death for LVS adjusted for hospital 
volume: 1.16 (95% CI 0.99-1.36), reference HVS 
Smith et al 
USA (152) 
Admin 2000-
2010 
2295 512 NA NA Overall adjusted mortality for HVS (reference LVS): HR 0.70 (95% 
0.58-0.84) 
Lung cancer specific adjusted mortality for HVS (reference LVS): 
HR 0.71 (95% CI 0.53-0.95). 
*Number of procedures performed by a surgeon/year 
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2.3.4.1.3 The impact of surgeon speciality 
 
Studies have noted not only the importance of the volume of procedures a surgeon conducts 
but also the specialist training of that surgeon. The impact of whether a surgeon is trained in 
general surgery (GS), cardiac surgery (CS) or thoracic surgery (TS) is the subject of four 
identified articles (n=119,495 patients) and summarised in Table 2.11. (153–156) 
The method in which surgeons were designated a specialty differed between the studies. 
Surgeons that appeared on the American Board of Thoracic surgeons list and did not perform 
any cardiac procedures were designated thoracic surgeons in two studies. (153,155) Whereas 
Ellis et al split surgeons into three groups based on the percentage of their total case volume 
spent doing general thoracic surgery, cardiac surgery or any other type of surgery. (156) 
Finally, Martin- Ucar et al studied the impact of adding a speciality trained surgeon to the 
staff in a before and after, single institution study based in the UK. (154) In this study the 
authors report a threefold increase in resection rate in histologically confirmed NSCLC cases 
(12.2% to 23.4%, p<0.001). In addition, the resections that were being done were more 
complex. However, this increase in resection rate did not result in improved operative 
mortality or 1- or 5-year survival rates.  
Three studies found that resections performed by thoracic surgeons were associated with 
improved survival. (153,155,156) Goodney et al report a reduction in adjusted operative 
mortality of 2% for TS compared to GS (p<0.001). (153) Ellis et al report that the odds of in 
hospital death are increased by 47% for resections performed by GS compared to operations 
by TS (In hospital mortality risk (OR): GS: 1.47 (95% CI: 1.14-1.90), p=0.003)). (156) 
Finally, Farjah et al demonstrate that operations by TS have a 17% and 9% lower hazard of 
death compared with operations by GS and CS patients, respectively, after adjusting for 
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patient and disease characteristics. (155) Adjusting for hospital features as well resulted in a 
reduction of 11% for TS compared to GS, but differences between GTS and CTS or CTS and 
GS were no longer significant (adjusted HR of death for GS (0.89 (0.82-0.97), reference TS).   
Two studies examined the hypothesis that the difference found in mortality and morbidity 
rates with CTS compared to GS is contributed by the completeness of intraoperative 
oncological staging (155,156). 
Ellis et al examined the NIS database and found TS performed lymphadenectomy with lung 
resection in 72.8% of patients compared to GS (55.1%) and CS (54.1%), p<0.0001). (156) 
The authors also examine the impact of case volume and found that surgeons that had greater 
case volumes were more likely to perform a lymphadenectomy. When thoracic surgical case 
volume was introduced into the adjusted model the effect of speciality was no longer 
significant highlighting the importance of case volume.  
In addition to higher lymphadenectomy rates for TS, Farjah et al proposed that the higher use 
of PET and minimally invasive procedures conducted by TS compared to CS and GS 
contribute to improved outcomes. (155) 
88 
 
Table 2.11 The impact of surgeon speciality on patient outcomes 
Study Data 
source 
Data 
year 
Number 
of 
patients 
Speciality 
designation 
Outcome 
 
Goodney et 
al 
USA (153) 
Admin 1998-
1999 
25,545 Board 
certification 
Adjusted operative mortality: 7.6% for GS; 5.6% for TS; 5.8% for non-cardiac surgeons. 
P=0.001 
Martin-
Ucar et al 
UK (154) 
Clinical 1994-
1999 
2,891 Before and 
after 
Resection rate before vs after appointment of TS: 12.2% vs 23.4% (p<0.001) 
No significant difference for in-hospital mortality or 1- and 5-year survival before and after 
appointment of CTS.  
Ellis et al 
USA (156) 
Admin 1998-
2007 
222,233 Case mix Lymphadenectomy rate: TS 72.8%, GS: 55%, CS: 54%, (p<0.0001) 
Mediastinoscopy rate: TS: 15.8%; GS: 10.9%, CS: 9.6% (p<0.0001) 
In-hospital mortality odds (OR): GS: 1.47 (95% CI 1.14-1.90), p=0.003); CS: 1.50 (95% CI: 
1.18-1.91), p<0.001. (reference TS) 
Risk of complications (OR): GS: 1.16 (95% CI 1.00-1.35), p=0.04, (reference TS).  
Farjah et al 
USA (155) 
Admin 1992-
2002 
19,745 Board 
certification 
Use of PET: TS: 36%; GS: 26%, CS: 26%, p=0.005) 
Lymphadenectomy rate: TS: 33%; GS: 11%; CS: 22%), p<0.001.  
Adjusted HR of death for GS: 0.89 (95% CI 0.82-0.97), reference TS 
HR for death did not vary significantly for CS vs GS or TS vs CS.  
Adjusted operative mortality, tracheostomy, reoperation, LOS, discharge to institutional care 
facility and readmission did not vary significantly by surgical speciality.  
GS: General surgeon; TS: Thoracic surgeon; CTS: Cardiothoracic surgeon 
89 
 
2.3.4.1.4 The impact of hospital teaching status 
 
Four studies (n=84,340 patients) explore the hypothesis that the teaching status of an 
institution significantly affects mortality in lung cancer resection patients with differing 
results. (133,134,141,157) 
The definition of what constitutes a teaching hospital varied and is shown in Table 2.12. 
Three showed that teaching status positively influenced survival with the remaining study 
showing no significant difference. (134,141,157) 
In 2008, Meguid et al (n=47,364) published results from examination of the NIS database 
revealing that the odds of death were reduced by 17% in hospitals with a teaching status (OR: 
0.83 (95% CI: 0.73-0.93), p=0.002. (157) This was corroborated by Cheung and colleagues 
the following year who showed a reduction in 30-day mortality by 1.5% (p<0.001) favouring 
teaching hospitals. (141) They also demonstrated similar reductions for longer term outcomes 
(90-day mortality for TH vs NTH: 6.8% vs 3.8%, p<0.001; 5-year mortality: 63.9% vs 
59.2%). In contrast a study conducted in Finland using data from national registries (n=4878) 
found that surgery conducted in a university hospital was not significantly associated with in 
hospital mortality in multivariate analysis. (134) However, it was a significant positive 
predictor of cancer survival and overall survival. A Canadian study of 2698 patients showed 
no significant association with short- or long-term mortality rates. (133) 
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Table 2.12 Studies examining the impact of hospital teaching status 
Study Data 
source 
Data 
year 
Number 
of 
patients 
Number 
of 
hospitals 
Definition of teaching status Outcome 
 
Simunovic 
et al 
Canada 
(133) 
Admin 1990-
1993 
2698 67 Hospital affiliated with a medical school Adjusted odds for operative death for NTH: OR 1.4 (95% 
CI 0.8-2.5), p=0.27, reference TH 
Adjusted odds for long term survival for NTH: OR 1.1 
(95% CI 1.0-1.3), p=0.10, reference TH 
Cheung et 
al 
USA (141) 
Admin 1998-
2002 
13,469 190 Recognition as a teaching institution by 
Association of American Colleges 
30-day mortality rate for NTH vs TH: 2.6% vs 1.1%, 
p<0.001 
90-day mortality rate for NTH vs TH: 6.8% vs 3.8%, 
p<0.001 
5-year mortality rate for NTH vs TH: 63.9% vs 59.2%, 
p=0.005.  
Mean survival time for NTH vs TH: 40.5 months vs 47.1 
months 
Meguid et 
al 
USA (157) 
Admin 1998-
2004 
46,951 3210 Hospitals that have residency training 
approval, belong to the Council of Teaching 
Hospitals or have a ratio of no more than 4:1 
bed to WTE interns/residents. 
In hospital death for NTH vs TH: 4.0% vs 3.2%, p<0.001 
Adjusted odds of death for TH: 0.83 (0.73-0.93), 
p=0.002, reference NTH 
Sioris et al 
Finland 
(134) 
Admin 1998-
2002 
4878 26 Tertiary hospital responsible for training of 
medical students and specialists in medicine. 
30-day mortality rate was not significantly associated 
with hospital university status 
Adjusted odds of cancer related death in non-university 
hospitals: OR 1.3 (1.1-1.5), p=0.01, reference university 
hospital 
Adjusted odds of overall survival in non-university 
hospitals: OR 1.3 (1.1-1.5), p=0.01, reference university 
hospital 
NTH: Non-teaching hospital; TH: Teaching hospital; OR: Odds ratio; WTE: whole time equivalent  
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2.3.4.1.5 The impact of a specialist centre 
 
The influence of a specialist setting on patient outcomes is examined by ten studies 
(n=607,215 patients) and summarised in Table 2.13. (136,151,158–165) Specialist centres 
were defined as 1.) Surgical centres 2.) Centres providing anticancer treatment and 3.) Centres 
designated as comprehensive cancer centres by the National Cancer Institute in the USA. Four 
studies examined mortality (136,161–163,165) with two showing improved survival rates 
favouring specialist centres. (161,163). All but one study (136) found improved treatment 
rates. 
Four (151,158–160) of the five (151,158–160,162) UK based studies used NLCA data in 
cross sectional epidemiological studies to examine the impact of surgical centres. Firstly, Rich 
et al found that after adjustment for patient factors, patients with NSCLC who are first seen in 
a thoracic surgical centre are 50% more likely to have surgery than those first seen in a non-
surgical centre. (158) This finding is supported subsequently by Lau et al who found the 
resection rate in hospitals where surgeons are based are 8.4% higher than in peripheral 
hospitals (p<0.001). (160) In addition, Khakwani et al report similar results using data over 
four years (2008-2012), including 95,818 patients. (159) They find that the odds of a surgical 
resection are increased by approximately 37% for patients first seen in a centre where thoracic 
surgeons are based compared to non-surgical centres (OR: 1.37 (95% CI 1.29-1.45)). Stewart 
et al corroborates these findings by demonstrating that patients were more likely to receive 
any therapy if first seen in a centre offering speciality treatment facilities after clustering for 
regional network and adjusting for patient and organisational factors compared no speciality 
treatment facilities (surgery RRR 1.80; chemotherapy RRR 1.81; radiotherapy RRR 1.47). 
(151) 
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Two surgical centre studies did not find a significant improvement in surgical resection rates 
or survival. (136,161)  Firstly, Li et al reported that being treated in a cardiothoracic centre 
did not significantly improve treatment or five-year survival rates. (136) However, centres 
which were categorised as university affiliated centres or specialist cancer centres had 
significantly improved odds of receiving treatment ((OR 1.72 (95% CI 1.06-2.80), p<0.05). 
Secondly, Bendzsak et al used Canadian administrative data to study patient outcomes before 
and after the implementation of a policy to regionalise surgery to fourteen designated 
hospitals that have the following resources: 1.) On site certified specialist thoracic surgeons 
2.) dedicated thoracic unit 3.) affiliation with a cancer centre 4.) minimum surgical volumes. 
(161) The policy did not result in an improvement in patient outcomes (operative mortality, 
resection rate, complication rate) beyond those that were already occurring over time.  
Three studies examined the impact of being treated in a hospital that are designated cancer 
centres. (163–165) Sher et al categorise centres into three groups: Academic/research 
program, comprehensive community cancer program and community cancer programs. (164) 
The first two categories require a case load of a minimum of 500 new cancer cases per year, 
but the academic centre group must additionally have at least four postgraduate medical 
education programs including internal medicine and surgery. The community cancer program 
treats between 100-500 cases per year. The authors explored the US National Cancer 
Database to investigate treatment patterns in Stage IIIA NSCLC. They found that patients first 
seen in academic centres were more likely to receive surgery and receive preoperative therapy 
than those in community cancer centres as well as those in comprehensive community cancer 
centres after adjusting for patient, clinical and geographic factors. The volume of the 
institution was not a significant determinant of treatment receipt. Similarly, the impact of 
National Cancer Institute designated cancer centres (NCICCCs) in the State of Los Angeles 
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were studied by Wolfson et al. (163) They demonstrated that patients managed at such 
institutions had a higher 5 year over survival (adjusted 5-year survival if first seen in a 
NCICCC vs non NCICCC: 27.7% vs 16.5%, p<0.001). They estimate that for those in the non 
NCICCCs institution were 40% more at risk of dying than those in the NCICCCs at any point 
during the study (HR 0.73 (95% CI 1.3-1.6), p<0.001). 
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Table 2.13 Studies examining the impact of lung cancer patients treated at a specialist centre 
Study Data 
source 
Data 
year 
Number  Definition of specialist 
centre 
Outcome 
 
Rich  
UK (158) 
Admin 2004-
2008 
33,964 Surgical centre Odds of receiving surgical treatment in a surgical centre: OR 1.51 (95% CI 1.16-1.97), 
reference non-surgical centre 
Khakwani  
UK (159) 
Admin 2008-
2012 
95,818 Surgical centre Odds of receiving surgical treatment in a surgical centre: OR 1.37 (95% CI 1.29-1.45), 
reference non-surgical centre 
Lau 
UK (160) 
Admin  2008-
2009 
46,615 Surgical centre Resection rate in a surgical centre vs non-surgical centre: 20% vs 11.6%, p<0.001 
Stewart 
UK (151) 
Admin 2007-
2011 
109,079 Provision of specialist 
anticancer treatment 
facilities 
RRR for receipt of the following with availability of onsite surgical facilities (reference no 
speciality facilities):  
- Surgery 1.80 (95% CI 1.42-2.28); Chemotherapy 1.81 (95% CI 1.45-2.26); 
Radiotherapy 1.47 (95% CI 1.20-1.80) 
RRR for receipt of the following with availability of onsite chemotherapy facilities (reference 
no speciality facilities):  
- Surgery 1.22 (95% CI 0.95-1.56); Chemotherapy: 1.39 (1.10-1.75); Radiotherapy 
1.27 (1.05-1.53) 
Bendzsak 
Canada (161) 
Admin 2004-
2012 
16,641 Surgical centre Before and after regionalisation of care to surgical centres:  
- Resection rate: 71% vs 89% 
- Mortality rate: 4.1% vs 2.9% 
Adjusted odds for death after regionalisation: 0.68 (95% CI 0.58-0.81), p<0.001 
Jack  Admin 1995-
1999 
32,818 Radiotherapy centre Adjusted odds for being first seen in a radiotherapy centre for receipt of:   
- Active treatment: OR 1.72 (95% CI 1.21-2.46), p=0.003 
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UK (162) - Radiotherapy: OR 1.86 (95% CI 1.28-2.71), p=0.001 
- Chemotherapy: OR 1.38 (95% CI 1.06-1.80), p=0.008 
Adjusted odds for being first seen in a radiotherapy centre for: 
- 1-year survival: OR 1.20 (0.97-1.50), p=0.10 
- 3-year survival: OR 1.18 (0.97-1.43), p=0.09 
Wolfson 
USA (163) 
Admin 1998-
2008 
10,844 NCICCC Adjusted 5-year survival if first seen in a NCICCC vs non NCICCC: 27.7% vs 16.5%, 
p<0.001 
Adjusted HR for mortality if first seen in a non NCICCC: 1.4 (95% CI 1.3-1.6), p<0.001, 
reference NCICCC 
Li  
Netherlands 
(136) 
Admin 1998-
2003 
5846 Surgical unit/Specialist 
centre (university affiliated 
& cancer specialist 
hospitals) 
Adjusted odds of receiving treatment for surgical centre: OR 0.73 (95% CI 0.47-1.14) 
Adjusted odds of receiving treatment for specialist centre: OR 1.72 (1.06-2.80), p<0.05 
Cumulative 5-year mortality for surgical centres: HR 0.73 (95% CI 0.53-1.01), reference 
non-surgical centre 
Cumulative 5-year mortality for specialist centre: HR 1.26 (0.94-1.70), reference non-
specialist centre.  
Sher 
USA (164) 
 
Admin 2003-
2010 
18,581 Academic centres vs 
Comprehensive CCC vs 
CCC 
Adjusted odds of receipt of surgery for comprehensive CCC: OR 0.65 (95% CI 0.54-0.78), 
reference academic centre 
Adjusted odds of receipt of surgery for CCC: OR 0.48 (95% CI 0.38-0.60), reference 
academic centre 
Shulman 
USA (165) 
Admin 2005-
2012 
252.392 NCICCC vs 
Comprehensive CCC vs 
Academic centre vs CCC 
Adjusted HR (95% CI) for: NCI CCC: 0.83 (0.80-0.88); Comprehensive community: 1.07 
(1.05-1.09); community: 1.41 (1.11-1.17) 
NCICCC: National Cancer Institute designated Comprehensive Cancer Centre; CCC: Community Cancer Centre OR: Odds ratio; HR: Hazard ratio  
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2.3.4.1.6 Site of care 
 
This section recognises the importance of the setting that treatment is delivered. Khakwani et 
al demonstrated that centres with the largest catchment populations were unable to provide 
equal access to surgery for patients seen at non-surgical centres they serve, compared with 
patients presenting to their own. (159) This finding suggests that the distance to specialist 
centres may be a barrier to accessing specialist care. 
Eight studies (n=99,651 patients) investigated the effects of distance (n=7) or site of care 
(n=1) in the treatment of lung cancer. (166–171) Studied outcomes included treatment rates 
(n=5), mortality (n=4) and timeliness of care (n=3). Two studies (167,172) used clinical data 
with relatively small numbers of included patients with six using administrative datasets 
(166,168,170,171,173,174). There were variable measures of distance/travel burden with 
arbitrarily defined cut off values shown in Table 2.14.  
Three studies report hazard ratios examining the effect of increasing distance on survival. 
(166,168,174) One found no significant association with distance. (168) Campbell et al found 
a modest increase in risk of death with increasing distance from the nearest hospital (HR for 
death after diagnosis for living ≥38km from hospital, reference ≤5km: 1.09 (1.01-1.18), 
p=0.024). (174) Additionally, Tracey et al showed that the risk of death for those first seen in 
a specialist hospital and live >100km is 36% less than those first seen in a specialist hospital 
but live 0-39.9km. (166) When a post hoc analysis was conducted for patients that did not 
have a resection, the risk of death was not significantly different for specialist or general 
hospitals. Therefore, the authors conclude that the two main factors that influenced survival 
was attendance at a specialist hospital and having a resection regardless of distance. 
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The effect of distance on treatment rates is examined by five studies. (166,167,170,171,173) 
Tracy et al is the only study that demonstrate that that the resection rate is higher in the group 
living closer in their study using Australian Cancer Registry data of 23,871 patients with 
NSCLC. (166) However, when split into those that were first seen in a specialist hospital or 
general hospital, resection rates between these groups did not significant vary. In fact, those 
that were first seen in a specialist hospital, the resection rate was higher in the group of 
patients living >100km from the hospital.  
Timeliness of care is investigated by three studies. (167,171,172) Gotfrit et al and Verma et al 
report significant reductions in time delays. (167,172) Gotfrit et al quote a reduction in time 
from first consult to treatment by 16 days (p=0.012) and 12 days for diagnosis to treatment 
(p=0.034) for patients living <60 min drive vs >60min drive. (167) Verma and colleagues 
conducted a small prospective cohort study of 252 patients investigating the impact of living 
in a rural vs urban location. (172) They report that the difference in median time delay from 
first symptoms to treatment was 50 days favouring patients that lived in an urban location. 
Conversely Scoggins et al demonstrate a time delay of 0.82 days per driving hour or 4.84 days 
per driving mile from time to first treatment which was non-significant. (171) 
Several of the articles conclude that other factors are likely to play a significant role in the 
association. This is demonstrated by Crawford et al. (173) They found that when examining 
travel distance with the likelihood of receiving active or surgical treatment that there was no 
significant difference with those that lived the closest to those that lived the farthest, adjusting 
for age and sex. However, when studied by deprivation index, those that lived the furthest and 
in the most deprived areas were least likely to have active treatment (OR: 0.55 (95% CI 0.46-
0.67) or thoracic surgery for NSCLC (0.55 (95% CI 0.39-0.76) compared to those who lived 
the closest and least deprived. 
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Table 2.14 Studies examining the impact of site of care 
Study Data 
source 
Data 
year 
Number  Site of care 
variable used 
Outcome 
 
Tracy 
Australia 
(166) 
Admin 2000-
2008 
23,871 0-39.9km vs 
>100km 
Resection rate for >100km vs 0-39.9km: 49.4% (45.8-53.1) vs 62.5% (60.3-64.4) 
HR for death for (reference first seen in specialist hospital 0-39.9km) 
- first seen in general hospital>100 km: 1.82 (95% CI 1.55-2.13) 
- first seen in specialist hospital>100km: 0.64 (95% CI 0.51-0.81) 
Gotfrit 
Canada 
(167) 
 
Clinical 2009-
2012 
514 <60 min drive vs 
>60 min drive 
Rate of receipt of systemic therapy for <60 min drive vs >60 min drive: 55% vs 53%, 
p=0.72 
Median overall survival for <60 min drive vs >60 min drive (months): 7.4 vs 8, p=0.055 
Time from first consult to first treatment (days): 51 vs 67, p=0.012 
Time from diagnosis to treatment (days): 22 vs 35 days, p=0.034 
Distance not significant predictor of treatment receipt in multivariate analysis 
Scoggins 
USA 
(171) 
Admin 1997-
2003 
1,787 Linear model for 
driving distance 
(miles) and 
driving time 
(hour) from 
home to PCP 
Adjusted OR for likelihood of receipt of treatment for increasing driving time to PCP: OR 
0.99, p=0.93 
Adjusted OR for likelihood of receipt of treatment for increasing driving distance to PCP: 
OR 0.97, p=0.90 
Adjusted co-efficient for increasing time to first treatment and increasing driving time to 
PCP: 0.82, p=0.843 
Adjusted co-efficient for increasing time to first treatment and increasing driving distance 
to PCP: 4.84, p=0.54 
Jones Admin 1994- 34,923 Linear model of Adjusted HR for increasing travel time to hospital (min): 0.998 (0.998-0.999) 
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UK (168) 2002 travel time Adjusted HR for increasing distance (km) to nearest cancer centre: 1.000 (0.998-1.002) 
Crawford 
UK (173) 
Admin 1992-
2002 
34,923 Quartiles for 
travel time (min): 
≤7; 7.1-
10.90;10.91-
15.48:≥15.49 
Adjusted OR for active treatment for furthest hospital, reference closest: 1.01 (95% CI 
0.95-1.08) 
Adjusted OR for operation for furthest surgical centre, reference closest: 0.91 (95% CI 
0.82-1.01) 
Adjusted OR for chemotherapy receipt for longest travel time, reference shortest: 1.12 
(95% CI 0.95-1.32) 
Campbell 
UK (174) 
Admin 1991-
1995 
19,449 Quintiles (km): 
≤5; 6-13;14-
23;24-37; ≥38. 
One-year survival for closest vs furthest (%): 21.7 vs 22.1, p=0.862.  
Adjusted HR for furthest (reference closest): 1.09 (95% CI 1.01-1.18), p=0.024. 
Verma 
Australia 
(172) 
Clinical 2009-
2012 
252 Urban vs rural Median time from first symptoms to treatment urban vs rural (days): 125 (21-465) vs 170 
(32-938), p=0.01 
Hopson 
USA 
(170) 
Admin 2008-
2012 
3119 Outpatient vs 
Physician office 
Rate of receiving biologic therapy, Bevacizumab and platinum-based chemotherapy, 
biologic and chemotherapy, platinum-based drug only, platinum-based combination, other 
by SOC: no significant difference 
Quality of care by SOC: No significant difference.  
PCP: Primary care provider; SOC: Site of care; HR: Hazard ratio; OR: Odds ratio 
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2.3.4.1.7 Impact of specialist staff 
 
An aspect of specialist care that was featured in six studies (n=192,336 patients), is access to 
specialist staff (Table 2.15). (151,160,175,176) These studies hypothesised that patients seen 
by specialist providers of lung cancer care achieve better patient outcomes and reported 
significant results. 
All studies demonstrated improved treatment rates. Ganti et al reported that the rate of cancer 
directed therapy in those seen by a specialist was 54% higher than those that did not see a 
cancer specialist (p=0.01). (175) Similarly, Erridge et al estimated that those who were not 
seen by a specialist were 47% less likely to receive radiotherapy than those that were 
(p<0.001). (176) Thirdly, Lau et al demonstrated that input of thoracic surgeons provided by 
attendance at more than two thirds of multidisciplinary (MDT) management meetings 
improved resection rates by 2.4% (12% vs 14.6%, p=0.046). (160) 
Three studies emphasise the positive impact of the lung cancer specialist nurse (LCNS) or 
nurse navigator. (151,177,178) Stewart et al showed that patients that had an assessment by 
an LCNS were approximately twice as likely to receive surgery or chemotherapy (RRR for 
receipt of therapy compare to not being assessed: surgery RRR 1.98 (95% CI 1.11-
3.53);chemotherapy: RRR 2.18 (95% CI 1.24-3.82)) and radiotherapy: RRR 1.84 (95% CI 
1.17-2.87)), after adjustment for patient/organisational factors and clustered by regional 
network. (151) Additionally, early LCNS input was associated with a greater likelihood of 
receiving anti-cancer treatment compared to an assessment after diagnosis for all three 
therapy groups, with the greatest effect seen for surgery (RRR: 1.85 (95% CI 1.63-2.11).  
Integral to the role of LCNS is assistance with navigating the health system. In North 
America/Canada, this role is encompassed by a ‘nurse navigator’. Two before and after 
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studies investigated the impact of the nurse navigator. (177,178) Zibrik et al examined 408 
stage IIIB/IV NSCLC patients in Vancouver. (177) Findings revealed significant 
improvements in receipt of anticancer therapy and timeliness of care. A significant reduction 
in time from referral to systemic therapy (10 days) and radiotherapy (6.5 days) was shown. 
Kunos et al demonstrate similar results with a reduction of 19 days from suspicion of cancer 
on CXR to receipt of treatment after the implementation of a nurse navigator. (178) It should 
be noted that analysis of the ‘after’ data in both studies occurred between three to five years 
after the ‘before’ data was collected.  
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Table 2.15 Studies examining the impact of specialist staff 
Study Data 
source 
Data year Number  Outcome 
 
Ganti  
USA (175) 
Admin 2007-2011 31,919 Receipt of cancer directed therapy in patients seen by cancer specialist vs not: 92% vs 38%, p=0.01 
Erridge 
UK (176) 
Admin 1995 3855 Receipt of radiotherapy in patients who were diagnosed by a specialist vs not: 40.4% vs 18.6%, p<0.01 
Adjusted odds of receiving radiotherapy if not been seen by a specialist: OR: 0.47 (95% CI 0.38-0.57), p<0.001 
Lau 
UK (160) 
Admin 2008-2009 46,615 Resection rate for cancer networks served by ≥2 thoracic surgeons vs not: 14.6% vs 12.0%, p=0.028 
Resection rate for surgical attendance for >2/3rds of MDTM vs not: 14.4% vs 12%, p=0.046.  
Stewart  
UK (151) 
Admin 2007-2011 109,079 Adjusted RRR for receipt of therapy for LCNS assessment (reference: not assessed): 
-  Surgery RRR 1.98 (95% CI 1.11-3.53); Chemotherapy RRR 2.18 (95% CI 1.24-3.82); radiotherapy RRR 
1.84 (95% CI 1.17-2.87) 
Adjusted RRR for receipt of therapy LCNS assessment before/at diagnosis (reference after diagnosis): 
- Surgery RRR 1.85 (1.63-2.11); Chemotherapy RRR: 1.27 (1.14-1.42); Radiotherapy RRR: 1.16 (1.05-
1.28).  
Zibrik 
Canada 
(177) 
Admin 2011 
(before) 
and 2014 
(after) 
408 
(Stage 
IIIB/IV) 
Systemic therapy rates before and after appointment of NN: 57% vs 69%, p=0.05 
Radiotherapy rates before and after NN: 91%% vs 87%, p>0.05 
EGFR testing rates before and after NN: 62% vs 91%, p<0.001 
Time from referral to being seen by medical oncology before and after NN (days): 18 vs 15.5, p=0.11 
Time from referral to being seen by radiotherapy oncologist before and after NN (days): 10 vs 8, p=0.005) 
Time from referral to systemic therapy before and after NN (days): 48 vs 38, p<0.016 
Time to referral to radiotherapy before and after NN (days): 18 vs 11.5, p=0.0016.  
Time from referral to EGFR results before and after NN (days): 34 vs 20, p<0.001 
Kunos 
USA (178) 
Clinical 2009-2010 
(before) 
2011-2014 
(after) 
460 Time from suspicion of cancer on CXR and treatment before and after NN (days): 64 vs 45, p<0.001.  
OR: Odds ratio; MDTM: Multidisciplinary team meeting: RRR: relative risk ratio 
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2.3.4.1.8 Staff workload 
 
Access to specialist staff consists of adequate provision of staffing numbers and time. The 
impact of staff workload on patient outcomes is examined by three studies (n=109,711 
patients) that investigate three different professional groups: CT radiographers, surgeons and 
lung cancer specialist nurses. (151,179,180). The findings are summarised in Table 2.16.  
One study investigated the effect of increasing staffing provision of CT radiographers by 
extending working hours and staff number. (179) This single centre before and after study in 
Canada ascertained changes in wait time and tumour stage migration in patients with a 
pathological diagnosis of NSCLC. They found that before increasing staffing provision there 
was a significant increase in tumour size (mean difference 0.67 cm, p<0.0001) and stage 
(p<0.00001) from initial image to biopsy. Whereas, after the intervention, the mean wait was 
reduced by 11.5 days and there was no statistically significant increase in tumour stage or 
size.  
The second study examined the workload of surgeons undertaking pulmonary lobectomies for 
lung cancer patients in another single institution. (180) Thomas et al analysed the workload of 
six surgeons and the impact on 481 patients’ mortality and morbidity. They showed that 
increased surgeon workload was an adverse predictor of complications (OR: 1.036, p=0.03) 
and length of stay (average increase of 0.16 days for each additional hour, 0=0.006) after 
adjusting for patient variables. This study adds to the literature on the complex relationship 
between hospital and surgeon volume on outcomes. The authors highlight the importance of 
assessing staff workload to gain a holistic picture of a centre’s quality of care.  
Finally, Stewart et al conducted a sub analysis of patients considered suitable for surgery in 
their interrogation of the NLCA dataset. (151) Patients that saw a LCNS with a caseload of 
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>250 patients/year were approximately one third less likely to have surgery compared to 
patients that were assessed by a LCNS with a case load of ≤150 patients/year (RRR 0.71 
(95% CI 0.51-0.97)). 
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Table 2.16 Studies examining the impact of staff workload 
Study Data 
source 
Data 
year 
Number  Staff role 
studied 
Outcome 
 
Byrne 
Canada 
(179) 
Clinical 2009-
2011 
151 CT 
radiographer 
Mean wait to CT: 19 days to 7.2 days 
Thomas 
USA 
(180) 
Clinical 2008-
2009 
481 Surgeon Adjusted odds for risk of complications by total number of operative hours/days: OR 
1.036, p=0.03 
Length of stay: 0.16 days more per additional operative hour worked, p=0.006 
Stewart 
UK 
(151) 
Admin 2007-
2011 
109,079 LCNS RRR for receiving surgery with LCNS caseloads in those suitable for surgery >250: 
0.71 (95% CI: 0.51-0.97) compared to LCNS caseloads <150 
RR: risk ratio; RRR: relative risk ratio; LCNS: lung cancer specialist nurse 
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2.3.4.2 Co-ordination of care 
 
The optimal management of lung cancer involves the co-ordination of specialities that may be 
co-located. The searches on this theme identified thirty studies that include interventions to 
improve multidisciplinary management and pathway speed/efficiency. The following 
subthemes are explored below 1.) Multidisciplinary care 2.) Rapid diagnostic programmes 3.) 
Care co-ordination programmes.  
2.3.4.2.1 Multidisciplinary care 
 
Multidisciplinary team (MDT) management in lung cancer aims to improve the quality of 
cancer care, access to treatment and enhance co-ordination. There were 13 studies (n>20,577) 
that met the inclusion criteria, published between 2005 and 2018. (181–192) Studies were 
classified into two groups: those that examined the value to discussing management plans in a 
multidisciplinary meeting (MDTM) (Table 2.17) and studies that evaluated the impact of a 
multidisciplinary clinic (MDC) (Table 2.18).   
2.3.4.2.1.1 Multidisciplinary team meeting (MDTM) 
 
All 9 studies (n>19,232) included in this category were observational. (181–183,185,187–
189,193,194) A multidisciplinary team meeting was defined as a meeting attended by a 
variety of health care professionals, meeting at least fortnightly to discuss the diagnosis and 
management of patients with suspected lung cancer. Eight studies examined survival as an 
outcome quoting a median survival time of 3.2-15.6 months for patients with no MDTM’s vs 
6.6-25.2 months for MDTM management. (181–183,185,186,188,189,194) Six papers 
considered at least one confounding factor in survival analyses. (181–183,186,188,189) Two 
showed that accounting for confounders rendered significant unadjusted analyses 
insignificant. (181,186) 
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Dillman et al studied patients at a large community hospital in a before and after study.(181) 
The observed 5-year survival rate was significantly different in the MDT group (19%) 
compared to the non MDT group (16%, p=0.012). However, when examined by stage, the 
difference seen between the MDT vs non-MDT group became insignificant (local 
disease=0.66; regional: p=0.45; distant p=0.51). The authors state that the influence of stage 
differences is likely to mediate much of the effect on survival.  
Boxer et al found that discussion at MDT did not predict survival in a study examining 988 
patients in South West Sydney in a cox regression model (OR: 1.0 (95% CI 0.86-1.17) 
adjusting for patient and tumour factors. (186) 
The most recent three studies found significant findings. (182,183,188) In 2018 Stone et al 
studied 1197 cases in a prospective cohort study in a single institution and showed improved 
adjusted survival at one and two years but not at five. (182) Further results favouring MDTM 
discussion were demonstrated by Mitchell et al with an overall survival benefit of 5.5 months 
(p<0.001) and a 38% reduction in risk of death shown by Rogers et al in 2017 (HR for 
survival: 0.62 (95% CI 0.50-0.76), p<0.01).  
Changes in treatment rates were observed in four studies (183,185,186,194) with three 
showing increased rates in the MDTM group Improvements in specific treatment categories 
varied across studies.(183,186,194) Mitchell et al demonstrated an increase in curative 
treatment rates (22.2% vs 44%, p=0.001) and active treatment rates (70.5% vs 81.6%, p-0004) 
in their study of 841 patients in the state of Victoria, Australia. (183) Boxer et al reported a 
positive influence on chemotherapy and radiotherapy receipt (but not for surgery) and Forrest 
et al showing an increase of 16% in chemotherapy rates but no significant difference in 
radiotherapy (curative or palliative intent) rates. (186,194) 
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The above described studies examined the impact of patients being discussed at the MDT 
meeting. Osarogiabon et al study the impact of decisions made at such meetings being 
actioned compared to patients where care was discordant to the discussed management plan. 
(189) In their single centre study of 376 patients 63% of patients received concordant care and 
this group had a shorter time to treatment (25 vs 14 days, p<0.002), improved stage adjusted 
overall survival (HR for survival for concordant care: 1.7, reference discordant care, p=0.02) 
and stage adjusted progression free survival (HR for survival for concordant care 1.4, 
reference discordant care, p=0.04).  
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Table 2.17 Studies examining multidisciplinary team (MDT) meeting management on patient outcomes (No MDT management vs MDT 
management)  
Study Data 
source 
Data year N Outcome 
 
Dillman  
USA (181) 
Admin 1986-1991 
(Before) 
1992-1999 
(After) 
1562 5-year survival rate: 16% (before) vs 19% (after), p=0.012 
Median survival time (months): 11 (before) vs 13 (after), p=0.012 
Stone  
Australia 
(182) 
Admin 2006-2012 1197 5-year HR for death: HR 0.7 (95% CI 0.58-0.85), p0.0001, reference no MDT 
Bydder 
Australia 
(185) 
Clinical 2006 98 Radical RT/Chemo-RT: 6% vs 10%, p=0.318 
Active treatment rate: 35% vs 52%, p=0.288 
Chemotherapy rate: 29% vs 42%, p=0.141 
Palliative RT: 35% vs 25%, p=0.152 
Palliative care: 29% vs 23%, p=0.204 
Median survival (days): 208 vs 237, p=0.048 
1-year survival: 18% vs 33% 
Boxer (193) 
Australia  
Clinical 2005-2008 988 Treatment rate: 4% vs 13%, p<0.01 
Surgical treatment rate: 13% vs 12%, p=0.84 
RT rate:  33% vs 66%, p<0.001 
Chemo rate: 29% vs 46%, p<0.001 
Adjusted OR for receiving the following treatment for MDT discussion (reference no MDT discussion): 
- RT: OR 2.64 (95% CI 1.96-3.56) 
- Chemo: OR 1.30 (95% CI 1.01-1.84) 
Median time to diagnosis to (days): 
- Surgery: 50 vs 42, p=0.49 
- RT (curative): 91 vs 106, p=0.65; RT (palliative): 89 vs 87, p=0.89 
- Chemo (curative): 45 vs 45, p=0.97; Chemo (palliative) 44 vs 60, p=0.03 
Odds for survival (reference no MDT discussion): OR: 1.0 (95% CI: 0.86-1.17) 
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Mitchell  
Australia 
(183)  
Admin 2003 841 Curative intent treatment rate: 22.2% vs 44%, p<0.001 
Active treatment rate: 70.5% vs 81.6%, p=0.004 
Overall survival (months) 5.5 vs 10.8, p<0.001 
Survival (landmark analysis, months): 9.3vs 13.3, p<0.001 
Freeman 
USA (187) 
Clinical 2008-2012 13,254 Time from diagnosis to treatment (days): 19 vs 32, p<0.0001 
Rogers 
Australia 
(188) 
Admin 2009-2012 593 Risk of death for MDT discussion (reference no MDT discussion): Adjusted HR 0.62 (95% CI 0.50-
0.76), p<0.01 
Forrest 
UK (194) 
Clinical 1997 (before) 
2001 (after) 
323 Chemo treatment rate: 7% vs 23%, p<0.001 
Palliative care rate: 58% vs 44%, p=0.045 
Radical RT rate: 5% vs 2% 
Palliative RT rate: 30% vs 30% 
Mortality rate (minimum 33 months follow-up):  99.1% vs 92.1%, p=0.011 
Median survival (minimum 33 months follow-up, months): 3.2 vs 6.6, p<0.0001 
Osarogiabon 
USA (189) 
Clinical 2006-2009 376 Those discussed at MDT meeting and plan not actioned: vs those discussed but plans actioned: 
- Time to treatment (days): 25 vs 14, p<0.002 
- Survival (years): 1.3 vs 2.1, p<0.004 
- Progression free survival (years): 0.8 vs 1.3, p<0.02 
- Unadjusted overall survival (reference discordant care): HR 1.8, p=0.004 
- Unadjusted progression free survival (reference discordant care): HR 1.5, p0.02 
- Stage adjusted overall survival (reference discordant care): 1.7, p=0.02 
Stage adjusted progression free survival (reference discordant care): 1.4, p=0.04 
MDT: Multidisciplinary team; RT: Radiotherapy; Chemo: Chemotherapy; HR: Hazard ratio 
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2.3.4.2.1.2 Multidisciplinary clinics (MDC) 
 
Multidisciplinary clinics aim to provide a consistent and holistic approach to patient care. 
Four studies investigated this intervention shown in Table 2.18. (184,190–192)   
Three studies examined timeliness of care with varying results. (184,191,192) Seek et al 
showed an improvement in median time from diagnosis to treatment (29.3 vs 18.76 days) in a 
single centre before and after study of a community hospital. (184) Friedman et al reported 
similar results (29.1 vs 19.6 days) when studying 220 Stage III lung cancer patients in their 
centres. (191) However, no significant differences were found between the groups from time 
of initial radiology to treatment.  
Onukwugha et al also investigated Stage III NSCLC patients, examining MDC care in 
fourteen National Cancer Institute Community Cancer Centres in the USA. (192) They 
hypothesised that MDC’s provides higher quality MDT care by more timely care. An MDC 
development assessment tool was used to categorise the level of MDC implementation into 
high, moderate and low across seven domains. These were 1.) Case planning 2.) Physician 
engagement 3.) Co-ordination of care 4.) Infrastructure 5.) Financial 6.) Clinical trials and 7.) 
Medical records. They found no significant difference between the group scoring high 
compared to the low group in time to treatment for any of the above domains. A positive 
finding was found for centres reporting high MDC care for the care co-ordination domain 
compared to the low group with increased odds of receiving multimodality treatment (OR 
10.94 (95% CI 1.68-71.42), p=0.01).  
Finally, Kedia et al was the only qualitative study included. (190) The authors researched 46 
patients’ experiences of MDC care, conducting focus groups with patients receiving care with 
and without the involvement of an MDC that was co-ordinated by a nurse navigator. Patients 
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report a good experience stating that MDT care was more patient centred, effective, efficient, 
timely, equitable and co-ordinated. Whereas standard care was perceived to have delays with 
an emphasis on poor communication.  
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Table 2.18 Studies showing impact of multidisciplinary clinics (MDC) on patient outcomes 
Study Data 
source 
Data 
year 
N Outcome 
 
Seek 
USA (184) 
Clinical 2004 NA Mean time from diagnosis to treatment (days) 29.3 vs 18.76 
 
Kedia 
USA (190) 
Qualitati
ve 
2013-
2014 
46 Perceived benefits of MDC compared to standard care: patient centred, effective, 
safe, efficient, improved timeliness/equitable care/co-ordination 
Perceived negative aspects of standard care: poor communication amongst 
physicians, delays, mistreatment, insensitive communication about illness 
Friedman 
USA (191) 
Clinical 
 
2007-
2012 
220 
(Stage 
III) 
Median time from first contact with MDC/clinic to treatment (days): 29.09 vs 
19.85, p=0.043 
Median time from initial radiology to treatment (days): 54 (36-103) vs 61 (51.5-
81.5), p=0.549 
Staging of the mediastinum rate: 24.5% vs 57.7%, p<0.001 
Unsuspected N2 disease rate: 36% vs 7.7%, p<0.001 
Median overall survival (months): 14 vs 17, p=0.054 
Onukwugha 
USA (192) 
Clinical  2007-
2012 
560 
(Stage 
III) 
Adjusted HR for high MDC implementation (3 categories: low (evolving MDC), 
moderate and high (excellent)) for (reference low): 
- Time to treatment: HR 0.64 (95% CI 0.24-1.69) 
Receipt of multimodality treatment: HR 10.94 (95% CI 1.68-71.42) 
HR: hazard Ratio; NR: Not reported; MDC: Multidisciplinary clinic 
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2.3.4.2.2 Rapid diagnostic pathways (RDP) 
 
Timeliness of care was considered an important outcome in many of the included studies. It 
has been hypothesised that speedier care leads to better patient outcomes. The implementation 
of rapid or fast track systems to reduce delays for lung cancer patients were studied by six 
studies (n>779 patients) using clinical data shown in Table 2.19. (87,89,195–198) All six 
studied wait times and demonstrated a decrease however, not all reported or tested for 
statistical significance. A variety of time intervals were reported but the most common were 
time from diagnosis to treatment and time from referral to a specialist to diagnosis.  
Murray et al was the only randomised control trial in this category. They enrolled patients 
with a possible diagnosis of lung cancer from three district general hospitals in the UK. and 
randomised patients to a two-stop pathway or standard care via an outpatient pathway. In the 
intervention arm patients received diagnostic tests on their first visit and then a treatment plan 
was developed at a MDT meeting three days later. (89) Patients in the intervention arm had a 
statistically significantly improved time from first presentation to treatment by four weeks 
(p=0.0025) and the chemotherapy rate was higher by 29% (p=0.03). There was no significant 
decrease in time from diagnosis to treatment. This was the only study that investigated 
survival as an outcome and found no significant difference in two-year survival between the 
groups.  
Three observational studies reported a statistically significant decrease in pathway times. 
(87,195,196) Ezer et al examined the effect of a rapid investigation clinic (RIC) compared to 
patients undergoing standard care. (196) In this programme a pulmonary physician and nurse 
clinician assisted the co-ordination of care of patients with suspected lung cancer. A reduction 
in the median time from first contact with a physician to two points were reported favouring 
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the RIC arm: time to treatment from 78 to 65 days (p<0.01) and time to pathological 
diagnosis from 40 to 26 days (p<0.01).  
Lal et al’s retrospective before and after study in the UK showed significant decreases in time 
from referral to diagnosis, to first discussion at the MDTM and to decision to treat after the 
implementation of a fast track CT initiative. (87) 
Finally, the remaining study that found statistically significant reductions in delays was a 
prospective observational study conducted in the Netherlands comparing rapid outpatient 
diagnostic programmes to a standard step wise approach. (195) Brocken et al showed a 
reduction in median time from first clinic to diagnosis by 7 days (p<0.001) and to 
management discussion by 11 days (p<0.001). This study was one of three in this category 
that examined patient reported outcomes. They showed a decrease in the first six weeks in 
emotional distress in the RDP group, with no such change in the control group. However, at 
three months there was no significant difference in emotional distress or quality of life scores 
between the groups. Murray et al and Lal et al reported patient experience was better in the 
intervention arm with patients feeling the standard pathway was too slow. (87,89)  
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Table 2.19 Studies examining the impact of rapid diagnostic programmes (RDP) 
Study Data 
source 
Data 
year 
Components of 
intervention 
N Outcome 
 
Brocken 
Netherlands 
(199) 
Clinic
al 
2009
-
2010 
Following interventions 
within 2 days: PET-CT, 
respiratory physician 
consult, bronchoscopy, 
pulmonary function tests 
and results of cytology 
193 Mean HADS score at day 1 and day 38 (SE): 
- RDP malignant group: 14.5 (0.9) to 13.6 (1.2) 
- Standard malignant group: 15.0 (1.1) to 17.6 (1.5) 
EORTC QLQ-C30 score at day 1 and day 38 (SE): no significant changes for 
both groups.  
Median time from first clinic to diagnosis for RDP vs no RDP (days): 7 vs 14, 
p<0.001 
Median time from first clinic to discussion of management plan for RDP vs no 
RDP (days): 8 vs 19, p<0.001  
Ezer 
Canada (196) 
Clinic
al 
2010
-
2011 
Nurse and clinician monitor 
investigation progress and 
assess co-ordination of care 
with psychological support.  
195 Median time from first contact with physician to treatment for RDP vs no RDP 
(days (IQR)): 65 (46-92) vs 78 (49-119), p<0.01 
Median time from first contact with physician to pathological diagnosis (days 
(IQR)) for RDP vs no RDP (days): 26 (14-42) vs 40 (16-68), p<0.01 
Adjusted time interval to first treatment (days) for RDP group (reference no 
RDP): -24 (95% CI -35 to -12), p<0.01.  
Murray 
UK (89) 
Clinic
al 
2002 Two stop pathway (max 2 
weeks): CT scan and 
bronchoscopy/biopsy (same 
day)  
Discussion at MDTM 
88 Time from presentation to treatment for RDP vs no RDP (weeks): 3 vs 7, 
p=0.0025 
Time from diagnosis to treatment for RDP vs no RDP: no difference.  
Radical treatment rate for RDP vs no RDP: 43% vs 33%, p=no sig diff (value 
NR) 
Chemotherapy treatment rate for RDP vs no RDP: 66% vs 37%, p=0.03 
No significant difference for surgery or radiotherapy treatment rates 
Role (p=0.02), social (p=0.03) and financial functioning (p=0.03) on QLQ: 
significantly worse in RDP group (figures NR) 
QLQ: no significant difference in overall score  
2-year survival rates for RDP vs no RDP: 40% vs 33%, p=0.7 
Lo 
Canada (197) 
Clinic
al 
2004
-
New referral process and 
form; newly appointed 
52 Median time from specialist consultation to CT for RDP vs no RDP (days): 3 vs 
52 
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2005 navigator; physician 
consult and spirometry on 
the same day; dedicated CT 
& bronchoscopy slots; 
MDT meeting; target wait 
times set; primary care 
education. 
Median time from CT to diagnosis for RDP vs no RDP (days): 6 vs 39 
Median time from suspicion of lung cancer to diagnosis for RDP vs no RDP 
(days): 20 to 128   
Aasebo 
Norway 
(198) 
Clinic
al 
2006
-
2010 
Lung package: automatic 
referral to physician on call 
by radiologist for 
suspicious imaging. 
Diagnostic workup max 4 
weeks and time to start 
therapy 1 week from 
diagnosis. 
109 Median time from referral to treatment for RDP vs no RDP (days): 16 vs 64 
Median time from referral to surgery for RDP vs no RDP (days): 15 vs 26.5 
Lal 
UK (87) 
Clinic
al 
2006
-
2007 
Fast track CT pathway: CT 
scan within 1 week of 
suspicious CXR. CT scans 
reviewed by chest 
physician, radiologist and 
LCNS and those with a 
suspicious CT scan are 
offered an urgent consult.  
142 Median time from referral to diagnosis for RDP vs no RDP (days): 17 (IQR 13) 
vs 22 (IQR 14), p<0.001 
Median time from referral to first discussion at MDTM for RDP vs no RDP 
(days): 22 (IQR 11) vs 32 (IQR 15), p<0.001 
Median time from referral to decision to treat for RDP vs no RDP: 35 (IQR 23) 
vs 42 (IQR 30), p<0.05 
Median time from referral to first treatment for RDP vs no RDP: 49 (IQR 36) vs 
55 (IQR 36), p=0.095.  
Proportion of patients who felt the process took too long for RDP vs no RDP: 6% 
vs 19%, p<0.05 
HADS: Hospital Anxiety and Depression score; EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer 30 item quality of life 
Questionnaire; QLQ: Quality of life questionnaire; MDTM: Multidisciplinary team meeting; NR: Not reported; LCNS: lung cancer nurse specialist 
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2.3.4.2.3 Care Co-ordination programmes  
 
Care co-ordination programmes incorporate several changes aimed at impacting patient 
outcomes and were the focus for eight studies (n>11269 patients). (200–207) Such 
programmes combine interventions that have been investigated separately. These include 
initiatives to improve access to care, MDT aspect and timeliness of care. The assessed 
outcomes varied depending on the focus of the intervention shown in Table 2.20. Outcomes 
included time intervals, quality of life, treatment and survival rates.  
In the USA, the emergence of diagnostic assessment programmes (DAPs) has been shown to 
improve patient care. The principle of a DAP is to “organise services centrally so that access 
to multi-disciplinary facilities are accessed in a single location with the aim of a rapid 
diagnosis and efficient treatment decision making”. Alsamari et al evaluated the impact of 
DAPs in lung cancer on timeliness of care. They report a reduction from imaging to treatment 
by an average of 25 days (p=0.015) and 23 days to diagnosis (p=0.016). (200)  
Similar findings were reported by a Canadian study that investigated the impact of 
introducing a nurse navigator, weekly MDT meetings and structured communication with 
primary care in a retrospective study of 113 patients.  A decrease of 38 days and 25.5 days 
was found from the first abnormal image to treatment and to biopsy respectively. (207) 
Survival was assessed by one study. (202) Bilfinger et al studied the impact of a programme 
where an MDT meeting was instituted with ancillary resources for facilitating referrals and 
appointments allowing for care to be centralised to one location. In adjusted propensity 
matched analyses, a significant reduction in mortality was reported for the intervention arm 
compared to standard care (HR: 0.65 (95% CI 0.54-0.77).  
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Improvements in treatment rates were reported by two studies, (203,205) with Lefresne et al 
reporting statistical significance (Radiotherapy receipt rate same day as consultation for CCP 
vs non CCP: 72% vs 41%, p<0.001). (203) Check et report increased treatment receipt rates 
for chemotherapy and radiotherapy (radiotherapy receipt rate for CCP vs no CCP: 51.1% vs 
47.9%; chemotherapy receipt rate for CCP vs no CCP rate: 27.5% vs 33.8%) in the 
intervention arm but no significant different for receipt of surgery.  
Finally, patient related outcomes were the focus of one study.(204) Smeltzer et al investigated 
the impact of a programme focused on improving communication and co-ordination of care 
through the implementation of MDT meetings, MDCs, and enhanced communication 
pathways. They showed no significant difference in quality of life scores. 
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Table 2.20 Studies examining the impact of care co-ordination programmes (CCP) 
Study Data 
source 
Data 
year 
N Components of CCP Outcome 
 
Alsamari 
USA (200) 
Admin 2005-
2010 
352 Full time cancer care co-ordinator, creation of 
a ‘Cancer Alert’ code by radiologist to identify 
suspicious scans to alert the co-ordinator, 
computerised tracking system, weekly MDT 
nodule conference, hiring of a thoracic surgeon 
with an interest in lung cancer.  
Median time from imaging to diagnosis for stage I for CCP vs non 
CCP (days): 87 vs 131, p=0.013 
Median time from imaging to diagnosis for cancer found incidentally 
for CCP vs non CCP (days): 86 vs 114, p=0.031 
Adjusted mean days from image to diagnosis for CCP vs non CCP: 
53 vs 76, p=0.016 
Adjusted mean days from image to treatment for CCP vs non CCP: 
101 vs 126, p=0.015.  
Adjusted mean days from diagnosis to treatment for CCP vs non 
CCP: 43 vs 46, p=0.60.  
Leary 
UK (201) 
Clinical 2002-
2004 
NR Triage of referral, education and collaborative 
working with secretarial staff and Bed 
Management Team, patient information shared 
across the network; educational initiatives, 
increased availability of patient information 
Mean time from decision to treat to treatment for CCP vs non CCP 
(days) 8 vs 38 
Length of stay (days) for CCP vs non CCP (days): 6.5 vs 8.  
Bilfinger 
USA (202) 
Admin 2002-
2016 
4271 Patients see all specialities in one location with 
ancillary help to facilitate co-ordination of 
care. All patients discussed at an MDT 
meeting.  
Propensity matched 5-year survival rates for CCP vs non CCP: 
33.6% vs 23%, p<0.001 
Propensity matched HR for survival for CCP (reference non CCP): 
0.65 (95% CI 0.54-0.77) 
Lefresne  
Canada (203) 
Clinical 2011-
2012 
219 
(met
astati
c) 
I hour consultation with radiation oncologist 
and nurse practitioner, discussion at an MDT 
meeting, additional radiation oncologist hired 
Radiotherapy receipt rate same day as consultation for CCP vs non 
CCP: 72% vs 41%, p<0.001 
Rate of patients double booked into oncologists’ schedule for CCP vs 
non CCP: 13% vs 23%, p<0.001 
Assessed for curative intent treatment for CCP vs no CCF: 43% vs 
33%, p<0.001 
Smeltzer 
USA (204) 
Admin 2014-
2015 
526 Focus groups to assess optimal care delivery 
pathways and barriers creation of a new 
benchmarked co-located multidisciplinary 
QOL score for CCP vs no CCP: no significant difference 
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clinic with infrastructure to implement 
benchmarked activities focusing on enhanced 
co-ordination and communication.  
Check  
USA (205) 
Admin 2004-
2011 
5786 Co-ordinated information and referral 
networks 
Radiotherapy receipt rate (no surgery) for CCP vs no CCP: 51.1% vs 
47.9% 
Chemotherapy receipt rate (no surgery) for CCP vs no CCP: 27.5% 
vs 33.8% 
Surgery receipt rate: no significant difference 
Common 
Canada (206) 
Clinical 2005-
2016 
133 Nurse navigation, weekly MDT meetings, 
regular communication with primary care 
provider.  
Median time from first abnormal image to biopsy for CCP vs no 
CCP: 36 vs 61.5 days, p<0.0001 
Median time from first abnormal image to treatment for CCP vs no 
CCP: 80 vs 118 days, p<0.00072 
Hunnibell 
USA (207) 
Admin 2003 
(before) 
2010 
(after) 
NA Care co-ordinator (CC) hired 
Protocol established for radiology to alert CC 
of new cases 
Electronic alert to primary care providers on 
films order with Fleichner recommendations 
Creation of a pulmonary tumour board 
Electronic referral process of lung biopsies 
All lune biopsies conducted by interventional 
radiologists 
Nurse hired to triage pulmonary referrals  
Time from suspicion of lung cancer to treatment before and after 
appointment of NN: 136 days vs 55 days 
CCP: Care co-ordination programme; NR: Not reported; PSACCS: Picker System of Ambulatory Cancer Care Survey; SCNS-SF 34: The Supportive Care 
Needs Survey Short Form 34; MDT: Multidisciplinary team 
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2.3.4.3 Others: Patient led care and impact of technology-based interventions 
 
Identified studies that did not fit into the above themes included patient led care, nurse led 
follow-up and technology-based interventions (Table 2.21 and Table 2.22).  
Patient led interventions were examined by two studies (n=3125 patients) that did not find a 
positive association with patient outcomes. (208,209) Mills et al found that completing a QOL 
diary did not improve patient satisfaction with care, communication or discussion of patient 
problems. (208) Pollack et al found that patients who self-referred themselves to a service 
scored their satisfaction with physician communication lower than those that were referred via 
conventional referral pathways. (209) In addition, there were no significant differences 
between the groups for satisfaction with nursing care, co-ordination or responsiveness to care.  
Moore et al conducted a randomised controlled trial examining nurse led follow-up of 
outpatients compared with standard care in 203 lung cancer patients that had completed their 
initial treatment. (210) In the intervention arm they found significantly improved scores for 
emotional functioning (p=0.03) and patient satisfaction as well as and less severe dyspnoea 
(p=0.03) amongst several assessed quality of life domains. There were no differences in 
survival or rates of progression between the groups.  
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Table 2.21 Studies examining the impact of patient led care/nurse led follow-up 
Study Data source Data 
year 
N Intervention Outcome 
 
Mills  
UK (208) 
Clinical 2005-
2007 
115 Patient held QOL diary  Mean change in score for diary vs standard care using TOI: -5.0 vs 0.4, p=0.14 
Mean score for diary vs standard care using FACT-L: -6.3 vs 3.5, p=0.05 
Pollack 
USA (209) 
Admin 2003-
2005 
3010 Self-referral Beta co-efficient for association between self-referral and physician 
communication satisfaction: -2.92 (95% CI -5.49 to 0.35).  
No significant differences for self-referral vs standard care with experiences with 
nursing care, co-ordination or responsiveness of care. 
Moore 
UK (210) 
Clinical NR 203 Nurse led follow-up Median ERTC QOL score for dyspnoea (IQR) at 3 months: 25 (16.7-41.7) vs 33.3 
(25.0-58.3), p=0.03.  
Median ERTC QOL score for emotional functioning at 12 months: (IQR): 91.7 
(66.7-100) vs 66.7 (54.2-87.5), p=0.03.  
Other domains not significant.  
Patient satisfaction better in intervention group in all subscales at 3 months 
(organisation of care, information, personal experience of care, satisfaction of 
care, support overall). (p<0.005). 6 months (p=0.001) in first three domains. 12 
months p<0.05 in first three domains.  
Median survival for intervention vs usual care (months): 9.2 (95% CI: 6.2-12.1) vs 
10.4 (7.6 -13.2), p=0.99 
QOL: Quality of life; TOI: Trial Outcome index; FACT-L: Functional Assessment of Cancer Therapy-Lung; NR: Not reported; EORTC QOL: European 
Organisation for Research and Treatment of Cancer Quality of life 
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Telemedicine aimed at improving the efficiency of communication between health care 
professionals was the subject of three studies (n=566 patients). (211–213) Stevens et al 
demonstrated that video conferencing used in MDT meetings did not impact on treatment 
rates in a single site study in New Zealand of patients referred for radiotherapy. (212) 
However, Seeber et al showed that the implementation of video MDT at an oncology day 
centre in Austria resulted in a 40% increase in radiotherapy treatment rates (p=0.001). (213) 
However, similar significant improvements were not observed for receipt of chemotherapy. 
The final study introduced bespoke technology-based support systems and assessed patient 
related outcomes. (211) One system involved automated delivery reports of clinically 
significant symptoms to clinical teams for further assessment. In addition, teams had access to 
graphical and longitudinal displays of symptom scores. The control group in this study simply 
monitored their symptoms weekly and discussed the results at scheduled appointments. They 
found no significant difference in overall symptom burden or health related quality of life. In 
fact, the patient satisfaction score was higher in the control group. 
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Table 2.22 Studies examining the impact of technology-based interventions 
Study Data source Data 
year 
N Intervention Outcome 
 
Yount 
USA (211) 
Clinical NR 253 Technology based 
symptom monitoring 
and reporting 
No significant differences in mean overall symptom burden adjusted for baseline 
No significant difference in health-related quality of life 
Patient satisfaction score higher in control group compared to interventional 
group, p<0.027. 
Stevens 
New Zealand 
(212) 
Clinical 2009 110 Video MDT conference For video vs standard group: 
Proportion seen in RO clinic: 87% vs 87%, p=1.0 
Proportion recommended curative intent RT in clinic: 23% vs 10%, p=0.11 
Proportion recommended palliative intent RT in clinic: 55% vs 68%, p0.11 
Median time from diagnosis to RT (days) 64 (IQR 23,86) vs 42 days (IQR 20,60), 
p=0.37.  
Seeber 
Austria (213) 
Clinical 2003-
2011 
203 Video MDT conference Radiotherapy rate for video vs standard care: 70% vs 30%, p=0.001 
Chemotherapy rate for video vs standard care: figure NR, p0.415 
Bisphosphonate rate for video vs standard care: figures NR, p=0.166 
LC: lung cancer; RT: Radiotherapy; RO: Radiation oncology; NR: Not reported 
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2.3.4.4 Summary of results by outcome 
 
Figures 2.7 a-c show a summary of the results by the two broad themes (co-ordination of care 
and specialist care) by the four main outcomes studied (survival, improved treatment rates and 
improved timeliness of care). These show that the majority of studies in both themes showed 
a positive association with all outcomes. 
 
 
 
Figure 2.7a: Outcome by theme: Survival 
 
Figure 2.7b: Outcome by theme: Treatment rates 
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Outcome by theme: Survival 
Positive association No significant association Negative association
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Figure 2.7c: Outcome by theme: Timeliness of care 
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Positive association No significant association Negative association
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2.3.5 Risk of Bias 
 
Overall there was a high risk of bias across all studies (Figure 2.8). The majority of studies 
used large administrative data sets which led to issues with confounding, selection and 
performance bias. Contributing factors include difficulty controlling for known effect 
modifiers, isolating the studied intervention, lack of statistically accounting for the 
hierarchical nature of the data and inherent problems with recording clinical information on 
administrative databases, Details of attrition and reporting bias were unclear mainly due to 
poor reporting. Finally, arbitrary cut offs for groups led to high risk of bias for the 
misclassification domain 
Figure 2.8 Risk of bias for main review 
 
.
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2.4 Discussion 
 
2.4.1 Introduction to discussion 
 
The National Lung Cancer Audit (NLCA) show that there is variability in patient outcomes 
across the country that is in part due to geographical differences in the patient population. 
(214) This review presents evidence that the organisation of health care plays a significant 
role in influencing lung cancer outcomes. 
At a time when change in the organisation of cancer services is being considered it is 
important that information is collated in a systematic way so that models of care that benefit 
patients can be adopted. In addition, improvements in efficiency and effectiveness of working 
is vital in an increasingly resource stretched National Health Service (NHS).  
To my knowledge this is the first review that has synthesised the current evidence on 
organisational interventions in lung cancer linked to patient outcomes; it is comprehensive, 
including 84 papers and a total of 1,897,184 patients from ten countries.  
In the following section the results of the findings are discussed in greater detail and the 
evidence is contextualised to a UK health system.  
The studies included in the review fall into two main themes: specialist care and co-ordination 
of care.  
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2.4.2 Specialist care 
2.4.2.1 What are the main findings? 
 
The results show that the best outcomes are achieved in high procedure volume and specialist 
hospitals that provide specialised staff with dedicated time to deliver care to lung cancer 
patients. There is evidence to support improved survival, lower morbidity and increased 
treatment rates at these centres compared to non-specialised/low volume hospitals.  
The section with the most studies (n=23) available examined the hospital volume-outcome 
relationship with conflicting outcomes. A trend for a modest positive association with 
survival is demonstrated for HVC. This is in keeping with the growing amount of evidence 
found in the scoping review that high volume hospitals undertaking procedures such as 
coronary artery bypass grafting, aortic valve replacement and oesphagectomy provide higher 
resection rates, shorter length of stay, improved survival, and lower readmission risk than low 
volume hospitals. (215–217) Luchenborg and Moller et al demonstrated that this relationship 
holds true despite the high-volume hospital group having an older, more co-morbid and 
deprived population. (139,148) They advocate that larger hospitals are more likely to take on 
riskier cases and the analyses are likely to underestimate the magnitude of favourable 
outcomes obtained by HVH due to statistical adjustment for patient features.  
Nine of the 24 studies estimated the likelihood of death for early and late postoperative 
outcomes. (128–130,133,136,137,139,141,148) All demonstrated that there is a greater 
mortality reduction in HVC compared to LVC in the early post-operative period compared to 
late outcomes. This suggests that the management beyond the operation is likely to be 
important highlighting a common conclusion amongst the included studies: the studied 
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intervention is likely to be a proxy for an efficient lung cancer pathway resourced to deliver 
best practice.  
2.4.2.2 Postulated reasons for how specialist care influences patient outcomes? 
 
These results point to four main factors that are important in the association between 
specialist care and patient outcomes. These are: 1.) The infrastructure of the hospital 2.)  
Consistency of decision making 3.) The importance of equitable access to care and 4.) 
Education and networking opportunities.  
2.4.2.2.1 Hospital Infrastructure 
 
Each of the examined organisational factors are likely to be a proxy for the infrastructure of 
the treating institution; a finding replicated in studies of other cancer sites and other 
specialities. (218)  
A systematic review comparing inpatient specialised stroke unit care with an alternative 
service reported a significant reduction in the likelihood of death by 17% (p<0.05), 
death/institutional care by 25% (p<0.0001) and death/dependency by 31% (p<0.0001).(219) 
This evidence led to the widespread establishment of stroke units and implementation into 
national guidelines.  Early evaluation of stroke unit care found significant variation in patient 
outcomes still existed. (220) Rudd et al showed via audit data that less than half of hospitals 
that stated they had dedicated units reported having all five organisational characteristics that 
previous research literature identified as key features of a specialised stroke unit. This 
suggests that there was national pressure to provide specialist care without the additional 
allocated resources provided to support the local hospital infrastructure to achieve this aim. In 
2004, a UK government directive stipulated that all stroke care should occur on a stroke unit 
132 
 
fulfilling resource criteria. Subsequently, data have demonstrated improvements in patient 
outcomes. (221) 
In lung cancer, Alsamari et al showed that specialised care via diagnostic assessment 
programmes (DAP’s) in the USA improved patient care. (200) Subsequently Honeiun et al 
investigated the organisational characteristics for the optimal DAP design via a mixed 
methods approach. (222) In keeping with the results of this review, the authors identified the 
following characteristics of the hospital infrastructure as being important: improved 
information systems, greater numbers of staff and co-ordinated care achieved through staff 
co-location and patient navigators.  
2.4.2.2.2 Consistent decision making 
 
Three findings from the included surgical studies suggest that consistent decision making in 
preoperative patient selection is more likely to occur in a specialist centre. Firstly, the 
difference in patient outcomes between specialist centres and non-specialist centres is 
sustained beyond the short term. This finding can be explained by the fact that in lung 
resections patients rarely die from complications from the surgery itself. (223) Long term 
survival is contributed by access to adjuvant therapies, quality of nursing/allied health input 
and hospital processes ensuring appropriate follow-up. (223) This demonstrates the 
importance of specialist multidisciplinary decision making that is likely to occur in specialist 
centres.  
Secondly, Rich et al show that in the UK there was no difference in case mix between the 
surgical centre group and non-surgical centre group. (158) However, patients in the former 
group were more likely to have an operation. Consequently, it is likely that MDTs in such 
centres have the expertise and skills in optimal patient selection.  
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Finally, the American studies show the positive influence of specialist thoracic surgeons with 
a high procedure volume on patient outcomes. Such surgeons are more likely to operate in 
high volume centres. Birkmeyer et al report that the surgeon and hospital procedure volume 
contribute equally to the observed association with improved patient survival. (215) 
Consequently, it is likely that these hospitals have the specialist personnel, support and skills 
to make appropriate consistent decisions for lung cancer patients.  
2.4.2.2.3 Access to care 
 
Access to specialist care is vital if outcomes are to be improved. Evidence to support this 
hypothesis is that patients that are less deprived are seen in high volume specialist hospitals. 
Therefore, it may be the ability of these patients to access specialist hospitals that drives the 
favourable patient outcomes seen in specialist institutions.    
The UK studies examining hospital volume-outcome association show that there is no 
difference in case mix between HVC and LVC. (139,148) However, several of the studies 
based in the USA report that LVC treat patients that have a higher overall risk of mortality, 
complications and prolonged length of stay. (128,141,144) The reasons contributing to this 
finding are likely to be multifactorial. One factor may be that this category of patients are 
from more deprived areas, with lower educational levels and less likely to have private 
insurance cover. This theory is supported by other studies. Crawford et al found that when 
investigating the influence of travel distance to hospital on outcomes that increasing distance 
to their hospital did not significantly influence treatment rates. (173) When studied distance 
was combined with deprivation index, lung cancer patients that lived in the furthest and a 
deprived area were approximately 50% less likely to receive active treatment compared to 
those living near and in the least deprived area. The importance of socioeconomic class is 
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additionally demonstrated by Ganti et al that show patients from a deprived area have a 
reduced chance of seeing a cancer specialist. (175)   
Many of the studies do not adjust for social class as a confounding factor. This review 
provides evidence that it is likely to interact with organisational factors to impact patient 
outcomes though this relationship is poorly understood.  
2.4.2.2.4 Professional development 
 
All four studies examining differences in outcomes by surgical speciality found that specialist 
thoracic surgical training was associated with improved patient outcomes. (153–156) The 
authors propose that differences may not only be because of specialist surgical expertise but 
opportunities to keep practice up to date are likely to be more readily available in specialist or 
teaching hospitals. Hence the most innovative practice leading to better patient outcomes gets 
centred around these hospitals. In time, such institutions will attract better facilities, more 
experienced multidisciplinary staff and therefore more advanced working environment. 
Therefore, general hospitals are left with decreasing support and resources, exacerbating the 
disparity between the two hospital types.  
2.4.2.3 What are the limitations of the evidence? 
 
The above results need to be taken in the light of several limitations common to the included 
studies which will be discussed in the following section.  These are: -1.) Use of administrative 
databases 2.) Challenges of quantitatively pooling data 3.) Biases 4.) Study population.  
2.4.2.3.1 Use of administrative databases 
 
55 studies (65%) utilised administrative databases. This has the advantage of including large 
numbers of cases but comes with inherent flaws. Firstly, it is retrospective in nature with 
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limited capacity to capture long term outcomes and important patient or tumour specific 
details such as stage, performance status and patient co-morbidities. In addition, the large 
number of cases increases the risk that statistically significant value is obtained by chance. A 
review collating the evidence on the hospital volume-outcome relationship recommend the 
use of a C statistic to assess the quality and performance of the statistical model used on the 
ability to discriminate between observed instances of death and survival. (224) Only two 
studies reported this statistic. (143,225)  
2.4.2.3.2 Challenges of quantitatively pooling the data 
 
Performing a quantitative synthesis of the data posed four main challenges. Firstly, the 
category likely to be amenable to meta-analysis due to having the greatest number of studies 
was those investigating the hospital-volume relationship. However, Table 2.8 shows that each 
study reported differing volume cut offs to define HVC and LVC making comparison 
difficult. The rationale for the cut off values were generally poorly reported in the study. 
Stukenborg et al highlight that comparing odd ratio values across arbitrary volume categories 
is problematic. In order to determine cut of values methodologically the authors advocate a 
technique called restricted spline regression. This uses multiple data points to estimate the 
association between volume and mortality. This method was not adopted by papers published 
subsequent to this finding.  
Furthermore, the variability in cut off values between countries makes comparison difficult to 
contextualise to a UK setting. Pezzi et al define HVHs as conducting over 90 procedures per 
year. (130) This would be considered very low by UK and European standards; (139) Moller 
et al used a cut off of 190 procedures per year in their UK based study for a HVC. In addition, 
the number of procedures conducted by each hospital within the category varied widely 
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between studies. For example, the authors in the study by Cheung et al state that sixteen 
hospitals in the LVC category performed an average of one or fewer lung resections per year 
and 23 performed only one resection in the entire four year study period. (141)  
Secondly, risk adjustment for confounding factors was variable across the studies. Stukenborg 
et al highlight the variability in statistical techniques used to account for co-morbidity; an 
important patient characteristic known to influence lung cancer mortality risk. (143) The 
focus of the study by Stukenborg et al was to compare three methods of co-morbidity risk 
adjustment. These were adjustment using a present at admission diagnoses technique, the 
Elixhauser method and an adaptation of the Charlson index. They found that each model 
yielded different mortality risk outcomes depending on the method used. Therefore, 
emphasising the importance of assessing the accuracy of risk adjustment when interpreting 
and combining results from different studies.  
Thirdly, all the studies used a logistic regression model taking into account patient level data 
and hospital level data (procedure volume). However, only four studies explicitly took into 
account the hierarchical nature of the data. (128,131,141,148) It is only possible to understand 
the effect of hospital volume rather than the effect of a hospital by statistically acknowledging 
the multi-level structure of the data. Urbach et al show that models that do and do not 
incorporate multi-level modelling produce different results. (147) Models that fail to cluster 
for hospitals tend to overestimate the effect of the intervention and therefore any comparison 
with other studies should be interpreted with caution.  
Lastly, inconsistency in definition of the categories was found. The definition of teaching 
status varied amongst studies shown in Table 2.12. In the USA, a ‘major’ teaching hospital 
was defined as 1.) A hospital on the council of teaching hospitals of the Association of 
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American Medical Colleges. 2.) Had a specified ratio of beds to interns/residents 3.) 
Affiliated with a medical school. (157) Other hospitals classed as ‘teaching’ did not fulfil 
these criteria but were assessed in the same category.  
2.4.2.3.3 Biases 
 
It is notable that all but one study included in this section are observational in nature with the 
majority utilising retrospective data. This comes with inherent biases not already discussed 
that should be considered when interpreting the results. These include issues with stage 
migration, lead time bias and recording bias.  
Studies that adjusted for stage may have over-estimated the effect of the organisational 
characteristic through stage migration. (218) It is likely that specialist hospitals have more 
ready access to onsite diagnostic modalities. Hence patients seen at such centres are more 
likely to be accurately staged. Therefore, the apparent adjusted improvement in survival rates 
seen in specialist organisation may be due to accurate staging.  
Similarly lead time bias occurs when the period of observation is different for specialist 
hospitals versus general hospitals. Several of the included studies acknowledge that specialist 
hospitals are likely to have a more advanced infrastructure leading to timely treatment. 
Therefore, the differences seen in survival are to do with the hospital infrastructure rather than 
the characteristic under study e.g. the speciality of the surgeon or teaching status.  
Finally, the results of several included studies depend on the accuracy of the data recorded. 
The quality of the data entry is likely to be better in institutions where there are resources to 
facilitate data management; this tends to be in specialised hospitals.  
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2.4.2.3.4 Study population 
Twenty-four studies (29%) were based on a surgical population. However, in an era of 
immunotherapy showing promising results in the management of lung cancer, the significance 
of studying a non-surgical population requires attention. This review captured only one study 
that explores hospital volume in a non-surgical population and shows a modest survival 
advantage in HVC (150)  
2.4 Summary of specialist care findings 
 
Acknowledging these limitations, the trend suggests that specialist care is likely to be an 
important determinant of patient outcomes in lung cancer. However, elements of a hospital 
infrastructure and the relationship between such factors playing a significant role in altering 
outcomes requires further investigation. These findings also show the importance of equitable 
access to specialist services, with deprived populations highlighted as facing significant 
barriers. This inequity is associated with a decreased likelihood of treatment and receipt and 
poorer survival compared to patients from other socioeconomic backgrounds. Longer travel 
distances is perceived to be a barrier however, the presented results suggest this does not 
manifest as an obstacle to treatment receipt.  
2.4.3 Co-ordination of care 
 
2.4.3.1 What are the main findings? 
 
Care co-ordination is an approach to healthcare that is delivered in a logical, comprehensive 
and timely manner ensuring all patients’ needs are met and there is continuity of care. Co-
ordinated care in lung cancer is shown to be vital in achieving improved outcomes. (226) 
Therefore, several UK guidelines including the ‘National Optimal Pathway’ and NICE 
guidelines emphasise the importance of timely care. (86,227) Moreover, qualitative data 
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collected from providers, patients and carers described delays and lack of co-ordination as a 
major challenge to accessing high quality cancer care. (228)  
This review examines interventions that aim to improve the co-ordination and timeliness of 
care. These include multidisciplinary care, care co-ordination programmes and rapid 
diagnostic programmes. 
The majority of studies in this section demonstrate an improvement in the timeliness of care 
through the implementation of the described interventions which is in keeping with the 
literature. The aim of nurse navigators is to improve the flow of lung cancer care and address 
barriers to low income individuals to gaining access to cancer care. (229) Navigators share 
information between the MDT and patient, co-ordinate clinical schedules and provide 
emotional support. (230) This review shows there is evidence to support the utility of this role 
which is in keeping with other cancer studies. (231) The impact on timeliness of care and 
increased treatment rates are unsurprising given the navigators experience with working with 
patients with lung cancer and the familiarity with the health system setting.  
Rapid diagnostic and care co-ordination programmes lead to speedier care by addressing 
delays through the implementation of simultaneous interventions. This is in keeping with the 
results of two systematic reviews that found that interventions aimed at improving co-
ordination of care decreased wait times, though not all studies reported or found statistical 
significance. (83,96) Finally, multidisciplinary care aims to improve the quality of cancer 
management and access to treatment. It has been established as the standard of care in several 
countries including the UK. However, evidence for the effectiveness of the MDT is lacking. A 
systematic review published in 2008 failed to demonstrate a beneficial effect on patient 
outcomes such as treatment rates or survival. (97) This review presents an updated review of 
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the evidence and reiterates the lack of robust evidence supporting an impact on survival, 
treatment rates or timeliness of care.  
However, though there was a general trend for improved timeliness of care, results of other 
outcomes such as survival or quality of life were mixed. In addition, limited conclusions can 
be drawn from these studies due to the following limitations.   
2.4.3.2 Limitation with co-ordination of care intervention studies 
 
Three issues to consider when interpreting the evidence are 1.) Study heterogeneity 2.) Study 
variation and 3.) Adjustment for confounders.  Firstly, in each category there is large 
heterogeneity in the included studies. For example, for those where timeliness of care was the 
main outcome of interest, the definition in the measures of wait times including start and stop 
times varied. Similarly, the details of what comprised MDT care were sometimes poorly 
reported and details of length, number of cases discussed, professionals present and context of 
the management discussion in the patient pathway were sparse in all the studies.  
In addition, there was significant variation in study design and patient population. This 
variation makes quantitative comparison challenging. On the other hand, the spread of 
interventions across a variety of countries suggests that a reflective snapshot of tested 
interventions is provided that captures a large population.  
Secondly, there was poor adjustment for confounding factors such as age, stage, tumour 
subtype and co-morbidities. This may explain why some studies found results showing that 
speedier care resulted in worse survival rates. In these studies, patients with more advanced 
disease, require fewer diagnostic investigations and are more likely to receive a prompt 
radiological diagnosis and best supportive care but die earlier than those with early stage 
disease.  
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Finally, due to the number of confounding factors influencing lung cancer outcomes, it is 
difficult to isolate the intervention as being definitively associated with patient outcomes. 
Many of the studies were before and after design. In a rapidly developing speciality, it is 
likely that changing treatment and diagnostic paradigms contributed. In addition, hospital 
infrastructures are unlikely to remain static. Therefore, in common with other similar reviews 
caution should be exercised when evaluating organisational interventions as independent 
factors in a whole pathway. (232)  
2.4.3.3 Summary of care co-ordination findings 
 
With the above limitations in mind, the presented results represent a comprehensive synthesis 
of studied interventions aimed at improving the co-ordination of care and the impact on 
patients with lung cancer. This summary highlights three main findings. Firstly, it emphasises 
the need for continued improvement in timeliness of care demonstrated by the variability in 
reported mean and median wait times. Secondly, a range of successful interventions are 
described, the delivery of which are dependent on the availability of sufficient staff with 
appropriate skills. Finally, important research gaps are identified.  
 
2.4.4 How does this apply to lung cancer commissioning in the UK?  
 
Data from the NLCA has shown that the care for patients with lung cancer has improved over 
the last ten years. Surgical resection rates have increased from 13.7% in 2010 to 17.1% in 
2017 with one year survival improving from 31% to 37% in the same time period. (214) 
Despite these improvements, outcomes in the UK still lag behind those in comparable 
countries. (79)  
142 
 
This review suggests that improvements in patients’ outcomes can be achieved through 
improved access to specialist time and reduced staff workload. Governing bodies, in the UK 
recognise staffing is a priority, with a plan set out in the “Cancer Workforce Plan”. (233) 
However, this review and national reports identify that as well as increasing number and skills 
of staff, a change in the way services are accessed nationally is required to deliver equitable 
standards of modern cancer care. (234)  
The UK has a ‘hub and spoke’ model of delivery of specialist cancer care organised in 
networks. My results question whether this represents equality in access to lung cancer 
service provision. (148)(158)(162)(90). Despite the acknowledged limitation of the evidence, 
large centres with specialists that have dedicated time to deliver lung cancer care are shown to 
achieve better treatment and survival rates. Specialised hospital infrastructures with dedicated 
on-site facilities are likely to contribute to such a success. It has, therefore been proposed that 
a centralised approach to services may minimise the variation in care and outcomes in the 
UK. (235) This might enable the adequate recruitment and retention of specialist staff, timely 
access to key diagnostic and treatment modalities, co-ordinated multidisciplinary care and 
access to research studies and clinical trials.  
However, a survey conducted in 2013 of hospital physicians in the UK with an interest in 
lung cancer reported that three quarters of participants did not feel that lung cancer should be 
managed in fewer centres. (91) There are six main arguments in favour of this viewpoint. 
Firstly, it can be argued that the holistic care of this multi-comorbid group is better placed in a 
general hospital. With the majority of lung cancer cases presenting at an advanced stage and 
two thirds of patients being diagnosed over the age of 70, therefore ready access to other 
specialities such as a diabetes or cardiology is vital. (214) Secondly, centralising lung cancer 
services may lead to the de skilling of local hospital staff who will still manage cancer 
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patients in an emergency setting. This is particularly relevant in lung cancer where over 40% 
of lung cancer cases are diagnosed as part of an emergency. (20) Thirdly, local centres have 
the potential to model the same standard of care provided in specialist centres. This review 
provides some evidence that service delivery through local hospitals fosters collaboration and 
networking. The use of technology (e.g. video conferencing) can maximise regular team 
working in a time efficient manner. Fourthly, each cancer network, on average, sees 
approximately 2,500 new cases per year. Given this volume, there is currently insufficient 
capacity for all lung cancer patients to be seen in specialist centres. Fifthly, it should be noted 
that the majority of studies advocating for a move to large volume specialist centres are based 
on American studies, hence the results may not be directly transferable to a UK setting where 
distances may be smaller. An individuals’ private insurance status and affordability to access 
care is shown to be a major factor in predicting outcome with some studies demonstrating a 
greater effect than hospital volume or specialist status (153) and again this would be less 
applicable to UK care. Finally, despite, the existence of a public health system in the UK that 
is free on the point of receipt, significant variation in access to optimal care is reported. This 
review emphasises that more deprived patients are less likely to receive treatment or have 
access to specialist care and the site of care studies highlight that level of deprivation is the 
main driver of outcome. Therefore, there is an argument that services should be redesigned to 
remove barriers to accessing specialist lung cancer care rather than potentially increasing 
barriers through the regionalisation of services.  
In summary, there are advantages and disadvantages to both models of service delivery. What 
is clear is that to improve outcomes for patients with lung cancer, services must ensure that 
patients can access the same high-quality specialised care. The provision of adequate 
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dedicated time for specialised staff to care for patients is key to achieving this. Whether this is 
done in a local hospital or a specialised centre is still up for debate.  
2.4.5 Strengths and limitations of the review 
 
As far as I am aware this is the first systematic review that synthesises the evidence 
investigating organisational interventions directly linked to patient outcomes. The unique use 
of a scoping review of the general medical literature and broad search criteria enhanced 
capture of articles and provides a robust overview of the subject. Additionally, a systematic 
approach to article selection, review methods and formal quality assessment provides clarity 
on the methodological quality of the included articles allowing meaningful interpretation of 
the observed results to a UK setting.  
However, in addition, to the limitations acknowledged in the section 2.4.2.3 and 2.4.3.2, three 
main areas of weakness are recognised. Firstly, the challenges of conducting a comprehensive 
search of health systems literature have been described in section 2.1.3 and described in 
previous reviews. Three approaches were used to address this. 1.)  A scoping review was 
conducted to ascertain important subject areas to include in the final search strategy. 2.) Three 
databases were searched using a deliberately broad search strategy. 3.) Experts in literature 
searching were consulted to optimise the search strategy 4.) Field experts identified further 
relevant articles. These techniques resulted in the inclusion of a variety of articles studying a 
range of interventions in several settings. However, it is acknowledged that relevant articles 
may have been missed.  
Secondly, many included studies scored high in the risk of bias assessment. Several of these 
biases have already been discussed but two further biases pertain to the entire review: 
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confounding and publication bias.  The influence of confounding is shown in Figure 2.8. 
Difficulty in isolating organisational interventions from other influencing factors represented 
a challenge in the majority of studies. Additionally, there is likely to be a number of 
unrecognised confounding factors at play such as patient preference. For example, studies 
investigating the impact of teaching hospitals may not be able to account for patients that elect 
to seek care from non-teaching hospitals if they want less aggressive treatment. Details of 
decision making are not captured by clinical or administrative datasets and are out of the 
scope of this review.   
Another bias is the influence of publication bias. Studies that report a positive result are more 
likely to be published that those that report negative or no significant findings. This has been 
acknowledged as a significant factor to consider in organisational reviews. (99) Several 
studies implementing organisational change are likely to occur at a local level and therefore 
less likely to be published in full article format. Consultation with experts in the field of lung 
cancer ensured that results and conclusions presented in this review are in keeping with 
general consensus.  
2.4.6 Gaps in the literature 
 
A key aim of this review was to identify gaps in the literature and areas for future research. 
The paucity of robust studies on the subject is demonstrated by the fact that only four 
randomised controlled trials were identified. Prospective, good quality studies are required to 
gain a better understanding of how organisational interventions impact patients with lung 
cancer; in part this led to my studies reported in Chapter 3.  
The review highlights that the interplay of organisational factors in impacting lung cancer 
outcomes is under investigated.  The discussion sections of several of the included studies 
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recognise that it is likely that a group of organisational factors influence patient outcomes. 
However, which factors drive the association is not well understood. In Meguid et al’s study 
investigating the impact of hospital teaching status on outcomes demonstrated that a high-
volume status was the driving factor associated with improved outcomes. (157) Additionally, 
when controlled for surgeon speciality in a post hoc analysis, the significant association found 
with improved survival was lost. Similar findings have been shown by other studies at 
different cancer sites. Dimick et al also showed that the association with hospital teaching 
status and mortality was due to increased hospital volumes for patients with pancreatic, 
hepatic and oesophageal cancers. (236) The ability of a hospital system to function effectively 
and efficiently is influenced by several organisational factors other than case mix. Moreover, 
these factors are likely to be inter-dependent. However, few studies examine the individual 
influence of such characteristics in univariate and multivariate analyses with other 
organisational factors. This is key to identifying key organisational components that are vital 
for a high-quality lung cancer service.
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2.5 Conclusions 
 
Review of the lung cancer literature highlight that the co-ordinated access to specialist care is 
likely to be an important determinant of patient outcome. The results present some evidence 
for improved survival, treatment rates and quality of life associated with specialist centres. 
However, strong conclusions cannot be drawn from the available evidence due to the 
heterogeneity and methodological quality of the included studies. There are pros and cons to a 
move to specialist centres in the UK but access to specialist services remains a key theme. If 
this is best achieved through the provision of care in specialist treatment centres or with a hub 
and spoke model is up for debate. What is clear, is that several gaps in the literature exist 
meriting further investigation. A greater understanding of the influence of the interplay of 
organisational factors on patient outcomes would enable models of lung cancer service 
delivery to be commissioned that are evidenced to improve care for lung cancer patients.   
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CHAPTER 3 THE SECOND NATIONAL LUNG 
CANCER ORGANISATIONAL AUDIT: 
RESULTS AND IMPACT OF ORGANISATION 
AND SPECIALIST SERVICE DELIVERY ON 
LUNG CANCER OUTCOMES 
3.1 Introduction 
 
Lung cancer outcomes within the UK show significant unwarranted variation. (85) Chapter 2 
demonstrates that organisational factors contribute to this variation but the interplay of these 
factors on lung cancer outcomes is poorly understood.  
This chapter assesses the current state of UK lung cancer service provision and investigates 
the relationship between resource provision and lung cancer outcomes using an organisational 
score.  
3.1.1 The commissioning of lung cancer services 
 
Making diagnoses earlier and faster is central to the National Cancer Programme. (234) To 
achieve this a timed lung cancer diagnostic pathway has been implemented. This pathway 
emphasises the importance of ruling out cancer within 28 days so that those with cancer 
receive treatment earlier. This ‘Faster Diagnosis Standard’ is to be fully introduced in April 
2020.  
The ‘National Optimal Lung Cancer Pathway’ sets out how lung cancer services can be 
organised to achieve this target. (86) It aims to improve treatment times, increase the 
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proportion of patients treated with curative intent through better performance status and 
reduce variation in clinical practice. Key features include the following: 1.) CXR to CT and 
clinic in less than 24 hours 2.) Rapid turnaround times for testing and reporting 3.) Daily 
respiratory clinic opportunities 4.) Curative intent management pathway. A document entitled 
‘Clinical Advice to cancer alliances for the commissioning of the whole lung cancer pathway’ 
provides recommendations to commissioners and lung cancer ‘Expert Advisory Groups’ on 
the investments required to implement change. (11)  
3.1.1.2 The provision of lung cancer services in UK 
 
The National Lung Cancer Organisational Audit in 2014 provided the first snap shot of 
service provision in England and Wales. (85) The article highlighted significant variation in 
the availability and workload of lung cancer specialists, diagnostic and treatment services. 
The audit show that some trusts had no access to essential resources such as video assisted 
thoracoscopy (VAT) lobectomy and stereotactic radiotherapy. To address national gaps in 
service provision the following recommendations were made: 
1. Maximum of 30 patients discussed per MDT meeting. 
2. Diagnostic and non-cancer cases discussed at a separate MDT meeting. 
3. Lung CNS’s workload should not exceed 80 new cases per whole time equivalent per 
year. 
4. All lung cancer MDTs should have access to all diagnostic tests and prompt thoracic 
radiology and pathology input. 
5. All treatment modalities, including VAT lobectomy and stereotactic radiotherapy, 
should be available to all patients. 
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6. All trusts should participate in the next round of the national lung cancer 
organisational audit. 
The authors additionally performed a multivariate logistic regression analysis to assess the 
feasibility of linking service provision to patient outcome. They demonstrate an association 
between higher surgical resection rates and on-site availability of advanced staging modalities 
such as PET scan and VAT lobectomy. These findings add weight to the hypothesis that there 
is an association between resource factors and lung cancer outcomes. However, this 
relationship needs further detailed exploration to understand how services can be optimally 
organised.  
3.1.2 The need for a second national organisational lung cancer audit 
 
Lung cancer is the third most common diagnosed cancer in England but accounts for the most 
deaths(3). Section 1.7.1 shows that UK has low cancer survival when compared with other 
European countries. (237) In addition, national variation in one-year survival is demonstrated 
with five-year survival figures ranging from 12.4% to 17.6% across cancer alliances. (238)  
The first organisational audit reflected this variation. (85) However, three years on, little is 
known about the current provision of lung cancer services. Understanding national gaps in 
access to services is vital if improvements in outcomes are to be made.  
Chapter 2 demonstrated that ready access to key diagnostic and treatment facilities is key to 
achieving improved outcomes. This was shown to be more likely to be achieved by specialist 
centres that have facilities on site. Therefore, this chapter explores the national availability of 
key diagnostic and treatment facilities in the UK. The following modalities allow optimal 
lung cancer management: EBUS, local anaesthetic thoracoscopy, video assisted thoracoscopy, 
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PET CT, cardiopulmonary exercise testing, EGFR/ALK/PD-L1 testing, biological therapy, 
immunotherapy, stereotactic radiotherapy, thoracic surgery, VAT lobectomy, pulmonary 
rehabilitation and smoking cessation service. The significance of these facilities are described 
in section 1.5  
In addition to establishing national access to resources, an understanding of how the 
organisation of services directly impact patients is required if outcomes are to be improved. It 
is hypothesised that the recommendations proposed by the commissioning guidance will lead 
to better patient care. However, there is a paucity of evidence available to underpin such 
recommendations. The systematic review in the previous chapter outlines some service 
factors shown to improve outcomes. However, there is lack of knowledge of how these 
components individually and as a combination contribute to the optimal model. Exploring the 
relationship between organisational factors and patient outcomes individually and combined 
in an organisational score will be critical in defining factors evidenced to improve lung cancer 
outcomes. This will guide policy about the minimum resources required for a hospital to 
deliver a safe and effective lung cancer service.  
3.1.3 Organisational scores 
 
The creation of an organisational score based on the metrics recommended in the 
commissioning guidance aims to investigate the hypothesis that implementation of the 
National Optimal Pathway will lead to improved patient outcomes.  
Few scores assessing organisational aspects of care are commonly used in healthcare despite 
the increasing body evidence suggesting that resource factors significantly contribute to 
patient outcomes. (85) The majority of scores that do exist combine clinical measures to 
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predict a particular health outcome to guide clinical decision making. (239) For example, the 
CURB 65 score predicts mortality for patients that present to hospital with community 
acquired pneumonia. (240) A low score can prompt outpatient oral antibiotic treatment whilst 
a higher score correlates with a higher risk of mortality and hence requires more aggressive 
monitoring and treatment.  
Organisational scores in use mostly originate in the USA. (239) They are created by private 
healthcare providers to gain an overview of cost effectiveness of a hospital. Consequently, 
such scores have limited applicability to a UK service structure.  
A literature search for organisational scores used in a UK population revealed one study 
described in section 2.1.5.2. (108) Price et al explored the relationship between the resources 
available for the care of COPD patients and patient outcomes. Patient level data was derived 
from forty consecutive patient notes and organisational components collected from a survey. 
The score comprised of fourteen organisational components thought to represent good clinical 
practice. The authors show that units with the worse scores had proportionately more patients 
staying longer in hospital. No significant associations were found with mortality or 
readmission rates. However, Price et al show that mortality was lower in units with more 
respiratory staff per 100 beds and suggests that units with four or more respiratory physicians 
per 1000 beds have better mortality rates. This trend was not replicated with increased general 
physician numbers at a senior or junior level. The authors conclude that the availability of 
more respiratory physicians in a unit is proxy for a resource rich environment. They advocate 
that this whole systems approach affects patients care rather than any individual component. 
Their score did not include staffing components, but the article acknowledges the importance 
of addressing this deficiency in future scores. As mentioned in section 2.4.2.2.1, factors that 
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describe a well organised stroke unit have been set out and a similar process needs to occur 
for cancer care. (220)  
There are two main advantages in creating a composite organisational score for lung cancer 
services. Firstly, an overview of the processes within an organisation facilitates 
benchmarking. High performing organisations can be identified and studied to understand 
process that can be applied to low performing units. Additionally, policy makers can target 
extra resources to trusts where inequity has been demonstrated.  
Secondly health care providers of low scoring institutions are equipped with robust evidence 
to present to local service commissioners when lobbying for adequate resource provision. A 
single number is more easily understandable then several individual measures to monitor 
change within an organisation. (241)  
3.1.4 Aims and objectives 
 
The aim of this chapter is to study the national variation of lung cancer services and study the 
impact of specialist service delivery on lung cancer outcomes.  
The specific objectives are:  
1. What proportion of people with lung cancer have on site availability of key diagnostic tests: 
EBUS, local anaesthetic thoracoscopy, video assisted thoracoscopy, PET CT, 
cardiopulmonary exercise testing, EGFR mutation testing /ALK/PD-L1 testing? 
2. What proportion of people with lung cancer have on site availability to the following 
treatment modalities: biological therapy, immunotherapy, stereotactic radiotherapy, thoracic 
surgery, VAT lobectomy, pulmonary rehabilitation and smoking cessation service? 
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3. What are the individual organisational factors that influence time to treatment, one-year 
survival and curative intent treatment rate? 
4. What is the association between a bundle of organisational factors with time to treatment, 
one-year survival and curative intent treatment rate?  
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3.2 Methods 
 
3.2.1 The second ‘National lung cancer audit’ (NLCA) organisational audit 
 
An electronic survey was sent to all lung cancer leads (156) in England and Wales in June 
2017. The survey included questions on workforce provision, diagnostic procedures and 
treatment modalities. The questions were based on the 2014 survey but modified following 
feedback from three pilot testing sites and the NLCA clinical team. Table 3.1 shows the 
survey questions and definition of items included.  
The NLCA team consist of a project manager, project co-ordinator, four clinical leads and the 
author (clinical research fellow). This team works in collaboration with several key 
stakeholders. The University of Nottingham provides analysis of the collected data(4). 
Clinical leadership is provided by lung cancer experts recruited through the Care Quality 
Improvement Department of the Royal College of Physicians. (4) Finally, the NLCA 
executive group is constituted by the Society for Cardiothoracic Surgery (SCTS), the Roy 
Castle Lung Cancer Foundation (representing lung cancer patients), Wales Cancer Network 
Lung Cancer Group, the National Lung Cancer Forum for Nurses and the British Thoracic 
Oncology Group. (4)  
Participants were required to undergo a registration process prior to completing the survey. 
This was to ensure up to date contact details were available for all respondents. The survey 
opened on the 5
th
 of June 2017 with a close date of 30
th
 June 2017. A ‘helpdesk’ was provided 
via email and telephone to provide trusts support with completion of the survey and ensure 
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consistency of results. The ‘Help notes’ provided to trusts are shown in Table 3.1. Weekly 
reminders were sent via email to trusts that had not completed the survey.  
Once the responses were collated, a process of data cleaning was undertaken. In view of the 
wide variability in the reporting of staffing provision, emails seeking data verification were 
sent to trust reporting a figure of >2. The replies were collected on 4
th
 August 2017. The final 
responses were tabulated in an Excel spreadsheet.  
An evaluation of the process of the organisational audit was conducted in March 2018. 
Feedback sources were as follows:  
1.) Evaluation forms were sent to the NLCA user group. This is a group of lung cancer 
specialists that have volunteered to provide feedback to the work of the NLCA.  
2.) Additional free text comments included at the end of the survey 
3.) Email and telephone communication from participants.  
4.) NLCA team feedback 
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Table 3.1 Survey questions and definitions 
Question 
No 
Data Item Data Definition 
1 Please enter the name of your Trust/Health board Hospital: An organisation providing secondary healthcare services in England/Wales. A 
hospital trust may be made up of one or several hospitals within a region. 
 
If you are in England: we will be asking about services that relate to your specific trust 
If you are in Wales: we will be asking about services that relate to your specific hospital 
 
2 Please enter your trust/health board code   
3 Please provide us with the following details about 
the lung cancer lead 
Lung cancer lead: The professional in your hospital taking overall responsibility for the 
services provided to lung cancer patients.  
 
This person will have overall responsibility with the audit department for the data quality 
from your hospital. This person will ‘sign off’ the responses to this audit.  
4 Do you have separate diagnostic and treatment 
MDT meetings? 
MDT: ‘multidisciplinary team’-a group of healthcare professionals working in a coordinated 
manner for patient care.  
 
Diagnostic MDT Meeting: Meeting where the patients’ diagnostic work up is planned. Non-
cancer cases may be discussed at this meeting. Typically attended by an MDT co-ordinator, 
chest physician and thoracic radiologist.  
 
Treatment MDT Meeting: Meeting where the patients’ management is discussed. Only 
patients with a suspicion of lung cancer are discussed at this meeting. Must have the 
following core members in attendance throughout the meeting: MDT co-ordinator, lung 
cancer physician, thoracic radiologist, thoracic pathologist, lung cancer clinical nurse 
specialist, lung cancer medical oncologist (chemotherapy), lung cancer clinical oncologist 
(radiotherapy) and a thoracic surgeon.  
 
 
5 How often are your full MDT meetings? Full MDT= Treatment MDT 
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6 On average, how many patients are discussed at 
your full MDT meeting/s per week? 
The number reflects the average number of cases per week discussed at a full MDT in June 
2017. 
If more than one full MDT per week- the average number of patients discussed in a week 
during these meetings is required.  
 
7 What is the time allocated for your full MDT 
meeting/s? 
Time that is allocated for all core members to be in attendance at the meeting.   
If there is more than one MDT per week the total time allocated in a week is required.  
8 Please provide us with the following information 
relating to staff who are involved in the 
management of lung cancer patients at your Trust. 
It is very important that accurate information is 
submitted, therefore please verify the number (of 
whole-time equivalents) with the appropriate 
departments. 
 
(a) Lung cancer clinical nurse specialist 
(b) Lung cancer physician 
(c) Lung cancer medical oncologist 
(chemotherapy) 
(d) Lung cancer clinical oncologist 
(radiotherapy) 
(e) Thoracic surgeon 
(f) Thoracic radiologist 
(g) Research Nurse 
 
Whole time equivalent (WTE): An WTE of 1.0 means that the person is equivalent to a 
full‐ time worker, while an WTE of 0.5 signals that the worker is half‐ time or half of their 
full-time work is dedicated to lung cancer/thoracic work.  
For example, a medical oncologist may work full time but has 3 sessions dedicated to lung 
cancer per week. Assuming a 10-session week-the number quoted should be 0.3.  
 
Lung cancer clinical nurse specialist:  
A nurse specialising in the care of people diagnosed with lung cancer (and mesothelioma). 
 
Lung cancer physician: A consultant physician with specialist skills in diagnosing and 
managing lung cancer (>50% of their job plan should be dedicated to lung cancer work which 
may include clinics, bronchoscopies, MDT’s and administration time) 
 
Lung cancer medical oncologist:  Oncologist with specialist skills in providing 
chemotherapy to lung cancer patients. 
 
Lung cancer clinical oncologist: Oncologist with specialist skills in providing radiotherapy 
and chemotherapy to lung cancer patients. 
 
Thoracic surgeon: A consultant thoracic surgeon who has performed at least one lung cancer 
resection in the last 12 months.  
 
Thoracic radiologist: A consultant radiologist with specialist skills in thoracic imaging.  
 
Research nurse: A registered nurse who is involved with the delivery of lung cancer clinical 
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trials and studies.  
9 Please provide the following information relating 
to diagnostic and staging modalities available to 
your lung cancer patients. 
 
a. EBUS 
b. Local anaesthetic thoracoscopy 
c. Video assisted thoracoscopy 
d. PET 
e. Cardiopulmonary exercise testing  
f. EGFR mutation testing 
g. ALK mutation testing 
PDL1 testing 
 
On site: This service is provided for your lung cancer patients at your trust/healthboard.  
 
Off site: Access to this service is provided for your lung cancer patients via an established 
referral pathway to another trust/healthboard. 
 
Not available: There is not a provision for access to this service for your lung cancer patients 
at your trust/healthboard or via an established referral pathway. 
 
 
10 Please provide us with the following information 
relating to treatment modalities available to your 
lung cancer patients. 
 
a. Biological therapy e.g. TKIs 
b. Immunotherapy e.g. PDL1 inhibitor 
c. Stereotacic radiotherapy 
d. Thoracic surgery 
e. VAT lobectomy 
f. Pulmonary rehabilitation 
g. Smoking cessation  
Biological therapy: Therapies targeting specific cell mutations. E.g. Tyrosine kinase 
inhibitors.  
 
Stereotactic radiotherapy: External radiation that precisely delivers a high irradiation dose 
to a target.  
 
VAT lobectomy (Video assisted thoracoscopy) lobectomy: Removal of a lobe of the lung 
via a VAT procedure.  
 
Immunotherapy: treatment inhibiting PDL1 pathway 
 
FOR TRUSTS PROVIDING THORACIC SURGERY ON SITE 
11 How many WTE thoracic surgeons do you have?  
Whole time equivalent (WTE): An WTE of 1.0 means that the person is equivalent to a 
full‐ time worker, while an WTE of 0.5 signals that the worker is half‐ time or half of their 
full-time work is dedicated to thoracic work. 
 
Thoracic surgeon: A consultant thoracic surgeon who has performed at least one lung cancer 
resection in the last 12 months. 
 
12 How many thoracic surgery theatre sessions are 
there per week? 
13 How many thoracic high dependency beds do you 
have?  
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Surgical theatre session: A scheduled period of operating theatre time allocated to a 
consultant thoracic surgeon. 1 session is half a day.  
 
Thoracic high dependency bed:  A level 2 bed staffed with a minimum of one nurse to two 
patients. The bed is specifically allocated to cardiothoracic patients.  
 
14 Please use this space to provide any additional 
comments you may have.  
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3.2.2 Development of the organisational score 
 
An organisational score for lung cancer services was produced by adding one point for eleven 
organisational factors. Studies have reported that a significant limitation of composite scores 
is that components are based on information that is easily gathered or available. (239) To 
address this, a score was created on pre-determined objectives as outlined in the ‘Lung Cancer 
National Commissioning Guidance’. Table 3.2 shows the items included in the organisational 
score. The total score was split into three groups for analysis.  
Table 3.2 Items included in the organisational score 
Access to the following:  Score 
One whole time equivalent (WTE) respiratory physician direct clinical care 
per 200 new diagnoses per year 
1 
Radiologist with at least a third of their job plan devoted to lung cancer 1 
Medical oncologist with at least a third of their job plan devoted to lung 
cancer 
1 
Clinical oncologist with at least a third of their job plan devoted to lung 
cancer 
1 
One WTE LCNS per 80 new diagnoses per year 1 
Separate diagnostic planning multi-disciplinary team (MDT) meetings from 
treatment MDT meetings 
1 
Onsite PET scan 1 
Onsite Endobronchial Ultrasound (EBUS) 1 
Onsite Thoracoscopy 1 
Access to molecular testing (EGFR and ALK)  1 
Cardiopulmonary exercise testing (CPEX) 1 
  
Total score 11 
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3.2.3 Patient level data collection 
 
The organisational results were linked to trust level patient outcomes for trust first seen using 
the NLCA dataset for England and Wales. This is a validated database established in 2005, 
which consists of anonymised records of individuals with a diagnosis of lung cancer.  
The patient population includes all individuals receiving a diagnosis of lung cancer which 
may include histological diagnosis or clinical diagnosis. At the time of the survey the most 
recently available data from the NLCA included patients diagnosed up to 31
st
 December 2015 
(updated for survival till 01/10/2016). Patients were included if they had a diagnosis of lung 
cancer (ICD code C34).  
NHS hospitals in England submit details for all lung cancer patients including patients 
undergoing lung cancer surgery via the Cancer Outcomes and Services Dataset (COSD) to the 
NLCA via the National Cancer Registration and Analysis Service (NCRAS) at Public Health 
England. COSD is a generic cancer registry dataset that includes additional clinical and 
pathological site-specific data items relevant to different tumour types. The data for Wales are 
collated and quality assured by the Wales Cancer Network (WCN). The NLCA dataset is 
linked to the following: Hospital Episode Statistics (HES), the National Radiotherapy Dataset 
(RTDS), the Systemic Anti-Cancer Dataset (SACT) and Office of National Statistics Data. A 
pseudo-anonymised extract is then submitted to the NLCA analysis team.  
Case ascertainment is measured by the audit annually to ensure that cases are not selected to 
be submitted by trusts. Case ascertainment rates are measured by comparing the number of 
cases submitted each year with the expected numbers based on historic data from other cancer 
registries. In England, the use of processed cancer registration data linked to the above data 
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sources means that a case ascertainment of approximately 100% is achieved for all trusts. 
(242)  
Unique to other routinely collected worldwide datasets, the NLCA collects detailed clinical 
data. (242) This allows accurate risk adjustment analyses to be conducted. Data completeness 
for the 2015 patient cohort was high. 76% of patients had performance status recorded, 95% 
had stage recorded and 53% of patients with good performance status and early stage disease 
had FEV1% recorded and 55% had FEV1 recorded.  
Patients are allocated to hospitals trusts on a “trust first seen basis” which is recorded as a data 
item routinely collected. This avoids duplication where patients may have been first seen at 
one trust but received treatment elsewhere. In 18% of trusts in England this field was blank or 
contained two contradictory values. (242) In these cases, an algorithm is used to assign trust 
first seen on the basis of other data in the database.  Patients are assigned to peripheral centres 
over tertiary centres and site of diagnostic testing over site of treatment receipt.   
3.2.4 Patient level data cleaning 
 
Start and end dates were created for survival analyses. The date of diagnosis was used as the 
start date. In the absence of a date of diagnosis the following were used as an alternative in the 
following order: 
1.) Date of first histological or cytological confirmation of this malignancy 
(except for histology or cytology at autopsy). The date is in the following 
order:  
a.) Date when the specimen was taken  
b.) Date of receipt by the pathologist  
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c.) Date of the pathology report 
2.) Date of admission to hospital because of this malignancy 
3.) When evaluated at an outpatient clinic only: - date of first consultation at the 
out-patient clinic because of this malignancy.  
4.) Date of diagnosis other than above 
An end date was generated using the date of death (obtained from the Office for Statistics 
database) or the date that data cleaning commenced which was the 01/10/2016. 
3.2.5 Covariates 
 
The following variables were identified from the NLCA data: sex, age at diagnosis, 
socioeconomic status (derived from the postcode and linked with the Index of Multiple 
Deprivation), Eastern Co-operative Oncology Group (ECOG) performance status (according 
to the WHO definition) and stage of disease at presentation TNM version 7 (as classified by 
‘The IASLC Lung Cancer Staging Project’). (18) The HES database was used to calculate the 
Charlson Co-morbidity Index (a composite score that has been validated for use in this 
dataset) preceding the date of lung cancer diagnosis. (158) These co-variates were chosen as 
they are established as affecting patient outcome in lung cancer and have been used in 
previous studies using the NLCA dataset. (158) In particular, the importance of 
socioeconomic status is highlighted in section 2.4.2.2.3. Variable definitions are described in 
Table 3.3. 
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Table 3.3 Variable definitions 
Variable Source Comment/Definition 
Sex NLCA Recorded as male or female 
Age NLCA Age at diagnosis 
Performance status NLCA Eastern Co-operative Oncology Group (ECOG) performance status according to WHO definition:- 0: fully active, 
able to carry on all pre disease performance without restriction; 1: restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature e.g. light house work, office work; 2: 
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of 
waking hours; 3: capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4: 
completely disabled. Cannot carry on selfcare. Totally confined to bed or chair; 5: dead.  
Stage NLCA Stage of disease at presentation as classified by TNM version 7 (as classified by ‘The IASLC Lung Cancer Staging 
Project’).  
Socio-economic status using 
the Townsend Score for 
Deprivation 
NLCA 
derived 
This measure is derived from a patients’ postcode which is linked with the Townsend score for deprivation. This is 
divided into quintiles with 1 being the most affluent quintile and 5 representing the least.  
Co-morbidity status using the 
Charlson Co-morbidity Index 
HES derived The HES dataset contains up to twenty diagnoses for each hospital episode coded using ICD-10. This data will be 
used to calculate the Charlson Index, which is a composite score of co-morbidity which has been validated in 
cohorts of men and women with both malignant and non-malignant diseases. ICD-10 codes for lung cancer were 
excluded for the calculation.  
Received surgery NLCA/HES All patients with a valid date recorded of a curative surgical procedure Surgical operation were identified with the 
Office of Populations Census and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) 
codes for each patient indicating thoracic surgical procedure with curative intent. The surgical procedures were 
categorised as 1) pneumonectomy, 2) lobectomy, including sleeve and bilobectomy, 3) sub-lobar resections, 
comprising segment and wedges, 4) complex resection and others 
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Received radiotherapy NLCA/RTDS All patients with a valid date recorded for the receipt of radiotherapy. 
Received chemotherapy NLCA/SACT All patients with a valid date recorded for the receipt of lung chemotherapy.  
Received best supportive care NLCA 
derived 
All patients that did not receive active treatment (see below for definition of active treatment).  
Date of diagnosis NLCA 
derived 
The date of diagnosis is a derived field from the following order of declining priority: 
1.) Date of first histological or cytological confirmation of this malignancy (except for histology or 
cytology at autopsy). The date is in the following order a.) date when the specimen was taken, or 
b). date of receipt by the pathologist or c). date of the pathology report.  
2.) Date of admission to hospital because of this malignancy 
3.) When evaluated at an outpatient clinic only: date of first consultation at the out-patient clinic 
because of this malignancy.  
4.) Date of diagnosis other than the above.  
Date of death NLCA/Office 
for Statistics 
As per Office for Statistics database 
Received curative intent 
radiotherapy 
Derived All patients with non-small cell lung cancer (NSCLC) with a valid date of radiotherapy with a dose of >50Gy.  
Received curative intent 
treatment 
Derived All patients with NSCLC that received surgery or curative intent radiotherapy. 
Time to first treatment Derived Date of first treatment (chemotherapy, radiotherapy or surgery) minus date of diagnosis in days 
Received treatment within 62 
days 
Derived All patients where the time to treatment is ≤62 days 
Survival Derived Date of death-Date of diagnosis or 01/10/2016 in days 
One-year survival NLCA 
derived 
All patients with survival ≥12 months  
167 
 
3.2.6 Outcomes 
 
Three outcomes were measured. The first was curative-intent treatment rate, which was 
defined as the proportion of patients with non-small cell lung cancer (NSCLC) with a record 
of a curative surgical procedure or patients who received radiotherapy with curative intent 
(>50Gy).  The second was receipt of active treatment within 62 days. Active treatment was 
defined as the proportion of patients who had a valid treatment start date for surgery, 
chemotherapy or radiotherapy. The third was the proportion of patients alive at one year.  The 
studied outcomes relate to treatment rates as treatment is critical to improving overall patient 
outcomes. The rationale for the chosen outcome variables are summarised in Table 3.4.  
 
Table 3.4 Rationale for outcome variables 
Outcome Rationale for assessment 
One-year 
survival 
The biggest chance of survival is receiving appropriate treatment.  
To test the hypothesis that having access to specialist staff and resources correlates 
is associated with better survival. 
Receipt of 
active 
treatment 
within 62 days  
Faster pathways are evidenced to improve patient outcomes. National cancer 
standards mandate that cancer treatment should be provided within 62 days from 
referral. NLCA does not record referrals dates so the date of diagnosis was used as 
a proxy. To test the hypothesis that access to specialist resources is associated with 
an increased chance of receiving treatment within 62 days.  
Curative intent 
treatment 
To test the hypothesis that patients with access to resources are more likely to 
receive radical intent treatment. Patients that receive curative intent treatment have 
a better chance of improved survival. 
 
3.2.7 Statistical Analysis 
All data and statistical management were performed by STATA V.14 (StataCorp). Multi-
variate logistic regression analysis was used to estimate the odds of receiving curative intent 
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treatment, treatment within 62 days and one-year survival by the organisational score 
adjusting for patient and organisational factors. A mixed model effects model was chosen to 
account for the hierarchical nature of the data. This method recognises that organisational 
features are measured at a trust level whilst patient features are measured at an individual 
patient level. To minimise bias resulting from reverse causation, only patient factors known at 
the time of diagnosis were considered in the final multi-variate model. The organisational 
score data was categorised into three groups. A p value of <0.05 was considered statistically 
significant. 
3.2.8 Power 
 
The dataset provided by the National Lung Cancer Audit is one of largest and most complete 
cancer datasets worldwide. (4) Therefore, there is statistical power associated with the 
analyses even when assessing subgroups of patients.  
3.2.9 Ethical considerations 
 
The author is a member of the NLCA team; therefore an amendment was granted on the data 
sharing agreement between the Office of Data Release and the University of Nottingham 
NLCA research team as an additional processor. This allows access to audit data at the 
University of Nottingham site, for the purposes of analysis of the organisational audit only. 
Additionally, ethical approval was gained for access to patient level data (IRAS number: 
237237).  
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3.3 Results 
 
3.3.1 Results of the second organisational audit 
 
One hundred and thirty-eight responses to the organisational audit survey were submitted 
from 156 trusts (88% participation rate; 85% for England; 92% for Wales). After removal of 
duplicate and empty records 129 records (83%) were available for analysis, which compares 
to 57% participation rate in 2014.  
3.3.1.1 Comparison of 2014 organisational audit results to 2017 
 
Table 3.5 shows the number of hospitals that met the recommendations made in the first 
organisational audit in 2014 compared to 2017. The number of units with a separate 
diagnostic MDT meeting has increased from 29% to 43%, however one third of providers still 
discuss more than 30 patients per MDT meeting list. 
Table 3.5 Number (%) that met the recommendations made in the first organisational 
audit in 2014 compared to 2017 
Recommendation 2014 
n (%) 
2017 
n (%) 
Maximum of 30 patients discussed per MDT meeting 75 (74) 91 (69) 
Diagnostic and non-cancer cases discussed at a separate MDT 
meeting 
29 (29) 57 (43) 
Lung CNSs workload should not exceed 80 new cases per whole 
time equivalent per year 
16 (20) 24 (18) 
All lung MDTs should have access to all diagnostic tests 79 (85) 99 (77) 
All treatment modalities should be available to all patients 84 (90) 116 (90) 
All trusts should participate in the national lung cancer 
organisational audit 
101 (57) 132 (83) 
LCNS: Lung cancer specialist nurse 
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3.3.1.2 Multidisciplinary team meeting 
 
The first organisational audit recommended that trusts should have separate diagnostic and 
treatment MDT meetings. The diagnostic MDT meeting is where the patients’ diagnostic 
work up is planned. Non-cancer cases may be discussed at this meeting as well. The treatment 
MDT meeting is where patients with a suspicion of lung cancer management is discussed. 
44% (n=58) of trusts have a separate diagnostic and treatment MDT meeting. The majority of 
treatment MDT’s occur weekly (94%, n=124). There is variation in the amount of time 
allocated by MDT’s for this meeting illustrated in Figure 3.1. The majority (55%) of trusts 
allocate 1-2 hours with 24% allocating just one hour. 
  
Figure 3.1 Time allocated for discussion of patients by NHS trusts in the main MDT 
meeting 
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3.3.1.3 Diagnostic/staging services 
 
Figure 3.2 illustrates the spread of access to diagnostic facilities. There is variation in 
availability of diagnostic facilities at NHS trusts. All trusts have access (on or off site) to 
EBUS, PET scan and molecular testing (ALK and EGFR) facilities. The provision of onsite 
EBUS has increased from 44% to 67% in three years. All but one trust has access to PDL-1 
testing. 123 trusts (95%) have on or off-site access to cardiopulmonary exercise (CPEX) 
testing, with 6 trusts (5%) having no access to this testing modality. Finally, local anaesthetic 
thoracoscopy is unavailable in 20% of trusts (14% in 2014). 
  
Figure 3.2 National access to diagnostic modalities for lung cancer 
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3.3.1.4 Lung cancer treatments 
 
The national provision of lung cancer treatments in summarised in Figure 3.3. All trusts have 
on or off-site access to thoracic surgical services. All but one trust has access (on or off site) 
to immunotherapy. Very few trusts had no access to biological therapy (2%) and stereotactic 
radiotherapy (SABR) (2%). Provision of onsite pulmonary rehabilitation (81% to 67%) and 
smoking cessation services (86% to 67%) has decreased over three years.  
 
Figure 3.3 National access to treatment modalities for lung cancer 
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3.3.1.5 Staffing 
The mean (range) number and workload of lung cancer specialists available to each trust is 
shown in Table 3.6. There is national variation in workforce provision. The number of annual 
lung cancer diagnoses seen per whole time equivalent (WTE) of time dedicated to lung cancer 
work for thoracic surgeons ranges from 0 to 4520 with a median of one surgeon per 256 new 
lung cancer patients per year.  The role with the least variability is lung cancer clinical nurse 
specialists (LCNS). Units have a median of two WTE nurses (range 0.2-5). The median 
workload varied from one LCNS per 9 to 479 new patients per year with a median of 106. 
Only 18% of units met the 2014 recommendation that LCNS’s workload should not exceed 
80 new cases per WTE per year.  
 
Table 3.6 The median (range) number and workload of lung cancer specialists available 
to each unit 
 Number of whole-
time equivalents 
(WTE) 
Workload  
Lung cancer clinical nurse specialist 2 (0.2-5) 106 (9-479) 
Lung cancer physician 1.47 (0-8) 136 (0-2009) 
Lung cancer medical oncologist 
(chemotherapy) 
0.5 (0-4) 189 (0-4110) 
Lung cancer clinical oncologist 
(radiotherapy) 
1 (0-5.2) 316 (0-4520) 
Thoracic surgeon 1 (0-4.5) 256 (0-4520) 
Thoracic radiologist 1 (0-5) 187 (0-1910) 
Research Nurse 0.2 (0-4.3) 125 (0-4060) 
PA’s: Programmed Activities: four hours work within a normal working week; Workload is expressed 
as annual lung cancer diagnoses per WTE specialist allocated to lung cancer work.  
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3.3.2 Organisational score 
 
The overall organisational score varied by hospital trust from zero to eleven. Thirty-eight 
(29%) units had a score of 0-4, 64 (50%) units had a score of 5-7 and 27 (21%) units had a 
score of 8-11. Table 3.7 shows the number of lung cancer units that met each of the individual 
recommendations included in the score. There was a wide range of compliance with the 
recommendations, from only 24 (18%) units meeting the recommendation of one whole time 
equivalent lung cancer nurse specialist per 80 new diagnoses per year, to 107 (83%) units 
reporting a radiologist with a third of their job plan devoted to lung cancer. 
 
Table 3.7 Number of hospitals that met the recommendations included in the 
organisational score from the second organisational audit (n=129) 
 Number % 
One whole time equivalent respiratory physician direct clinical care per 200 new 
diagnoses per year 
79 61 
Radiologist with at least a third of their job plan devoted to lung cancer 107 83 
Medical oncologist with at least a third of their job plan devoted to lung cancer 77 60 
Clinical oncologist with at least a third of their job plan devoted to lung cancer 90 70 
One whole time equivalent LCNS per 80 new diagnoses per year 24 19 
Separate diagnostic planning multi-disciplinary team meetings  57 44 
Onsite PET scan 40 31 
Onsite Endobronchial Ultrasound 87 67 
Onsite Thoracoscopy 68 53 
Onsite access to molecular testing 25 19 
Onsite cardiopulmonary exercise testing 72 55 
LCNS: Lung clinical nurse specialist, PET: positron emission tomography 
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3.3.3 Patient level results 
 
The NLCA identified 42,307 patients who were diagnosed with lung cancer between 1 
January 2015 and 31
st
 December 2015. The cohort criteria are illustrated in Figure 3.4. A total 
of 33,312 patients were included in the final analysis. The patient demographic details for the 
study cohort are shown in Table 3.8. Fifty-three per cent (n=17,797) were men and 55% 
(n=18, 165) were aged between 65- 80 years old. 7433 patients (25.0%) received treatment 
with curative intent, 16773 (50.4%) patients received treatment with 62 days of diagnosis and 
11547 (34.7%) patients were alive at one year from diagnosis. 
 
Figure 3.4 Cohort flow diagram 
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Table 3.8: Patient demographics 
   Patients (n) % 
Sex Female 15,516 46.6 
 Male 17,796 53.4 
Age  <65years 7,329 22.0 
 65-80 years 18,165 54.5 
 >80 years 7,818 23.5 
Stage IA 3,359 10.1 
 IB 2,233 6.7 
 IIA 1,269 3.81 
 IIB 1,178 3.54 
 IIIA 3,812 11.4 
 IIIB 3,019 9.06 
 IV 16,778 50.3 
 Missing 1,664 5.0 
Performance status 0 4,816 14.5 
 1 8,681 26.1 
 2 5,373 16.1 
 3 4,877 14.6 
 4 1,613 4.8 
 Missing 7,952 23.9 
Townsend quintile 1 (most affluent) 4,534 13.6 
 2 5,968 17.9 
 3 6,787 20.4 
 4 7,520 22.6 
 5 (least affluent) 8,431 25.3 
 Missing 72 0.2 
Charlson index 0 10,715 32.2 
 1 5,405 16.2 
 2 5,397 16.2 
 3+ 11,795 35.4 
 
3.3.4 Linkage of the organisational audit with NLCA patient results  
 
The results of the multivariate logistic regression analyses of patient factors and 
organisational score on patient outcomes are shown in Table 3.9. The results demonstrate that, 
compared to organisational score of 0-4, patients seen at hospitals with a score of 8-11 had a 
higher one-year survival (adjusted OR (95% CI)= 2.30 (1.04-5.08), p<0.001), higher curative-
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intent treatment rate (adjusted OR (95% CI) = 1.62 (1.26-2.09), p<0.001) and greater 
likelihood of receiving treatment within 62 days (adjusted OR (95% CI) = 1.49 (1.20-1.86), 
p<0.001).  
The provision of onsite diagnostic/treatment modalities (onsite provision of EBUS, PET, 
EGFR, ALK mutation testing, PDL-1 testing, smoking cessation services, pulmonary 
rehabilitation, stereotactic radiotherapy, surgery, biologics, immunotherapy) individually were 
not significantly associated with the studied patient outcomes (when adjusted for patient and 
organisational factors and clustered for trust). Full results of the proportions, unadjusted and 
adjusted odd ratios of patient of organisational and staffing factors by patient outcome 
(likelihood of curative-intent treatment, all treatment within 62 days and one-year survival) 
are shown in the appendix (A4) 
. 
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Table 3.9 Results of multivariate logistic regression analyses using a mixed effects model investigating the influence of patient factors 
and organisational score on studied outcomes  
 
  One-year survival 
(n=33,312) 
Treatment within 62 days 
(n=33,312) 
Curative intent treatment 
(n=29,793)   Adjusted OR (95% 
CI) 
p value for 
chi squared 
Adjusted OR 
(95%CI) 
p value for chi 
squared 
Adjusted OR 
(95%CI) 
p value for chi 
squared 
Sex Female 1.00  1.00  1.00  
 Male 0.71 (0.70-0.75) <0.001 0.97 (0.93-1.03) 0.378 0.91 (0.84-0.98) 0.016 
Age  <65years 
old 
1.00  1.00  1.00  
 65-80 
years old 
0.76 (0.71-0.82)  0.60 (0.56-0.64)  0.77 (0.70-0.85)  
 >80 years 
old 
0.45 (0.41-0.50) <0.001 0.18 (0.16-0.19) <0.001 0.22 (0.19-0.25) <0.001 
Stage IA 1.00  1.00  1.00  
 IB 0.65 (0.56-0.76)  1.03 (0.91-1.17)  0.96 (0.83-1.10)  
 IIA 0.41 (0.35-0.49)  1.05 (0.91-1.23)  0.69 (0.58-0.82)  
 IIB 0.31 (0.26-0.36)  1.02 (0.87-1.19)  0.50 (0.43-0.60)  
 IIIA 0.17 (0.15-0.20)  1.10 (0.98-1.22)  0.19 (0.17 (0.21)  
 IIIB 0.08 (0.07-0.10)  1.42 (1.26-1.60)  0.04 (0.33-0.05)  
 IV 0.04 (0.03-0.04) <0.001 0.84 (0.77-0.92) <0.001 0.01 (0.01-0.01) <0.001 
Performance status 0 1.00  1.00  1.00  
 1 0.60 (0.55-0.66) 
 
 0.66 (0.60-0.72)  0.54 (0.48-0.60)  
 2 0.30 (0.27-0.34)  0.31 (0.28-0.34)  0.20 (0.17-0.22)  
 3 0.12 (0.10-0.13)  0.09 (0.08-0.10)  0.03 (0.03-0.04)  
 4 0.05 (0.04-0.06) <0.001 0.03 (0.03-0.04) <0.001 0.09 (0.00-0.02) <0.001 
Townsend quintile 1 (most 
affluent) 
1.00  1.00  1.00  
 2 0.87 (0.79-0.97)  0.91 (0.83-0.99)  1.02 (0.88-1.17)  
 3 0.94 (0.85-1.05)  0.85 (0.77-0.93)  0.93 (0.81-1.07)  
 4 0.88 (0.80-0.98)  0.82 (0.75-0.90)  0.96 (0.84-1.12)  
 5 (least 
affluent) 
0.82 (0.74-0.90) 0.060 0.75 (0.68-0.82) <0.001 0.87 (0.75-1.00) 0.614 
Charlson Index 0 1.00  1.00  1.00  
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 1 0.94 (0.86-1.02)  1.28 (1.18-1.39)  1.15 (1.40-1.73)  
 2 0.85 (0.77-0.92)  1.10 (1.02-1.20)  1.32 (1.18-1.50)  
 3+ 0.62 (0.58-0.67) <0.001 1.14 (1.07-1.22) <0.001 1.07 (0.96-1.20) <0.001 
Organisational 
score 
0-4 1.00  1.00  1.00  
 5-7 1.89 (0.99-3.61)  1.14 (0.95-1.37)  1.13 (0.92-1.40)  
 8-11 2.30 (1.04-5.08) <0.001 1.49 (1.20-1.86) <0.001 1.62 (1.26-2.09) <0.001 
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3.4 Discussion 
 
These data provide an important overview of lung cancer services in England and Wales. We 
show that there remains significant variation in the provision of services, specifically 
diagnostic and treatment modalities, and provision of staff across the UK. The results go 
further to demonstrate that the provision of resources and organisation of care is associated 
with patient outcomes through the novel use of an organisational score.  
3.4.1 Organisational audit findings 
 
3.4.1.1 Access to onsite diagnostic/treatment modalities 
 
It is reassuring that most diagnostic and treatment modalities are available on or off site. The 
results for the provision of these facilities are discussed further below.  
EBUS facilities provided on site has increased by 23% over the last three years. The 
importance of ready access to EBUS been demonstrated by Navani et al in a randomised 
controlled trial comparing lung cancer diagnosis and staging with EBUS transbronchial 
needle aspiration with conventional approaches. (88) They showed that the use of EBUS as 
the initial investigation after staging CT results in a faster treatment decision, fewer 
investigations and improved survival. Therefore, improving access to the third of trusts that 
currently do not have onsite access to EBUS has the potential to optimise the management of 
lung cancer patients.  
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All units reported access to a PET scan however, this was off site for two thirds. Over the last 
decade it is increasingly recognised that access to PET scanning is essential for the modern 
management of lung cancer. (227) The NICE guidelines for the diagnosis and management of 
lung cancer recommended that all patients potentially suitable for curative intent treatment are 
offered a PET-CT and every cancer network should have a system of rapid access to this 
facility. (227). This is underpinned by randomised controlled trial evidence showing that 
compared with conventional staging, PET scanning reduces the frequency of thoracotomy 
without cure (243,244). It is therefore a concern that seven units specifically commented on 
the slow speed of access to PET scanning at their organisation in the free text portion of the 
survey.  
A key part of the future of lung cancer management is access to targeted treatment. Molecular 
diagnostic tests assess the genetic make-up of a patients’ cancer to identify whether that 
individual is eligible for targeted medicine. (245) Access to these tests are fundamental to 
ensure that all management options are explored. Among patients with a mutation in the 
EGFR gene, 80-90% show evidence of response to targeted treated compared to only 20-40% 
responding well to standard chemotherapy. (245) Whilst all trusts have access to molecular 
testing, the majority (approximately 80%) reported off site testing which is likely to impact on 
speed of testing to inform clinical decision making. These results are in keeping with finding 
published by CRUK on the provision of molecular diagnostics in England. (245) This report 
estimates a gap of 13,825 tests in 2014 by subtracting the provision of tests (22,097) from the 
demand (35,922). A contributing factor to this gap in provision may be timely access to 
testing.  
Trials investigating immunotherapy agents (a form of targeted therapy) have shown improved 
overall survival and progression free survival compared to standard chemotherapy treatment 
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alone (72,246). Therefore, improving the access to these drugs through on-site availability and 
provision of adequate oncology specialists is vital. The survey shows that the over three 
quarters of units have on site access to immunotherapeutic agents and 70% of trusts have a 
clinical oncologist with at least one third of their job plan devoted to lung cancer. The 
continued provision of these resources will be increasingly important with new agents being 
appraised by NICE.  
The reduction in provision of essential smoking cessation and pulmonary rehabilitation 
services is a major concern. The importance of smoking cessation services in the prevention 
and management of lung cancer is discussed in section 1.4.1. In addition it is emphasised in 
lung cancer management guidelines. (11,86,227) In addition, two recent publications 
demonstrate the need to prioritise such services. (247,248) Firstly, a report by the Tobacco 
Advisory Group of the Royal College of Physicians (RCP) published in 2018 state that 
“health service commissioners and practitioners have a responsibility to ensure that cost 
effective smoking interventions are provided and properly implemented. Failure to identify 
and treat smokers is no less negligent than failure to identify and treat patients with cancer”. 
(247) Secondly, Gemine et al add to the existing evidence that quitting smoking after a 
diagnosis of lung cancer improves survival. They report a 25% reduction in mortality in those 
that stopped smoking within three months of diagnosis compared to those who continued 
smoking. (248)  
Despite the growing evidence base highlighting the need to invest in smoking cessation 
services, local budgets for stop smoking services have been consistently cut for the last four 
years; which may be reflected in the organisational audit results. (247) In 2016, 59% of local 
authorities made budget cuts to such services, and 50% in 2017. (247) Total spending in 
England on stop smoking services in 2013/2014 amounted to approximately 128.1 million, 
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falling to just 89 million in 2017/18. (247) It is clear that if optimal outcomes for lung cancer 
are to be achieved, then investment in smoking cessation facilities must be prioritised as 
advocated by the RCP report.  
Studies have shown that pulmonary rehabilitation (PR) has successfully improved outcomes 
for patients with lung cancer. (249) In a pre or post-operative setting, PR leads to fewer 
surgical complications. (249) Additionally, improved quality of life has been demonstrated 
with PR in a non-surgical setting after patients have received chemotherapy or radiotherapy. 
(250,251) However, compared to the wealth of evidence supporting PR in other respiratory 
diseases such as chronic obstructive pulmonary disease (COPD), good quality prospective 
studies are still lacking for lung cancer. (249) Details regarding the optimal duration and time 
of initiation are lacking. Nevertheless, studies estimate the prevalence of COPD in lung 
cancer patients varies from 8% to as high as 50% (252,253), where PR is an established 
management strategy. (254) Improved access to this treatment is therefore integral to the 
multidisciplinary and holistic management of lung cancer patients.  
Finally, only one fifth of trusts have access to onsite thoracic surgery. Previous interrogation 
of the NLCA demonstrated that the odds of a surgical resection are increased by 37% for 
patients first seen in a centre where surgeons are on site compared to non-surgical centres. 
(159) Therefore, strategies to improve access to such facilities must be considered to improve 
the chance of cure for lung cancer patients.  
3.4.1.2 Multidisciplinary care and staffing provision 
 
Multidisciplinary team meetings play a pivotal role in quality decision-making for lung cancer 
patients. The first organisational audit recommended that trusts should have two MDT 
meetings. (85) There has been a 20% increase in the number of trusts that now have two 
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meetings, however the average time spent per patient discussion remains the same 
(approximately 4-8 minutes/patient). Results from the first organisational audit and lung 
cancer commissioning guidance recommend a maximum number of 30 patients discussed per 
MDT meetings to ensure there is adequate time for to discuss treatment options for all 
patients. (11,85) Analysis of the free text section of the survey revealed strategies that have 
been implemented to enable a unit to adhere to this recommendation which may have 
contributed to the improvement in this metric. These included the creation of a dedicated 
nodule meeting and a triage system reducing the number of patients discussed at MDT. In 
addition, there are currently several pilot NHS projects evaluating the impact of streamlining 
MDT meetings which may develop further strategies to achieve this recommendation.  
The inequity in staff workload has previously been highlighted as a key issue. (85) This data 
shows that variability still exists, with only 18% (decreased from 20% in 2014) of trusts 
meeting the recommendation that there should be one WTE LCNS per 80 new lung cancer 
diagnoses per year. In a study examining LCNS working practices in the UK, Stewart et al 
show that increased LCNS workload directly impact patients. (151). They found that LCNS’s 
with a caseload of >250 patients/year were approximately one third less likely to have surgery 
compared to patients assessed by an LCNS with a workload of ≤150 patients/year. 
Additionally, data from the NLCA show that patients seen by a LCNS are twice as likely to 
active treatment (60% vs 30%) than patients that are not(255).  
The importance of improving access to specialist lung cancer staff, including LCNSs, is 
emphasised in section 2.3.4. In addition, a briefing by Cancer Research UK published in 
November 2018 highlighted this need. (256). They estimate that staff numbers would need to 
double in 2027 to meet the needs of the population. The report states that even without 
delivering lung cancer screening, it is likely that 70% more radiologists will be needed in ten 
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years compared to current levels. If screening is implemented, then hundreds more would be 
needed on top of this. Government policies have placed workforce requirements central to 
NHS England’s ten-year plan (256); a need reflected in the results of this audit.  
3.4.2 Organisational score 
 
A novel organisational score was developed to assess the relationship between the 
organisation of a lung cancer service and the outcomes for patients who are seen at that 
service. Chapter two demonstrates that the interplay of several organisational factors is likely 
to achieve better patient outcomes, rather than an isolated factor. In addition, studies suggest 
that organisational scores are likely to be a reliable way of comparing units. (108,257,258) 
However, there are few validated scores that examine organisational factors within a 
healthcare unit.  
The created organisational score used in this study is a composite score based on the 
recommendations made by the national commissioning guidance for lung cancer. (11) These 
guidelines are primarily based on clinical opinion and relatively little has been published on 
how these standards affect patient care. This data provide evidence that adherence to this 
guidance directly impacts patient outcomes discussed further below.  
3.4.3 Linkage results 
 
To the authors knowledge this is the first study to demonstrate that a bundle of organisational 
factors is significantly associated with improved lung cancer patient outcomes (one-year 
survival, receiving curative-intent treatment and treatment within 62 days). Previous studies 
demonstrate improved treatment outcomes for individual organisational components. For 
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example, Lau et al demonstrated that increasing the number of thoracic surgeons was 
associated with increased resection rates. (160). Additionally, previous interrogation of the 
NLCA dataset demonstrated increased odds of having surgery if a patient is first seen in a 
surgical centre. (158,159) However robust evidence linking resource factors with survival is 
lacking.  
These results demonstrate that examining organisational factors individually do not robustly 
contribute to improve outcomes in keeping with findings from the systematic review. 
However, significant results are found when factors are combined to form a score. The odds 
of surviving to one year for patients seen at a unit with a high organisational score are more 
than double than those seen at a low scoring unit after adjusting for patient factors. These 
findings are unsurprising given that lung cancer patients are often multi-morbid, requiring 
multiple investigations and combinations of treatment. (4) The challenge for lung cancer 
services in the UK is to deliver rapid access for all patients to these treatment modalities 
whilst ensuring that each treatment centre treats sufficient volume of patients to maintain 
performance and cost-effectiveness. 
Finally, it has been demonstrated that speedier lung cancer pathways are associated with 
better patient outcomes and several guidelines establish standards for the timely care for 
patients. (96) National UK targets stipulate that patients should receive treatment within 62 
days. (227) This study examines the outcome of patients receiving treatment within 62 days 
and finds that the odds of receiving timely treatment are increased by approximately 50% if 
seen in a high scoring unit (compared to a low scoring unit).  It is intuitive that ready access to 
key resources within an increasingly complex patient pathway would relate to a faster 
pathway and the results confirm that this is the case.   
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3.4.4 Clinical relevance and recommendations  
 
I show that national variation in provision of services and workforce exist despite the 
publication of several initiatives to address this inequality. We provide evidence that 
adherence to the National Commissioning Guidance for lung cancer has the potential to 
improve patient outcomes within the current service structure.  
Four specific recommendations are made to address the national variation in lung cancer 
services shown in Box 1 and published in the latest NLCA report. (4) 
 
3.4.5 Strengths and limitations 
. 
The main strength of the study is the completeness and quality of the NLCA dataset. This 
now includes the linked RTDS and SACT dataset which allows accurate assessment of 
treatment rates and provides a detailed picture of lung cancer treatment and management in 
England. In addition, participation in the organisational audit was high, with the quality of 
responses enhanced by the provision of help notes and a help desk.  
Box 1: Key recommendations from the second organisational audit 
1.) Local access to smoking cessation and pulmonary rehabilitation should be available 
to all patients 
2.) Dedicated time for all core MDT members to attend a weekly MDT meeting 
discussing no more than 30 patients in 2 hours.  
3.) Provision of specialist time commitment as specified in the National Commissioning 
Guidance, in particular lung clinical nurse specialists.  
4.) All providers without a separate diagnostic MDT should implement this within the 
next 12 months as per commissioning guidance.  
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Four main limitations are acknowledged. Firstly, the results are retrospective and may be 
subject to confounding and selection bias despite adjustment for patient factors. However, a 
range of trust size and geographical spread across the country were included in the audit.  
In terms of confounding there are likely to be organisational elements that are not able to be 
accounted for such as details of the quality of the services investigated. In the free text portion 
of the survey, one trust reported that they had on site PET facilities, however, the demand on 
that service is high. Therefore, patients wait seven to fourteen days to have their scan and get 
results back. On the other hand, another trust reports off site PET CT scanning resources but a 
good relationship with the provider allowing for a quick turnaround on results. Other 
confounders to consider is the inability of datasets to account for patient preferences or ability 
to access services. However, the high participation rate and findings in keeping with previous 
work means that these effects of bias are likely to be minimal and therefore the results are 
likely to be generalisable to the UK population.  
Secondly, data submitted to NCRAS making up the NLCA dataset is inputted during the 
MDT meeting. Therefore, NLCA data reflects the MDT decision rather than the final 
treatment received. It is acknowledged that there may be potential issues with competing risks 
where patients may die before they have started the documented treatment modality. This is 
common to all large nationally collected datasets. In addition, accurate UK data on MDT 
decision implementation rates is not available. However, patient factors known to determine 
eligibility for treatment and survival are included in multivariate analysis.  
Additionally, it should be noted that the survey results are not externally validated and may be 
subject to recall bias. This is particularly relevant to the reporting of staffing numbers. To gain 
accurate data, the second organisational audit required participants to respond with a greater 
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level of detail compared to the first. Evaluation of this audit revealed that respondents found 
estimating specialist workload overly complex. To address this, trusts had the opportunity to 
verify their data with further guidance provided. However, issues in accuracy may remain and 
difficulty with defining staff workload has been acknowledged by previous researchers. (259)   
Lastly, data regarding service provision was collected in 2017 and was linked to patient data 
from 2015 This is the most recently available patient data at the time of the organisational 
audit results, as there is a fourteen-month lag from a patient being seen to their data being 
reported to the NLCA.  However, the linkage results are likely to be valid for two reasons. 
Firstly, services are unlikely to have changed significantly in twelve months. Secondly, the 
NLCA results for key performance indicators have remained largely static for the last five 
years.  
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3.5 Conclusions  
 
Inequity to access to key resources nationally exists contributing to variability in lung cancer 
outcomes. This study provides robust evidence that improvements in survival and timeliness 
of care can be achieved through national adherence to the lung cancer commissioning 
guidance. For this to be a reality further investment in specialist lung cancer services is key. 
Lung cancer still receives the least funding of all common tumours yet has the lowest survival 
rates. (91) These findings strengthen the case that urgent ring-fenced funding is required if 
patient outcomes are to be improved to be in line with comparable countries. 
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CHAPTER 4 MANAGEMENT OF STAGE III 
NSCLC IN ENGLAND 
4.1 Introduction  
 
Stage III non-small cell lung cancer (NSCLC) as defined by the International Association for 
the study of Lung Cancer 8
th
 Edition TNM staging classification is a heterogenous disease. 
(18) The extent can vary from small volume, potentially curable locoregional disease to bulky 
invasive multinodal disease.  
Approximately 20% of patients in the UK present with Stage III NSCLC (12% at Stage IIIA 
and 8% at Stage IIIB) which has an estimated five-year survival of approximately 20%. (4) 
The optimum treatment, based on randomised trials and meta-analyses, for unresectable 
disease is concurrent chemoradiation. (260) However, a study investigating treatment patterns 
in patients with Stage III NSCLC reported the most common treatment delivered to 2365 
patients from British Columbia, Canada, was radiotherapy alone; given to just over a half of 
all actively treated. (261) In an Australian population studied, the authors found the 
commonest treatment given to approximately one third of patients was also radiotherapy 
alone. (262) Whereas, data from the USA showed that multimodality treatment regimens with 
chemotherapy/radiotherapy or surgery in combination with either chemotherapy or 
radiotherapy were more commonly used than in the Australian or Canadian studies. (263) 
This corresponds to a five year survival figure quoted in US population studies of 33%. (264) 
Differences in management are reflected in international variation in survival outcomes. The 
overall age standardised one-year net survival for stage III NSCLC studied in four countries 
with comparable incomes (Denmark, Canada, UK and Sweden) varied from 30% in the UK to 
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46% in Sweden. (80) In addition to international differences, stage specific variability in 
survival outcomes have been shown within regions of the UK. (4,148) 
Three factors may contribute to this observed variation in practice and outcomes: 1.) The lack 
of consensus on optimal treatment regimens 2.) Variability in access to diagnostic and 
treatment resources 3.) Applicability of trial evidence to real life  
4.1.1 Management of Stage III NSCLC 
 
The treatment of stage III NSCLC represents a challenge because of variability in 
presentation.  Randomised trial evidence has established the standard of care for unresectable 
stage III NSCLC being concurrent chemoradiotherapy. (260) However, the management of 
potentially resectable Stage IIIa(N2) disease remains controversial with data to support both 
surgical and non-surgical approaches.  
A multimodality approach to treatment is considered optimal with locally advanced disease 
being controlled with systemic treatment (chemotherapy) and local disease treated with either 
radiotherapy or surgery. (265) Over the last decade, trials have investigated the optimal 
bimodality or tri-modality treatment for patients with N2 disease. A metanalysis published in 
2015 suggested there was no difference in overall survival between patients treated with 
surgery with chemotherapy or chemotherapy and radiotherapy. (266) The most recent 
randomised controlled trials that have studied tri-modality treatment are the ESPATUE trial 
by Eberhardt et al and The Swiss Group for Clinical Cancer Research (SAKK) trial, both 
published in 2015. (267,268) In the ESPATUE trial patients were all given induction 
chemoradiotherapy and then randomised to either surgical resection or completion of 
definitive chemoradiation. (267) They found no overall five- year survival difference between 
the two groups. In the SAKK trial, all patients had induction chemotherapy and then either 
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surgery alone or radiotherapy followed by surgery between 2002 and 2012. (268) Again, there 
was no significant difference in their primary endpoint which was progression free survival 
but there was a higher radiological response, mediastinal downstaging, complete resection and 
complete pathological response rates in the tri-modality group.  
In summary, the evidence suggests that no one bimodality/tri-modality treatment regimen has 
superiority in terms of overall survival for stage IIIA (N2) disease. However, there is some 
evidence to support induction treatment with chemotherapy in terms of complete pathological 
response rates and downstaging.  
The uncertainty in the optimal regiment from trial evidence is reflected in differences between 
international guidelines on the management of this subgroup (summarised in Table 4.1). In 
addition, differences in eligibility for surgery are seen.  
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Table 4.1 Summary guideline recommendations on the management of potentially resectable N2 NSCLC 
Guideline Definition of eligibility for surgery Recommendations 
BTS & SCTS 
(2010) 
Non-fixed and non-bulky lymph nodes 
Single zone N2 disease with a reasonable chance of 
complete resection and clear pathological margins.  
If the definition for surgery fulfilled: consider surgery as part of 
multimodality treatment. 
Adjuvant chemotherapy in preference to preoperative chemotherapy.  
ACCP 
(2013) 
Discrete lymph nodes which are easily measures 
and defined. Disease is free from major structures.  
Definitive chemoradiotherapy or induction therapy (chemotherapy or 
chemoradiotherapy) followed by surgery.  
Surgery followed by adjuvant chemotherapy not recommended.  
ESMO 
(2015) 
Minimal, non-bulky, single station N2 disease.  Definitive chemoradiotherapy, induction therapy (chemotherapy or 
chemoradiotherapy) followed by surgery.  
NCCN 
(2018) 
Lymph nodes that are low volume, non-invasive, 
<3cm and pathologically proven.  
Definitive chemoradiotherapy, induction therapy (chemotherapy or 
chemoradiotherapy) followed by surgery. 
Maintenance Durvalumab following chemoradiotherapy 
NICE 
(2019) 
Does not define eligibility Definitive chemoradiotherapy followed by surgery 
BTS: British Thoracic Society; SCTS: Society for Cardiothoracic Surgery; ACCP: American College of Chest Physicians; ESMO: European 
Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; NICE: National Institute of Clinical Excellence
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4.1.2 Organisation of lung cancer services and stage III NSCLC 
 
The ability of patients to access specialist care is key in this subgroup of patients who require 
accurate staging and multimodality treatments. This is emphasised in the ESMO guidelines 
that recommend that stage III patients should be managed in experienced multi-disciplinary 
teams in high volume treatment centres. (269)  
The accuracy of mediastinal staging is integral to this care. This is dependent on ready access 
to modern diagnostic modalities. Positron emission tomography (PET) CT should be used to 
rule out distant metastases and initiate mediastinal staging. However, PET scans have a false 
positive rate of 25% for N2 disease. (269–271) Consequently, PET positive findings should 
be pathologically confirmed to inform appropriate treatment strategies. (269) One study 
showed that half of patients with clinical stage IIIa (N2) disease treated surgically were 
subsequently shown to have been staged incorrectly. (272) The majority of patients being 
down staged to stage I or II. Therefore, to ensure patients are given the best chance of cure, 
accurate staging dependent on availability of key diagnostics is necessary.  
Curative intent strategies require expertise from staff and access to treatment modalities. (269) 
Thoracic surgery for stage III disease may involve complex operations including sleeve 
resections, and resection of locally invaded mediastinal organs. (269) Additionally, access to 
specialist radiation oncology services is required to evaluate the toxicities and efficacies of the 
treatment as well as specify volumes and doses that minimise risk to other organs. Expert staff 
are key to the delivery of these services and specialist care has been associated with greater 
access to curative treatment and significantly better survival. (262) 
Section 3.3 demonstrates that access to such resources varies across the country and this has 
been shown to affect patient outcomes. Therefore, understanding the relationship between the 
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availability of specialist services and lung cancer outcomes in this important subgroup, will 
facilitate policy design to bring up survival to the highest international standard.  
4.1.3 Applicability of trial evidence 
 
It is evident that controversy exists as to the optimal management of Stage IIIA NSCLC. 
However, the generalisability of clinical trial evidence to patients discussed in the lung cancer 
multidisciplinary team (MDT) meeting should be questioned for three main reasons.  
Firstly, most of the investigating clinical trials encountered significant problems with 
recruiting enough numbers of patients to meet their pre-defined power calculations, leading to 
insufficient power. In addition, the time taken to recruit patients meant that the diagnostic and 
management modalities used during the trial were outdated by publication of the results. For 
example, most randomised controlled trials were carried out before the routine use of PET 
scans. Secondly, most patients with this stage of disease are elderly with multiple co-
morbidities, a group that is under-represented in clinical trials(273). De Ruysscher et al 
estimate that half of stage III patients do not fulfil the criteria from randomised controlled 
trials evaluating chemoradiation therapy. (274) The median age of diagnosis of lung cancer is 
72 years old, yet these trials included few patients over the age of 70. (260,269) These factors 
result in limited high-level evidence to base treatment for many patients. Finally, patient 
experience outcomes are poorly reported in such trials. When there are largely equivalent 
survival outcomes associated with the different management approaches, patients experience 
data is critical in decision making.  
With the above factors in mind, it is likely that the feasibility of conducting further clinical 
trials in this area are limited. However, the interrogation of detailed prospective population 
data sets has the potential to add significant value to the current literature base.  
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4.1.4 Rationale 
 
Population based data registries can fill the knowledge gap between clinical trial data and 
clinical practice. The above factors highlight the importance of using such data to understand 
variability in practice and outcomes, target quality improvement initiatives and guide national 
resource allocation. An example of how this process has been successfully implemented is 
illustrated in the EUROCARE studies. Data was used to assess outcomes resulting in changes 
on healthcare funding and structure. (275)  
To my knowledge, the establishment of current national patterns of treatment and 
corresponding survival outcomes in stage III NSCLC patients in the UK has not been 
previously established. Utilising the National Lung Cancer Audit (NLCA) database to achieve 
this presents a unique opportunity for three reasons. Firstly, the NLCA dataset is one of the 
most complete cancer datasets available worldwide. (95) The data has been historically used 
to make improvements in quality key performance indicators. (4)  Secondly, the availability 
of details of treatments received by patients including drug names, doses, frequency and 
timing, through linked datasets allows accurate allocation of treatment regimens; a deficiency 
highlighted in other population based studied investigating Stage III patients. Finally, 
understanding treatment patterns of stage III NSCLC patients is topical given the recently 
updated National Institute of Clinical Excellence (NICE) lung cancer guidance (March 2019) 
newly recommending tri-modality treatment for stage IIIA (N2) disease as well as the new 
NICE technology appraisal for use of adjuvant Durvalumab after concurrent chemoradiation. 
(42)  
4.1.5 Aims  
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The aims of this study are to: 
1.) Investigate the uptake of difference treatment regimens and the corresponding survival 
outcomes for Stage III NSCLC in England 
 2.) Examine the association with hospital infrastructure and access to key treatment and 
diagnostic modalities with the likelihood of receiving curative intent treatment and one-year 
survival in patients with Stage III NSCLC in UK 
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4.2 Methods 
 
4.2.1 Data source and study population  
 
The NLCA dataset and data collection process has previously been described in section 3.2. 
The following patients are excluded from the data: patients identified with lung cancer 
through death certificate only, patients with non-lung cancer related pathology codes and 
patients who cannot be assigned a trust of diagnosis. 
The dataset is linked to other registry datasets submitted by trusts to accurately define the 
studied variables. These include pathology reports, Hospital Episode Statistics (HES) data, the 
National Radiotherapy Dataset (RTDS), the Systemic Anti-Cancer Dataset (SACT) and the 
Office for National Statistics (ONS) dataset which provides death certificate data. All patients 
with a diagnosis of lung cancer (International Classification of Diseases code C34) with 
pathologically confirmed NSCLC (based on the recorded Systematised Nomenclature of 
Medicine (SNOMED) codes) and clinically confirmed NSCLC, over the age of 18 years, 
diagnosed between 01/01/2016 to 31/12/2016 were included. Analyses were restricted to 
those with stage III using TNM version 7. (18) Patients allocated to a trust in Wales and 
Guernsey were excluded because linked data to accurately allocate treatment regimens is 
unavailable. Staging was defined as that recorded by trusts at the time of data input and prior 
to intervention. For the 2016 cohort of data, lung cancer multidisciplinary teams (MDT’s) 
were contacted by the National Cancer Registration and Analysis Service (NCRAS) with an 
opportunity to validate their data. (4) 122 trusts (86.5%) requested data and 96 trusts (68.3%) 
returned validated data. Those that requested data received spreadsheet of patient identifiable 
data on cases believed to be allocated to their trust. This included cases where no data was 
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submitted, but NCRAS had received pathology or death data. After receiving validated data 
from trusts NCRAS updated the NLCA dataset before analysis. In addition NCRAS also 
perform internal validation of their datasets.  
4.2.2 Definition of variables 
 
The data cleaning process is described in section 3.2.4. The treatment variables include 
surgery, radiotherapy, chemotherapy and no active treatment (best supportive care). The 
modalities are described below:  
i. Surgery Surgical operations were identified with the Office of Populations Census 
and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) 
codes for each patient indicating thoracic surgical procedure with curative intent. 
The surgical procedures were categorised as 1) pneumonectomy, 2) lobectomy, 
including sleeve and bilobectomy, 3) sub-lobar resections, comprising segment 
and wedges, 4) complex resection and others.  
ii. Chemotherapy: Lung cancer specific systemic anti-cancer therapy identified from 
the SACT database. Patients are allocated to this treatment if a date is recorded 
with a valid regimen. Chemotherapy is part of a curative regimen if given in 
conjunction with surgery or radical radiotherapy. If give alone, the intention of 
treatment is allocated as palliative.  
iii. Radical radiotherapy: Identified from the RTDS using a combination of data items 
including treatment intent, total prescribed dose >50 Gray (Gy) and prescribed 
number of fractions (10 or more, but with the vast majority delivered 20 or more 
fractions). If radiotherapy was extra-thoracic, this was not counted in treatment 
categorisation.  
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iv. Palliative radiotherapy: A dose of <50 Gy.  
Radiotherapy treatments described in RTDS were used to determine if given with radical or 
palliative intent. Patients allocated to receiving radical radiotherapy alone were defined as 
receiving radiotherapy at a dose >50Gy alone or with chemotherapy that was delivered >120 
days from the date of radiotherapy. In this circumstance, chemotherapy was likely given for 
disease recurrence or progression. Similarly, patients receiving chemotherapy within 120 days 
of their date of surgery were classed as receiving adjuvant treatment. The definitions of 
combination treatments are shown in Table 4.2. Systemic therapy drug names and 
radiotherapy doses and fractionations were sense checked by an oncologist to ensure that all 
regimens were commonly used to treat NSCLC and patients had been accurately allocated to 
the appropriate group. 
Chapter 3 shows that patient outcomes are likely to be related to a bundle of organisational 
factors representing hospital infrastructure. Therefore, to investigate the relationship between 
hospital service delivery and lung cancer outcomes in patients with Stage III disease, the 
organisational score described in section 3.3.2 is used as a proxy for hospital infrastructure.  
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Table 4.2 Treatment variable definitions 
Variable Definition Calculation 
Surgery alone 
 
Patient received surgery alone 
OR > 120 days from other 
treatment 
All patients in the cohort population with a valid surgical code receiving no other treatment OR > 
120 days date of receiving ‘Chemotherapy’ AND/OR Radiotherapy.  
Exclude: Patient received chemotherapy AND/OR any radiotherapy <120 days from surgery date 
Surgery and adjuvant 
chemotherapy 
 
Patient received surgery then 
chemotherapy with a gap of < 
120 days  
All patients in the cohort population with a valid surgical code AND valid chemotherapy regime < 
120 days from date of surgery.  
Exclude: patient has received radical radiotherapy 
Neoadjuvant 
Chemotherapy and 
surgery 
Any patient receiving 
chemotherapy and then 
surgery.  
All patients in the cohort population with a valid chemotherapy regime followed by a valid surgical 
date.  
Exclude: patient has received radical radiotherapy 
Surgery and curative 
intent radiotherapy 
Any patient receiving surgery 
and radical radiotherapy OR 
radical radiotherapy and 
surgery with a gap of <120 
days 
All patients in the cohort population with a valid surgical date and valid radiotherapy dose with a 
gap of <120 days.  
Exclude: patient has received a valid chemotherapy regime.  
Triple therapy Any patient receiving surgery 
and radiotherapy and 
chemotherapy in any order.  
All patients in the cohort population with a valid surgical date AND a valid radiotherapy dose AND 
a valid chemotherapy regimen.  
Curative intent 
radiotherapy 
Any patient receiving curative 
intent radiotherapy alone or 
curative intent radiotherapy 
and chemotherapy with a gap 
All patients in the cohort population with a valid radiotherapy dose only OR valid radiotherapy dose 
first and then chemotherapy regimen with a gap of > 120 days 
Exclude: 1. Patient has received surgery 2. Patient received chemotherapy < 120 days from 
radiotherapy 3. Patient received chemotherapy first and then radical radiotherapy. 4. Patient 
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of 120 days received radical radiotherapy and chemotherapy concurrently 
Concurrent 
chemoradiotherapy 
Any patient receiving curative 
intent radiotherapy and 
chemotherapy at the same 
time or curative intent 
radiotherapy delivered within 
60 days of chemotherapy 
All patients in the cohort population with a valid radiotherapy dose and chemotherapy regimen 
delivered at the same time OR with a gap of <60 days.  
Exclude: 1. Patient with curative intent radiotherapy and chemotherapy with gap of >60 days 2.) 
Patients with a valid surgical procedure code.  
Sequential 
chemoradiotherapy 
Any patients receiving 
chemotherapy first and then 
curative intent radiotherapy.  
All patients in the cohort population with a valid chemotherapy regimen delivered followed by 
radiotherapy delivered at a valid dose.  
Exclude 1.) Patients who had chemotherapy delivered within 60 days of curative intent radiotherapy 
2.) Patients with a valid surgical procedure code.  
Palliative radiotherapy 
and chemotherapy 
Any patient with a palliative 
radiotherapy dose and 
chemotherapy regimen 
All patients in the cohort population with a palliative radiotherapy dose AND chemotherapy 
regimen.  
Exclude: Patient has received curative intent radiotherapy OR surgery 
Palliative radiotherapy Any patient with a palliative 
radiotherapy dose 
All patients in the cohort population with a palliative radiotherapy dose.  
Exclude: patient has received radical radiotherapy OR surgery OR chemotherapy.  
Chemotherapy alone Any patient receiving a valid 
chemotherapy regimen 
All patients in the cohort population with recorded valid chemotherapy regimen.  
Exclude: patient has received radical radiotherapy OR palliative radiotherapy OR surgery.  
Best supportive care (no 
treatment) 
Any patient who has not 
received any of the above 
treatment modalities.  
All patients that have not received radical radiotherapy OR palliative radiotherapy OR a valid 
chemotherapy regimen OR has a valid surgical procedure code.  
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4.2.3 Covariates 
 
The following variables were identified from the NLCA data: sex, age at diagnosis (split into 
three groups: <65; 65-80 and >80 years old), socioeconomic status (derived from the postcode 
and linked with the Index of Multiple Deprivation), Eastern Co-operative Oncology Group 
(ECOG) performance status (according to the WHO definition) recorded at the time of 
diagnosis and stage of disease at presentation TNM version 7 (as classified by ‘The IASLC 
Lung Cancer Staging Project’). (18) The HES database was used to calculate the Charlson 
Co-morbidity Index (a composite score that has been validated for use in this dataset) 
preceding the date of lung cancer diagnosis. (158) These co-variates were chosen as they are 
established as affecting patient outcome in lung cancer and have been used in previous studies 
using the NLCA dataset. (158) Variable definitions are further described in Table 3.3.  
4.2.4 Outcomes  
 
 Two outcomes were measured. The first was curative intent treatment rate defined as patients 
with stage III NSCLC and a record of a curative surgical procedure or received radiotherapy 
with curative intent (>50Gy). The second was the proportion of patients alive at one year. 
Curative intent treatment rate was studied because it is essential to improving overall patient 
outcomes in this group of patients. Further rationale for outcome variables is described in 
Table 3.4.  
4.2.5 Statistical analysis  
 
All data and statistical management were performed by STATA V.14 (StataCorp). 
Descriptive analyses were conducted for patient and organisational variables.  Treatment rates 
were calculated as per treatment definitions described in Table 4.2 for patients with 
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performance status 0-2 with stage IIIA and stage IIIB separately. Adjusted and unadjusted 
Kaplan-Meier overall survival curves were obtained with survival defined from date of 
diagnosis to date of death. Adjustment was made for sex, age, performance status and 
socioeconomic status. Finally, multivariate logistic regression analysis was used to estimate 
the odds of receiving curative intent treatment and surviving to one year by the organisational 
score adjusting for patient factors and clustered for NHS trust. Clustering was used to account 
for the hierarchical nature of the data. To minimise bias resulting from reverse causation, only 
patient factors known at the time of diagnosis were considered in the final model. The 
organisational score was categorised into three groups. A p value of <0.05 was considered 
statistically significant.  
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4.3 Results 
 
4.3.1 Cohort Definition 
 
36,761 patients were diagnosed with lung cancer between 1 January 2016 and 31
st
 December 
2016 and recorded in the NLCA dataset. 6,276 patients with Stage III NSCLC were analysed, 
3,827 stage IIIA cases and 2,449 stage IIIB cases. The cohort criteria are illustrated in Figure 
4.1.  
Figure 4.1 Cohort flow diagram 
 
39,799 records in the 
2016 NLCA dataset 
39,038 records 
Exclusion criteria n 
Diagnosis outside analysis 
period 
1 
Date of death prior to 
diagnosis date 
4 
Records with missing trust 697 
Diagnosis of sarcoma 33 
Unknown morphology codes 15 
Cancer other than lung cancer 9 
 
38,269 records Patients from Guernsey (n=40) and 
Wales (n=2,240) excluded 
36,761 records 4,284 patients are not pathologically 
confirmed NSCLC 
32,477 records 26,201 records are not staged as Stage III 
NSCLC 
6276 records available 
for analysis 
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The demographics details for patients with stage III disease is shown in Table 4.3. 56.3% of 
patients were male and 56.7% were aged 65-80 years old. 51.2% of patients have a 
performance status of 0-1. The median follow-up time from diagnosis was 313 days (10 
months) with an interquartile range of 115 days (4 months) to 627 days (20 months). 
Table 4.3 Patient demographics for stage III patients (n=6276) 
  Patients(n) % 
Sex Female 2,746 43.8 
 Male 3,530 56.3 
Age  <65years 1,340 21.9 
 65-80 years 3,559 56.7 
 >80 years 1,377 21.4 
Stage IIIA 3,827 61.0 
 IIIB 2,449 39.0 
Performance status 0 1,158 18.5 
 1 2,054 32.7 
 2 1,073 17.1 
 3 951 15.2 
 4 235 3.7 
 Missing 805 12.8 
Townsend quintile 1 (most affluent) 790 12.6 
 2 1.079 17.2 
 3 1,229 19.6 
 4 1,501 23.9 
 5 (least affluent) 1,671 26.6 
 Missing 6 0.1 
Charlson index 0 2,511 40.0 
 1 1,442 23.0 
 2 1,549 24.7 
 3+ 774 12.3 
 
4.3.2 Treatment patterns 
 
Treatment patterns for stage IIIA and IIIB NSCLC are shown in Table 4.4. 1,860 (30%) 
patients received therapy with curative intent (surgery or radical radiotherapy) alone or as part 
of combination treatment. Out of those staged as IIIA, 1,482/3,827 (38.7%) received curative 
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intent treatment. 770 of these patients underwent surgery, half of which (390 patients) also 
received chemotherapy, predominately delivered in the adjuvant setting.  
1,047 (17%) were treated with radical radiotherapy with 676 (65%) also receiving 
chemotherapy. For patients receiving chemotherapy and radical radiotherapy where complete 
dates were available (589 patients), 34% received concurrent chemoradiation (137/366 (37%) 
stage IIIA) and 66% (229/336 (68%) stage IIIA) received sequential chemoradiation. Where 
performance status (PS) was available, 171/481 (36%) PS 0-1 cases received concurrent 
chemoradiotherapy (115/300 (38%) for stage IIIA) and 310 (64%) received sequential 
chemoradiotherapy (185/300 (62%) for stage IIIA).  
Bi-modality treatment with chemotherapy and surgery or radiotherapy with curative intent 
was delivered to 1123 (18%). 43 out of the 1,123 patients (1%) received tri-modality therapy 
in either the adjuvant or neoadjuvant setting. 2,265 (36%) people had no record of receiving 
any active treatment for their stage III lung cancer and 2136 (34%) received treatments of 
palliative intent. Out of those with stage IIIa disease 1,023 (26.7%) received palliative intent 
treatment with 1,322 (34.5%) patients receiving supportive care.  
4,285 (68%) of patients with stage III NSCLC had a performance status of 0-2. 70% 
(394/565) of patients with stage IIIA, PS 0-1 and <65 years received curative intent treatment 
and 56% (671/1,201) in the 65-80 age bracket. 30% (112/390) of patients with stage IIIB, 
Ps0-1 and <65 years received curative intent treatment with 24% (173/707) in the 65-80 age 
bracket. Treatment patterns for patients with performance status 0-2 are presented in Table 
4.5. 1,671 (39%) received curative intent treatment with a regimen including surgery or 
curative intent radiotherapy. Out of those staged IIIA 1,322 (51%) received curative intent 
treatment. 722 (17%) (26% for stage IIIA) had surgery alone or part of multimodality 
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treatment and 949 (22%) (25% for stage IIIA) had curative intent radiotherapy. Out of the 
patients that received surgery 56% (431 patients) also received chemotherapy mainly as 
adjuvant chemotherapy. Multimodality treatment was delivered to 1069 (25%) of patients. 
Out of these patients 4% received tri-modality therapy. A total of 1,776 (41%) of patients 
received treatment with palliative intent and 838 (20%) received no active anti-cancer 
treatment. For those with stage IIIA 32% received palliative intent treatment and 18% best 
supportive care. 
Table 4.4 Treatment patterns for patients with stage III NSCLC (n=6276) 
 Stage IIIA 
(n=3,827) 
% Stage IIIB 
(n=2,449) 
% 
Group 1: Surgery 770 20.1 43 1.8 
Surgery 302 7.9 19 0.8 
Surgery and adjuvant chemotherapy 356 9.3 12 0.5 
Neoadjuvant chemotherapy and surgery 34 0.9 2 0.1 
Surgery and radiotherapy 37 1.0 8 0.3 
Triple therapy 41 1.1 2 0.1 
          
Group 2: Radical radiotherapy 712 18.6 335 13.7 
Radical radiotherapy 291 7.6 80 3.3 
Radical radiotherapy and chemotherapy 421 11.0 255 10.4 
          
Group 3: Palliative intent treatment 1023 26.7 1,125 45.9 
Palliative radiotherapy and chemotherapy 182 4.8 234 9.6 
Palliative radiotherapy 396 10.3 321 13.1 
Chemotherapy alone 396 10.3 570 23.3 
          
Group 4: Best supportive care (no 
treatment) 
1,322 34.5 946 38.6 
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Table 4.5 Treatment patterns for patients with stage III NSCLC and performance status 
0-2 (n=4,285) 
 Stage IIIA 
(n=2,601) 
% Stage IIIB 
(n=1,684) 
% 
Group 1: Surgery 684 26.3 38 2.3 
Surgery 260 10.0 15 0.9 
Surgery and adjuvant chemotherapy 314 12.1 9 0.5 
Neoadjuvant chemotherapy and surgery 34 1.3 2 0.1 
Surgery and radiotherapy 34 1.3 8 0.5 
Triple therapy 42 1.6 4 0.2 
          
Group 2: Radical radiotherapy 638 24.5 311 18.5 
Radical radiotherapy 254 9.8 73 4.3 
Radical radiotherapy and chemotherapy 384 14.8 238 14.1 
          
Group 3: Palliative intent treatment 822 31.6 954 56.7 
Palliative radiotherapy and chemotherapy 169 6.5 219 13.0 
Palliative radiotherapy 274 10.5 238 14.1 
Chemotherapy alone 379 14.6 497 29.5 
          
Group 4: Best supportive care (no 
treatment) 
457 17.6 381 22.6 
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4.3.3 Regional variation 
 
The variation in use of curative intent treatment for stage IIIA disease with either surgery or 
radical radiotherapy by NHS trust (anonymised) is shown in Figure 4.2. Rates vary from 8% 
to 80%. Variation rates were not analysed for stage IIIB due to the heterogeneity of this stage 
and therefore low likelihood of surgery being offered.  
Figure 4.2 Variation in use of curative intent treatment for stage IIIA by NHS trust  
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4.3.4 Linkage with organisational score 
 
For the trusts that participated in the organisational audit described in Chapter 3, 5460 (87%) 
out of all those with stage III NSCLC had an organisational score assigned. The results of the 
multivariate logistic regression analyses of patient factors and organisational score on curative 
intent treatment and one-year survival are shown in Table 4.8. For patients from trusts that 
have a score of 8-11 compared to a score of 0-4, a trend is shown that these patients are more 
likely to receive curative intent treatment though this did not reach statistical significance. 
(Adjusted OR (95% CI) = 1.22 (0.83-1.80, p=0.310). There was no significant difference 
between the groups found in adjusted analyses for one-year survival. Patient factors 
significantly associated with decreased odds of surviving to one year and receiving curative 
intent treatment include increasing age and performance status (p<0.001 for both).  
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Table 4.8 Results of multivariate logistic regression analyses investigating the influence of patient factors and organisational score on 
curative intent treatment and one-year survival  
  One-year survival 
(n=33,312) 
Curative intent treatment 
(n=29,793) 
  Adjusted OR (95% 
CI) 
p value for 
chi squared 
Adjusted OR 
(95%CI) 
p value for chi 
squared 
Sex Female 1.00  1.00  
 Male 0.91 (0.80-1.03) 0.142 0.95 (0.84-1.07) 0.372 
Age  <65years old 1.00  1.00  
 65-80 years 
old 
0.74 (0.64-0.85)  0.64 (0.57-0.72)  
 >80 years old 0.55 (0.46-0.66) <0.001 0.27 (0.21-0.34) <0.001 
Stage Stage IIIA 1.00  1.00  
 Stage IIIB 0.56 (0.50-0.63) <0.001 0.24 (0.20-0.28) <0.001 
Performance status 0-1 1.00  1.00  
 2 0.49 (0.41-0.58)  0.34 (0.28-0.43)  
 3-4 0.25 (0.21-0.30) <0.001 0.05 (0.03-0.07) <0.001 
Townsend quintile 1 1.00  1.00  
 2 1.05 (0.86-1.30) 0.94 0.94 (0.74-1.20)  
 3 1.08 (0.87-1.33)  0.83 (0.66-1.06)  
 4 1.06 (0.87-1.30)  1.00 (0.81-1.25)  
 5 1.03 (0.84-1.26) 0.386 0.92 (0.74-1.14) 0.441 
Charlson Index 0 1.00  1.00  
 1 0.88 (0.76-1.01)  0.91 (0.77-1.07)  
 2 0.93 (0.81-1.08)  1.00 (0.83-1.13)  
 3+ 0.79 (0.65-1.00) 0.780 0.96 (0.78-1.17) 0.675 
Organisational 
score 
0-4 1.00  1.00  
 5-7 0.96 (0.83-1.12)  0.95 (0.71-1.29)  
 8-11 1.00 (0.83-1.19) 0.702 1.22 (0.83-1.80) 0.310 
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4.3.5 Survival  
 
Proportions surviving to one year for all stage III patients are shown in Table 4.6. The highest 
survival is seen for those receiving multimodality treatment. The percentage alive at one year 
for those that received surgery with chemotherapy (66%) is similar to those that received 
chemoradiotherapy with curative intent (60%).  
The one-year survival for stage III NSCLC was 32.9% (37.4% for stage IIIA). Survival 
stratified by stage, age and performance status is shown in Table 4.7. 44.7% of patients with 
performance status 0-1 were alive at one year compared to 14.6% of patients with 
performance status 3-4. The curative intent treatment rate varied from 45.4% for patients with 
performance status 0-1 to 3.2% for performance status 3-4. For patients aged <65 years a one-
year survival rate of 44 % was found in comparison to 33.1% for those aged 65-80 and 21.6% 
for patients over the age of 80 years old. Curative intent treatment rates varied from 44.7%, 
31.2% to 12.1% for the respective age groups. When stratified by PS0-1, stage IIIA, 54.5% of 
patients survived to one year if aged <65 years old compared to 42.7% of those aged over 80 
years. 
Table 4.6 Proportion alive at one year for patients with stage III NSCLC 
  
Total 
patients 
Patients 
alive at 
one year 
% 
alive 
Surgery alone 319 151 47 
Surgery with chemotherapy 445 292 66 
Surgery and radiotherapy 44 20 45 
Radical radiotherapy alone 370 157 42 
Radical radiotherapy with 
chemotherapy 
675 402 60 
Palliative intent treatment 2,145 695 32 
Best supportive care 2,278 347 15 
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Table 4.7: One-year survival (%) by age, stage and performance status 
 One-year survival (%) Curative intent treatment (%) 
Overall 32.9 39.0 
Stage IIIA 37.4 50.8 
Performance status   
0-1 44.7 45.4 
2 25.4 19.4 
3-4 14.6 3.2 
Age group (years old)   
<65 44.0 44.7 
65-80 33.1 31.2 
>80 21.6 12.1 
Stage IIIA & PS 0-1 by age   
<65 54.5 69.7 
65-80 48.2 55.9 
>80 42.7 38.4 
 
Unadjusted and adjusted Kaplan-Meier survival curves by treatment received for all stage III 
cases and for stage IIIA cases are shown (Figures 4.3, 4.4 and 4.5). These data highlights 
three notable points. Firstly, the survival curves for bi-modality treatment regimens 
(chemotherapy and surgery versus chemotherapy and radiotherapy) diverge before one year in 
unadjusted, adjusted and stage IIIA specific analyses, with the highest survival seen for 
patients receiving the former regimen. Secondly the surgery alone arm crosses the 
chemoradiotherapy group at just over one year in the adjusted stage III and IIIA analyses. 
Finally, over this relatively short follow-up timescale, there was no difference in survival 
identified between people receiving concurrent or sequential radiotherapy (Figure 4.6).  
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Figure 4.3 Unadjusted Kaplan Meier survival estimates by treatment group for all 
patients with stage III NSCLC 
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Figure 4.4 Adjusted Kaplan Meier survival estimates by treatment group for all patients 
with stage III NSCLC 
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Figure 4.5 Adjusted Kaplan Meier survival estimates by treatment group for patients 
with stage IIIA NSCLC 
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Figure 4.6 Kaplan Meier estimates for patients with stage III NSCLC receiving 
concurrent chemoradiotherapy versus sequential.  
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4.4 Discussion 
 
Stage III NSCLC is a heterogenous disease and can be challenging to optimally treat. This is 
because patients in this group tend to be elderly with multiple co-morbidities and hence 
poorly represented in clinical trials. (273) Therefore, there is difficulty applying trial evidence 
to these patients. To my knowledge this is the first comprehensive analysis of the 
management of stage III NSCLC conducted in England using population-based data linked 
with specific radiotherapy and chemotherapy datasets. In addition, the association between 
hospital infrastructure and lung cancer outcomes is explored. The following section discusses 
how these findings compare internationally and highlight areas for quality improvement.  
4.4.1 Summary of findings 
 
Approximately 40% of stage III NSCLC receive curative intent treatment and about half of all 
patients with stage IIIA disease. The commonest curative intent regimen is bi-modality 
treatment (chemotherapy with either surgery or radical radiotherapy), however less than one 
fifth of patients receive this. One third receive palliative intent treatment or no anti-cancer 
treatment (36%). 
Approximately one third of patients survive to one year (37% for stage IIIA). Patient factors 
found to be significantly associated with increased likelihood of surviving one year or 
receiving curative intent treatment include a performance status of 0-2; younger age and stage 
IIIA.  When stratified by age (<65 years old), stage (stage IIIA) and performance status (0-1), 
about one third of patients receive curative intent treatment and a half survived one year.  
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4.4.2 Comparison with international studies 
 
A literature search for studies investigating the management and outcomes of patients with 
stage III NSCLC using national datasets was conducted. The following databases were 
searched for articles published from January 2007 to September 2018 with no language 
restrictions: PubMed and MEDLINE with the following terms: “non-small cell lung cancer”, 
“stage III” and “population based” or “database”. All titles/abstracts were reviewed and those 
that met the inclusion criteria were selected. The selection criteria are summarised in Figure 
4.7.  
Figure 4.7 PICO chart detailing inclusion criteria 
 
This search produced 70 papers that were reviewed using the above criteria. Eleven articles 
met the criteria from the database search. Table 4.9 summarises the inclusion criteria of these 
studies. This study represents the most recent analysis of population-based stage III data with 
other study data varying from as early as 1998 to 2013. Six of the studies were based in the 
USA (263,276–280), with two from the Netherlands (272,281), and others including British 
Columbia, Canada (261), Belgium (282) and New South Wales Australia (262). Numbers of 
Adults (≥18 years old) 
Stage IIIA NSCLC patients 
Treatment/management patterns 
Survival (mean survival, one-year 
survival, 5-year survival).  
Analysis of a national dataset 
Population 
Intervention 
Outcome 
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included patients range from 308 to 123,629. The inclusion criteria of five studies were 
similar to this study of all clinically staged III patients. Two studied the management of stage 
III disease in the elderly (>65 years) and only included patients where staging was 
pathologically confirmed. (272,277) Three American studies investigated specific treatment 
regimens and three only included patients with clinical stage IIIA.  
Table 4.10a shows results for this cohort in comparison to studies reporting treatment rates by 
modality for patients with clinical stage III NSCLC. Driessen et al include those >65 years 
only. (281) Figure 4.8 graphically illustrates that curative treatment rates in England are the 
second lowest in comparison to studies from Australia (262), the Netherlands (281) and 
Belgium (282), lowest for multimodality treatment and highest for patients not receiving any 
anti-cancer therapy. It should be noted that the study with the lowest curative intent treatment 
rate (25.9%) only studied four centres in British Colombia, Canada. (261) Vinod et al account 
for low rates for patients receiving surgery and best supportive care by selection bias. Only 
63% of all patients with lung cancer in British Colombia were included. The excluded group 
had either localised disease with good performance status and therefore likely to have had 
surgery or metastatic disease with poor performance status and therefore belong to the best 
supportive care group. Excluding this study, the percentage of patients receiving surgery as 
part of their treatment (12.2%) is comparable with others that range from 6% in New South 
Wales, Australia to 13.7% in the USA. (262,263) However, less than one fifth of patients 
receive radical radiotherapy as part of their treatment compared to approximately half of 
patients in Australia, USA and the Netherlands. (262,263,281) This is true even though 
Driessen et al included only patients >65 years in their analysis of the Netherlands Cancer 
Registry. This corresponds with the comparatively high numbers of patients receiving no 
active treatment or palliative intent treatment. 
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Table 4.9 Selection criteria for population-based studies investigating treatment patterns and outcomes of patients with stage III NSCLC 
in comparison to this study 
Study N Country Data 
date 
Data source Inclusion criteria 
NLC*A 6,276 England 2016 National Lung 
Cancer Audit and 
linked datasets 
Clinical stage III NSCLC 
Driessen (281) 7,057 Netherlands 2009-
2013 
Netherlands Cancer 
Registry 
Clinical stage III NSCLC; age 65 years or older 
Vinod (261) 2,365 British 
Columbia 
(BC), Canada 
2000-
2007 
BC Cancer Agency 
database (data from 
four cancer centres) 
Clinical stage III NSCLC 
Vinod/O’Connell 
(262) 
308 New South 
Wales 
(NSW), 
Australia 
2001-
2002 
NSW Central Cancer 
Registry 
Clinical stage III NSCLC 
Verleye (282) 1,987 Belgium 2010-
2011 
Belgian Cancer 
Registry 
Clinical stage III NSCLC 
Little (263) 11,263 USA 2001 National Cancer 
Database 
Clinical stage III NSCLC 
MacClean (279) 18,684 USA 2006-
2012 
National Cancer 
Database 
Pathologically confirmed Stage III NSCLC who received surgery and 
neoadjuvant/adjuvant chemotherapy  
Harris (276) 1,943 USA 2002-
2009 
Medicare-SEER 
database 
Pathologically confirmed stage III NSCLC, aged >65 years who received 
chemoradiotherapy 
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Miller (277) 57,602 USA 2003-
2014 
National Cancer 
Database 
Clinical stage III NSCLC 
Dickhoff (272) 4,816 Netherlands 2010-
2013 
Netherlands Cancer 
Registry 
Clinical stage IIIA NSCLC 
Patel (280) 123,629 USA 1998-
2010 
National Cancer 
Database 
Clinical stage IIIA NSCLC who received chemoradiotherapy or 
chemotherapy, surgery and radiotherapy (in any sequence) only.  
Hancock (278) 83,913 USA 1999-
2011 
National Cancer 
Database 
Clinical stage IIIA NSCLC 
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Table 4.10a: Comparative published treatment rates by modality for Stage III patients  
 NLCA 
(n=3,827) 
Vinod/O’
Connell 
(262) 
(n=1,812) 
Little (263) 
(n=11,168) 
Driessen* 
(281) 
Verleye 
(282) 
(n=1,987) 
Vinod 
(261) 
(n=2,36
5) 
Surgery alone 5.1 4.0 6.6 9.5** 11.7** 4.5 
Surgery with 
chemotherapy 
7.1 2.0 7.1 4.6 
Radical 
radiotherapy 
5.9 31.0 16.5 35.9 6.6 3.5 
Radical 
radiotherapy 
with 
chemotherapy 
10.8 19.0 36.2 14.5 33.9 13.3 
Curative 
intent therapy 
28.9 56.0 66.4 59.9 32.8 25.9 
Multimodality 
treatment 
17.9 21.0 43.3 14.5 52.1 17.9 
Palliative 
intent 
treatment 
34.2 11.0 11.5 13.4 32.8 61.0 
Best 
Supportive 
Care 
36.1 28.0 18.5 26.5 15.4 10.5 
*Patients>65 years old only included 
**Results not reported separately  
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Figure 4.8 Treatment pattern by country for stage III NSCLC 
BSC: Best supportive care; BC: British Colombia 
 
Table 4.10b compares treatment patterns in the NLCA dataset to studies that reported 
management of patients with clinical stage IIIA. Figure 4.9 shows that excluding the study by 
Vinod et al, curative intent treatment rates remain the lowest for England in comparison to the 
Netherlands (281), Belgium (282) and USA (278). The same pattern as that shown in Figure 
4.8 for all stage III patients is seen for stage IIIA too. Surgical resection rates are 
comparable:- 19.2% in England compared to 17% in Belgium (282), 21% and 15% in the two 
studies from the Netherlands (272,281) and 14% in the USA (278). However, radical 
radiotherapy rates remain low for stage IIIA (18.6% for England, 40.9% in Belgium (282), 
55%/57% for the Netherlands (272,281) and 69% in the USA (278)). Over one third of 
patients at stage IIIA do not receive any active treatment which compares to 13%-18% in the 
other studied countries. (272,278,281,282)  
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Table 10b: Comparative published treatment rates by modality for Stage IIIA patients  
 NLCA 
(n=3,827) 
Vinod 
(261) 
Verleye 
(282) 
(n=1,197) 
Driessen* 
(273) 
(n=3,960) 
Dickhoff 
(272) 
(n=4816) 
Hancock 
(278) 
(n=83,913) 
Surgery alone 7.9 5.8 17.0** 21.0 11.0 14.0** 
Surgery with 
chemotherapy 
11.3 7.5 47.0 4.0 
Radical 
radiotherapy 
7.6 4.0 8.1 8.0 12.0 69.0** 
Radical 
radiotherapy 
with 
chemotherapy 
11.0 16.5 32.8 11.0 45.0 
Curative 
intent therapy 
37.8 33.8 57.9 76.0 72.0 83.0 
Multimodality 
treatment 
22.3 24.0 NR NR 49.0 NR 
Palliative 
intent 
treatment 
26.7 52.4 27.1 11.0 9.0 17.0 
Best 
Supportive 
Care 
34.5 9.6 15.0 13.0 18.0 NR 
NR: Not reported separately 
*Patients>65 years old only included 
**Results not reported separately.  
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Figure 4.9 Treatment pattern by country for stage IIIA NSCLC 
UK: United Kingdom; BC: British Colombia; BSC: Best supportive care 
 
 
The one year survival rate of 33% reported in the current study does not compare favourably 
to other studies (British Colombia (51%) (261), Belgium (53.1%) (282) and the Netherlands 
(44.8%; patients >65 years only) (281)) shown in Figure 4.10. The rate of 55% found in the 
optimised subgroup (<65 years, PS 0-1 and stage IIIA) is consistent with international data. 
These figures may be reflective of the high rates of patients not given any active anti-cancer 
treatment or treated with palliative intent.  However, NLCA data includes all lung cancer 
cases diagnosed in England. Therefore, it is important to note that the total number of cases is 
likely to be larger than in other reported series. 
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Figure 4.10 One-year (unadjusted) survival by country (%) 
UK: United Kingdom; BC: British Colombia 
 
 
4.4.3 Reasons for international differences in treatment patterns and survival 
 
Reasons for these comparatively low outcomes are likely to be multifactorial including 
patient, tumour, clinician and organisational factors. These factors are discussed in turn 
below.  
4.4.3.1 Patient factors 
 
Patient factors cannot wholly explain our findings. The demographics in this cohort are shown 
to be similar to other lung cancer populations from Western countries in terms of age and 
performance status. (92,261,263,283)  
Patients included in the NLCA dataset were found to have a lower co-morbidity burden than 
in other studied populations. Eighty percent of the Australian population in the study by 
Vinod et al and 72% of the cohort in Little et al had at least one co-morbidity. This compares 
to only 60 % in the NLCA population. Charlson Index was used as a proxy for co-morbidity 
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burden. This composite score has been validated in cohorts of men and women with 
malignant and non-malignant diseases. (284) Studies using NLCA data derive this index from 
hospital admission data, therefore all diagnoses may not be captured if a condition is managed 
by a general practitioner. This may explain our comparatively low co-morbidity burden and 
raises the possibility of residual confounding. (158) Despite this, the methodology used to 
derive the score has been validated for use in the NLCA cohort. (158) Furthermore, the 
distribution of the index is similar to general practitioner datasets (285) and cohorts of 
patients with NSCLC. (286,287)  Comparative international data on deprivation index is 
lacking.  
In the multi-variate analysis, the presence of co-morbidity did not independently affect the 
likelihood of treatment or one-year survival. This is in keeping with findings from other stage 
III studies. (262,288) This may be because the majority of patients had a good performance 
status despite the presence of co-morbidities. (262)   
Patient factors that were found to be significantly associated with improved one-year survival 
or curative intent treatment on multivariate analyses were a performance status of 0-2, 
younger age (<65 years) and stage IIIA. However, approximately one third of patients in this 
optimised group did not receive curative intent treatment suggesting that treatment decisions 
are influenced by factors other than patient and tumour variables.  
4.4.3.2 Clinician factors 
 
Clinician factors may explain the high proportion of patients receiving palliative intent 
treatment or no active treatment. Qualitative work conducted in early stage NSCLC 
demonstrates that a failure of clinicians to effectively discuss all treatment options with 
patients influence treatment rates. (289) Additionally, Legare et al show that the most 
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significant variable determining whether patients will engage in shared decision making is the 
clinicians attitude and there is evidence to show that differences in attitudes towards the 
management of this specific stage exist amongst health professionals. (290)(291) Hence it is 
possible that nihilistic attitudes amongst health professionals may contribute to our low 
radical radiotherapy and multimodality treatment rates. Such attitudes among respiratory 
physicians may contribute to low referral and pathological confirmation rates. (292) Similarly, 
a fatalistic attitude amongst treating clinicians may limit receipt of treatment. (293,294)  
One factor that has been shown to significantly influence treatment decision making is age. 
(281) Previous studies demonstrate that elderly patients with NSCLC receive standard 
treatment less often. (281) Table 4.7 shows that amongst patients with a PS of 0-1 and stage 
IIIA in England, the rate of curative intent treatment varied from 70% in the <65 age bracket 
to under 40% in >80-year olds. Additionally, on multivariate analysis, the odds of receiving 
treatment in patients over the age of 80 were 70% less likely than those <65 after accounting 
for other patient factors. This finding is consistent with the literature. (277,281) Previous 
analysis of the NLCA showed that the odds of being investigated and treated decreased 
progressively with age. (295) Additionally, Miller et al show that patients with stage III 
disease over the age of 70 years old were twice as likely not to receive any treatment and 1.4 
times more likely to receive palliative intent treatment if treatment was received compared to 
those under 70 years old. (277) In addition, when curative intent treatment was delivered, 
elderly patients were three times more likely to receive radiotherapy alone rather than 
multimodality treatment.  
These findings can be explained by multiple factors. Firstly, there is a lack of evidence to base 
treatment decisions because elderly patients are under-represented in clinical trials. (296) In 
addition, other factors such as patient preferences, malnutrition and cognitive impairment are 
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likely to be important. (281) Lastly, elderly patients are shown to be particularly vulnerable to 
acute severe toxicities resulting from multimodality treatment such as oesophagitis, 
haematological toxicity and pneumonitis. (273,297–299) Therefore, morbidity concerns are 
likely to significantly influence treatment decision making. Nevertheless, the literature 
suggests that current criteria applied to decision making may be too strict, leading to a 
suboptimal number of patients receiving curative intent treatment. Driessen et al show that 
mortality for stage III patients does increase with age, but these differences are rendered 
insignificant once stratified by treatment. (281) Additionally there is evidence that older 
patients with similar clinical features to a younger age group can tolerate and equally benefit 
from investigation and treatment. (295) Finally, a statement by the European Organisation for 
Research and Treatment of Cancer states that suitability for treatment should not be defined 
by chronological age alone. (300) 
Four interventions have the potential to address such variability in decision making. The 
British Thoracic Society recommend providing patients with surgical and oncology treatment 
assessments by the relevant teams. (265) Widespread implementation of this approach has the 
potential for quality improvement interventions to address two findings. Firstly, the low 
number of patients receiving multi-modality treatment including neoadjuvant or tri-modality 
therapy in surgical patients, which currently sits at just 10%. Secondly the high numbers of 
patients (n=321) receiving surgery alone; a treatment approach not supported by evidence or 
guidelines. This is pertinent given the updated NICE lung cancer guidelines newly advocate 
chemoradiotherapy prior to surgery in multimodality stage IIIA treatment; a practice that is 
clearly not currently executed. (41) However, it should be noted that the definition of radical 
radiotherapy in this study is >50 Gy which is higher than what be used in practice in a tri-
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modality regimen. Additionally, factors such as patient preference and decline in patient 
performance status post-surgery may explain this finding.  
Secondly, the use of comprehensive geriatric assessment (CGA) as described in the scoping 
review in section 2.1.5.2 can provide a structured approach to holistic patient assessment. 
Hence, ensuring those suitable for curative intent treatment are fully informed of their 
treatment options whilst avoiding overtreatment. Schulkes et al found in their systematic 
review of the use of the CGA tool in elderly patients with NSCLC that it can help detect 
health concerns not reflected by performance status alone and predict mortality and treatment 
completion. (301)  
Thirdly, this registry-based data reported in the current study includes all stage III NSCLC 
patients diagnosed in England and some will be too unwell or frail for treatment and many 
will not be surgical candidates. However, the variation across hospital trusts in the proportion 
of patients treated with either surgery or radical radiotherapy would suggest that as a country, 
there is room to increase the amount of radical radiotherapy offered to stage III patients and to 
critically review how this is given in combination with chemotherapy. This is particularly 
relevant in light of a recent trial showing significantly improved overall survival with the 
addition of adjuvant Durvalumab after concurrent chemoradiotherapy. Out of all patients 
receiving chemoradiotherapy only one third had this is the concurrent setting. This compares 
to rates of 94% in USA and 92% in Canada. (261,276) Therefore, large change in practice is 
required if adherence to the latest NICE guidance is to be achieved. Understanding barriers to 
access and re-evaluating preconceptions of what is considered radically encompassable with 
the use of modern radiotherapy techniques such as intensity modulated radiation therapy 
(IMRT) may improve low radical concurrent radiotherapy rates. Koshy et al  demonstrated 
that patients with stage III NSCLC treated with IMRT had an eleven per cent relative 
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reduction of risk of death compared to those treated with non IMRT techniques. (302) 
Additionally, the former group had a lower incidence of treatment interruptions. Another 
study showed that IMRT is associated with lower rates of severe radiation pneumonitis. (303) 
Therefore, the reduced mortality and morbidity associated with this technique indicates that 
elderly patients may be better able to tolerate curative intent treatment. One barrier may be 
that encompassability can only be adequately assessed with planning attempts to ascertain 
dose and volume data. Therefore, these attempts require reimbursement even if patients do not 
progress to receive a radical dose. 
Finally, improvements in consistent performance status assessment is crucial to determining 
appropriate management plans. Studies report conflicting data in the reliability of clinician 
assessed performance status measurement with variable levels of inter-observer agreement. 
(304–306) Additionally, the recorded measurement tends to that assessed on initial 
presentation rather than that at the time of assessment by a treating clinician. This 
inconsistency is likely to have an impact on results and is explored further in section 5.3.3.3.  
4.4.3.3 Organisational factors 
 
There is an increasing body of literature indicating that organisational characteristics and 
access to specialist care significantly impacts patient outcomes and contributes to national 
variation. (261,282,307) Therefore, even though the association between the organisational 
score and lung cancer outcomes did not reach statistical significance for stage III patients, this 
factor still warrants further discussion.  
Access to up to date staging modalities is key in stage III NSCLC. Details of the extent of 
staging is not available in the NLCA dataset. However, with endobronchial ultrasound being 
available on site in England in only 67% of trusts combined with the fact that 102 trusts fall 
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below the 75% target for pathological confirmation; patients run the risk of missing out on 
potentially curative treatment. (214) The latest NLCA report reports a pathological 
confirmation rate of 72% which compares to a figure of 91% quoted by Vinod et al in their 
Australian cohort.(262)  
Similarly, limited access to treatment facilities can influence treatment receipt. Verleye et al 
found that in their study of NSCLC patients in Belgium, that important differences between 
institutions were observed. (282) Organisations that had on site radiotherapy facilities treated 
a higher proportion of stage III patients with chemoradiotherapy. Therefore, the variability in 
access to surgical and radiotherapy shown in Chapter 3 is likely to have an influence on 
treatment patterns.  
Another factor is inequity of access to specialist staff shown by the second NLCA 
organisational audit. (214) Lung cancer CNSs have been shown to be key in enhancing 
communication and patient decision making yet less than a fifth of trusts meet the lung cancer 
national commissioning guidance requirement of having a minimum of one whole time 
equivalent specialist nurse per 80 new lung cancer diagnoses per year. (214,255,308) It is not 
possible to ascertain from the data if patients consulted specialist health professionals. 
However, there is UK evidence to show that patients that see a lung CNS or an oncologist are 
more likely to receive active treatment. (255,309) This is in line with SEER data from the 
USA showing that 36% of patients who did not receive chemotherapy for their advanced lung 
cancer were not seen by a medical oncologist. (310) Therefore, difficulty with access to 
specialist staff is likely to be a barrier to a patient receiving optimal treatment.  
Lastly, timeliness of access to facilities is important as emphasised by national guidance. 
(86,227) Lung cancers can progress, and the performance status of patients can drop in the 
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waiting time for diagnostics, advice and treatment. (311) This is particularly important for this 
subgroup of patients who frequently require additional staging investigations and complex 
treatment planning. (292,311,312) Timely access to specialist facilities is essential if 
improvements are to be made which can be achieved through adoption of the national optimal 
lung cancer pathway. (86)  
Despite the above evidence, we show that a higher organisational score was not statistically 
significantly associated with improved one-year survival or curative intent treatment rates in 
this subgroup unlike for the overall population shown in Chapter 3. This highlights the 
importance of other factors that are likely to contribute to treatment patterns for this cohort 
discussed above. The management of stage III patients is complex. Hence factors such as 
therapeutic nihilism, over estimation of risks of treatments by clinicians and uncertainty on 
the extent of information patients receive to base decisions on, all play a part in influencing 
treatment patterns; factors not fully encompassed by the organisational score. 
In summary, improving outcomes for patients with stage III disease in England requires a 
multi-faceted approach. Undertreatment has the potential to be addressed by specialist MDT’s 
for complex stage III patients and training in optimal patient selection. However, financial 
investment in lung cancer services and deficiencies in service structure require urgent 
attention to enable timely access to essential diagnostic and therapeutic modalities to 
ultimately change patient outcomes.   
4.4.4 Strengths and limitations  
 
The main strength of this study is the completeness and quality of the NLCA data providing 
an accurate picture of patient management in this subgroup. In fact, the accuracy and 
validation of UK data may contribute to reasons why our results compare poorly to others. It 
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is important to note that NLCA data includes all lung cancer cases diagnosed in England, 
therefore the proportion of all patients whose data is included is likely to be larger than other 
reported series.   
Four main limitations should be acknowledged. Firstly, the retrospective nature of the 
population-based data may be subject to confounding, under-reporting and selection bias. 
Selection bias may in part explain why treatment regimens involving surgery are shown to 
have better survival than the other curative intent regimens. These patients may represent a 
fitter group or more accurately staged intraoperatively. Secondly, as previously mentioned, 
details on the quality of staging or the tumour volume or location is not available in the 
NLCA dataset, therefore eligibility for curative intent treatment and details of stage 
designation cannot be verified. Thirdly, only short-term survival was examined because 
linked data has only recently been available to allow accurate treatment allocation. However, 
one-year survival has been shown to be an important driver in longer term survival. (313) 
Finally, it is not possible to ascertain the reasons for treatment decisions from population-
based data. Further understanding into decision making practices in lung cancer will increase 
our understanding of barriers to patients receiving optimal treatment. This will be addressed 
in the following chapter.  
238 
 
4.5 Conclusions 
 
We highlight important gaps in the optimal care of patients with stage III NSCLC. 
Establishing current treatment patterns is important at this pivotal era of immunotherapy. 
Significant improvements in progression free survival seen with the addition of Durvalumab 
to chemoradiotherapy in stage III disease heralds a treatment paradigm shift. However, 
without addressing deficiencies in care, only 4% of our patients would currently benefit from 
such advancements. (76) Timely access to specialist resources and staff, the practice of 
effective shared decision making, and challenging preconceptions require urgent attention to 
address regional variation in curative intent treatment if patients are to have the best chance of 
surviving this disease. 
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CHAPTER 5 DECISION MAKING IN LUNG 
CANCER: A LOCAL QUALITATIVE STUDY 
5.1 Introduction 
 
Outcomes in lung cancer are known to be influenced by patient factors and provision of 
resources. However, hospital trusts that have similar patient populations and resource 
allocation have shown variation in outcomes. (17) It has been hypothesised that outcomes are 
also dependent on the quality of decision making that occurs within the multidisciplinary 
team (MDT) of that hospital. This type of detailed information is not captured by large 
datasets such as the NLCA due to the complexity of the data that would be required. 
However, addressing barriers to effective decision making locally is likely to have a direct 
impact on patients.  
The following chapter critically examines the process of lung cancer MDT decision making 
with a focus on shared decision making (SDM) in one hospital trust with the aim of 
developing an implementation strategy to identify and address areas of improvement.  
5.1.1 Models of decision making in healthcare 
 
The three most commonly referenced models of decision making in healthcare are 
paternalistic, shared and informed summarised in Table 5.1. (314) Previously, the most 
prevalent model was paternalistic. (314) This is where the physician drove decisions 
according to their experience, expertise and assumptions about the patient. Models involving 
collaboration with patients have gained popularity over recent years however the paternalistic 
model of consultation is still that most widely practiced by healthcare professionals. (315) 
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Table 5.1 Models of decision making 
 
 Paternalistic Shared Informed 
Consultation style Directed by 
physician 
Physician and patient 
contribute 
Directed by 
physician 
Decision maker Physician Physician and patient Patient 
Associated health 
model 
Biomedical
1 
Biopsychosocial 
model
2 
Bio medical 
1 
Biomedical model of disease is focused on physical and biological factors of disease(316) 
2 
A wide range of factors are considered in the biopsychosocial model of health including a person’s social 
circumstances, beliefs and values.  
 
5.1.2 Factors influencing decision making in lung cancer 
 
Clinical decision making in lung cancer is a complex process. Figure 5.1 illustrates a ‘typical’ 
patient journey and indicates points where decision making may occur. Time targets are 
highlighted as per the ‘Independent Cancer Taskforce Report’ which was formulated to 
reduce delays and increase treatment utilisation. (94) 
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Figure 5.1 Patient pathway and decision-making points  
 
* Maximum pathway times according to the Independent Cancer Taskforce Report. The times are the maximum allowed but 
the National Optimal Lung Cancer Pathway aims for the majority of patients to be diagnosed within 28 days and treated 
within 42 days.  
** DM point: Decision making point 
 
Figure 5.2 summarises factors that are known to influence decision making in lung cancer. 
Decisions in lung cancer are heavily influenced by guidelines such as the NICE guidelines 
(“The diagnosis and treatment of lung cancer”) and the aforementioned “National Optimal 
Lung Cancer Pathway” document produced by the Lung Clinical Expert Group in 2017. 
(86,227) These recommendations provide the basis of the best available evidence of clinical 
and cost effectiveness for health care professionals and patients to make decisions in lung 
cancer.  
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Factors other than clinical guidelines that are known to influence decision-making are 
patients’ medical history and tumour characteristics. (315) This may include the patients’ age, 
diagnoses, co-morbidities and prior treatments as well as the tumour stage, radiological and 
histological results. This information is key to assessing the options available for a patient 
with lung cancer. Additionally, knowledge and beliefs of both patients and health care 
professionals impact on decision making in cancer. (317) Patients’ knowledge of treatment 
options and disease are affected by the way in which clinicians’ beliefs are expressed as well 
as the way the risks of benefits of potential options are presented to them. (317) Factors such 
as health literacy, symptom burden as well as past experiences of the clinicians’ have also 
been shown to play a part in decision making. (315,318,319)  
Figure 5.2 Factors influencing decision making in lung cancer 
 
 
5.1.3 The MDT meeting 
 
It has been shown that the majority of cancer decision making occurs in the MDT meeting. 
(320) The MDT meeting was introduced after the Calman-Hine report documented poor 
outcomes for cancer patients. (321) The aim of the MDT meeting is to address variation in 
Attitudes, beliefs and 
preferences of patients, 
healthcare professionals 
and family 
DECISION MAKING 
IN LUNG CANCER 
Patient factors e.g. well-
being, health literacy 
Clinician skills and 
experience Disease factors e.g. stage 
and histological subtype 
of the tumour 
Guidelines and evidence 
from clinical trials 
Team working 
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care across UK and improve decision making by involving several health care professionals. 
It is recommended by the National Comprehensive Cancer Network and in 2001 The NHS 
Cancer plan committed to ensuring that all patients with cancer were reviewed by a tumour 
specific MDT. (322) It is now established as the standard of care for patients with cancer in 
the UK.   
Guidelines mandate that membership of the lung cancer MDT should include at least one of 
the following specialists: a respiratory physician with an interest in thoracic oncology, a 
radiologist and histopathologists with thoracic experience, a clinical nurse specialist, clinical 
and medical oncologists, a palliative care physician, a thoracic surgeon and an MDT 
administrator. (323–326) All these specialists should attend the MDT meeting for it to be 
considered quorum.  
All patients with a confirmed or suspected diagnosis of lung cancer are discussed at the MDT 
meeting. The first organisational audit recommended that MDTs should hold two meetings 
per week; a diagnostic and treatment MDT. (85) A diagnostic MDT attended primarily by 
respiratory physicians and a thoracic radiologist discusses the initial optimal approach at the 
start of the patient pathway. The treatment MDT predominately discusses treatment decisions 
for patients with a histological diagnosis. However, discussions may also include post-
operative outcomes and re-discussion of patients if situations or circumstances have changed. 
The inclusion of the ‘diagnostic MDT’ as a separate meeting aims to maximise resources by 
avoiding unnecessary investigations and therefore minimising delays to treatment.  
 
5.1.4 Shared Decision Making 
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SDM is defined as the “interactional process in which the patient and the clinician aim to 
reach a decision together that is based on shared information and the best available evidence”. 
(327) SDM underpins patient centred care because it helps patients understand their disease 
and consider the benefits and harms of proposed treatment options in terms of their own 
context, values and beliefs. (315)  
5.1.4.1 The process of SDM 
 
Experts in SDM advocate a step wise approach to facilitate decision making in an oncology 
setting. These steps are summarised in Table 5.2. (328)  
Table 5.2 Steps in the Shared Decision-Making Process 
 
Steps Shared Decision-Making Action 
1 Determine the situations in which SDM is critical 
2 Acknowledge the decision to the patient 
3 Describe the options, risks, benefits and uncertainty associated with options 
4 Elicit patient preferences and values 
5 Agree on plan for the next steps in the decision-making process.  
 
5.1.4.2 Evidence supporting SDM 
 
SDM is supported by several national and international bodies. An international group at the 
Salzburg global seminar advocated for clinicians, patients and policy makers to support SDM. 
(329) The principle of “No decision about me without me” adopted at this seminar has been 
embraced by national guidelines in the UK promoting the use of SDM in routine care. (330)  
There is a growing body of evidence demonstrating the benefits of SDM. Studies have 
established that patients who experience SDM have more accurate expectation about care, 
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decreased levels of fear and depression, improved quality of life and increased treatment 
satisfaction. (331–334) Importantly, patients want to be involved in management decisions. 
There is evidence demonstrating that decisions made by such patients differ to decision made 
by patients that experience other consultation models. (290,335,336) These decisions are also 
shown to differ from those made by treating clinicians. (337). These may be because medical 
professionals and patients have been shown to vary in their interpretation of risk or the value 
of survival and quality of life is judged differently. (334,335) Therefore, it is evident that 
SDM is not only an essential component of patient centred care but also an ethical imperative. 
(338,339) 
5.1.4.3 Challenges incorporating SDM in clinical care 
 
Two main challenges impeding the routine application of SDM have been summarised in 
Table 5.3.  
Table 5.3 Challenges incorporating SDM in clinical care 
Issue Challenge Consequence 
Biomedical model of 
disease and paternalistic 
style of consultation is 
predominant model of 
practice in 
healthcare(315,340). 
- Changing organisational 
culture and attitudes is 
challenging. (341) 
- Patients are not present 
in the MDT meeting. 
- Decisions reflect the values of 
MDT members rather than 
patients 
- Agreed MDT outcomes can be 
framed by the clinician 
communicating the 
information to the patient 
Burden of decision 
making is on the patient  
- Patient decisions are 
dependent on several 
factors such as family 
pressures, emotional 
state and ability to 
interpret information. 
(342)  
- Clinicians require time 
to adequately assess if 
the decision truly 
reflects the values and 
opinions of the patient  
- Resources are lacking in the 
NHS to dedicate such time. 
- Shorter lung cancer pathways 
are linked to improved patient 
outcomes. (343) Delaying 
treatment decisions may not be 
in a patient’s best interests. 
(210) 
- no robust mechanism to judge 
the extent to which he decision 
is informed or free from 
coercion. (338)  
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5.1.4.4 Shared Decision Making in Lung Cancer 
 
SDM is relevant to lung cancer for three main reasons. Firstly, the lung cancer trial population 
is not representative of real life, as discussed in section 4.1.3. Consequently, shared decision 
making is vital to ensure patient priorities are met. This is particularly important in clinical 
situations where the optimal management is uncertain. (344) The management of stage IIIa 
(N2) disease discussed in chapter 4 is one such clinical scenario. Another situation of clinical 
equipoise is the treatment of early stage NSCLC in patients with a good performance status as 
discussed in section 1.6.2. In these preference sensitive decisions, actively involving the 
patient provides personalised treatment and better outcomes. (340)  
Additionally, clinical trials introducing novel treatments for lung cancer patients are occurring 
more frequently than ever. For example results of the recent PACIFIC trial presented at the 
latest ‘World Conference on Lung Cancer’ has shown promising survival gains with the use 
of Durvulumab (an immunotherapy agent) in patients with stage III unresectable lung cancer 
when used after chemoradiotherapy. (246) The increase in treatment options is clearly good 
news for patients. However, the risks, benefits and effectiveness of such new treatments are 
yet to be established. Therefore, communicating this uncertainty to patients and involving 
them in decisions is necessary.  
Finally, lung cancer has a median prognosis of one year. (3) A diagnosis is associated with 
psychological distress and poor quality of life. SDM allows patients to be guided through 
difficult risk benefit calculations that are life changing. (345)  
Despite the relevance of SDM practice to good lung cancer management, there is evidence to 
show it is not routinely practiced. (338,346) The Care Quality Commission’s national patient 
surveys show that 48% of inpatients and 30% of primary care patients would have liked more 
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involvement in decisions about care. (347) In addition to the previously mentioned 
challenges, studies have found there is a lack of training and familiarity with the concept 
amongst lung cancer MDT members. (346)  
5.1.8 Rationale 
 
Decision making, is an under investigated aspect of care and requires further investigation in 
lung cancer for four main reasons. Firstly, the majority of the literature on decision making in 
oncology is based on all cancer patients or patients with gynaecological/breast cancer where 
management decisions are heavily guideline driven. In comparison, lung cancer is shown to 
involve an older, more complex population where the optimal strategy may not be as 
directive.  
Secondly, studies that have investigated decision making in lung cancer have concentrated on 
one portion of the patient pathway such as the MDT meeting. Few have investigated the 
effectiveness of the whole decision-making process. For example, if the recommendation 
made in the MDT meeting was subsequently discussed with the patient and implemented. 
With a cost of approximately £87.41 per case discussion, it is essential that the whole process 
is proven to improve outcomes for patients. (348) Section 2.4 highlights the difficulties of 
randomised controlled trials in demonstrating such benefits. Consequently, other research 
methods should be adopted to holistically assess decision making in the MDT.   
Thirdly, variability in patient decision making between units has been demonstrated 
illustrated by studies citing refusal rates for curative intent lung cancer treatment between 20 
and 32%. (92,186) The factors contributing to this variation remain under investigated  
Finally, research on SDM has focused on the creation of decision support tools rather than 
understanding the attitudes and behaviours of the health care professionals who are in a 
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position to deliver this model of care.  To gain a wider understanding of decision making it is 
not only necessary to identify the factors that influence decision making, but it is also 
important to uncover attitudes to SDM in the lung cancer community. Legare et al found that 
the most significant variable determining whether a patient will engage in SDM is the 
physicians’ attitude to SDM. (349)  
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5.2 Methods 
 
5.2.1 Aim 
 
The aim of this study is to critically examine the process of local decision making and 
influence on patient outcomes in one hospital trust in order to develop an implementation 
strategy to improve the effectiveness of decision making within this MDT. 
5.2.2 Justification of qualitative methods 
 
A qualitative methodology has been chosen to address the above aim. There is evidence to 
demonstrate that qualitative research methods are valuable in investigating health service 
organisation and consequently enable changes in policy for four main reasons. (350)  
Firstly, qualitative data has been shown to be key in understating and uncovering meaning 
behind complex behaviours such as decision making. (351) This is particularly useful when 
the decision-making process involves team-based interactions such as an MDT meeting. (351) 
It is accepted that the motivations behind individual behaviours and interactions are complex.  
Secondly, it has been established in section 5.1.8 that data on decision-making in lung cancer 
is lacking. Qualitative research generates novel knowledge through a rich understanding of 
clinical decision making in its natural context. (351) This is key to giving meaning to views 
and has the potential to form the basis of change.  
Thirdly, change is facilitated by collecting data, identifying areas of improvements and 
developing potential solutions simultaneously. This type of research is termed action research. 
(352) Incorporation of fundamental elements of action research has been shown to be a 
successful method for quality improvement; thus, addressing this studies’ objectives. (353) 
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These elements include that participants define contexts for change and therefore changes are 
more likely to be implemented and sustained. In addition, the researcher works with the 
participants’ in a democratic manner to instigate change. This is particularly important in a 
health care setting where traditional hierarchical systems prevail. Participants that may not be 
involved with formal organisational change in an institution can ‘have a voice’  
Finally, the qualitative study process itself can be an educational tool for the healthcare team 
which is key to instigating organisational change. (354) It has been shown that the process of 
data collection through interviews and observations uncover unacknowledged attitudes that 
can lead to behaviour change. (352)  
5.2.3 Setting and Context 
 
The lung cancer MDT from the Heartlands, Good Hope and Solihull (HGS) sites of 
University Hospitals Birmingham was the subject of this study. The combined hospital sites 
are one of the largest acute hospital trusts in the country. It serves an ethnically diverse 
population of 1.2 million across east and north Birmingham, Solihull, Sutton Coldfield and 
South Staffordshire (355), and in lung cancer also acts as the regional thoracic surgery centre 
receiving patients in a radius of approximately 50 miles. In 2016/17 the sites saw 
approximately 267,793 Emergency Department (ED) attendances and 856,556 outpatient 
attendances with a workforce of 10,565 staff. (355) The lung cancer MDT deals with 
approximately 1560 patients per year. The majority of lung cancer diagnostic and treatment 
modalities are provided within the three sites, including thoracic surgery and medical 
oncology services. Radiotherapy and PET imaging services are provided by the newly merged 
(in 2018) Queen Elizabeth Hospital site.  
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The rationale for choosing this site for the study originated from the results of a local study 
investigating the barriers to curative intent treatment in early stage Non-Small Cell Lung 
Cancer (NSCLC) in patients with a good performance status. (309) NHS Improvement 
highlighted a local resection rate of 15.8% compared to a national average of 17.5%. (356) 
Therefore, the case notes of all such patients discussed at the lung MDT meeting in 2015 and 
did not undergo surgery were examined. The commonest reason for patients not to undergo 
curative intent treatment was recorded as ‘patient preference’ (44.4%) and none of these 
patients saw a surgeon or oncologist. The detail behind the decision making was unclear. 
Consequently, it is vital there is a better understanding of decision making within this MDT to 
improve outcomes for patients.  
The study of one MDT was undertaken to allow in depth study of service provision. The 
results do not aim to be generalised on a national scale, although if generalizable messages 
emerge, they might be the subject of future work via the NLCA. I anticipate that aspects of 
this MDT’s decision-making process will provide common links to other lung cancer MDT’s. 
Previous qualitative studies have demonstrated this concept successfully. (354)  
5.2.4 Participants and data collection 
 
Three methods of data collection were chosen to capture the complexity and longitudinal 
aspect of the decision-making process. These were semi structured interviews with lung 
cancer MDT members, MDT meeting observations and electronic record documentation 
review. A study flow diagram (Figure 5.3) illustrates the data collection process.  
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Figure 5.3 Study flow diagram 
 
 
Using several data sources and methods enables triangulation of findings and with the aim of 
providing a richer understanding of the decision-making process. (357,358) Triangulation is a 
process where a topic is examined with multiple methods or data sources to determine the 
degree of convergence across the components. (359)  
To ensure the MDT was engaged in the research project, JBA met with the lung cancer lead 
physician and MDT team on several occasions to explain proposed methods, emerging results 
and improvement strategies. Feedback from the team contributed to the iterative process.  
This study focuses on health care professional behaviour rather than that of the patient. 
Previous studies have looked at the patient perspective and as reported in section 5.1.5 there is 
evidence to support the assertion that patients want to be involved in decision making. (335) 
In addition, such studies have reported two main challenges when investigating a patients’ 
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perception of SDM. Firstly, responses tend to reflect a patients’ satisfaction with the chosen 
treatment rather than the decision-making process itself. Secondly, a patient is not able to 
know if they were provided with all the options. Therefore, to address the gap in knowledge 
within the remit of this study, the focus was on health professionals’ actions and attitudes.  
5.2.4.1 Semi structured Interviews 
 
Interviews are considered the most appropriate method for exploring health professional 
decision making because they capture a real life understanding of individuals’ attitudes and 
actions. (358) This provides additional insights over observation by exploring the subject 
from the participant’s point of view rather than the assumptions of the researcher. (359) 
The format of an interview can be unstructured, semi structured or structured. A semi-
structured approach was used for four reasons. Firstly, it allows the flexibility to explore new 
ideas that may not have been considered by the researcher. Additionally, the use of probes, 
prompts respondents to clarify the meaning of what has been discussed. Rich detail can be 
gained by this participant led approach. (358) Secondly, non-visual cues are obtained 
facilitating the modification of the line of questioning accordingly. (354) Additionally, it has 
been shown that the rapport gained between the researcher and participant creates an 
environment where more truthful responses are elicited, and fears of social desirability are 
minimised. (358) Finally, health care professionals have several competing demands on their 
time and this method has been shown to be useful in gaining access to such groups that are 
unlikely to respond to surveys. (354)  
A purposive sample of MDT members was obtained by face to face contact or email 
invitation by the research team. Purposive sampling is defined as selective sampling based on 
characteristics of a population and the objective of the study. (351) The invitation to 
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participate was open to all members of the MDT via email. However, individuals were 
targeted to obtain a range of professional disciplines to be approached that have lung cancer 
decision-making experience. Sample size was informed by the principle of thematic 
saturation. (360) This is where a point is reached where “no new concepts emerge from the 
review of successive data from a sample that is diverse in pertinent characteristics and 
experiences”. (358)  
A topic guide (A5.1) was developed which explored participants’ views, attitudes and 
experiences of decision making in this MDT and SDM in their practice. It also sought views 
on improving the current organisation of services. This guide was piloted on two members of 
staff to ensure that the questions and probes were easily understood. As part of the iterative 
process the topic guide was modified according to evolving themes and professional role of 
the interviewee. Subsequent versions of the guide are also included in the appendix (A5).  
The interviews took place in participants’ offices, clinic or meeting rooms and lasted 10-30 
minutes.  They were conducted by JBA (primary researcher) and SK. SK is a clinical 
psychologist who has expertise in qualitative methods and health behaviours. JBA is a 
respiratory registrar and previously worked as part of the lung cancer MDT with training in 
qualitative methods and research interview technique. SK interviewed members of the MDT 
whom JBA has directly worked with in order to minimise bias.  
5.2.4.2 MDT meeting observations 
 
Observation and recording of the MDT was chosen to capture detailed data about the 
behaviours of health care professionals in their natural setting. Previous work demonstrates 
that this is a valuable method of exploring decision-making in a healthcare setting and thus 
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explain variations in patient outcomes. (361) Additionally, self-reported behaviour can 
introduce social desirability and recall bias. (351)  
MDT members were notified that a succession of meetings would be recorded via email and 
in person at the beginning of the recorded meetings. The study was presented as an 
investigation into decision making in lung cancer. The lack of detail given in the initial 
information was intended to prevent a change in behaviour of the participants based on the 
detailed aims of the project. This is called the ‘Hawthorn effect’ (351). The whole meeting 
was audio taped and field notes were written immediately after the meeting including details 
about the meeting attendance, chairing, team working, infrastructure (venue, seating and 
equipment) and meeting organisation. In addition, non-verbal information was recorded 
including personal reactions to the events. This is a recognised technique in observational, 
ethnographic research, and such notes frequently form the basis of initial hypotheses. (351) 
The MDT meeting observations occurred in parallel with the series of interviews and 
contributed to the iterative modification of the interview topic guide.  
JBA conducted all the meeting observations. As a previous participatory member of this MDT 
meeting, her presence was not anticipated to be an intrusion. Observations were conducted 
until thematic saturation was reached.  
5.2.4.3 Document review 
 
Written documents can be a valuable source of data particularly when studying the outcomes 
of patients. Therefore, a review of electronic case notes and MDT meeting outcome 
documents was conducted to document demographic, diagnostic, management and MDT 
outcome information.  
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5.2.5 Data Analysis 
 
5.2.5.1 Transcription 
 
Interviews and MDT meetings were audio-taped and transcribed verbatim. This method of 
recording data is recommended because allows the interviewer to be more responsive during 
the observation process. Additionally, taping ensured accuracy of the data which can be 
verified by another researcher if necessary. Finally, an in-depth analysis of the data can be 
conducted of the transcribed content. (362)  
All the MDT meeting and six interview recordings were transcribed verbatim by the JBA as 
per standardised rules of transcription. (354) An external transcription service was used for 
the remaining interviews in accordance to the same rules. All transcripts were checked 
alongside the recordings by JBA to ensure consistency of transcription and amend errors. In 
addition, this allowed the researcher to familiarise with the data to aid the process of data 
analysis. Importantly, all patient, health care professional and site identifiers were removed to 
ensure participant confidentiality.  
 
5.2.5.2 Computer assisted qualitative data analysis (CAQDAS) 
 
The use of CAQDAS has been shown to be an accurate method of managing, storing and 
coding qualitative data. (363) Therefore, after the transcribed material in Microsoft Word was 
stored and managed in a specialist software programme (NVivo-7).  
5.2.5.3 Thematic Analysis 
 
5.2.5.3.1 Choice of Method 
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The approach used to analyse the data set was thematic analysis. This is a method of 
“identifying, analysing, organising and reporting patterns (themes) within a data set”. (364) 
Themes are recurrent unifying concepts about the subject. (358) Meaning is attached to 
themes in the development of theory.  
Thematic analysis was chosen for two main reasons. Firstly, the aims of study will lead to 
differing categories of results. The exploration of attitudes, and experiences leads to 
descriptive results, whereas identifying areas of quality improvement leads to more factually 
based information. Thematic analysis is suited to addressing these differing results because it 
is not tied to a particular theory such as grounded theory, ethnography or phenomenology. 
(364) Consequently, this flexibility is advantageous to health service studies. (352,364) 
Secondly, there are published methodology guidelines. (364) This increases the rigour and 
reliability of the analytic process.  
A commonly used qualitative analytical approach within the umbrella of thematic analysis is 
the framework method. (365) This method identifies relationships between sections of the 
data. (365) The output is usually formatted in a matrix. where data is organised into rows 
(cases), columns (codes) and ‘cells’ of summarised data. The advantages of this method 
relevant to the aims of this study include the following. (365): 
1.  Several data sources can be systematically examined and analysed at the same time. 
2. Interpretation of experiences and attitudes of participants are transparent through 
illustrative quotes increasing the rigour of the analysis. (365)  
3. A case and theme-based approach can be applied to interpreting the MDT meeting and 
documents review data. (365)  
258 
 
4. A combined inductive and deductive approach can be applied. (365) The aims 
stipulate the investigation of specific issues. However, this method also allows 
unexpected aspects of experience to be uncovered.  
5.2.5.3.2 Applying a thematic framework approach 
 
The stages of analysis are illustrated in Table 5.4.  
 
Table 5.4 Stages of thematic analysis 
Step Description 
1. Data 
management  
The data was transcribed, checked for accuracy and re read. Initial 
ideas were generated, and notes made on these impressions.  
2. Coding Interesting features of the data were categorised into codes by 
considering each line or paragraph of the transcript by the primary 
researcher using NVivo.  
3. Developing an 
analytical 
framework.  
Codes were grouped together to form categories, and this formed a 
working framework. This was developed from one MDT meeting 
transcript and four interview transcripts till no additional codes 
emerged. The framework and sections of the transcripts were 
continuously discussed and reviewed with a second researcher. 
Refinement of the framework occurred simultaneously and 
throughout the process.  
4. Applying the 
analytical 
framework 
The framework was applied to the subsequent transcripts using the 
existing categories and codes.  
5. Charting data 
into the matrix 
Data was charted into a matrix and included references and 
illustrative quotes.  
6. Interpreting the 
data 
Impressions and initial interpretations were recorded via analytic 
memos. Characteristics, relationships and differences were explored 
alongside the identification of areas for quality improvement.  
 
5.2.5.4 Formulation and implementation of an improvement strategy.  
Throughout the above process, the findings were fed back to the participants for validation 
and discussion about an improvement strategy occurred. The resulting strategy was derived 
from the main results of the study and modified according to the responses of the participants.  
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5.2.6 Ethics 
 
The protocol and study were reviewed and approved by the ‘Research and Development’ 
department of the HGS sites and ‘Information Governance’ team as being consistent with 
delivering a quality improvement project. Participation in the study was on the basis of 
informed consent and study was carried out in compliance with the Helsinki Declaration. 
Participation was voluntary. MDT members were made aware of the occurrence of the MDT 
observations and recording via email and prior to the start of the meeting. Participants were 
given time to raise objections or ask questions. Anonymity was ensured throughout the study. 
  
260 
 
5.3 Results 
 
5.3.1 Data Sources 
 
5.3.1.1 Interviews 
 
Twenty-three members of the MDT were invited for interviews via email or in person. 13 
interviews were conducted before thematic saturation was reached. All but one healthcare 
professional agreed to the initial invitation. The professional roles include lung clinical nurse 
specialist (LCNS) (x2), MDT co-ordinator (x2), lung cancer service lead (also respiratory 
physician), thoracic surgeon (x2), thoracic histo-pathologist (x2), clinical oncologist (x2), 
clinical cancer service nurse lead (previous lung CNS) and respiratory physician.  
5.3.1.2 Documentation review 
 
For each patient discussed in the MDT meeting, the correspondence, investigation results and 
MDT outcome documents were reviewed. Details of eighty patients were recorded. A 
summary of the patient demographics is shown in Table 5.5.  
Table 5.5 Patient demographics of the discussed patients 
  N % 
Age (years) 
(n=80) 
Median 70 (Range: 27-90) 
Sex (n=80) Male 43 54 
 Female 37 46 
Stage (n=50) I 12 24 
 II 7 14 
 III 15 30 
 IV 16 32 
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5.3.1.3 MDT meeting observations 
 
Three meetings were recorded in May and June 2018 before saturation point was reached. 
Table 5.6 illustrates the attendees’ professional roles and a description of their responsibilities 
and contribution in the MDT meeting.  
 
Table 5.6 Attendees at the lung cancer MDT meetings 
Professional Role Role/responsibilities/contribution to MDT 
meeting 
Number present 
in the meeting on 
average* 
Respiratory physician -Co-ordinates the lung cancer pathway 
- Presents the majority of patient cases 
- Needs to collate patient and investigation 
information 
X4 consultants and 
x1 SPR 
Lung cancer medical 
oncologist 
-Contributes specialist knowledge in providing 
chemotherapy to lung cancer patients 
X2 consultants and 
x1 SPR 
Lung cancer clinical 
oncologist 
-Contributes specialist knowledge in providing 
chemotherapy and radiotherapy to lung cancer 
patients 
X1 consultant 
Thoracic Surgeon -A surgeon who has performed at least one lung 
cancer resection in the last 12 months 
-Contributes specialist knowledge on potential 
surgical interventions for lung cancer patients 
X2 consultants and 
x1 SPR 
Lung cancer clinical 
nurse specialist (LCNS) 
-A nurse specialising in the care of people 
diagnosed with lung cancer (and mesothelioma) 
-Presents patients cases 
-Contributes patient specific information 
-Involved in co-ordinating the patient pathway 
and ensuring continuity of care and 
communication with the patient 
X3 
MDT co-ordinator -Facilitates co-ordinating the patient pathway 
-Responsible for organising, running and 
documenting the meeting 
-MDT outcomes are recorded at the time of the 
meeting and projected on a small screen at the 
front of the room 
X1 
Thoracic radiologist -Contributes specialist knowledge on thoracic 
imaging  
-Determines the stage of cancer 
X1 
Thoracic histo-
pathologist 
-Contributes specialist knowledge on diagnostic 
samples  
-Determines the type of cancer 
X1 
*based on an average over 10 MDTs in the time period of the observations 
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5.3.2 MDT format and context 
 
The principal activities that occurred in the observed MDTs were information gathering and 
sharing as well as decision making. Decision making involved seeking opinions, debating 
options and seeking approval for previously made decisions. The atmosphere was cooperative 
and there were several instances of banter or joking during the meeting to keep the 
atmosphere light. Apart from discussions about patients, other interactions included sharing 
frustrations with access to resources or local team working networks: 
“….they have had no involvement with me..they have..I don’t know why they are dealing 
with…they don’t speak to me about my patients. They don’t therefore decide what to do with 
my patients. If I wish my patients to be considered by another clinician, I will refer to 
them….” 
(Talking about frustrations with links with a local specialist MDT) 
(Male, Surgeon) 
 
Colleagues listened to each other and asked for opinions and clarifications illustrated in the 
following excerpt. Several members are debating the optimal management strategy for a 
patient and consider other professional viewpoints:  
 
Surgeon1: “Could we not be radical with this?” 
Surgeon2: “Not surgery..I was thinking ..maybe…I mean..what do you think” 
Surgeon3: “there is something..very close to that…” 
Physician: “we cant do neoadjuvant without tissue…..” 
Surgeon1: “What (radiologist’s name) saying it is tracking along the mediastinum, isn’t 
it?” 
Radiologist: “So yeah..biopsy…mediastinum..” 
Surgeon1: “I would be very wary about a neoadjuvant followed by a left pneumo…is 
anybody giving concurrent..chemo and ..” 
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Oncologist1: “not preop..its not standard..I mean in the States they do neoadjuvant 
followed by surgery…in Europe we tend to do surgery followed by 
adjuvant..its doesn’t decide in any individual case what you should and 
shouldn’t do but uhmm I think the bottom line from your of view is do you 
think he is going to be operable? …or what do you say?” 
Surgeon1: “Well I mean..well its always..your right (name of oncologist1) is it operable? 
Well I mean no. Its not..no we would get positive margins at that…” 
 (Excerpt from MDT 2) 
 
The meeting lasted between two to three hours and took place in the education centre of one 
of the trust sites. The room layout and ground rules has been re-established in the last six 
months. These standards (Box 1) are emailed to the participants with the list of patients 
scheduled for discussion each week. Clinicians list patients to be discussed on an online 
system where a proforma with patient details are completed. The MDT co-ordinator will 
email a provisional list to the MDT members and ask them to check that all patients still 
require discussing.  
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The format of the meeting follows a standard protocol. Firstly, the chair opens the meeting 
and swiftly moves on to the first patient. Each patient is then presented by a member of the 
MDT. The presenter presents information in the form of a summary which may include their 
clinical presentation, past medical history, functional status, treatment plans, diagnosis if 
already known and the reason the patient is brought to the meeting. A radiologist then 
presents the radiographic findings and then the pathology is commented on by the 
histopathologist. The radiology images and pathological slides are projected for all members 
to view. A discussion regarding the next step will then ensue which in the main involves the 
surgeons, oncologists and respiratory physicians at consultant level. Nurses sometimes 
commented but only usually if they were asked a question. It was rare for junior medical staff 
to participate in the discussion unless asked a direct question. Once the discussion ends, the 
outcome is sometimes dictated to the co-ordinator who writes this down and the chair moves 
Box 1: MDT Standards 
1. Strict starting time at 2pm to allow an early finish 
2. MDT table layout: with experimentation over recent months, a “U” shaped arrangement of 
tables seems to bring closer all MDT members and minimises the chance for side talks and 
makes sound quality better. So please refrain from sitting at the back or separately.  
3. Patients with an empty proforma will not be discussed (please complete all relevant 
information) 
4. Patients without a responsible clinician or lung CNS to present will not be discussed (so 
please nominate another person to present your cases if you are not able to).  
5. If it is the responsibility of the referring clinician to make sure all information required is 
complete before the MDT date to enable a decision on either surgical or oncological 
treatment. This includes lung function, or any test required to assess fitness. (please refer to 
the attached surgical referral criteria which should be adhered to internally as much as 
externally).  
6. MDT time is to be used for MDT only and not admin work. Please refrain from completing 
your admin work or using your laptop during the MDT which often is a distraction to the 
clinician from the ongoing conversation about the patient in question.  
7. For complex patients that attract a detailed discussion at the MDT: It is the responsibility 
of the clinician offering the treatment plan to make sure the MDT outcome matched their 
standards and reflects the discussion that took place.  
8. Referrals from outside the MDT quorum members will not be discussed and such patients 
either seen first or discussed at the radiology meeting (LIM/LID).  
265 
 
to the next patient. On occasion the wording of the outcome will be verified with the rest of 
the MDT. At the end of the meeting there are usually a few patients that are discussed who are 
not on the list which go through the same format.  
5.3.3 Themes emerging from the data 
 
Participants described, and the researchers observed, that decision making in lung cancer was 
complex: 
 
“…lung patients in general have multiple investigations as well.  So the pathway is quite 
complex.  Well I've noticed well it’s a site that I haven't done before, so it's quite complex 
really.  They come for multiple investigations, so it's keeping a track of all that as well, isn't 
it?” 
 (MDT co-ordinator, female) 
 
The patient journey involved several health care professionals, multiple investigations and 
decisions were made at several points. Oversight of this journey by a single responsible 
professional led to efficient decision making, improved shared decision making and outcomes 
for the patient. The knowledge, attitudes and skills of the MDT members were additionally 
key to influencing this process.  
Therefore, three main themes emerged from the data with several subthemes. This is 
summarised in Table 5.7 and Table 5.8 details how the themes were derived with example 
quotes. 
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Table 5.7 Conceptual framework summarising the main themes and sub themes 
  
Main Themes Sub-themes 
1. Continuity of care 
 
 
a.) Ownership of the patient journey 
b.) Barriers to effective information flow 
c.) Facilitators to effective information 
flow 
2. Knowledge and Attitudes a.) Understanding and attitudes to SDM 
b.) Challenges to implementing SDM 
3. Training and Skills a.) Patient assessment skills 
b.) Incorporation of guidelines/clinical 
trials 
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Table 5.8 Transformation of themes: illustration of the analytical procedure  
The procedure used in similar studies was followed (366). Important meaning units were identified, units were transferred into language relevant to the 
research (transformation I) and then collated into common experiences (transformation II). Finally, common features were transformed into key constituents.  
 
THEME 1: CONTINUITY OF CARE 
Ownership of the patient journey 
Meaning unit Transformation I Transformation II Key constituents 
In response to questions about improving 
the effectiveness of decision making: 
 
“A dedicated lung cancer physician would 
then probably have a much better oversight 
of what was happening and be able to carve 
slots out for this and that as their dedicated 
work, triage what’s coming through, two 
weeks waits, what’s going to MDT, what 
needs to be followed up from MDT.  So I 
would say that a dedicated consultant is 
what is needed.” (LCNS, female) 
The participant states that 
a dedicated lung cancer 
physician is required to 
ensure that there is 
oversight over the whole 
patient pathway.  
A dedicated physician is 
needed to ensure there is 
continuity of care for the 
patient.  
An important aspect of improving 
decision making is ensuring a dedicated 
professional is responsible for the whole 
patient pathway.  
Barriers to effective information flow 
 “…but sometimes I feel especially when 
enough information is not available MDT 
members can be more pessimistic than what 
they should be and hence some patients may 
Participant stating that 
insufficient information 
presented at the MDT 
meeting can affect 
treatment options offered 
Insufficient patient 
information presented at the 
MDT meeting can impact on 
patient outcomes. 
Missing and inaccurate information 
impacts patient outcomes 
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not be offered treatment ….”  
(Physician, male) 
to the patient..  
Facilitators to effective information flow 
In discussing the optimal management of a 
patient: 
Surgeon1: “..essentially if this is an 
endometrial met then I don’t think we should 
do anything about it” 
Lead: “There is no need for metastectomy 
for this cancer?” 
Surgeon1: “Well no she is known to have 
recurrence ..” 
Clinical oncologist:” No but if she has had 
controlled primary disease for 6 months she 
can have SABR to that as part of 
CTU..commissioned through re-evaluation.” 
Excerpt from MDT 3 
Clinicians are discussing 
the optimal management 
of a patient in the MDT 
meeting. The initial 
proposal of not treating the 
lesion is challenged and 
other options are proposed 
including surgery and 
radiotherapy. In this case, 
all options were discussed 
with the patient and the 
discussion did not require 
further input at a MDT 
meeting.    
Opinions are challenged in 
the MDT. This leads to the 
exploration of further options 
for the patient which means 
that the case is less likely to 
require re-discussion.  
Debate and challenging of ideas 
facilitate effective decision making.  
THEME 2: KNOWLEDGE AND ATTITUDES 
Understanding and attitudes to SDM 
“…But I have a very strong belief that I 
should not be pushing a patient enforcing a 
patient into a decision I should be 
Participant expresses the 
opinion that if possible, 
clinicians should help 
Members feel that the 
preferred model of decision-
making is where the health 
Some participants have a positive 
attitude to SDM.  
269 
 
facilitating the patient make a decision 
where possible.”(Surgeon, male) 
patients make decisions.  care professional helps the 
patient make the decision.  
Challenges to implementing SDM    
“There is a small number of patients who 
just do not wish to make a decision and 
there are occasions where you have to 
decide on their behalf” 
(Physician, female) 
The participant describes 
that there are 
circumstances that patients 
express a wish not to 
engage in decision 
making.  
A challenge of implementing 
shared decision making is 
reluctance of patients to 
engage with the decision-
making process.  
Patients’ wish as a barrier to 
implementing SDM.  
THEME 3: TRAINING AND SKILLS 
Patient assessment skills 
“I think a lot of people could do with 
additional training in performance status.” 
(Oncologist, male) 
Participant feels training in 
performance status is 
required.  
There is a need for training in 
PS assessment amongst 
members of the MDT.  
Training in performance status is 
required.  
Incorporation of guidelines and clinical trials 
During a discussion of a patient with a 
ground glass nodule: 
“that if we noticed there is no solid 
component.. then the guidance is not to PET 
them and not to take them out.”(Excerpt 
from MDT 2) 
In this MDT meeting 
discussion, guidance in the 
management of ground 
glass nodules is referred 
to. In this case, the 
guidance was adhered to 
and the patient did not 
require further discussion.  
The reporting of guidelines in 
MDT discussion facilitate 
implementation of the 
documented outcome and 
avoidance of re-discussions. 
The incorporation of guidelines into 
MDT discussion facilitates successful 
decision making.  
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5.3.3.1 Theme 1 Continuity of care 
 
5.3.3.1.1 Ownership of the patient journey 
 
Interviewees talked about successful decision making in terms of decisions not being brought 
back for multiple re-discussions. An important aspect of this process was “ownership” or 
“responsibility” over an individual patient. This was reflected in the observations and 
interviews.   
There were some differences in opinion as to who should be responsible for oversight of the 
pathway. Some felt that it should be a dedicated person/s: 
 
“I think probably the best person to do this, so you are talking about every single patient in 
the entire system, so it is either going to be the MDT lead or plus/minus or in conjunction 
with one of the senior nurses I suspect would probably be the best combination.” 
(Female, physician) 
 
Whereas another participant felt it should be the clinician who referred the patient to the 
MDT. When asked about who they felt should have oversight of the patients’ pathway, this 
participant responded: 
 
“…the person who referred the patient. …..but you know the person who referred the patient 
they should organise that investigations. It relies on them, if you organise the investigation 
you need to follow-up and act on it so its their responsibility, you brought this patient to 
MDT, we have recommended this investigation and if its this result they go there and if not 
and its your responsibility to refer.” 
(Male, oncologist) 
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The lack of consensus over who should have responsibility for a patient was additionally 
observed. In 35% of the MDT case discussions (28/80), it was unclear if the presenter had 
previously met the patient. This demonstrates confusion over who should oversee the process 
of seeing a patient, listing them on the MDT, presenting them and then following up the 
actions. This participant describes how the lack of participation in decision making by a 
responsible professional occurs frequently within this MDT leading to multiple unnecessary 
re-discussions. 
 
“…but then as the person who is looking after the patient isn’t there we frequently get just a 
case presented and everybody is having a discussion but the person then needs to go back and 
discuss it with the patient who isn’t there.  To me that doesn’t make any sense at all.  At the 
end of the day if the person who looking after the patient is not in the room that case 
discussion is completely redundant and we simply should not discuss it…..We always have 
one or two who are not there, we have patients listed, for example this last MDT and some of 
the surgeons of the patients on that were not there and that is about four or five cases and we 
end up having discussions and saying we think this is what the clinician thinks about it and 
we end up having a discussion when we are not 100% sure and I guarantee those cases will 
come back on the list when that consultant comes back from holiday or is able to attend the 
meeting where we will discuss those cases and wasted MDT time and not achieved anything 
in terms of the patient” 
(Male, Radiologist) 
 
The observed consequences were that in 29% of cases the documented outcome did not get 
implemented and in 25% the case was brought back to the meeting for re-discussions leading 
to delays in treatment.  
The following example from MDT 3 is an excerpt from a discussion of a patient that was seen 
in clinic by a junior doctor and illustrates this issue. The named consultant of the patient is 
presenting the case: 
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“He is a 74 year old man who had a small ground glass abnormality at the top of his left lung 
last year. We uhm ahem have been following it looks like its was beginning to grow. Uh he 
has subsequently had a PET scan we are here to discuss the possibility of him having it 
removed. “ 
(MDT 3) 
There is subsequent documentation reporting the patient has several co-morbidities including 
dementia and the patient and family did not want further investigation. The lack of continuity 
of care meant that vital information about the patient’s preference was not shared. This led to 
un-necessary investigations and inappropriate multiple MDT discussions.  
In addition, missing and inaccurate information presented in the MDT was shown to impact 
patient outcomes. It is unclear in the following excerpt whether the presenter has met the 
patient. They are discussing a patient that had previously been discussed at MDT with a plan 
for neo-adjuvant chemotherapy.  
 
“67 year old guy uhmm initially we spoke about it earlier this year with a possible neoplastic 
lesion in the left apex and he had a biopsy of that went then ahem onto oncology for 
neoadjuvant treatment and we’re hmm basically looking to how he got on after that and 
where we go from here. “ 
(MDT 2) 
 
After further discussion it is evident that this patient had not actually received chemotherapy. 
On documentation review this was the third MDT discussion for this patient. On the first 
occasion the PET scan results were not available then subsequently the CT guided biopsy had 
not been performed. Due to the lack of continuity of care and accurate presented information 
a referral to oncology was not made until six weeks after the initial MDT recommendation. 
The consequence of this meant that significant delays to oncology assessment led to tumour 
progression and change of management from curative intent to palliative intent treatment.   
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This was apparently not an isolated scenario as demonstrated by the following quote: 
 
“I mean there have been a few cases actually where it was uncertain it was uncertain of the 
diagnosis and then they were presented many times …..treatment was delayed that I mean 
they were surgical when we first discussed and then after about 5 discussions they were not 
and then I was called by (surgeon name) clinic saying that she got basically got cord 
compression and then it all becomes palliative. I mean if we had acted, I mean essentially she 
was surgical if we had acted upon I mean if its surgical its surgical. If we have a tissue 
diagnosis of cancer then you can operate. So in that particular case she now become 
palliative and …..” 
(Male, oncologist) 
 
This is supported by the finding that there was incomplete or inaccurate information presented 
in 39% (31/80) discussions. Out of those 31, 22 patients (71%) were for potentially curative 
intent treatment and experienced pathway delays. The consequences of which were that 7 of 
these 22 patients (32%) had a documented decline in performance status or a management 
plan change from curative to palliative intent treatment.  
In contrast, there were cases where clear ownership of the patient pathway was demonstrated: 
 
“This is a 85 year old gentleman with several co-morbidities including arthritis, TIA’s, 
previous ablation for tachycardia, palpitations and ….he is doing quite well for himself up 
until recently till his wife who he is the main carer and has got dementia, bedbound. Since 
then his mobility has gone down as he is bedbound..not bedbound has been housebound 
looking after her. Urmmm he…we had a good chat…he got good lung function etc…we had a 
good chat..didn’t really think that invasive therapy was going to be the way forward. His 
main problem was back pain so we have referred to (clinical oncologist’s name) who is kindly 
going to do it” 
(MDT 2) 
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Examination of clinic documentation revealed that the presenter had a detailed discussion 
about potential management options with the patient in clinic. This led to a shared decision of 
being referred for palliative radiotherapy. The patient received an assessment by a clinical 
oncologist and symptom management within seven days of referral and three days of the 
MDT meeting. This case exemplifies that knowledge of patient centred information and 
clinician responsibility for the patient journey has the potential to improve effective and 
efficient decision making. 
 
5.3.3.1.2 Barriers to effective information flow 
 
Accurate information sharing was observed to be a key component of the decision-making 
process; two barriers were identified.  
Firstly, key factors that impact decision making differ between what is perceived and that 
observed. This is problematic because key information that is considered to be vital to 
determining a patients’ management is evidenced as not being considered in practice.  
Observation of the MDT meetings revealed that the information that was consistently 
presented were the patients age (100% of discussions), stage of tumour (98%) and 
histopathology if available. Whereas, patient specific information was reported less 
frequently: that in only 10% of discussions, performance status was presented; 28% co-
morbidities and patient views in 6%. Therefore, disease specific information was shown to 
predominately influence decision making. However, participants stated that they considered 
patient centred factors to be most important when asked in an interview. These included a 
patients’ performance status, co-morbidities, general well-being and preferences. 
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The following are examples of responses to the question: “what in your opinion should 
influence decision making in lung cancer?” 
 
“Patients performance status Comorbidities. And you know the general overall performance 
status” 
(Male, LCNS) 
 
“Well-being the patients Yeah I think that's one of the main factors” 
(Male, Pathologist) 
 
 “…main decision is obviously the stage of the tumour and obviously the performance status. 
So if the patient is fit and has an early stage cancer”  
(Male, Oncologist) 
 
Several participants describe general well-being as the predominant factor which is not in 
keeping with what was observed in the MDT.  
Secondly, the documented outcome was perceived and observed not to reflect the discussion 
occurring in the MDT meeting. Observation of the MDT meetings revealed that the 
documented outcome did not completely reflect the discussion in 54/80 cases (68%). 
Subsequent review of patient records showed that this was associated with multiple re-
discussions and delays to appropriate patient care.  
In MDT 2, participants discuss treatment options of a patient with several lung lesions. A full 
debate included the consideration of several options including immunotherapy, surgery and 
radiotherapy. The outcome of this complex discussion was recorded as below: 
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“MDT outcome: Performance status 0. Right upper lobe lesion measuring 13mm, left upper 
lobe 11/12mm , both lesions slightly increased in size, continual slow growth since 2009, 
show no activity on PET scan. Radiologically slow growing leision over 5 years for clinical 
review to suggest no further action.” 
 
Consequently, a clinician saw the patient in clinic and communicated this outcome and 
discharged the patient from clinic. In this case the outcome failed to encompass the lack of 
consensus within the team. Therefore, potential management options were not discussed with 
the patient and a fully informed decision would not have been made.  
Several participants describe experiences where the documented MDT outcome lacks vital 
information. In light of the previously mentioned issues with continuity of care accurate 
documentation of discussions is crucial to implementing MDT decisions.  
 
“the complexity of the MDT discussions are not translated adequately into the MDT outcome 
recording. This means that the discussion is only as good as the recording of the outcomes.” 
(Female, Physician) 
“some of the communicated decisions are odd and I have taken patients back because I just 
totally disagree with decisions” 
 (Male, Surgeon) 
 
The MDT co-ordinators document the meeting outcome in real time. This was acknowledged 
by several members to be a difficult task and requires more support. 
 
“….they (referring to the MDT co-ordinators) do a difficult job and they do have a lot of 
responsibilities in that MDT. ……I think the co-ordinators are should be the right people to 
minute the meeting but I think they could do with more support in what is important in adding 
to the MDT and whats not…… but I don’t always feel like they know whats important I think 
we could do working closer with the MDT co-ordinators with regards to that”  
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(LCNS, female) 
 
5.3.3.1.3 Facilitators to effective information flow 
 
Observations highlight that a full discussion where ideas and opinions are challenged and 
expressed by several members of the MDT leads to effective and efficient decision making. 
Cases where several members contributed to in-depth discussions were associated with 
implementation of the MDT outcome and avoidance of re-discussions. Complex patient cases 
appeared to encourage such debate; therefore, the complexity of the case was not associated 
with a poor outcome. For example, in MDT 3, participants are considering the next best step 
for the management of a patient: 
 
(Advocating surgery) 
Oncologist: “ but I mean..prognosis of thymoma  depends on getting it all out..thats 
the prognostic issue.” 
 
(Challenging surgery and exploring other options): 
Physician: “whats the consequence..the diaphragm?” 
Surgeon: “well..uh uh the phrenic..we see lots of …they compensate well. As she 
gets older..she might need something. And the question is do we do 
everything together with a debilitating thoracotomy and sacrifice the 
phrenic and plicate the diaphragm at the same time. So I..I ..I have to 
put all of that to her” 
Radiologist: “If you did do surveillance, you would get reasonable images on 
MRI..” 
Pathologist: “It might be worth another opinion” 
 (Excerpt from MDT 3) 
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In this discussion ideas are challenged, and the voices of several professional groups are 
heard. Subsequently, an in-depth conversation occurred with the patient with exploration of 
several management options.  
Participants frequently talked about how information articulated by the LCNS was key to 
quality decision making: 
 
“….that the clinical specialists act as the patients advocate in that meeting so I would hope 
that the patient is represented within that meeting.  All their thoughts, feelings are 
represented within that meeting by the clinical nurse specialists, so that their not being falsely 
represented and decisions are not being made that may not necessarily agree to.” 
(Nurse lead for cancer services, female) 
 
The advocacy role of the LCNS is demonstrated in the following case presentation.  
 
“He is a chap with performance status of 1. Possible asbestos exposure and worked as a 
carpenter and he is not really keen on having biopsies. I spoken to him the other day and he is 
just not really keen at all on having biopsies so if there is a possible radiological diagnosis 
then he is happy with that to be left alone. “ 
(LCNS, female) 
 
Patient centred information is presented in this case leading to effective decision making in 
line with the patients’ views.  
5.3.3.2 Theme 2 Knowledge and attitudes 
 
5.3.3.2.1 Understanding and attitudes to SDM 
 
Understanding of the term ‘shared decision making’ was variable amongst members. Some 
interpreted the term to mean decision making within the MDT. 
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“….as a collective decision making so everyone sat round discussing patients and different 
treatment that’s there” 
(Male, LCNS) 
 
Others described SDM to be sharing information with the MDT and the patient. 
 
“One is sharing of information within the MDT and the other sharing with the patient..  It is a 
two-step process.” 
(Female, Physician) 
 
Finally, a patient centred meaning was attached to the term by some members. 
 
“…its the involvement of patients in terms of what treatment options they have involving 
patients and saying these are your options and you know if you go down this route this is 
possible and if you go down this route this is possible” 
(Oncologist, male) 
 
Once a shared understanding of the term was gained, attitudes towards the concept were 
generally positive. Participants talked about how this is the preferred model of decision 
making and described experiences where clinicians took steps to ensure that patients drove 
decision making. 
 
“Ultimately it is their decision, so they do have to make that choice, and I’m all for promoting 
patient self-management and actually giving them a voice and some control over what’s 
happening” 
(LCNS, female) 
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5.3.3.2.2 Challenges to implementing SDM 
Challenges to the implementation of SDM into routine clinical care were discussed with 
participants and observed in MDT meetings. Three main challenges emerged from the data.  
Firstly, the attitudes of the clinician were seen as a barrier. The participant below describes 
how they perceive arrogance can inhibit SDM: 
 
“..I think the clinicians approach to patients has a lot to do with it and this is down to certain 
personalities of certain clinicians something clinicians who embrace you know in discussions 
with patients and very much give them all the information and allow them to ask questions 
and give them all the information to make an informed decision and then there are other 
clinicians who don't who I feel their arrogance tends to shine through and overrule the 
discussion and quite often patients can feel railroaded and kept in the dark..” 
(LCNS, male) 
 
Secondly, assumptions made about patients’ views or well-being were shown to limit 
proposed management options. For example, in this MDT discussion the participant makes an 
assumption that the patient is frail due to their age despite the fact that the presenter who has 
assessed the patient does not describe the patient has frail.  
 
Oncologist: “Did you say frail?” 
Surgeon: “Well he is ok..more kind of..no..not……” 
Oncologist: “Is he symptomatic?” 
Surgeon: “No , not symptomatic” 
Oncologist: “But hes..frail….we checked his age”. 
Oncologist: “But you have not proved it..and you have had a go and its not changed 
for two years..I think I would leave well alone at the moment..I don’t 
know what everyone else thinks in a frail 84/85 year old.” 
(Excerpt from MDT 3) 
281 
 
 
Based on this expressed opinion of the oncologist, a decision was made for no further 
investigation or treatment. This finding was reflected in the participant interviews where 
members reflected on the consequences of assumptions being made about patients in the 
meeting. 
 
“Often MDT members they can make assumptions about the patient and what they want but if 
they haven't met the patient then they can’t truly say what's the best approach for a patient.” 
(Male, Physician) 
 
Finally, participants stated that, on occasion, patients’ present a barrier to engaging with 
SDM.  
 
“There is a small number of patients who just do not wish to make a decision and there are 
occasions where you have to decide on their behalf” 
(Male, Oncologist) 
 
5.3.3.3 Theme 3 Training and Skills 
 
5.3.3.3.1 Patient assessment skills 
 
Gaps in training and skills were found to have an important impact on MDT decision making. 
Inconsistencies in the evaluation and assessment of performance status were identified and 
this was linked to delayed care demonstrated in the observations and interviews. In the 
following example the presenter presents the following case from MDT 2: 
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“Performance status of 1 or 2….he is 80 and lives in sheltered accommodation. During his 
first admission he had a scan which was followed by an EBUS and he was readmitted with 
what sounds like a chest infection.” 
(Excerpt from MDT 2) 
 
In this case a performance status of 1 or 2 is not in keeping with the subsequent description. 
In addition, a review of the patient records documented the premorbid performance status as 3 
according to the ECOG performance status (PS) scale. After this MDT discussion the patient 
was assessed by the oncology team for consideration of chemotherapy and a PS of 3 was 
documented as this consultation, therefore chemotherapy was deemed to be inappropriate. 
This case illustrates that discrepancies in the judgement of performance status can lead to 
inappropriate referrals and a delay in the patient receiving the most appropriate care (in this 
case best supportive care).  
The following quote by one participant when asked about the assessment of performance 
status within the MDT meeting highlights this issue and the consequences: 
 
“Very variable I think its very variable some clinicians are quite poor at it. They will say you 
know say a 80 year old with a performance status of 0. And you know 0 can do a full day’s 
work well there are not many 80 year olds that can do that, there are some obviously, but 
often they will say in a wheelchair, well that’s not PS 0 is it? Its variable across the board 
even within the same speciality. There is often disagreement about performance status 
between the CNS’s and the clinicians about performance status so often it is just easiest to see 
them yourself which takes up a slot and it may not be suitable because they do have a poor 
performance status”. 
(Oncologist, male) 
 
The consequences described above describes delays in care for the patient but how this also 
has an additional impact for other patients due to delays to clinic appointments.  
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5.3.3.3.2 Incorporation of guidelines/clinical trials 
 
The incorporation of guidelines and clinical trials into decision making was linked to effective 
decision making. In all cases where a guideline or clinical trial was mentioned in the 
discussion, the outcome was implemented and not re-discussed. An example is shown in the 
following excerpt from MDT 2. Here the “Lead” talks about using the Herder model which is 
a validated risk prediction model recommended by guidelines for the investigation and 
management of pulmonary nodules”. (367) The guidelines advocate CT surveillance for a risk 
of <10%. The discussion of the management of the pulmonary nodule in this scenario follows 
guideline care.  
 
Lead: “..ok so its 2.5% so the Herder, yeah 2.5…..” 
Surgeon:  “So thats CT surveillance” 
Lead “So that will be 3 months from baseline”. 
(Excerpt from MDT 2) 
 
The importance of participants’ knowledge of current evidence in influencing successful 
decision making is also reported by participants in interviews. When asked about 
interventions that would help facilitate shared decision making, this interviewee talks about 
keeping up to date with current guidelines and evidence: 
 
“….clinicians I mean in reading updating themselves on a constant basis and keeping up to 
date with things as they change you know make sure that you know they keep these published 
studies or research around lung cancer.” 
(Physician, Male) 
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5.4 Discussion 
 
5.4.1 Principal Findings 
 
This study demonstrates that achieving co-ordinated care in lung cancer is key to achieving 
effective decision making. Crucially, it demonstrates the real-world consequences of poorly 
co-ordinated service provision. Several of the identified barriers to patient centred and timely 
clinical care have the potential to be overcome by improvements in the continuity of care. 
These include the presentation of adequate and accurate patient information at meetings and 
incorporation of SDM into routine clinical care. The unique examination of detailed MDT 
transcripts and longitudinal patient outcome data has enabled a deeper understanding of this 
issue.  
In addition, the results identify significant gaps in training and knowledge of MDT members. 
The following discussion explores such gaps and the impact in providing quality decision 
making in lung cancer patients in the context of the wider National Health Service (NHS).  
Finally, improvements in patient care have the potential to be improved by implementing a 
quality improvement strategy addressing identified barriers to effective decision making and 
conducting action research which will be discussed in section 6.2.3.  
5.4.2 The findings in the context of the existing literature 
 
5.4.2.1 Continuity of care 
 
Effective co-ordination of patient care was shown as a key factor associated with improved 
patient outcome in section 2.3. The systematic review reports the supporting evidence in the 
general medical literature as well as highlighting the gap in evidence in the lung cancer 
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literature. As evidenced in the review, there are few lung cancer studies that demonstrate the 
consequences to the patient or investigate the effects throughout the whole patient journey.  
The detailed analysis of verbatim transcripts and linked patient outcome data, in this study, 
emphasises that good patient pathway management is vital for effective patient centred 
decision making and avoidance of delays to treatment. This is uniquely demonstrated using 
the triangulation of qualitative data in this study. It is shown in chapter 2 and 3 that 
fundamental to achieving this, is the provision of adequate specialist staff.  In section 2.1.5.2, 
it was significant that six out of the eleven of the main review studies that reported improved 
patient survival were associated with reduced staff workload and increased access to specialist 
care. The results from the lung cancer literature and chapter 3 further highlight the beneficial 
effects of adequate staffing. (159,160) Whilst there is contrasting data regarding the 
association between workload and survival, it has been demonstrated in chapter 3 that access 
to the items included in the organisational score (of which 5 out of 11 pertain to the provision 
of adequate staff) is significantly associated with improved patient outcomes (one-year 
survival, receiving curative intent treatment and treatment within 62 days).  
The results of this study show discrepancy exists about which professional group/s should be 
responsible in ensuring continuity of care. The interviews undertaken show that participants 
felt that the role should be encompassed by the lung cancer lead, MDT co-ordinator or lung 
CNS. Currently, it is the responsibility of the patient’s named clinician. 
Previous bodies have advocated that the respiratory physician is best placed to co-ordinate 
lung cancer care. (368) They are usually the first point of contact for the patient in secondary 
care and can be involved from the initial diagnosis and staging through to treatment, restaging 
and end of life care. In addition, their ability to manage patients’ co-morbidities holistically is 
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crucial given the demographics of lung cancer patients. Finally, respiratory physicians have a 
pivotal role in acting as a gate keeper to other specialities. However, for a respiratory 
physician to successfully fulfil the above duties, adequate knowledge and time must be 
obtained. Currently, there is only one respiratory physician in the UK that has a whole-time 
position dedicated to the provision of lung cancer services in their hospital unit. The lung 
cancer service commissioning guidance recommends that one whole time equivalent (WTE) 
respiratory physician should be provided per 200 diagnoses per year in order to provide an 
effective lung cancer service; the HGS site has approximately 1 WTE per 500 diagnoses, 
indicating a shortfall of 1.5 WTE respiratory physicians. The organisational audit shows that 
60% of hospital units fulfil this criterion which is likely to be overestimated due to the self-
reporting nature of the questionnaire and difficulty accurately estimating workload. The lung 
cancer ‘Diagnostic Assessment Programmes’ (DAP’s) in the USA staffed by such specialist 
staff, described in chapter 1 have demonstrated significant reductions in pathway time. (126)   
The MDT co-ordinator role has also been acknowledged as being crucial to promoting 
seamless patient care. (369) The co-ordinator is responsible for preparing and running the 
meeting as well as providing a link between the lung cancer service and the patient. (344) 
However, they are not routinely considered in studies assessing the effectiveness of lung 
cancer decision. This study ‘gives voice’ to this position and highlights their competing 
demands and lack of support to fulfil the role effectively. A national survey of MDT co-
ordinators conducted in 2012 found that nearly half feel that their opinions are not considered 
in decision making. (369) Additionally, unmet educational needs were identified in this 
professional group. These findings are reflected by the results of this study. Furthermore, 
outcome documentation (a role undertaken by the MDT co-ordinator in the examined hospital 
trust) was found to not reflect the discussion in the majority of cases. Consequently, all 
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available options were not discussed with the patient leading to further re-discussions and 
delays to appropriate patient management. Interviews reveal that the co-ordinators feel 
inadequately trained to deal with the complexities specific to lung cancer patients. This 
highlights the unmet educational need of this undervalued group and an under investigated 
area where potential improvements can be made.   
Whilst, the results do demonstrate examples of clear ownership of a patient pathway there are 
two main challenges to ensuring that this occurs consistently.  
Firstly, the comments section of the second organisational audit conducted in chapter three 
show that few members of the MDT are given dedicated time and resources in job plans for 
this time-consuming task. This is in keeping with the results from this study that reveals that 
cases where there was lack of preparation for the meeting led to the presentation of inaccurate 
or incomplete information and ultimately delays to patient care. Information available at the 
meeting that was key to the successful implementation of the documented outcome and 
avoidance of multiple re-discussions were the patient’s performance status, co-morbidities 
and views. Presented in 10%, 28% and 8% of cases respectively. Moreover, out of the 31 
patients that were for potentially curative intent treatment, 22 had incomplete information 
presented at the meeting. Seven of whom had a decline in performance status or a treatment 
change from curative intent to palliative as a consequence. This finding is corroborated by 
participants experiences described in the results. These findings are in keeping with other 
MDT observational studies where Lamb et al found in their study that only 4% of MDT 
meeting discussions involved patients’ holistic information directly in the decision-making 
process(370). In two other studies that evaluated treatment decisions in MDT meetings, 
decisions that account for preferences, performance status and co-morbidities were more 
likely to be implemented. (371,372) This is considered important by MDT members as 
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evidenced by the interview responses in this study. A systematic approach to include such 
information through the use of structured proformas has been advocated in previous work to 
improve decision making. (339) 
Secondly, successful co-ordination of the pathway requires specialist knowledge of national 
pathways/targets, relevant guidelines and clinical trials; a theme that was identified. The fact 
that guideline adherence in lung cancer has been shown to be only 44-50% in population 
studies demonstrates that dedicated time for educational activities is additionally required. 
(373)  
5.4.2.2 MDT meeting effectiveness and shared decision making 
 
Implementation of the documented MDT meeting outcome has been used as marker of MDT 
effectiveness by other studies. (371,372) Half of documented decision outcomes were found 
to be implemented. In cases of non-implementation, patients were more likely to be brought 
back to the MDT meeting for re-discussion leading to delays in patient care. Blazeby et al 
reported that 15% of documented decisions were not implemented when evaluating 273 upper 
gastrointestinal MDT cases. (371) Other studies have quoted figures of up to 40%. (371) At 
present there is little similar lung cancer data published. However, the results are not 
unexpected given that the performance status of lung cancer patients demonstrate a quicker 
decline compared to other cancers. (3)  
There were four main reasons documented MDT decisions were changed: lack of patient 
centred information presented, poor participation from all professional groups in case 
discussions, the previously discussed issue of MDT outcome documentation and 
inconsistencies in patient assessment.  
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The most common reason for a change in a decision was due to incomplete or inaccurate 
information considered at the meeting. This included investigation results as well information 
about the patients’ health status. This finding is in keeping with the results from the study by 
Blazeby et al and has been discussed above.  
Several observational studies have found that the consideration of patients’ wishes to be an 
important factor. 8% of cases considered patients’ views as part of decision making in 
analysis of MDT meeting transcripts. This is in keeping with evidence from studies showing 
that there is poor integration of patient views into MDT meetings partly attributed to the lack 
of patient presence. (374) The qualitative methodology of this study enabled the researchers 
to understand the barriers to incorporation of SDM into routine clinical care. As shown 
previously, understanding of the term SDM was variable indicating a gap in knowledge. (346) 
However, in this study SDM was perceived to be an important component of decision making 
evidenced by the interview responses and similar findings are reported in the literature. (346) 
However, discrepant data was also identified. Some participants felt that the clinicians’ 
attitude was a barrier to effective SDM leading to assumptions about the patient. This further 
emphasises the need for MDT member training in SDM.  
A facilitator of effective decision making was the participation of several members of the 
MDT in discussion. Cases where ideas were challenged and opinions were expressed were 
less likely to be brought back for re-discussions. Interestingly, such debate was observed in 
the MDT more frequently with complex cases. This has been seen in other MDT 
observational studies. (375) Furthermore, this is in keeping with current re-evaluation of the 
MDT process, where a move to only discussing complex cases has been suggested. (232)  
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Finally, inconsistencies in performance status assessment were identified. This led to 
inappropriate referrals, wasted clinic appointments and multiple MDT discussions. The 
ECOG performance status (PS) scale is the most commonly used scale to assess the wellbeing 
of patients in lung cancer. (306) It is significantly associated with predicting treatment 
responses and survival. (30) Therefore, decision making is crucially dependent on the 
accurate estimation of PS. Studies have shown discordance between the PS assigned by 
oncologists compared to patient reported PS. (304–306,376) However, there is little known 
about the ability of other MDT members to effectively judge patients’ wellbeing. In lung 
cancer, the initial assessment of PS and hence that presented to the MDT is crucial to 
determining the patients’ treatment. In most cases this is evaluated in the initial two-week 
wait clinic by a respiratory physician or as an inpatient on a respiratory ward. In both such 
situations a junior doctor may be the first assessor. In the examined hospital trust it is notable 
that the majority of new lung cancer patients are first seen by a doctor of registrar level with 
varying experience in dealing with lung cancer patients. The real-world consequences of this 
identified gap in skills have been demonstrated in this study. Addressing such gaps is vital for 
lung cancer patients where the underestimation of PS can expose patients to treatments with 
toxic side effects and minimal survival benefits. Conversely, the over estimation of PS can 
exclude patients from potentially curative intent treatments.  
5.4.3 Strengths and Limitations 
 
The strengths of this study lie in the methodology which address the principles of credibility, 
dependability and transferability. (359)  
Credibility is demonstrated by the interrogation of study findings with the existing literature 
in the above section. Alternative explanations for results are provided with the provision of 
291 
 
deviant cases. Additionally, the direct portrayal of the participants’ experience and 
observation findings are illustrated in the tables and direct quotes providing evidence to the 
results.  
The iterative nature of the data collection process which was changed in response to the 
different contexts (e.g. the use of different topic guides as the research developed and 
according to the professional groups interviewed) demonstrates dependability. In addition, 
sections of the manuscripts were analysed and discussed with a second researcher. This 
researcher has an expertise in qualitative research and from a different professional 
background to the primary researcher. Therefore, valuable insights were introduced. Finally, 
triangulation of methods allowed self-reporting bias to be minimised. 
Four main limitations should be acknowledged. Firstly, only one MDT was examined limiting 
transferability. The MDT structure of hospitals units vary considerably so the unit in this 
study may not reflect the structure or expertise of other centres. However, it is anticipated that 
similar barriers to effective decision making are likely to be identified by other teams (for 
example the lack of time in job plans for MDT work) and the findings provide useful 
measures to peer review the effectiveness of other MDTs. Furthermore, steps were taken to 
increase the validity of the study. Firstly, through the large and diverse area encompassed by 
the three included hospitals. Secondly, the inclusion of several professional groups added 
strength to the findings in contrast to the majority of similar studies that focuses on treating 
clinicians. (369) Finally, MDT meetings and interviews were audiotaped and transcribed 
verbatim to reduce recall bias. The issue of generalisability is common to qualitative research 
and is frequently quoted as a strength rather than limitation. The sampling methods do not aim 
to identify a statistically representative set of respondents and would gain little by being 
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expanded. (377) In fact it is likely to detract from the detailed information and understanding 
gained from the data; negating the benefits of qualitative research methodology. (351)  
The background of the primary researcher should be acknowledged. JBA is medically trained 
and works clinically as a respiratory registrar within the examined MDT environment. It is 
important to consider that the researchers own attitudes and pre-conceptions about the subject 
may have influenced the direction of the discussion. In addition, the background of the 
researcher as an interviewer and MDT observer may have influenced responses and decision 
making. However, the presence of JBA at the meeting was commonplace and therefore was 
not considered to have had a significant effect on results. Inclusion of SK as an interviewer 
also reduced the potential for bias. 
Finally, selection bias may be introduced by convenience sampling limiting the participants to 
those that were willing to engage with the research. However, this was addressed by the MDT 
observations and the fact that over 2/3rds of regular members of the MDT were interviewed.  
5.4.4 Clinical relevance 
 
Despite the above limitations these results highlight two main issues of wider significance. 
Firstly, it questions the accuracy of national lung cancer outcome data. Such data included in 
large datasets is collected from individual hospital trusts. The majority of trusts input 
information, such as performance status and management plans, as planned in the MDT 
meeting. The inconsistencies found in PS assessment and proportion of cases where MDT 
decisions were not implemented found in this study challenges the interpretation of such 
outcome data and its ability to judge the quality of service provision.  It can be argued that 
these data sets fail to capture vital information such as patient views and the ability of a lung 
cancer service to implement SDM. There is growing evidence to suggest that this is increasing 
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important in a condition like lung cancer. Units that may be doing this well can be mis-
represented. This study adds to the evidence for the need of patient reported or observational 
measures to properly assess a service holistically to complement national data findings. (378–
383) 
Finally, these findings add to those of chapters 2 and 3, that the change that the provision of 
specialist staff is likely to be an important determinant of lung cancer outcomes. The evidence 
presented show that staff with specialist lung cancer knowledge and dedicated time, are 
required to ensure continuity of care and good quality decision making. Without addressing 
this essential component of service provision, improvements in patient outcomes through the 
access to novel treatments are unlikely to be accessed.  
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CHAPTER 6 DISCUSSION AND FUTURE 
WORK 
6.1 Discussion 
 
Lung cancer is the most common cause of cancer death worldwide. (2) Survival in the UK is 
lower than other comparable countries and national data demonstrates unwarranted variation 
in outcomes across the country. (214,384) Some of these differences can be explained by the 
type and severity of cases but gaps remain after accounting for such factors. This thesis 
presents evidence that inequity in access to essential services exist in the UK and this has a 
direct impact on lung cancer outcomes. 
Evidence presented in the systematic review highlights that co-ordinated access to specialist 
care is likely to be an important determinant of patient outcomes. In addition, it appears to be 
a bundle of service factors, rather than one individual factor, that is robustly associated with 
improved outcomes. The creation of a novel organisational score in chapter 3 explores this 
hypothesis, demonstrating that patients in England/Wales with NSCLC seen in a trust with a 
low organisational score are significantly less likely to survive to one year, receive curative 
intent treatment or receive timely care after adjusting for patient factors.  Chapter 5 provides 
real life evidence of this association. Deteriorations in performance status and progression of 
tumours are shown in the time it takes for patients’ to be diagnosed, staged and receive 
necessary expertise; shifting the intent of treatment from curative to palliative. This work 
makes the case for urgent review of investment and structure of our current service model.  
In the early 2000’s, centralisation and the establishment of targets through national reforms in 
policy drove change in practice and improved cancer patient outcomes. (384) However nearly 
two decades on, my work, and previous work by the NLCA , shows that inequalities still 
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exist. (214) Furthermore, this is on the backdrop of health service reform and efficiency 
savings, which have almost certainly reduced the funds available for some elements of cancer 
care. (385) The UK spends less on cancer then other Western European countries and ongoing 
cuts to key services (such as smoking cessation services) will have a significant impact for 
people with lung cancer. (384,386)  
Centralising care has the potential to provide equity in keeping with published evidence 
presented in Chapter 1. Specialisation has been shown to lead to lower post op mortality and 
improved treatment rates in other cancers. (384) However, there are advantages and 
disadvantages to such service models as discussed in section 2.4.4.  
The disparity with international outcomes found for stage III patients and the lack of 
association with these outcomes with hospital infrastructure suggests that factors other than 
patient, tumour and organisational variables impact lung cancer outcomes. Clinician 
preconceptions and nihilistic attitudes at an organisational level may additionally contribute to 
poor outcomes. This is illustrated in direct quotes in chapter 5 from staff interviews and MDT 
meeting excerpts in one NHS trust. 
Quality improvement strategies have the potential to implement organisational change of 
attitudes and behaviour through the systematic approach of continuous iterative change. 
However, embedding change within an organisation such as the NHS is challenging. Barriers 
found by previous studies are summarised in Table 6.1:  
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Table 6.1 Challenges to quality improvement change 
 
Issue Definition Consequence Reference 
Poor engagement Important knowledge is not 
incorporated from key 
stakeholders e.g. patients 
Lack of synergy 
between different 
improvement groups 
(387–390) 
Political  Groups block or resist change 
due to lack of 
acknowledgement of need for 
change or consensus on 
identification of the problem 
Disillusionment and 
inertia 
(391,392) 
Organisational 
culture 
Change not rooted in everyday 
thinking and practice 
Evaporation of change (393–395) 
Educational Staff not adequately trained in 
implementing and delivering 
quality improvement. 
Lessons and 
knowledge are lost or 
forgotten due to high 
staff turnover   
(388,396,397) 
Emotional Staff loose interest Change loses 
momentum  
(387,395,398) 
Infrastructure Lack of organisational support Exhaustion and fade 
out 
(391,392)  
 
It is therefore unsurprising that the majority of quality improvement projects fail. (399) A 
systematic review on studies implementing the plan-do-study-act quality improvement 
method in healthcare found that approximately 80% of identified studies did not fully apply 
the sequence of iterative cycles. (396) Furthermore, only 15% documented small scale 
change. (396) The commonest challenge of implementing quality improvement reported by 
Fitzgerald et al, from their qualitative work examining NHS improvement projects improving 
early diagnosis of cancer, is resistance of support from important stakeholders due to failure 
of recognition of the importance of the initiative. (392)  
The aim of this thesis is to empower trusts with evidence to campaign locally to align lung 
cancer services with the national lung cancer optimal pathway. However, there is evidence 
that organisation wide commitment to quality improvement is required if this is to be 
successful (including funding support, methodological expertise, buy in and sustained effort). 
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(400,401) This can be achieved by pressure on organisational bodies to acknowledge the 
relevance and urgency of change required in lung cancer. 
Population based studies, such as the work included in this thesis, have the potential to do 
this. Example can be taken from the population based EUROCARE studies conducted in the 
mid-nineties that showed England had lower survival outcomes than comparable countries. 
(237,275) These findings prompted increased investment in cancer services and governmental 
policy initiatives resulting in a change in healthcare structure. The data presented in this thesis 
also has the potential to do the same.  
6.2 Future work 
 
I have shown that there is a paucity of studies robustly demonstrating the optimal lung cancer 
service structure to underpin health policy. Only four randomised controlled trials were 
identified in the systematic review showing the need for prospective, good quality studies. 
This thesis presents evidence that three main issues require further research: 1.) Regular 
assessment of UK lung cancer service provision 2.) Further understanding of service factors 
and outcomes evidenced to impact on patients 3.) Implementing quality improvement 
strategies at a local multi-disciplinary team (MDT) level.  
6.2.1 Regular assessment of national lung cancer provision 
 
Regular assessment of the state of lung cancer services in the UK is necessary to determine if 
improvements are being made and examine trends in resource provision. The organisational 
audit is currently being repeated using the recommendations shown in Box 1 (section 3.4.4) as 
a benchmark.  
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An evaluation of the audit was conducted in November 2018 to identify strategies for 
improvement. The third organisational audit is planned for June 2019, where lessons learnt 
from the second audit (summarised in Table 6.2) will be incorporated. Regular quality 
improvement education and networking events by the National Lung Cancer audit team aim 
to drive subsequent improvement and overcome the previously mentioned challenges to 
quality improvement. Additionally, the data is used to underpin NICE guidelines and national 
targets. 
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Table 6.2 Evaluation of the second National Lung Cancer Audit (NLCA) organisational audit 
 
Process Item Issue Suggested Actions 
Registration 
Process 
 Necessity: Aim was the registered lead physician would take overall 
responsibility for the responses to the audit. 60% response rate, with 
overall audit response rate of 86%.  
 No negative feedback from evaluation forms received. 
 5 (out of 132) trusts queried who completed the survey.  
 Review the necessity of the registration 
process with the NLCA team.  
 Send to centre managers and email all other 
contacts.  
Pilot process  2 completed (sent to 6 trusts in total).  
 
 The NLCA team could complete a feedback 
form prior to approaching the user group.  
 
Audit Process  Some contacts were wrong and out of date.  
 Opportunity for data verification. 97 trusts contacted with 35% 
response rate.  
 Participants asked to complete survey at same time as data verification 
for main audit and over summer 
 Create an up to date contact list of all lung 
cancer leads.  
 Data verification not required.  
 Revise timing of audit for the next round 
The range of 
questions and 
responses 
covered in the 
audit 
 Histopathology and palliative care workforce provision should be 
included. 
 Some trusts uncomfortable with asking other MDT team members 
about their job plans.  
 Difficulty for trusts with more than one MDT to complete with results 
not being useful for each site.  
 
 Consider including histo-pathologists and 
palliative care service provision to 
workforce questions in next round.  
 Consider targeting MDT’s rather than trusts 
 Collect information on job vacancies (posts 
funded but no-one in post).  
 Consider questioning the quality of service 
provided e.g. many trusts commented that 
their PET service is slow significantly 
impeding their pathway 
The clarity of 
wording of the 
questions 
 The wording of the workforce section was confusing and difficult to 
calculate.  
 Required clarification of what constituted lung cancer work. 
 MDT questions and presentation of results did not accurately portray 
 Clear definition of what constitutes lung 
cancer work included in the ‘Help Notes’.  
 Express in reaching consultants’ time as 
input in sessions per week.  
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trusts that have 2 MDT’s/ week that combine treatment and diagnostic 
portions.   
 
 Define how thoracic surgical centres express 
their time.  
 Define total workforce figures as number of 
PA’s given to cancer for each person and 
their PA’s per week 
 Phrase questions as per the commissioning 
guidance: Do you have respiratory 
physicians that equate to 10 Pas of direct 
clinical care per 200 new lung cancer 
patients?  
The length of 
time needed to 
gather the 
relevant 
information and 
complete the 
survey 
 The workforce section was time consuming.  
 Not too time consuming.  
 Takes much longer than the 15-20 min stated at the beginning of the 
survey.  
 Revise the workforce section to balance 
ease of use with accuracy.  
 State realistic estimation of time to 
complete.  
Clarity and 
utility of the 
‘Help Document’ 
 Not read and not helpful, particularly for the workforce questions 
 Mostly helpful 
 
 Help notes should be included in the survey 
for increased utility rather than a separate 
document.  
 Revise workforce ‘Help section’ to increase 
clarity. 
Response to 
questions and 
queries 
 Helpful responses via email 
 Poor action on email queries 
 Very prompt 
 Several email queries and 4x telephone dialogues with team.  
 Email agreed action points to participant 
after email/telephone queries.  
Presentation and 
dissemination of 
results 
 Presentation ok.  
 Clear and easy to follow 
 Well produced report. Useful to benchmark service provision against 
other trusts 
 Trusts did not expect that results would be publicly available 
 Individual workforce results were compared to average from the audit. 
 No change to formatting.  
 Need for an explicit statement at the outset 
of the next round of the audit of anticipated 
outputs.  
 The comparison for workforce results could 
be the National Commissioning Guidance.  
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Those that answered accurately were mis represented.   
Data analysis  Raw data sent with clean data leading to confusion- one trust who 
withdrew their results had data published.  
 Wrong lines of data used for comparison 
 To formulate a standardised method of 
transferring data between team members to 
avoid mixing new and old versions of 
data/reports being disseminated.  
 Second checker of data/results before being 
published.  
 Allow participants to verify data in advance 
of publication 
Negative aspects 
of organisation 
of care in 
additional 
comments 
 Video conferencing has several technical problems meaning that there 
is no surgical presence at MDT meetings.  
 Gaps in staffing being covered by locums resulting in inconsistent 
care.  
 Patients not willing to travel distances involved with provision of some 
services e.g. SABR 
 
Positive aspects 
of organisation 
of care in 
additional 
comments 
 Sectorisation of services leading to good representation of specialities 
at MDT meeting.  
 Triage clinic keeps MDT numbers low.  
 Successful implementation of a dedicated nodule meeting.  
 Good communication with offsite oncology team. Enhanced by 
electronic chemotherapy prescribing.  
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6.2.2 Further understanding of service factors and outcomes evidenced to impact 
on patients 
 
It is acknowledged that the organisational score is not statistically validated, hence further 
work is required to test the reliability and validity of this score to accurately distinguish high 
and low performing organisations. Three further factors should be addressed in this work. 
Firstly, validation of cut off points into groups require statistical justification. Secondly, 
weighting of the score components needs consideration; one score component did not 
significantly contribute to the association more than another, as shown by non-significant 
results in linkage analyses of individual components. However, input from a national expert 
clinical panel on the components of the score would contribute further to validation of 
individual components, or perhaps greater delineation of important factors within a particular 
component. This could be achieved in an academically robust way by use of a Delphi 
approach. This is a systematic process based on the results of multiple rounds of 
questionnaires sent to a panel of experts. The anonymous responses are aggregated and shared 
with the group after each round. (402) An alternative method is a survey, which has the 
advantage of being able to reach a larger number of stakeholders, but the disadvantage that 
results are less likely to reach a natural conclusion through consensus.  
Future work should additionally consider studying other outcomes than those studied in this 
thesis. The outcomes studied in the linkage results (sections 3.3.4 and 4.3.5) are short term 
and do not address patient experience. Addressing these deficiencies would provide a greater 
depth of understanding. Further work is planned at exploring the association between service 
delivery factors and patient experience using the ‘Cancer Patient Experience Survey’. 
Finally, the detailed understanding of how socioeconomic status impacts on patient outcome 
was out of the scope of this work. Section 2.4.4 highlights the importance of this factor in 
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improving reducing variability in care. However, results in sections 3.3.4 and 4.3.5 show that 
socioeconomic status was not significantly associated with measured lung cancer outcomes 
contrary to published evidence mainly from US studies discussed in section 2.4.4. This may 
be reflective of the consistency and accuracy of completion of this data field but further robust 
investigation into this association in the UK health system is required.  
6.2.3 Quality improvement strategies at a local multi-disciplinary team (MDT) 
level 
 
The results presented in chapter 5 highlight several areas to improve the effectiveness of local 
decision making. Proposed interventions were discussed with the MDT team and refined to 
formulate a shared strategy. This strategy is summarised in Figure 6.1 as a driver diagram and 
are in the process of being implemented. It is based on the quality improvement principles of 
the model for improvement which provides a framework for developing, testing and 
implementing change and has been successfully used to implement change. (396) A repeat 
analysis of the service is planned as part of a PDSA cycle (plan, do, study, and act). These 
interventions address deficiencies found specific to the studied MDT. However, the methods 
used to identify contexts for change in this study can be generalised to other MDT’s to 
understand local quality improvement metrics.  
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Figure 6.1: Quality improvement driver diagram. 
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6.3 Conclusion 
 
The aim of this thesis is to identify factors other than patient and tumour variables that are 
evidenced to impact lung cancer outcomes.  I have generated evidence that investing in lung 
cancer services so units can align services with recommendations made in the lung cancer 
commissioning guidance may drive up standards of care.  
We are entering into an exciting era in lung cancer research where the development of new 
diagnostic and management options is occurring at a fast pace, particularly in the sphere of 
targeted therapies and immunotherapies. However, the findings from this thesis propose that 
the majority of patients in the UK will not be able to benefit from such advancements if 
deficiencies in investment and lung cancer service structure are not urgently addressed.  
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APPENDICES 
A1 Full search strategy for scoping review 
 
The following terms were used in each database.  
A1.1 Database: Medline (Ovoid)  
 
URL: http://ovoid.sp.com 
Date of search: 03 March 2017 
1. Organisation of care ti,ab 
2. Organization of care ti,ab 
3. Delivery of care ti,ab 
4. Hospital resources ti,ab 
5. Patient outcome ti,ab 
6. Or/1-4 
7. 5 and 6 
8. Limit 7 to humans 
 
A1.2 Database: Pubmed  
 
URL: https://www.ncbi.nlm.nih.gov/pubmed 
Date of search: 03 March 2017 
#1 Organisation of care AND patient outcome ti, ab 
#2 Organization of care AND patient outcome ti, ab 
#3 Delivery of care AND patient outcome ti, ab 
#4 Hospital resources AND patient outcome ti, ab 
#5 Search #1 AND #2 AND #3 AND #4 Filters: Humans 
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A1.3 Database: The Cochrane Library (Wiley) 2017: Cochrane Central Register 
of Controlled Trials (CENTRAL): Cochrane database of Systematic Reviews 
(CDSR) Issue 4 of 12; Database of Abstracts of Review of Effects (DARE); 
NHS EDD Issue 4 of 12 
 
URL: http://www.cochrane.org/ 
Date of search: 03 March 2017 
Search Strategy 
#1 Organisation of care AND patient outcome  
#2 Organization of care AND patient outcome  
#3 Delivery of care AND patient outcome  
#4 Hospital resources AND patient outcome  
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A2 Modified ROBIN I tool and judgement criteria 
Table A2.1 Modified ROBIN I tool and judgement criteria  
 
ROBIN I tool (modified) Judging criteria 
Confounding 
Is there a potential for confounding of the effect of 
intervention? 
Were appropriate analyses used to control for 
confounding? 
Were confounders measured validly and reliably? 
High Not all measurable effect modifiers are identified a 
priori and statistically adjusted for 
Moderate All measurable effect modifiers are statistically 
adjusted for but remains several difficult to measure 
factors. E.g. patient preference.  
Low All effect modifiers are adjusted for.  
Unclear Methods are unclear to make a judgement 
 
Selection 
Was selection of participants based on 
characteristics after the start of the intervention? 
High Includes registry data due to the inherent nature of 
difficult to accurately capture all data. Especially 
SEER data (>65 years old)/Medicare database (only 
those with that type of insurance) 
Moderate Includes clinical databases with lots of exclusion 
criteria or <3 centres included or administrative 
databases.  
Low Clinical database with non-restrictive 
inclusion/exclusion criteria 
Unclear Methods are unclear to make a judgement 
 
Misclassification 
Were the intervention groups clearly defined? 
Was information used to define the groups 
recorded at the start? 
Could knowledge of the classification status 
High Definition of assigning the groups are dubious. For 
example, site of care studies examining distance 
patients travel for care and outcomes. GP practice is 
used as a proxy for residence or nearest hospital 
assumed to be the hospital patient used.  
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influence the outcome? High risk of cross over. For example, both groups are 
at the same hospital at the same time.  
The cut offs for assigning the groups are arbitrary i.e. 
hospital volume studies.  
Moderate A proxy is used to represent the group;  
Cohort using administrative data with groups in 
different hospitals.   
Low Clinical studies with little potential for contamination 
or cross over.  
Assessors are blinded. 
Unclear Methods are unclear to make a judgement 
 
Performance 
Were there deviations from the intended 
intervention beyond what would be expected in 
usual practice? 
Were co-interventions balanced against the 
groups? 
Was the intervention implemented for most of the 
participants and did they adhere to the assigned 
intervention? 
High Difficult to isolate the interventions so likely that co-
interventions are not balanced between the groups or 
not adjusted for properly.  
Moderate Lots of interventions are assessed at the same time e.g. 
CCP and RDP. Co-interventions are likely to be more 
balanced between the groups.  
Low Co-interventions are likely to balance between the 
groups, few deviations from intended intervention, and 
intervention implemented and adhered to in most or all 
cases.  
Unclear Methods are unclear to make a judgement 
 
Attrition 
Was there outcome data for all or nearly all of the 
participants? 
Were participants excluded for missing data? 
High Administrative or clinical data with more missing 
patients than expected where there is no formal 
adjustment or methods for accounting for such data.  
310 
 
Were the proportions and reasons for missing data 
similar across interventions? 
Moderate Administrative or clinical data with small-moderate 
amount of missing data but accounted for via formal 
methods.  
Low Clinical data or administrative data where all patients 
are accounted for.  
Unclear Methods are unclear to make a judgement or no 
mention of missing data 
 
Detection 
Could outcome measurement have been 
influenced by knowledge of the intervention? 
Were methods of outcome assessment comparable 
across groups? 
Systematic errors in measurement of the outcome 
related to the intervention? 
High Patient aware of interventional status and outcome is 
subjective 
Moderate Outcome is objective but potential to be affected by 
knowledge of interventional status. E.g. RDP studies 
measuring timeliness of care.  
Patient unaware of interventional status (retrospective 
studies) but outcome is subjective.  
Low Blinded or patient unaware of interventional status 
(retrospective) and outcome subjective/objective 
Unclear Methods are unclear to make a judgement 
 
Reporting 
Could the reported results be because of multiple 
outcome measurements within the same outcome 
domain? 
Multiple analyses of the intervention-outcome 
relationship? 
Different subgroups?  
High Multiple statistical analyses with subgroup analyses 
and lots of potential variables that could be used in the 
model.  
Did not cluster.  
Used arbitrary cut off points.  
Moderate Multiple variables or models/used a subgroup analysis 
but the model used to assess the primary outcome used 
reasonable statistical adjustment model, clustered and 
other reported outcomes not contrary to the primary 
outcome.  
Low Outcome reported was not a subgroup analysis and 
there was no potential for multiple variables or models.  
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Unclear Methods are unclear to make a judgement 
 
Overall High One or more domain is high 
Moderate No high domains and mostly moderate 
Low All low 
Unclear Methods are unclear to make a judgement 
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A3 Full search strategy for systematic review 
 
The following terms were used in each database.  
A3.1 Database: Medline (Ovoid) and EMBASE  
 
URL: http://ovoid.sp.com; https://www.embase.com 
Date of search: 21 January 2019 
 
1 health care personnel/ or "personnel".mp. or hospital personnel/ 
 
2. health care manpower/ or "manpower".mp. or manpower/ or manpower planning/ 
 
3. nursing staff/ or "nursing staff*".mp. 
 
4. medical specialist/ or "specialist care".mp. 
 
5. "workload".mp. or workload/ 
 
6. "staff workload".mp. 
 
7. high volume hospital/ 
 
8. low volume hospital/ 
 
9. "multidisciplinary care".mp. 
 
10. "interdisciplinary care".mp. 
 
11. "patient care team".mp. or patient care/ 
 
12. "patient care planning".mp. or patient care planning/ 
 
13. health care delivery/ 
 
14. "Health services accessibility".mp. 
 
15. "care co-ordination".mp. 
 
16. "continuity of care".mp. or patient care/ 
 
17. health personnel attitude/ or "inter professional relations".mp. 
 
18. "Timeliness".mp. 
 
19. "wait time".mp. 
 
20. "cancer care facilities".mp. or cancer center/ 
 
21. health care management/ or "care management".mp. 
 
22. interdisciplinary communication/ 
 
23. "communication".mp. 
 
24. "regional medical program*".mp. 
 
25. "program* of care".mp. or health program/ 
 
26. "Organization and Administration"/ or Models, Organizational/ or models, 
organi*.mp.  
27. lung cancer.mp. or exp lung cancer/ 
 
28. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26  
29. 27 and 28 
 
30. limit 30 to (human and English language and yr="2000 -Current" and (article or 
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conference paper or "review") and (adult <18 to 64 years> or aged <65+ years>) and 
"humans only (removes records about animals)") 
 
A3.2 Database: Pubmed 
  
URL: https://www.ncbi.nlm.nih.gov/pubmed 
Date of search: 21 January 2019 
#1 Staff workload AND patient outcome AND Lung Cancer ti,ab 
#2 Specialist care AND patient outcome AND Lung Cancer ti,ab 
#3 Co-ordination of care AND patient outcome AND Lung Cancer ti,ab 
#4 Clinical pathways AND patient outcome AND Lung Cancer ti,ab 
#5 Record Keeping AND patient outcome AND Lung Cancer ti,ab 
#6 Use of technology AND patient outcome AND Lung Cancer ti,ab 
#7 Home care AND Patient outcome AND Lung Cancer ti,ab 
A3.3 Database: The Cochrane Library (Wiley) 2017: Cochrane Central Register 
of Controlled Trials (CENTRAL): Cochrane database of Systematic Reviews 
(CDSR) Issue 4 of 12; Database of Abstracts of Review of Effects (DARE); 
NHS EDD Issue 4 of 12 
 
URL: http://www.cochrane.org/ 
Date of search: 21 January 2019 
Search Strategy 
#1 Staff workload AND patient outcome AND Lung Cancer  
#2 Specialist care AND patient outcome AND Lung Cancer  
#3 Co-ordination of care AND patient outcome AND Lung Cancer  
#4 Clinical pathways AND patient outcome AND Lung Cancer  
#5 Record Keeping AND patient outcome AND Lung Cancer  
#6 Use of technology AND patient outcome AND Lung Cancer  
#7 Home care AND Patient outcome AND Lung Cancer  
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A4 Full results of the proportions, unadjusted and adjusted off 
ratios of patient, organisational and staffing factors by patient 
outcome (likelihood of curative intent treatment, receiving 
treatment within 62 days and one-year survival) 
 
Table A4.1 Results of logistic regression analyses investigating the influence of 
patient and organisational features on the likelihood of receiving curative-intent 
treatment and clustering by NHS trust (n=29,793) for NSCLC patients 
 
 
No of 
patients 
No who 
received 
curative-intent 
treatment 
% receiving 
curative-
intent 
treatment 
Unadjusted 
OR (95% CI) 
Adjusted OR 
(95% CI) * 
X
2 
p 
value for 
trends 
Sex 
Male 15,986 3,842 24.0 
0.90 (0.85-
0.95) 
0.90 (0.84-0.97) 
<0.01** 
Female 13,807 3,591 26.0 1.00  
Age 
 <65years 
old 
6,325 1,973 31.2 1.00 1.00 
<0.001 
65-80 
years old 
16,053 4,613 28.7 
0.88 (0.84-
0.94) 
0.75 (0.67-0.83) 
>80 years 
old 
7,415 847 11.4 
0.28 (0.26-
0.32) 
0.22 (0.19-0.25) 
Stage 
IA 3,303 2,340 70.8 1.00 1.00 
<0.001 
IB 2,183 1,509 69.1 
0.92 (0.81-
1.05) 
0.97 (0.84-1.12) 
IIA 1,209 772 63.9 
0.73 (0.63-
0.84) 
0.69 (0.59-0.82) 
IIB 1,144 640 56.0 
0.52 (0.45-
0.61) 
0.52 (0.43-0.62) 
IIIA 3,490 1,342 38.5 
0.26 (0.23-
0.29) 
0.20 (0.17-0.23) 
IIIB 2,462 356 14.5 
0.07 (0.06-
0.08) 
0.04 (0.04-0.05) 
IV 14,468 373 2.6 
0.01 (0.01-
0.01) 
0.01 (0.01-0.01) 
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Missing 1,534 101 6.6   
Performance status 
0 4,344 2,233 51.4 1.00 1.00 
<0.001 
1 7,616 2,761 36.3 
0.53 (0.49-
0.59) 
0.56 (0.50-0.63) 
2 4,666 875 18.8 
0.22 (0.19-
0.25) 
0.21 (0.50-0.63) 
3 4,427 162 3.7 
0.04 (0.03-
0.05) 
0.04 (0.03-0.05) 
4 1,497 12 0.8 
0.01 (0.00-
0.01) 
0.01 (0.01-0.02) 
Missing 7,243 1,390 19.2   
Townsend Quintile 
1 (most 
affluent) 
4,093 1,029 25.1 1.00 1.00  
2 5,353 1,341 25.1 
1.00 (0.90-
1.10) 
0.99 (0.88-1.12) 
0.493 
3 6,120 1,476 24.1 
0.95 (0.86-
1.05) 
0.90 (0.78-1.04) 
4 6,733 1,690 25.1 
1.00 (0.91-
1.09) 
0.99 (0.86-1.14) 
5 (least 
affluent) 
7,431 1,889 25.4 
1.01 (0.93-
1.10) 
0.94 (0.82-1.07) 
Missing 63 8 12.7    
Charlson Index 
0 9,737 2,537 26.1 1.00 1.00 
<0.001 
1 4,886 1,780 36.4 
1.63 (1.48-
1.78) 
1.75 (1.49-2.04) 
2 4,971 1,639 33.0 
1.40 (1.27-
1.54) 
1.52 (1.31-1.76) 
3+ 10,199 1,477 14.5 
0.48 (0.43-
0.53) 
1.27 (1.09-1.48) 
Organisational score 
0-4 7,045 1,594 22.6 1.00 1.00 
<0.001 
5-7 14,298 3,310 23.2 
1.03 (0.91-
1.16) 
1.1 (0.92-1.33) 
8-12 8,033 2,433 30.3 
1.49 (1.25-
1.77) 
1.61 (1.25-2.07) 
Missing 417 96 23.0    
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Treatment modalities 
Biologics 
Offsite 4,164 1,183 28.4 1.00 1.00 
<0.001** Onsite 25,212 6,154 24.4 
0.81 (0.69-
0.96) 
0.83 (0.65-1.05) 
Missing 417 96 23.0   
Immunotherapy 
Onsite 5,703 1,540 27.0 1.00  
<0.001** Onsite 23,673 5,797 24.5 
0.88 (0.75-
1.02) 
0.86 (0.70-1.06) 
Missing 417 96 23.0   
Stereotactic Radiotherapy 
Offsite 21,168 5,900 27.9 1.00 1.00 
<0.001** Onsite 8,208 2,308 28.1 
0.96 (0.81-
1.14) 
1.25 (0.98-1.59) 
Missing 417 96 23.0   
Surgery 
Offsite 20,720 4,801 23.2 1.00 1.00 
<0.001** Onsite 8,656 2,536 29.3 
1.37 (1.16-
1.62) 
1.32 (1.03-1.68) 
Missing 417 96 23.0   
Pulmonary Rehab 
Offsite 9,738 2,243 23.0 1.00 1.00 
<0.001** Onsite 19,638 5,094 25.9 
1.00 (0.83-
1.21) 
1.18 (0.96-1.45) 
Missing 417 96 23.0   
Smoking 
Cessation 
      
Offsite 11,528 3,012 26.1 1.00 1.00 
<0.001** Onsite 17,848 4,325 24.2 
0.90 (0.79-
1.04) 
0.88 (0.72-1.09) 
Missing 417 96 23.0   
Staffing provision using workload (cases/WTE)***  
LCNS       
<80 3,714 1,103 29.7 1.00 1.00 
0.002 
80-199.9 23,326 5,639 24.2 0.75 (0.61- 0.68 (0.51-0.92) 
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0.94) 
≥200 2,753 691 25.1 
0.79 (0.46-
1.36) 
0.80 (0.42-1.52) 
Respiratory Physician 
<80 6,082 1,462 24.0 1.00 1.00 
0.255 
80-199.9 11,228 2,851 25.4 
1.08 (0.87-
1.33) 
1.04 (0.80-1.35) 
≥200 12,483 3,120 25.0 
1.05 (0.85-
1.31) 
0.96 (0.74-1.26) 
Medical Oncologist 
<100 8,403 2,125 25.3 1.00 1.00 
0.001 
100-269.9 7,695 2,089 27.1 
1.10 (0.89-
1.36) 
1.25 (0.95-1.65) 
≥270 13,695 3,219 23.5 
0.91 (0.78-
1.06) 
0.88 (0.71-1.10) 
Clinical Oncologist 
<180 8,113 2,122 26.2 1.00 1.00 
<0.001 
180-399.9 8,355 2,131 25.5 
0.97 (0.77-
1.21) 
0.96 (0.73-1.27) 
≥400 13,325 3,180 23.9 
0.88 (0.76-
1.03) 
0.82 (0.66-1.02) 
Surgeon 
<160 8,007 2,202 27.5 1.00 1.00 
<0.001 
160-374.9 9,846 2,437 24.8 
0.87 (0.71-
1.06) 
0.86 (0.68-1.09) 
≥375 11,940 2,794 23.4 
0.81 (0.66-
0.98) 
0.65 (0.51-0.83) 
* OR adjusted for patient variables only 
** log likelihood odds ratio test 
***WTE: Whole time equivalent of sessions dedicated to lung cancer work 
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Table A4.2 Results of logistic regression analyses investigating the influence of 
patient and organisational features on the likelihood of surviving one year and 
clustering by NHS trust (n=33,312) 
 
 
No of 
patients 
No who 
survived 
one year 
% surviving 
one year 
Unadjusted OR 
(95% CI) 
Adjusted 
OR (95% 
CI) * 
X
2 
p 
value for 
trends 
Sex 
Male 17,796 5,705 32.1 1.00 1.00 
<0.001** 
Female 15,516 5,842 37.7 0.78 (0.75-0.82) 
0.74 (0.70-
0.78) 
Age 
<65years 
old 
7,329 3,108 42.4 1.00 1.00 
<0.001 
65-80 
years old 
18,165 6,611 36.4 0.78 (0.74-0.82) 
0.74 (0.70-
0.80) 
>80 years 
old 
7,818 1,828 23.4 0.41 (0.39-0.44) 
0.48 (0.43-
0.52) 
Stage 
IA 3,359 2,616 77.9 1.00 1.00  
IB 2,233 1,614 72.3 0.74 (0.65-0.84) 
0.73 (0.63-
0.85) 
<0.001 
IIA 1,269 830 65.4 0.54 (0.47-0.62) 
0.51 (0.41-
0.63) 
IIB 1,178 679 57.6 0.39 (0.34-0.45) 
0.39 (0.31-
0.48) 
IIIA 3,812 1,815 47.6 0.26 (0.23-0.45) 
0.24 (0.20-
0.29) 
IIIB 3,019 997 33.0 0.14 (0.13-0.16) 
0.12 (0.10-
0.16) 
IV 16,778 2,675 15.9 0.05 (0.05-0.06) 
0.06 (0.04-
0.07) 
Missing 1,664 321 19.3   
Performance status 
0 4,816 2,927 60.8 1.00 1.00 
<0.001 
1 8,681 4,061 46.8 0.57 (0.53-0.61) 
0.62 (0.56-
0.69) 
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2 5,373 1,557 29.0 0.26 (0.24-0.29) 
0.32 (0.28-
0.35) 
3 4,877 644 13.2 0.10 (0.09-0.11) 
0.12 (0.12-
0.14) 
4 1,613 87 5.4 0.04 (0.03-0.05) 
0.05 (0.04-
0.07) 
Missing 7,952 2,271 28.6   
Townsend Quintile 
1 (most 
affluent) 
4,534 1,650 36.4 1.00 1.00 
0.0602 
2 5,968 2,024 33.9 0.90 (0.83-0.97) 
0.86 (0.77-
0.96) 
3 6,787 2,376 35.0 0.94 (0.87-1.02) 
0.93 (0.84-
1.04) 
4 7,520 2,619 34.8 0.93 (0.86-1.01) 
0.91 (0.81-
1.03) 
5 (least 
affluent) 
8,431 2,876 34.1 0.90 (0.84-0.98) 
0.84 (0.75-
0.94) 
Missing 72 2 2.8   
Charlson Index 
0 10,715 3,898 36.4 1.00 1.00 
0.614 
1 5,405 2,528 46.8 1.54 (1.44-1.64) 
1.56 (1.17-
2.04) 
2 5,397 2,333 43.2 1.33 (1.25-1.42) 
1.42 (1.07-
1.87) 
3+ 11,795 2,788 23.6 0.54 (0.51-0.57) 
1.00 (0.77-
1.29) 
Organisational score ** 
0-4 7,843 2,430 31.0 1.00 1.00 
<0.001 
5-7 16,032 5,494 34.3 1.16 (1.10-1.23) 
1.29 (0.95-
1.75) 
8-12 8,964 3,547 39.6 1.46 (1.37-1.55) 
1.50 (1.07-
2.10) 
Missing 473 76 16.1    
Onsite treatment modalities 
Biologics  
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Off site 4,690 1,659  1.00 1.00 
<0.001** 
On site 28,149 9,812  0.98 (0.92-1.04) 
1.07 (0.85-
1.36) 
Missing 473 76 16.1    
Immunotherapy 
Offsite 6,412 2.236 34.9 1.00 1.00 
<0.001** 
Onsite 26,427 9,235 34.9 1.00 (0.95-1.06) 
1.05 (0.84-
1.30) 
Missing 473 76 16.1    
Stereotactic radiotherapy 
Offsite 23,679 7,737 33.7 1.00 1.00 
<0.001** 
Onsite 9,160 3,734 41.8 1.41 (1.35-1.49) 
1.48 (1.27-
1.73) 
Missing 473 76 16.1    
Surgery 
Offsite 23,159 7,804 33.7 1.00 1.00 
<0.001** 
Onsite 9,680 3,667 37.9 1.20 (1.14-1.26) 
1.10 (0.86-
1.41) 
Missing 473 76 16.1    
Pulmonary Rehabilitation 
Onsite 10,909 3,846 35.3 1.00 1.00 
<0.001** 
Offsite 21,930 7,625 34.8 0.98 (0.93-1.03) 
0.90 (0.76-
1.07) 
Missing 473 76 16.1    
Smoking Cessation 
Onsite 12,892 4,587 35.6 1.00 1.00 
<0.001** 
Offsite 19,947 6,884 34.5 0.95 (0.91-1.00) 
0.97 (0.80-
1.18) 
Missing 473 76 16.1    
Staffing provision using workload (cases/WTE)  
LCNS 
<80 4,170 1,411 33.8 1.00 1.00 
<0.001 
80-199.9 26,631 9,162 34.4 1.03 (0.96-1.10) 
1.12 (0.80-
1.61) 
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≥200 2,511 974 38.8 1.24 (1.12-1.37) 
1.43 (0.93-
2.22) 
Respiratory Physician 
<80 6,837 2,224 32.5 1.00 1.00 
0.062 
80-199.9 12,535 4,446 35.5 1.14 (1.07-1.21) 
1.15 (0.92-
1.43) 
≥200 13,940 4,877 35.0 1.12 (1.05-1.19) 
1.09 (0.85-
1.41) 
Medical Oncologist 
0-100 9.480 3,021 31.9 1.00 1.00 
<0.001 
100-269.9 8,560 3,236 37.8 1.30 (1.22-1.38) 
1.47 (1.10-
1.98) 
≥270 15,272 5,290 34.6 1.13 (1.07-1.20) 
1.24 (0.91-
1.68) 
Clinical Oncologist 
<180 9,143 3,176 34.7 1.00 1.00 
0.112 
180-399.9 9.286 3,421 36.8 1.10 (1.03-1.16) 
1.15 
(0.9101.45) 
≥400 14,883 4,950 33.3 0.94 (0.89-0.99) 
0.94 (0.71-
1.24) 
Surgeon 
<160 8,951 3,276 36.6 1.000 1.00 
<0.001 
160-374.9 11,023 3,892 35.3 0.95 (0.90-1.00) 
0.99 (0.80-
1.22) 
≥375 13,338 4,379 32.8 0.85 (0.80-0.90) 
0.81 (0.61-
1.07) 
* OR adjusted for patient variables only 
**Log likelihood odds ratio test 
***WTE: Whole time equivalent of sessions dedicated to lung cancer work 
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Table A4.3 Results of logistic regression analyses investigating the influence of 
patient and organisational features on the likelihood of receiving treatment 
within 62 days and clustering by NHS trust (n=33,312) 
 
 
No of 
patients 
No who 
received 
treatment 
within 62 
days 
% 
receiving 
treatment 
within 62 
days 
Unadjusted 
OR (95% 
CI) 
Adjusted 
OR (95% 
CI) * 
X
2 
p 
value for 
trends 
Sex 
Male 17,796 8,982 50.5 1.00 1.00 
0.243** 
Female 15,516 7,791 50.2 
1.01 (0.97-
1.05) 
0.97 (0.92-
1.02) 
Age 
 <65years old 7,329 5,097 69.5 1.00 1.00 
<0.001 
65-80 years 
old 
18,165 9,978 54.9 
0.53 (0.50-
0.57) 
0.60 (0.56-
0.64) 
>80 years old 7,818 1,698 21.7 
0.12 (0.11-
0.13) 
0.18 (0.16-
0.19) 
Stage 
IA 3,359 1,954 59.2 1.00 1.00 
<0.001 
IB 2,233 1,292 57.9 
0.99 (0.89-
1.10) 
1.02 (0.90-
1.17) 
IIA 1,269 750 59.1 
1.04 (0.91-
1.18) 
1.04 (0.87-
1.24) 
IIB 1,178 653 55.4 
0.89 (0.78-
1.02) 
1.00 (0.83-
1.21) 
IIIA 3,812 2,210 58.0 
0.99 (0.90-
1.09) 
1.08 (0.94-
1.23) 
IIIB 3,019 1,899 62.9 
1.22 (1.10-
1.35) 
1.36 (1.17-
1.59) 
IV 16,778 7,738 46.1 
0.62 (0.57-
0.66) 
0.81 (0.69-
0.94) 
Missing 1,664 277 16.6   
Performance status 
0 4,816 3,855 80.0 1.00 1.00 
<0.001 
1 8,681 6,141 70.7 0.60 (0.55- 0.68 (0.61-
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0.66) 0.76) 
2 5,373 2,694 50.1 
0.25 (0.23-
0.27) 
0.32 (0.28-
0.37) 
3 4,877 1,031 21.1 
0.07 (0.06-
0.73) 
0.10 (0.08-
0.11) 
4 1,613 149 9.2 
0.03 (0.02-
0.03) 
0.04 (0.03-
0.05) 
Missing 7,952 2,903 36.5   
Townsend Quintile 
1 (most 
affluent) 
4,534 2,408 53.1 1.00 1.00 
<0.001 
2 5,968 3,040 50.9 
0.92 (0.85-
0.99) 
0.88 (0.81-
0.97) 
3 6,787 3,369 49.6 
0.87 (0.81-
0.94) 
0.84 (0.76-
0.93) 
4 7,520 3,727 49.6 
0.88 (0.82-
0.94) 
0.84 (0.76-
0.93) 
5 (least 
affluent) 
8,431 4,205 49.9 
0.88 (0.82-
0.94) 
0.80 (0.71-
0.90)  
Missing 72 24 33.3   
Charlson Index 
0 10,715 5,484 51.2 1.00 1.00 
<0.001 
1 5,405 3,108 57.5 
1.29 (1.21-
1.38) 
1.47 (1.31-
1.66) 
2 5,397 2,674 49.5 
0.94 (0.88-
1.00) 
1.29 (1.31-
1.66) 
3+ 11,795 5,507 46.7 
0.84 (0.79-
0.88) 
1.34 (1.19-
1.51) 
Organisational score * 
0-4 7,843 3,714 47.4 1.00 1.00 
<0.001 
5-7 16,032 7,966 49.7 
1.10 (1.04-
1.16) 
1.12 (0.96-
1.31) 
8-12 8,964 4,890 54.6 
1.22 (1.26-
1.42) 
1.39 (1.12-
1.74) 
Missing 473 203 42.9   
Diagnostic modalities 
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EBUS 
Offsite 8,347 3,911 46.9 1.00 1.00 
<0.001** 
Onsite 24,492 12,659 51.7 
1.21 (1.15-
1.28) 
1.20 (1.04-
1.39) 
Missing 473 203 42.9    
PET scan 
Offsite 19,772 9,549 48.3 1.00 1.00 
<0.001** 
Onsite 13,067 7,021 53.7 
1.24 (1.19-
1.30) 
1.27 (1.09-
1.48) 
Missing 473 203 42.9    
Thoracoscopy 
Offsite 12,758 5,911 46.3 1.00 1.00 
<0.001** 
Onsite 20,554 10,659 51.9 
1.16 (1.11-
1.21) 
1.17 (1.02-
1.3) 
Missing 473 203 42.9    
EGFR/ALK testing 
Offsite 25,725 12,643 49.1 1.00 1.00 
<0.001** 
Onsite 7,114 3,927 55.2 
1.27 (1.21-
1.34) 
1.38 (1.13-
1.69) 
Missing 473 203 42.9    
PDL-1 testing 
Offsite 28,509 14,088 49.4 1.00 1.00 
<0.001** 
Onsite 4,330 2,482 57.3 
1.37 (1.29-
1.47) 
1.50 (1.12-
2.00) 
Missing 473 203 42.9    
Treatment modalities 
Biologics 
Offsite 4,690 2,368 50.5 1.00 1.00 
0.062** 
Onsite 28,149 14,202 50.5 
1.00 (0.94-
1.06) 
1.07 (0.89-
1.30) 
Missing 473 203 42.9    
Immunotherapy 
Offsite 6,412 3,169 49.4 1.00 1.00 
0.001** 
Onsite 26,427 13,401 50.7 1.05 (1.00- 1.12 (0.95-
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1.11) 1.32) 
Missing 473 203 42.9    
Stereotactic 
radiotherapy 
      
Offsite 23,679 11,453 48.4 1.00 1.00 
<0.001** 
Onsite 9,160 5,117 55.9 
1.35 (1.29-
1.42) 
1.45 (1.24-
1.70) 
Missing 473 203 42.9    
Surgery       
Offsite 23,634 11,334 48.0 1.00 1.00 
<0.001** 
Onsite 9,680 5,236 54.1 
1.23 (1.17-
1.29) 
1.27 (1.06-
1.52) 
Missing 473 203 42.9 
0.78 (0.65-
0.94) 
0.57 (0.35-
0.93) 
 
Staffing provision using workload (cases/WTE)*** 
LCNS 
0-69.9 4,170 2,142 51.4 1.00 1.00 
0.061 
70-119.9 26,631 13,291 49.9 
0.94 (0.88-
1.01) 
0.95 (0.74-
1.22) 
120-1850 1,340 1,171 87.4 
0.91 (0.82-
1.01) 
1.15 (0.73-
1.81) 
Respiratory Physician 
0-80 6,837 3,296 48.2 1.00 1.00 
0.006 
80-200 12,535 6,316 50.4 
1.09 (1.03-
1.16) 
1.13 (0.95-
1.35) 
>200 13,940 7,161 51.4 
1.13 (1.07-
1.20) 
1.14 (0.96-
1.35) 
Medical Oncologist 
0-100 9,480 4,800 50.6 1.00 1.00 
0.589 
100-270 8,560 4,295 50.2 
0.98 (0.93-
1.04) 
1.00-0.80-
1.25) 
>270 15,272 7,678 50.3 
0.99 (0.94-
1.04) 
0.99 (0.82-
1.18) 
Clinical Oncologist 
1-180 9,143 4,743 51.2 1.00 1.00 <0.001 
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180-400 9,286 4,759 51.2 
0.98 (0.92-
1.03) 
0.99 (0.80-
1.23) 
>400 14,883 7,271 48.9 
0.89 (0.84-
0.93) 
0.87 (0.73-
1.05) 
Surgeon 
0-160 8,951 4,681 52.3 1.00 1.00 
<0.001 
160-375 11,023 5,642 51.2 
0.96 (0.90-
1.01) 
0.92 (0.75-
1.13) 
>375 13,338 6,450 48.4 
0.85 (0.81-
0.90) 
0.80 (0.66-
0.97) 
* OR adjusted for patient variables only 
**log likelihood odds ratio test 
***WTE: Whole time equivalent of sessions dedicated to lung cancer work 
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A5 Topic guide for semi structured interviews 
 
A5.1 Topic guide for interviews: first iteration 
 
Introduction: I am doing a project looking at decision making in lung cancer. I am going to 
ask you some questions and I am interested to hear about your thoughts and experiences. 
Please feel free to be open and honest. I will kindly ask that you do not mention any names or 
personal identifiers.  
1. In your experience what influences decisions about treatment in lung cancer? 
PROMPTS: past experiences with similar patients; the MDT, guidelines, patient 
preference/characteristics 
2. In your opinion who should make decisions about lung cancer treatment. Why do you 
feel this way? 
Rephrase: Do you think lung cancer patients should be involved? Who do you think 
the final treatment choice should be made by? 
3. What is your understanding of the term: ‘Shared Decision Making’? 
What are the qualities involved in good SDM? 
4. Is SDM appropriate in all treatment decision making contexts in lung cancer? 
Rephrase: Is there a situation where SDM is not appropriate/less suitable? Do you 
think all treatment options should be discussed with the patient? 
Are there any situations where you feel SDM may not be appropriate? Why do you 
feel this is the case? 
5. What are the barriers to SDM? 
What do you feel are the barriers to SDM? 
What do you feel are the risks and benefits to SDM? 
PROMPT: patient/organisational barriers 
REPHRASE: What makes it difficult to apply SDM in current clinical practice? What 
circumstanced would you like to apply SDM but feel you are unable to at present? 
6. Do you feel confident/adequately trained to implement SDM into your practice? 
Why is this? 
7. Can you think of any interventions that could facilitate SDM? 
Are there any methods or interventions that you feel that could facilitate SDM? 
Thank you for your time. Is there anything else you would like to discuss?
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A5.2 Topic Guide for interviews: second iteration 
 
Introduction: I am doing a project looking at decision making in lung cancer. I am going to 
ask you some questions and I am interested to hear about your thoughts and experiences. 
Please feel free to be open and honest. I will kindly ask that you do not mention any names or 
personal identifiers.  
 
1. Question 1 
In your experience what influences decisions about treatment in lung cancer?   
In your experience, how does a team come to a decision about lung cancer treatment?  
What do you think about the assessment of performance status? 
What information do you need? What are the barriers to accessing that information? Is there 
anything you think that does not get discussed that should? 
Are there times when a decision is not made? Why? 
How much decision making occurs outside the meeting? 
PROMPTS: past experiences with similar patients; the MDT; guidelines; patient 
preference/characteristics 
 
2. Question 2 
In your opinion who should make decisions about lung cancer treatment. Why do you feel this 
way? 
Rephrase: Do you think lung cancer patients should be involved? Who do you think the final 
treatment choice should be made by?  
 
3. Question 3 
Are there any situations where you feel SDM may not be appropriate? Why do you feel this is 
the case?  
REPHRASE: Is there a situation where SDM is not appropriate/less suitable? Do you think all 
treatment options should be discussed with the patient? 
 
4. Question 4 
What do you feel are the barriers to SDM? 
In your experience, how much do you tend to know about patient preferences? 
What extent do they influence decision making?  
PROMPT: patient/organisational barriers 
REPHRASE: What makes it difficult to apply SDM in current clinical practice? What 
circumstanced would you like to apply SDM but feel you are unable to at present?  
 
5. Question 5 
How can we as an organisation improve in-cooperating SDM into clinical practice? 
The MDT? Efficiency of the MDT? Do you think MDT’s lead to better decisions for patients? 
Do you think there are times when poor or suboptimal decisions are made and why? 
Cases that have been re-discussed several times. 
Targets and timelines? 
How can we accurately portray the view of the patient at MDT? 
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Reporting of outcomes? 
Decision aids and guidelines, we could use? 
Proformas or patient information videos/leaflets?  
 
6. Question 6 
Do you feel confident/adequately trained to implement SDM into your practice? 
Why is this? 
 
7. Question 7 
Are there any methods or interventions that you feel that could facilitate SDM? 
 
Thank you for your time. Is there anything else you would like to discuss?
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A5.3 Topic Guide for multi-disciplinary team (MDT) co-ordinator interviews 
 
Introduction: The purpose is to get your thoughts and view on the lung MDT meeting and the 
process of decision making and also about ways you think we can improve this process and 
things that would help you do your role. Please feel free to be open and honest. I will kindly 
ask that you do not mention any names or personal identifiers.  
 
1. Tell me about your job role? What are your duties as part of your role? Do you feel 
your duties are suitable for your role/are you happy with them? 
2. How efficient do you think the MDT meeting is? 
3. Do you think that patient views are adequately in cooperated into the decisions made 
in the MDTM?  
4. In your view who contributes to decision making in the meeting. Does anyone 
professional group carry more weight? 
5. Do you feel you are able to speak up in MDT meetings such as to prompt for 
mandatory data items?  
6. Can you think of any barriers there are too decision making in the MDT? 
7. Can you think of ways we can improve the meeting/make the pathway more efficient? 
Ways we can improve decision-making. 
8. What training have you received for your role (courses/in house training)? Have you 
heard about an e learning tool for MDT co-ordinators and the MDT co-ordinator pack 
produced by UKACR?  
9. What training do you think would be useful to have to fulfil your duties that you have 
not received? How easy is it to prepare for meetings? What would help you do this 
easier? 
Thank you for your time. Is there anything else you would like to discuss?  
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A5.4 Topic Guide for pathologist interviews 
 
Introduction: I am investigating how we can improve decision making in lung cancer within 
this MDT and pathologists are key to this process I am going to ask you some questions and I 
am interested to hear about your thoughts and experiences. Please feel free to be open and 
honest. I will kindly ask that you do not mention any names or personal identifiers.  
 
I am keen to find out your thoughts and opinions about how you feel your job plan reflects the 
amount of time needed to dedicate to lung cancer. 
I am also keen to explore practical ways you can think changes in the structure or organisation 
of the service can aid you?  
In your experience of the MDT, what influences decisions about lung cancer?  
What do you understand about the term-shared decision-making? What do you think about 
SDM? 
In your experience how much do we tend to know about patient preferences in the MDT and 
what extent do they influence decision making?  
Do you think that MDT’s lead to better decisions for patients? How much decision making 
for you occurs outside the MDT?  
How can we improve the efficiency of the MDT? How do targets influence decision-making?  
Are there any methods or interventions that you feel could facilitate SDM?  
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